id,document_id,text,text_bound_annotations,events,relations,equivalences,attributes,normalizations
0,PMC-3585731-22-Materials_and_Methods,"Stable Infection of Myr-Akt1
To generate MSCV retroviruses, HEK293FT cells (Invitrogen) were transfected with 2 microg of viral DNA and 1 microg of gal/pol and VSV-G accessory plasmids in 6 well plates using GenJet transfection reagent (Signagen Labs). Virus-containing media was collected 72 hr later, filtered through 0.45 microm filter and applied to L929 cells with 8 microg/ml polybrene. Cells were selected and maintained in 10 microg/ml puromycin.","[{'offsets': [[20, 28]], 'text': ['Myr-Akt1'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
1,PMC-3320587-08-Materials_and_Methods,"siRNA transfection of MDM
An siRNA was constructed (Ambion Inc., www.ambion.com) to target a sequence unique to the NFAT5 transcript: 5'-CAACATGCCTGGAATTCAA-3' (nt 335 to 353) [31]. As described, a control for non-specific siRNA effects, we used an siRNA targeting the green fluorescent protein (GFP), 5'- GGCTACGTCCAGGAGCGCACC-3'. MDM were transfected in 6-well plates using 1 microM of the indicated siRNA in siPORT NeoFX transfection reagent (Ambion Inc., www.ambion.com), prepared as recommended by the manufacturer, in a final volume of 750 microl in Macrophage-SFM medium plus 5% heat-inactivated human AB serum. The cultures were left at 37degreesC overnight after which cells were washed and incubated in fresh medium. MDM were transfected two times for efficient knock down of NFAT5 expression before infection experiments were performed [31].","[{'offsets': [[116, 121]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[269, 294]], 'text': ['green fluorescent protein'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[296, 299]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[786, 791]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
2,PMC-3218875-10-Negative_regulation_of_NF-+%A6B_signalling_in_RA,"microRNAs
miRNAs are recently discovered regulators of gene expression and represent a class of noncoding RNA molecules essential in many cellular and developmental processes, including immune responses and inflammation. They bind the 3'-UTR of target mRNAs leading to the repression of protein expression and the promotion of target mRNA degradation [77].
miR-146a/b and miR-155 are of particular interest for inflammatory signalling to NF-kappaB, since these miRNAs can be induced by inflammatory stimuli such as IL-1beta, TNF and TLRs [78,79]. In addition, miR-146a is an NF-kappaB-dependent gene, and the NF-kappaB signalling molecules IRAK1 and TRAF6 were identified as target genes of miR-146a [78] (Figure 1). Similarly, miR-155 was shown to target transcripts for the NF-kappaB signalling molecules IKKepsilon and RIP1 [79,80]. Notably, both miR-146 and miR-155 are expressed at higher levels in RA synovial fibroblasts and synovial tissue [81,82], as well as in peripheral blood mononuclear cells of RA patients [83]. miR-146a is also overexpressed in CD4+ and IL-17-producing T cells from RA patients [84,85]. Interestingly, a polymorphism in the 3'-UTR of the miR-146a target gene was recently shown to be associated with RA susceptibility [86]. miR-155 overexpression in synovial fibroblasts was able to prevent the TLR and cytokine-inducible expression of specific matrix metalloproteinases that mediate tissue destruction in RA [81]. Moreover, miR-155 was shown to promote TNF production, a key process in the pathogenesis of RA [87]. miR-146 and miR-155 may therefore be important negative regulators of inflammation in RA and their potential for the development of new treatments is substantial. In addition, their increased expression in RA patients is potentially useful as a marker for disease diagnosis, progression, or treatment efficacy [88], but this will require confirmation using a large and well-defined cohort.
Besides miR-146 and miR-155, a number of other miRNAs with a potential role in the control of NF-kappaB-dependent inflammatory responses in RA pathology were recently identified. In this context, miR-124a - a key regulator of the chemokine monocyte chemoattractant protein 1 - was shown to be decreased in synoviocytes from RA patients [89]. Similarly, elevated levels of miR-203 - leading to increased secretion of matrix metalloproteinase-1 and IL-6 - were detected in RA synovial fibroblasts [90]. Finally, miR-16, miR-132, and miR-223 were also shown to have an altered expression in RA patients, indicating their potential as diagnostic biomarkers for pathogenesis [83,88,91].","[{'offsets': [[357, 365]], 'text': ['miR-146a'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[366, 367]], 'text': ['b'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[372, 379]], 'text': ['miR-155'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[515, 523]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[525, 528]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[560, 568]], 'text': ['miR-146a'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[640, 645]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[650, 655]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[691, 699]], 'text': ['miR-146a'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[728, 735]], 'text': ['miR-155'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[807, 817]], 'text': ['IKKepsilon'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[822, 826]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[862, 869]], 'text': ['miR-155'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1027, 1035]], 'text': ['miR-146a'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1061, 1064]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1070, 1075]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1171, 1179]], 'text': ['miR-146a'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1257, 1264]], 'text': ['miR-155'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1458, 1465]], 'text': ['miR-155'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1487, 1490]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1561, 1568]], 'text': ['miR-155'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1959, 1966]], 'text': ['miR-155'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2135, 2143]], 'text': ['miR-124a'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2179, 2213]], 'text': ['monocyte chemoattractant protein 1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2311, 2318]], 'text': ['miR-203'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2355, 2381]], 'text': ['matrix metalloproteinase-1'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2386, 2390]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2449, 2455]], 'text': ['miR-16'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2457, 2464]], 'text': ['miR-132'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2470, 2477]], 'text': ['miR-223'], 'type': 'Protein', 'id': 'T30'}]",[],[],[],[],[]
3,PMC-1359074-16-Materials_and_Methods,"Antibodies.
Sox6 antibodies used in this study were either kindly provided by Dr. Enzo Lalli (Universite Louis Pasteur, France [7]) or commercially obtained (Catalog No. sc-17332 X, Santa Cruz Biotechnology, Santa Cruz, California, United States). All Sox6 antibodies generated similar results. c-Myc antibody was purchased from Invitrogen. Normal rabbit IgG antibody was obtained from Upstate Biotechnology (Lake Placid, New York, United States).","[{'offsets': [[12, 16]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[252, 256]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[295, 300]], 'text': ['c-Myc'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
4,PMC-3312845-01-Background,"Status epilepticus (SE) is a medical emergency with significant mortality [1]. SE has been defined as continuous seizure activity, which causes neuronal cell death, epileptogenesis and learning impairment [2,3]. Some brain regions vulnerable to SE play a role in the generation and propagation of paroxysmal activity in experimental epilepsy models. The piriform cortex (PC) is one of the most susceptible brain regions to seizure-induced damage in the kainate, pilocarpine and other models of temporal lobe epilepsy (TLE) [4-6]. Pilocarpine, a cholinergic agonist, induces SE in rodents. This pilocarpine-induced SE, similar to human TLE, shows massive neuronal loss in the hippocampus followed by glial proliferation. This neuronal damage in the pilocarpine model is not restricted to the hippocampus, but often extends to extrahippocampal limbic structures. Indeed, pilocarpine-induced SE results in acute neuronal damages within layers II and III of the PC [5,6].
SE also induces severe vasogenic edema in the PC accompanied by neuronal and astroglial damages [5-8]. Brain edema proceeds in two phases, early cytotoxic edema phase and late vasogenic edema phase. Early cytotoxic osmotic edema is due to excess stimulation of glutamatergic pathways during SE, which increases intracellular Na+ and Ca2+ concentrations. The vasogenic edema results from dysfunction of endothelial cells and the blood-brain barrier (BBB). Many studies have reported increased permeability of the BBB during epileptic activity [9-13]. A fast and significant increase in systemic blood pressure, particularly shown during tonic epileptic seizures, induces a marked vasodilation of the large cerebral arteries and an increase in blood pressure in capillaries, small arteries, and veins leading to leakage of the BBB [9]. Loss of BBB integrity is not only due to an abrupt increase in the intraluminal pressure but also influenced by the properties of cerebral tissue. Indeed, an acute increase in blood pressure or epileptic activity causes an increase in pinocytosis at the level of the cerebral endothelium [11-13].
Recently, reports have also emphasized that seizure or epilepsy is a prolonged inflammatory condition, and that seizure activity rapidly increases the synthesis and release of various interleukins in rodent brain areas involved in seizure onset and their generalization. Cytokines act on endothelial cells and change the permeability of the BBB, which exerts significant effects on neuronal viability and excitability [14,15]. Indeed, Sztriha [16] reported that dexamethasone pretreatment reduces vasogenic edema in thalamus following kainic acid-induced seizure. Among cytokines, tumor necrosis factor-alpha (TNF-alpha) is a 17 kDa protein that is produced mainly by activated macrophages and T cells in the immune system. TNF-alpha is expressed at low levels in normal brain and is rapidly upregulated in glia, neurons and endothelial cells in various pathophysiological conditions, including SE [17,18]. TNF-alpha shows various effects on brain function depending on its local tissue concentration, the type of target cells, and especially the specific receptor subtype: TNF receptor I, or p55 receptor (TNFp55R); and TNF receptor II, or p75 receptor (TNFp75R) [19]. Furthermore, TNF-alpha induces macrophage inflammatory protein-2 (MIP-2) that recruits neutrophils under pathological conditions, including SE [14,20]. Neurons, microglia, and astrocytes produce MIP-2 when incubated with pro-inflammatory cytokines such as TNF-alpha and/or interleukin-1beta (IL-1beta) or after injury [21-23]. Indeed, we have recently reported that SE-mediated MIP-2 expression is relevant to leukocyte infiltrations following SE in an IL-1beta-independent manner [20]. However, the relationship between the TNF-alpha system and BBB disruption/neutrophil infiltration during vasogenic edema formation induced by epileptogenic insults has not been fully clarified. Therefore, in the present study, we investigated the roles of TNF-alpha in vasogenic edema and its related events in rat epilepsy models provoked by pilocarpine-induced SE.","[{'offsets': [[2680, 2707]], 'text': ['tumor necrosis factor-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[2709, 2718]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[2823, 2832]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[3006, 3015]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[3173, 3187]], 'text': ['TNF receptor I'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[3192, 3204]], 'text': ['p55 receptor'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[3206, 3213]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[3220, 3235]], 'text': ['TNF receptor II'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[3240, 3252]], 'text': ['p75 receptor'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[3254, 3261]], 'text': ['TNFp75R'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[3282, 3291]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[3300, 3333]], 'text': ['macrophage inflammatory protein-2'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[3335, 3340]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[3464, 3469]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[3525, 3534]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[3542, 3559]], 'text': ['interleukin-1beta'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[3561, 3569]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[3647, 3652]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[3722, 3730]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[3794, 3803]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[4012, 4021]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T21'}]",[],[],[],[],[]
5,PMC-3585731-09-Results,"Expression of Constitutively Active Akt, Rescues Necroptosis Under Serum Free Conditions
We used L929 cells stably expressing constitutively active wild type Akt1 (Myr-Akt) or the catalytically inactive mutant K179M in order to further understand the contribution of growth factors and RIP1 kinase to Akt activation during necroptosis. Constitutively active Akt1 (Myr-Akt) was generated as previously described [37] by the addition of a myristoylation signal which provides constitutive localization to the plasma membrane and by the deletion of the auto-inhibitory PH domain (Fig. 7A) resulting in an Akt that is active under serum free. It is important to note that the cells expressing Myr-Akt were viable, grew in a manner indistinguishable from the empty vector control cells, and were not triggered to induce necroptosis by serum starvation (Fig. 7B). This indicates that active Akt alone is not sufficient to induce necroptotic cell death. Under serum free conditions Myr-Akt, but not the K179M mutant, fully restored zVAD.fmk-induced necroptosis (Fig. 7A,B). Nec-1 prevented both Myr-Akt dependent cell death and the necroptosis-specific delayed increase in Akt Thr308 phosphorylation (Fig. 7B,C). Myr-Akt also allowed other zVAD.fmk-dependent events, including activation of JNK and c-Jun phosphorylation (Fig. 7C) and upregulation of TNFalpha mRNA (Fig. 7D) to occur under serum free conditions, confirming an important role for Akt at the apex of necroptotic signaling. These data demonstrated that the presence of active and membrane localized Akt is sufficient to uncouple Akt activation during necroptosis from growth factor signaling. RIP1 kinase was still able to regulate Akt activation during necroptosis, suggesting that growth factors and RIP1 kinase provide two independent inputs required for Akt changes during necroptosis.
RIP1 kinase-dependent Thr308 phosphorylation of Myr-Akt during necroptosis increased Myr-Akt activity as it did with endogenous Akt (Fig. 5). Phosphorylation of many previously described Akt substrates was increased upon the expression of Myr-Akt, but not the K179M mutant, confirming that these molecules are Akt substrates in L929 cells (Fig. 7C). The effect of zVAD.fmk on their phosphorylation varied, likely due to the increased basal activity of Myr-Akt. Some substrates, including p70S6K, S6, GSK-3 and FoxO4, were fully phosphorylated even in the absence of zVAD.fmk. On the other hand, phosphorylation of FoxO1 and MDM2 was significantly increased in the presence of zVAD.fmk, indicating that necroptotic Thr308 phosphorylation of Myr-Akt still promoted its activity.
Under serum free conditions all zVAD.fmk-induced downstream events (cell death, JNK activation, TNFalpha production) were dependent on the over expressed Myr-Akt. This allowed us to examine the effects of other Akt mutations on necroptosis. First, we found that membrane localization of Akt is required. Full length Akt or a mutant lacking both the PH domain and the Myr tag did not support the activation of cell death or increased Thr308 phosphorylation following zVAD.fmk addition under serum free conditions (Fig. S8A,B). Second, we found a specific and critical role for Thr308 phosphorylation in the regulation of the necroptotic functions of Akt. It has been reported that Ala mutations at Thr308 and Ser473 cause a reduction in the catalytic activity of Akt, while Asp mutants increase activity [38]. We examined the effect of Ala and Asp mutants at both sites during necroptosis. In our hands, both Asp mutants displayed activity comparable to wild type Akt, while both Ala mutants displayed comparable decreases in activity (Fig. S8C). Despite similar catalytic activities, Thr308 and Ser473 mutants displayed major differences in their ability to promote necroptotic changes (Fig. 7E,F,G). As expected, the S473D mutant, which was phosphorylated on Thr308 after the addition of zVAD, displayed only slightly reduced activity, while S473A was significantly less active in all aspects of necroptosis. S473A was unable to be efficiently phosphorylated on Thr308 possibly due to the inability of the Ala mutated 473 site to be phosphorylated and provide a docking site for PDK1 to phosphorylate Thr308 [39]. Strikingly, both Ala and Asp mutants of Thr308 were significantly less active in promoting cell death, phosphorylation of JNK and c-Jun, and TNFalpha mRNA. This suggests that T308D, in spite of being an active Akt construct, may not be a perfect mimic of phosphorylation and this mutant form of the kinase may not have sufficient activity to phosphorylate the entire repertoire of substrates in the cells. When tested, T308D did not support the downstream phosphorylation of several substrates that were phosphorylated by the Myr-Akt construct in the presence of zVAD including FoxO1, Foxo4, MDM2, and p70S6K (Fig. S8D). Our model, based on these results, is that necroptosis-specific Thr308 phosphorylation provides a critical link between necroptotic machinery and Akt kinase, allowing Akt to phosphorylate substrates during necroptosis, promote TNFalpha synthesis, JNK activation and eventual cell death.","[{'offsets': [[158, 162]], 'text': ['Akt1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[164, 171]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[210, 215]], 'text': ['K179M'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[286, 290]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[358, 362]], 'text': ['Akt1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[364, 371]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[689, 696]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[975, 982]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[996, 1001]], 'text': ['K179M'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1088, 1095]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1292, 1297]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1344, 1352]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1650, 1654]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1759, 1763]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1847, 1851]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1895, 1902]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1932, 1939]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2086, 2093]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2107, 2112]], 'text': ['K179M'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2299, 2306]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2335, 2341]], 'text': ['p70S6K'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2343, 2345]], 'text': ['S6'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2357, 2362]], 'text': ['FoxO4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2461, 2466]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2471, 2475]], 'text': ['MDM2'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2587, 2594]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2720, 2728]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2778, 2785]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3386, 3389]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3842, 3854]], 'text': ['S473D mutant'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3967, 3972]], 'text': ['S473A'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[4034, 4039]], 'text': ['S473A'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[4204, 4208]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4369, 4374]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4380, 4388]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4414, 4419]], 'text': ['T308D'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4658, 4663]], 'text': ['T308D'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4765, 4772]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4817, 4822]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[4824, 4829]], 'text': ['Foxo4'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[4831, 4835]], 'text': ['MDM2'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[4841, 4847]], 'text': ['p70S6K'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[5087, 5095]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T60'}]",[],[],[],[],[]
6,PMC-3585731-29-Caption-Figure_4,"Late Thr308 phosphorylation of Akt contributes to necroptosis.
(A) L929 cells were treated with zVAD.fmk and bFGF or PDGF, with or without Nec-1, for the indicated periods of time. (B,C) L929 cells were stimulated by zVAD.fmk or TNFalpha (B) or bFGF/zVAD.fmk under serum free conditions (C). Akt inh. VIII was added 15 min before necroptotic stimulation (Pre) or at indicated times after stimulation. Viability was measured 24 hr after activation of necroptosis. (D) L929 cells were stimulated with bFGF/zVAD under serum free conditions. PD173074 was added 15 min before or 1 hr after FGF/zVAD. Samples for western blot were collected at 15 min and 9 hr time points. (E) Cells were pretreated with PD173074 or it was added 1 hr after bFGF/zVAD.fmk, followed by viability assessment at 24 hr. In all graphs, average+/-SD was plotted.","[{'offsets': [[109, 113]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[229, 237]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[245, 249]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[499, 503]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[734, 738]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
7,PMC-1064873-07-Materials_and_methods,"Isolation of mRNA and real-time PCR
Total cellular RNA was extracted from PB CD4+ T cells using an RNA isolation kit (RNeasy Mini kit; Qiagen, Valencia, CA, USA), according to the manufacturer's instructions. cDNA was synthesized from total RNA with Molony murine leukemia virus reverse transcriptase (US Biochemical, Cleveland, OH, USA) and oligo-(dT)15 primers (Promega, Madison, WI, USA). Real-time PCR was performed with the LightCycler Instrument (Roche Diagnostics, Penzberg, Germany) in glass capillaries. The reaction mix containing Taq DNA polymerase and DNA double-strand-specific SYBR Green I dye (Lightcycler FastStart DNA Master SYBR Green I; Roche Diagnostics) and specific primers were added to cDNA dilutions.
The cDNA samples were denatured at 95degrees C for 10 min, and were then amplified for 40-50 cycles: at 95degrees C (10 s), at 65degrees C (15 s), and 72degrees C (22 s) for beta-actin; at 95degrees C (10 s), at 62degrees C (15 s), and at 72degrees C (10 s) for SOCS1; and at 96degrees C (10 s), at 68degrees C (15 s), and at 72degrees C (15 s) for SOCS3. Amplification curves of the fluorescence values versus cycle number were obtained, and a melting curve analysis was then performed. The levels of SOCS1 and SOCS3 expression were determined by normalizing relative to beta-actin expression. The forward and reverse primers were as follows: for beta-actin, 5'-GTGGGGCGCCCCAGGCACCA-3' and 5'-CTCCTTAATGTCACGCACGATTTC-3' ; for SOCS1, 5'-AGACCCCTTCTCACCTCTTG-3' and 5'-GCACAGCAGAAAAATAAAGC-3' ; and for SOCS3, 5'-CCCGCCGGCACCTTTCTG-3' and 5'-AGGGGCCGGCTCAACACC-3'.","[{'offsets': [[77, 80]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[541, 544]], 'text': ['Taq'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[900, 910]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[988, 993]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1075, 1080]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1228, 1233]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1238, 1243]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1298, 1308]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1374, 1384]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1454, 1459]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1529, 1534]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T11'}]",[],[],[],[],[]
8,PMC-3317373-00-TIAB,"The Absence of Nrf2 Enhances NF-kappaB-Dependent Inflammation following Scratch Injury in Mouse Primary Cultured Astrocytes
It has been proved that Nrf2 depletion enhances inflammatory process through activation of NF-kappaB in the brain after TBI, but little is known about the relationship between Nrf2 and NF-kappaB in astrocytes after TBI. Hence, we used primary cultured astrocytes from either Nrf2 wildtype or knockout mice to study the influence of Nrf2 on the activation of NF-kappaB and expression of proinflammatory cytokines in a model of TBI in vitro. Primary cultured astrocytes were scratched to mimic the traumatic injury in vitro. Then the DNA-binding activity of NF-kappaB was evaluated by EMSA. The mRNA and protein levels of TNF-alpha, IL-1beta, IL-6, and MMP9 were also evaluated. Gelatin zymography was performed to detect the activity of MMP9. The activity of NF-kappaB and expression of proinflammatory cytokines mentioned above were upregulated at 24 h after scratch. The expression and activity of MMP9 were also elevated. And such tendency was much more prominent in Nrf2 KO astrocytes than that in WT astrocytes. These results suggest that the absence of Nrf2 may induce more aggressive inflammation through activation of NF-kappaB and downstream proinflammatory cytokines in astrocytes.","[{'offsets': [[755, 763]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[765, 769]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[775, 779]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[860, 864]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1023, 1027]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
9,PMC-1064895-17-Results,"Activation of PI3K/Akt signal transduction pathway on IL-17 production by anti-CD3
To determine downstream effector molecules of the PI3K pathway, we evaluated the activation of Akt by western blotting. As shown in Fig. 6, at 10 min of incubation with anti-CD3 (10 mug/ml) or LY294002 (20 muM), no difference in the amounts of phosphorylated Akt was observed. However, after 30 min of incubation, phosphorylated Akt increased (lane 2), and the effect of inhibition by LY294002 (lane 3) reached a peak at 60 min, lasting to 120-240 min. In contrast, non-phosphorylated Akt and beta-actin remained unchanged regardless of incubation time. PHA, concanavalin A and IL-15 also demonstrated the same effect on phosphorylated Akt as shown with anti-CD3, which was an inhibition by wortmannin and PDTC as well as by LY294002 (data not shown).","[{'offsets': [[19, 22]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[54, 59]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[178, 181]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[342, 345]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[412, 415]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[568, 571]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[576, 586]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[637, 640]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[661, 666]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[719, 722]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T10'}]",[],[],[],[],[]
10,PMC-3589482-20-Results,"C/EBP-beta Binds the Murine SerpinB2 Proximal Promoter in vivo in an LPS-inducible Manner
We investigated the temporal dynamics of C/EBP-beta recruitment to the murine SerpinB2 promoter in response to LPS in vivo by chromatin immunoprecipitation (ChIP). RAW 264.7 cells were stimulated with LPS for up to 8 hrs, soluble chromatin was immunoprecipitated with antibodies against DNA binding proteins, and the enriched DNA amplified by both semi-quantitative and qPCR using SerpinB2 proximal promoter specific primers (illustrated in fig. 4A). The results showed that C/EBP-beta is constitutively present at the SerpinB2 promoter as demonstrated by its association with the promoter in unstimulated macrophages and increased temporally in response to LPS reaching as much as 10-fold over unstimulated cells after 8 hrs (Fig. 7). Since changes in C/EBP-beta phosphorylation states can affect C/EBP-beta's ability to transactivate target genes [38]; [63]; [64], we investigated recruitment to the SerpinB2 proximal promoter of the T217 phosphorylated C/EBP-beta isoform (p-C/EBP-betaT217), which has been associated with cell survival [65]. p-C/EBP-betaT217 was constitutively bound to the SerpinB2 proximal promoter and also present after 1 hr of LPS stimulation (Fig. 7). In contrast to total C/EBP-beta, the binding affinity of p-C/EBP-betaT217 for the SerpinB2 proximal promoter diminished with LPS stimulation at later timepoints (4 and 8 hrs)(Fig. 7). These data show an inverse relationship between C/EBP-beta and p-C/EBP-betaT217 recruitment, and indicate that T217-phosphorylated C/EBP-beta may not be responsible for increased transcription from the SerpinB2 promoter in response to LPS.","[{'offsets': [[0, 10]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[28, 36]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[131, 141]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[168, 176]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[471, 479]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[565, 575]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[609, 617]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[843, 853]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[888, 898]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[992, 1000]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1046, 1056]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1066, 1082]], 'text': ['p-C/EBP-betaT217'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1136, 1152]], 'text': ['p-C/EBP-betaT217'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1185, 1193]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1290, 1300]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1326, 1342]], 'text': ['p-C/EBP-betaT217'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1351, 1359]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1501, 1511]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1516, 1532]], 'text': ['p-C/EBP-betaT217'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1584, 1594]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1655, 1663]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T21'}]",[],[],[],[],[]
11,PMC-3342329-20-Caption-Figure_3,"Induction of apoptotic cell death in tumor tissues of CCR5 -/- mice.
A, Apoptotic cells in tumor sections were examined by fluorescence microscopy after DAPI and TUNEL staining as described in material and methods. The apoptotic index was determined as the number of DAPI-stained, TUNEL-positive cells that were counted. Values are the mean +/- S.D. of four experimental animals. * indicates statistically significant differences from CCR5+/+ mice. Scale bar indicates 50 microm. B and C, Apoptotic protein (cleaved caspase-3 and Bax) in tumor sections were detected by immunofluorescence assay. The reactive cell number was determined as the number of DAPI-stained, Specific antibody (cleaved caspase-3 and Bax)-positive cells that were counted. Values are the mean +/- S.D. of four experimental animals. * indicates statistically significant differences from CCR5+/+ mice. Scale bar indicates 50 microm. D, The expression of apoptotic proteins was detected by Western blotting using specific antibodies; cleaved caspase-3, cleaved caspase-9, cleaved PARP, Bax, Bcl-2 and c-IAP1 in the tumor tissues. The beta-actin protein was used as an internal control. Each band is representative of three independent experimental results. Data are means +/- S.D. of three experimental animals. * indicates significant difference from CCR5+/+ mice (p<0.05).","[{'offsets': [[54, 58]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[435, 439]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[861, 865]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1073, 1079]], 'text': ['c-IAP1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1106, 1116]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1324, 1328]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T6'}]",[],[],[],[],[]
12,PMC-1064895-03-Materials_and_methods,"Reagents
Recombinant IL-17, IL-18, IL-15, monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, IL-6 and IL-8 were purchased from R & D systems (Minneapolis, MN, USA). Recombinant transforming growth factor (TGF)-beta was purchased from Peprotech (London, UK). Recombinant TNF-alpha and IL-1 were purchased from Endogen Inc. (Cambridge, MA, USA). Cyclosporin A was provided by Sandos Ltd. (Basel, Switzerland). Phytohemagglutinin (PHA), pyrrolidine dithiocarbamate (PDTC), rapamycin, dexamethasone and curcumin were all obtained from the Sigma Chemical Co. (St Louis, MA, USA). Anti-CD3 monoclonal antibody and anti-CD28 monoclonal antibody were obtained from BD Biosciences (San Diego, CA, USA). LY294002, SB203580, FK506, wortmannin and PD98059 were obtained from Calbiochem (Schwalbach, Germany).","[{'offsets': [[21, 26]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[28, 33]], 'text': ['IL-18'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[35, 40]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[42, 76]], 'text': ['monocyte chemoattractant protein-1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[78, 83]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[86, 130]], 'text': ['macrophage inflammatory protein (MIP)-1alpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[132, 141]], 'text': ['MIP-1beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[143, 147]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[152, 156]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[227, 264]], 'text': ['transforming growth factor (TGF)-beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[320, 329]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[334, 338]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[458, 476]], 'text': ['Phytohemagglutinin'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[478, 481]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[663, 667]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T15'}]",[],[],[],[],[]
13,PMC-3585731-13-Materials_and_Methods,"Reagents and Chemicals
Necrostatin analogs were synthesized as previously described [23], [24]. The following reagents and final concentrations (unless otherwise specified in the text/figures) were used in the experiments: Akt inhibitor VIII (10 microM, Calbiochem), MK-2206 (10 microM, Selleck Chem), Triciribine (100 microM, National Cancer Institute), SP600125 (10 microM, Calbiochem), JNK inhibitor VIII (10 microM, Calbiochem), UO126 (10 mM, Cayman Chem), PD169316 (10 microM, Calbiochem), LiCl (10 mM, Sigma), SB216763 (10 microM, Calbiochem), BX912 (10 microM, Axon Med Chem), PF-4706871 (Sigma), rapamycin (100 nM, Santa Cruz), PI-103 (10 microM, Calbiochem), Torin-1 (500 nM, gift of Dr. Nathanael Grey (Harvard Medical School), LY249002 (10 microM, Cell Signaling), PD173074 (2 microM, Cayman Chem), PD166866 (20 microM, Calbiochem), 4EGI-1 (50 microM, Calbiochem). Pan-caspase inhibitor zVAD.fmk (20-30 microM) was purchased from Bachem. Human and mouse TNFalpha (10 ng/ml), human bFGF (25 ng/ml), EGF (50 ng/ml), PDGF-BB (20 ng/ml), and IGF-1 (50 ng/ml) were from Cell Sciences or Peprotech. All other reagents were from Sigma.","[{'offsets': [[965, 973]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[992, 996]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1009, 1012]], 'text': ['EGF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1049, 1054]], 'text': ['IGF-1'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
14,PMC-3342329-11-Materials_and_Methods,"Western Blotting
Tumor tissues were homogenized with protein extraction solution (PRO-PREPTM, Intron Biotechnology, Seoul, Korea), and lysed by 60 min incubation on ice. The tissue lysate centrifuged at 15,000 rpm for 15 min at 4degreesC. Equal amounts of proteins (40 microg) were separated on a SDS/12%-polyacrylamide gel, and then transferred to a polyvinylidene difluoride (PVDF) membrane (GE Water and Process technologies, Trevose, PA, USA). Blots were blocked for 1 h at room temperature with 5% (w/v) non-fat dried milk in Tris-Buffered Saline Tween-20 [TBST: 10 mM Tris (pH 8.0) and 150 mM NaCl solution containing 0.05% Tween-20]. After a short washing in TBST, the membranes were immunoblotted with the following primary antibodies: mouse monoclonal antibodies directed against p65 and p50 (1:500 dilutions; Santa Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal antibodies directed against Bax and PARP (1:500 dilutions; Santa Cruz Biotechnology), and against caspase-3, caspase-9, Bcl-2 and c-IAP-1 (1:1000 dilutions; Cell Signaling Technology, Beverly, MA). The blots were incubated with the respective horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG (1:4000 dilutions; Santa Cruz Biotechnology). Immunoreactive proteins were detected with the ECL detection system.","[{'offsets': [[789, 792]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[797, 800]], 'text': ['p50'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1010, 1017]], 'text': ['c-IAP-1'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
15,PMC-3589482-12-Experimental_Procedures,"Statistical Analysis
Data are presented as mean +/- SEM per group. Results were analyzed using the analysis of variance (ANOVA) or Student's t test where relevant. P-values <0.05 were considered significant.",[],[],[],[],[],[]
16,PMC-3586680-08-Conflict_of_Interest_Statement,The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.,[],[],[],[],[],[]
17,PMC-3589482-19-Results,"C/EBP-beta Mediates both Constitutive and LPS-induced SerpinB2 mRNA Expression in MEFs and Inflammatory Primary Macrophages
To investigate the importance of C/EBP-beta to endogenous SerpinB2 mRNA expression in response to LPS, we utilized C/EBP-beta-null (Cebpb-/-) and wild-type MEFs (Cebpb+/+), since RAW264.7 cells constitutively express endogenous C/EBP-beta. Wild-type MEFs express low levels of endogenous SerpinB2 and the absence of C/EBP-beta attenuated endogenous SerpinB2 mRNA expression. LPS stimulated an increase in SerpinB2 mRNA expression in wild-type MEFs (Fig. 6A), whereas LPS-stimulated SerpinB2 mRNA expression was significantly dampened in Cebpb-/- MEFs as compared to wild-type. We next tested if similar effects could be seen in thioglycollate-elicited inflammatory macrophages in which C/EBP-beta expression was knocked down using species-specific lentiviral shRNAs (Fig. 6B, left). As was observed in MEFs, both constitutive and LPS-induced SerpinB2 mRNA expression was significantly decreased in C/EBP-beta-deficient inflammatory macrophages (Fig. 6B, right). These data show that C/EBP-beta is critical for mediating constitutive and LPS-inducible transcription of endogenous SerpinB2 mRNA.","[{'offsets': [[0, 10]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[54, 62]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[157, 167]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[182, 190]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[239, 249]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[256, 261]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[286, 291]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[352, 362]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[412, 420]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[440, 450]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[473, 481]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[529, 537]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[606, 614]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[661, 666]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[810, 820]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[966, 974]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1022, 1032]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1107, 1117]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1203, 1211]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T19'}]",[],[],[],[],[]
18,PMC-3291650-05-Discussion,"In the present study we have investigated the contribution of A20 expression in myeloid cells in the innate immune response to IAV lung infection. In the pulmonary environment, macrophages populate both lung parenchyma and the alveolar lumen where they are referred to as alveolar macrophages. Under naive conditions, alveolar macrophages exert important immunomodulatory functions [65], [66]. However, alveolar macrophages are also crucial in the innate immune response against IAV as they are one of the first cells that encounter infectious IAV particles [67], [68]. They are an important source of proinflammatory cytokines and chemokines that attract innate immune cells to the lung during the primary phase of infection [69], and they are the primary producers of type I IFNs [70]. Alveolar macrophages are also known to phagocytose virus infected apoptotic cells and antibody coated viral particles, further contributing to viral clearance. We could show that BMDM or alveolar macrophages derived from A20myel-KO mice express higher amounts of chemokines, cytokines and type I IFNs compared to wild type mice in response to in vitro infection. Similarly, in vivo infection with IAV resulted in higher levels of primarily neutrophil attracting chemokines such as KC and MIP-2 and several proinflammatory cytokines such as IL-6, TNF and IL-1beta in the lungs of A20myel-KO mice compared to wild type mice. This was associated with a selective enhancement of neutrophil recruitment to the bronchoalveolar compartment, and resulted in improved viral clearance later on during infection. Although the role of neutrophils during viral infection is still under debate, recent evidence supports a protective function of these cells during IAV infection [71], [72]. MCP-1 levels were not affected by the absence of A20 in myeloid cells, which is consistent with the notion that airway epithelial cells are the primary source of MCP-1 production during IAV infection [73]. Mice deficient for the MCP-1 receptor CCR2, which is expressed on a subset of circulating monocytes, are protected against IAV infection and display reduced signs of immunopathology [74]-[76]. During IAV infection these monocytes develop into inflammatory dendritic cells or proinflammatory macrophages [77] and are considered major contributors to IAV-induced immunopathology [78]. A20myel-KO mice were protected against a lethal IAV infection, which is rather surprising since an excessive proinflammatory cytokine response and an excessive influx of inflammatory cells is generally believed to be associated with increased lethality [64], [79]. However, the selective effect of A20 deficiency on neutrophil recruitment, without altering inflammatory monocyte (Ly6C+ CD11b+) recruitment, further support the idea that monocytes and not neutrophils are major contributors to IAV-associated immunopathology and lethality [78].
We show that A20 deficient BMDM display enhanced NF-kappaB and IRF3 activation in response to RIG-I stimulation by synthetic LMW double stranded RNA. RIG-I has previously been shown to play a key role in the innate immune response to IAV [13], suggesting that the increased immune response of A20myel-KO mice to IAV lung infection reflects enhanced RIG-I signaling. We propose that A20 inhibits IAV-induced proinflammatory gene expression (as shown in our manuscript for TNF, IL-6, KC, MIP-2, and IFNbeta) by negatively regulating NF-kappaB and IRF3 activation, which are the major pathways controlling these genes. However, this does not exclude an additional effect of A20 on other signaling pathways that may contribute to proinflammatory gene expression. A20 is believed to exert its NF-kappaB and IRF3 inhibitory functions by modulating the ubiquitination status of different signaling proteins [80]. In this context, it was recently shown that A20 cooperates with the ubiquitin-binding proteins TAX1BP1 and ABIN1 to to disrupt the TRAF3-TBK1-IKKepsilon complex, thereby negatively affecting K63-polyubiquitination of TBK1 and IKKepsilon, and their ability to activity IRF3 [81], [82]. Whether similar mechanisms are involved in the regulation of RIG-I induced NF-kappaB activation is still unclear. So far we were unable to clearly detect ubiquitination of TBK1 and IKKepsilon in primary macrophages, preventing us from studying the effect of A20 deficiency on their ubiquitination status. It cannot be excluded however that A20 also targets other substrates that mediate NF-kappaB and IRF3 activation in myeloid cells. The identification of these substrates will be the topic of future investigations in our laboratory. Multiple other deubiquitinating enzymes (DUBs), such as DUBA [28], CYLD [29], [30], OTUB1/2 [31], and A20 [49]-[52] have been shown to negatively regulate RIG-I signaling to NF-kappaB and IRF-3, implicating possible redundancy. However, evidence so far was limited to in vitro data and was obtained under non-physiological conditions. The clear protective phenotype of A20myel-KO mice that we here describe indicates that A20 expression in myeloid cells is a central gatekeeper of RIG-I induced signaling in response to IAV infection and that other DUBs cannot substitute for A20 deficiency under physiological conditions. If A20 has a similar non-redundant role in other cell types that are implicated in the response to IAV, such as lung epithelial cells, remains to be investigated.
Understanding and controlling the activation of innate antiviral immune responses is an important step toward novel therapies. About a fifth of world's population is infected by IAV annually, leading to high morbidity and mortality, particularly in infants, the elderly and the immunocompromised. The high mutation rate of IAV turns all attempts of vaccine and antiviral design into a never ending battle. In recent years, RNA interference, triggered by synthetic short interfering RNA (siRNA), has rapidly evolved as a potent antiviral regimen. Properly designed siRNAs have been shown to function as potent inhibitors of influenza virus replication. Although specificity and tissue delivery remain major bottlenecks in the clinical applications of RNAi in general, intranasal application of siRNA against respiratory viruses including, but not limited to influenza virus, has experienced significant success and optimism [83]. Our results suggest that not only siRNA targeting IAV components, but boosting the antiviral immune response by intranasal administration of siRNA against A20 might be a valid therapeutic approach. Also small compound inhibitors of A20 might be an interesting alternative. Finally, similar targeting of A20 might be of interest in the battle against other viral infections including RSV and SARS coronavirus.","[{'offsets': [[1269, 1271]], 'text': ['KC'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1276, 1281]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1328, 1332]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1334, 1337]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1342, 1350]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1764, 1769]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1926, 1931]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[2960, 2964]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2991, 2996]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[3047, 3052]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[3246, 3251]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[3368, 3371]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[3373, 3377]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[3379, 3381]], 'text': ['KC'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[3383, 3388]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[3394, 3401]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[3442, 3446]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[3699, 3703]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[3910, 3915]], 'text': ['ABIN1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[4020, 4024]], 'text': ['TBK1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[4029, 4039]], 'text': ['IKKepsilon'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[4071, 4075]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[4149, 4154]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[4260, 4264]], 'text': ['TBK1'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[4269, 4279]], 'text': ['IKKepsilon'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[4489, 4493]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[4691, 4695]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[4779, 4784]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[4812, 4817]], 'text': ['IRF-3'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[5105, 5110]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T34'}]",[],[],[],[],[]
19,PMC-1064873-13-Results,"IL-6-mediated STAT3 phosphorylation and inhibition of IL-10 effect in normal CD4+ T cells
STAT3 is activated by many cytokines and growth factors such as the IL-6 family of cytokines (IL-6, IL-11, leukemia inhibitory factor, and oncostatin M), platelet-derived growth factor, and epidermal growth factor, in addition to IL-10 [4], but previous studies have demonstrated that IL-6 is the major factor in RA synovial fluid that induces constitutive activation of STAT3 in mononuclear cells [31]. Since IL-6 is also abundant in sera of active RA patients, frequently detected at > 1 ng/ml [27], we examined whether persistent exposure of CD4+ T cells to high concentrations of IL-6 in the blood circulation was responsible for their sustained STAT3 activation and resistance to IL-10 inhibition in active RA. Both STAT1 and STAT3 phosphorylation was activated by IL-6 in normal CD4+ T cells (data not shown), in agreement with previous observations [4]. Normal CD4+ T cells were thus incubated for 20 min with culture medium containing 30% serum from active RA patients and neutralizing anti-IL-6 antibody or control antibody, and STAT phosphorylation was examined by western blot analysis. RA serum was able to induce tyrosine phosphorylation of STAT3 but not STAT1, and this STAT3 activation was mostly abolished by neutralization of IL-6 activity (Fig. 5a). These results indicate that IL-6 is the dominant STAT3-activating factor contained in sera of active RA patients. The lack of STAT1 activation by RA serum suggests that much higher concentrations of IL-6 may be required for STAT1 activation as compared with STAT3 activation, or that inhibitors of STAT1 signaling may be present in RA serum.
We next examined whether IL-6 could suppress the effect of IL-10 to inhibit IFN-gamma production by CD4+ T cells. After preincubation with or without 10 ng/ml IL-6 for 36 hours, normal CD4+ T cells were stimulated by CD3 and CD28 costimulation in the presence or absence of 1 ng/ml IL-10 for 36 hours, and the IFN-gamma production was measured by ELISA. IL-6 pretreatment of normal cells reduced IL-10-mediated inhibition of IFN-gamma production (Fig. 5b), indicating that high concentrations of IL-6 could modulate T-cell responsiveness to IL-10. Taken together, these findings suggest that persistent exposure to serum IL-6 may have a role in both the induction of STAT3 activation and the resistance to the inhibitory effect of IL-10 in RA CD4+ T cells.","[{'offsets': [[0, 4]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[14, 19]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[54, 59]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[77, 80]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[90, 95]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[184, 188]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[190, 195]], 'text': ['IL-11'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[197, 223]], 'text': ['leukemia inhibitory factor'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[229, 241]], 'text': ['oncostatin M'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[244, 274]], 'text': ['platelet-derived growth factor'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[280, 303]], 'text': ['epidermal growth factor'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[320, 325]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[375, 379]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[461, 466]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[500, 504]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[635, 638]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[674, 678]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[740, 745]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[775, 780]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[811, 816]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[821, 826]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[860, 864]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[875, 878]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[958, 961]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1089, 1093]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1244, 1249]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1258, 1263]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1274, 1279]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1333, 1337]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1386, 1390]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1407, 1412]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1484, 1489]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1557, 1561]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1582, 1587]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1616, 1621]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1656, 1661]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1725, 1729]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1759, 1764]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[1776, 1785]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1800, 1803]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[1859, 1863]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[1885, 1888]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[1925, 1929]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[1982, 1987]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2010, 2019]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2054, 2058]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2096, 2101]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2125, 2134]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2196, 2200]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2241, 2246]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2321, 2325]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2367, 2372]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2431, 2436]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[2443, 2446]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T54'}]",[],[],[],[],[]
20,PMC-1064895-20-Conclusions,"We have detected a more pronounced production of IL-17 from RA PBMC in response to IL-15 and MCP-1 as well as stimulation by anti-CD3/anti-CD28. We have also shown that upregulation of IL-17 by activated T cells in patients with RA could be the result of activation via the PI3K/Akt pathway with resultant NF-kappaB activation. Our data provide insights into cellular mechanisms of the regulation of IL-17 production in RA, and highlight the role of T cells, which has hitherto been neglected in RA pathogenesis. Together with recent data on the successful introduction of anti-IL-17 in RA, our results have added information for the future molecular targeting of new therapeutic applications in RA.","[{'offsets': [[49, 54]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[83, 88]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[93, 98]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[139, 143]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[185, 190]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[279, 282]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[400, 405]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[578, 583]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
21,PMC-1472690-11-Methods,"Stimulation conditions
For induction of transcription factors and cytokines, PBMC were cultured in a volume of 4 ml in sterile pyrogen-free 6-well culture plates (Falcon, Heidelberg, Germany). Cultures were stimulated for 1 h (EMSA) or from 0 h to 48 h (ELISA) with 1 or 100 mug per 106 cells of GP, with 250 ng/106 cells TSST-1 (Toxin Technologies, Sarasota, FL, USA) or with 250 ng/106 cells wild-type LPS from Escherichia coli serotype 0111:B4 (Sigma, Munich, Germany). In costimulatory experiments, PBMC were supplemented simultaneously with a combination of GP and TSST-1 or with a combination of GP and LPS.","[{'offsets': [[322, 328]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[570, 576]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
22,PMC-3585731-10-Results,"Akt Controls TNFalpha Production in Other Cell Types
After establishing the role of RIP1 kinase-dependent signaling to Akt in L929 cells, we sought to expand our study to other cell types that are known to undergo necroptotic cell death. Fas-associated protein with death domain (FADD)-deficient Jurkat T lymphocytes and the macrophage cell lines (J774A.1 and RAW264.7) are other models of necroptosis, which can be induced by stimulation with TNFalpha or zVAD.fmk, respectively [17]. Similar to L929 cells, a RIP1 kinase dependent increase in the phosphorylation of Thr308 on Akt occurred during necroptosis (Fig. 8B,D,F) in these cell types. Furthermore, TNFalpha mRNA levels were increased in each of these cell types during necroptosis and efficiently inhibited by both RIP1 and Akt inhibitors (Fig. 8A,C,E). However, inhibition of Akt did not protect these cells from death (Fig. S9A,B,C). These results indicate that regulation of autocrine TNFalpha synthesis and necroptosis-associated inflammatory signaling may be a more important function of Akt pathway activation by RIP1 kinase in multiple cell types compared to its contribution to cell death.
We next chose to look at the role of Akt in necroptosis in mouse lung fibroblasts. Lung fibroblasts selected to survive after deletion of all three Akt isoforms [40] were resistant to cell death induced by the addition of TNFalpha and zVAD.fmk. Expression of catalytically active Akt (Myr-Akt) in these cells restored TNFalpha mRNA production in response to TNFalpha and zVAD.fmk (Fig. 8G) without re-establishing cell death (Fig. S9D). Consistent with our earlier Akt knockdown data, lung fibroblasts expressing endogenous Akt1 or Akt2 were phosphorylated on Thr308 in response to TNFalpha and zVAD.fmk (Fig. S9E) and in both cases robust RIP1-dependent TNFalpha mRNA upregulation occurred under necroptotic conditions (Fig. 8H). These data further support the notion that Akt activity is critical for autocrine TNFalpha synthesis, even in the absence of necroptotic cell death, indicating an unexpected differentiation between Akt-mediated inflammatory signaling under necroptotic conditions and cell death per se.","[{'offsets': [[13, 21]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[84, 88]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[238, 278]], 'text': ['Fas-associated protein with death domain'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[280, 284]], 'text': ['FADD'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[444, 452]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[510, 514]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[657, 665]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[774, 778]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[947, 955]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1078, 1082]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1379, 1387]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1475, 1483]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1515, 1523]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1681, 1685]], 'text': ['Akt1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1689, 1693]], 'text': ['Akt2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1739, 1747]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1797, 1801]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1812, 1820]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1970, 1978]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T19'}]",[],[],[],[],[]
23,PMC-3312845-05-Methods,"Tissue processing
At designated time points (non-SE: 12 hr, 1 day, 2 days, 3 days, 4 days and 1 week after SE; n = 5, for each time point), animals were perfused transcardially with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde in 0.1 M phosphate buffer (PB, pH 7.4) under urethane anesthesia (1.5 g/kg, i.p.; Sigma-Aldrich Co., St. Louis, MO). The brains were removed, and postfixed in the same fixative for 4 hr. The brain tissues were cryoprotected by infiltration with 30% sucrose overnight. Thereafter, the entire hippocampus was frozen and sectioned with a cryostat at 30 mum and consecutive sections were contained in six-well plates containing PBS. For stereological study, every sixth section in the series throughout the entire hippocampus was used in some animals.",[],[],[],[],[],[]
24,PMC-3320587-14-Results,"MTb increases HIV-1 LTR activity of HIV-1 subtypes B, C, and E
To compare the functional impact of MTb stimulation on subtype-specific HIV-1 LTR activity, we first constructed reporter plasmids containing viral subtype B, C, and E LTRs (-208 to + 64 nt relative to the transcription start site) linked to the firefly luciferase reporter gene. After transfection of the monocytic THP-1 cell line with these plasmids, cells were stimulated with an irradiated whole cell lysate of MTb (H37Rv). We note that MTb lysate induces inflammatory responses in monocytes that resemble those induced in response to live MTb (see for example, [35]-[37]). Upon stimulation, the B, C, and E LTR-driven reporters demonstrated a significant enhancement in luciferase activity (Figure 1A) and the magnitude of this effect was subtype-specific. Subtype C LTRs displayed the strongest activity, while the LTRs from subtype E isolates consistently showed the weakest activity (Figure 1A), consistent with previous studies demonstrating subtype-specific LTR activity that used TNF as a stimulus [38], [39].","[{'offsets': [[317, 327]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[738, 748]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1054, 1057]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
25,PMC-3291650-11-Materials_and_Methods,"Cells and transfection
HEK293T and MDCK cells were grown in DMEM (Gibco) supplemented with 10% FCS, 2 mM L-glutamine, 0.4 mM sodium pyruvate and antibiotics. HEK293T cells were transfected using the calcium phosphate precipitate transfection method with specific expression vectors (pCAGGS-E-hA20 (LMBP 3778), pCAGGS-E-RIG-I-CARD (LMBP 6517), pEF-HA-IRF-7 (kindly provided by T. Taniguchi, Graduate School of Medicine and Faculty of Medicine, University of Tokyo)), NF-kappaB, IRF3, IRF7 reporter plasmids (respectively pConLuc (LMBP3248), pISRE-luc (LMBP4011), pGL3-IFNalpha4-luc (kindly provided by J. Hiscott, McGill University, Montreal, Quebec, Canada), and pACTbetagal (LMBP4341) for transfection efficiency normalization. Details of plasmids are presented along with detailed sequence maps at the BCCM-LMBP plasmid databank http://bccm.belspo.be/index.php.
For the generation of BMDM, bone marrow cells were cultured 7 days in RPMI 1640 (Gibco) supplemented with 10% FCS, 2 mM L-glutamine, 0.4 mM sodium pyruvate, antibiotics and 40 ng/ml recombinant M-CSF. BMDM were of >=95% purity as measured by flow cytometry using F4/80 and CD11b specific antibodies. For the isolation of alveolar macrophages, the trachea was canulated and the lung was flushed 4 times with HBSS containing 1 mM EDTA. Alveolar macrophages were cultured in RPMI 1640 (Gibco) supplemented with 1% FCS, 2 mM L-glutamine, 0.4 mM sodium pyruvate and antibiotics.","[{'offsets': [[477, 481]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[483, 487]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
26,PMC-2817507-02-2._Methods,"2.1. Animals
Ninety Wister rats (male, body weight: 250 g to 300 g) were provided by Experimental Animal Center, China Medical University. The rats were assigned randomly to three groups: normal group (N, n = 10, without any treatment), normal saline control (S, n = 40, intra-cerebral injection of normal saline as control) and intra-cerebral hemorrhage group (ICH, n = 40). The experimental protocol used for animals was approved by the Animal Care and Use Committee, China Medical University. The rats were subjected to intra-cerebral injection of normal saline or autologous whole blood and were sacrificed on 6 hours, 1 day, 3 days and 7 days after the injection, respectively. Five rats in each group at each time point were sacrificed by transcardially perfusion of normal saline followed by 4% buffered Para formaldehyde (pH = 7.4). The brains were removed, postfixed, embedded in paraffin, and cut into sections (7 mum) as described previously [8]. Five rats in each group at each time point were sacrificed by over dose injection of Ketamine. The brains were removed and stored at minus 80degreesC for RT-PCR and Western Blots.",[],[],[],[],[],[]
27,PMC-3218875-03-Basic_principles_of_NF-+%A6B_signalling,"NF-kappaB proteins are sequestered in the cytoplasm as latent complexes by inhibitory proteins referred to as inhibitor of NF-kappaB (IkappaB) proteins, which prevent NF-kappaB nuclear translocation and DNA binding [19]. Whereas the majority of IkappaBs (IkappaBalpha, IkappaBbeta, IkappaBepsilon, p105 (also known as NF-kappaB1), p100 (also known as NF-kappaB2)) serve as inhibitors of NF-kappaB, IkappaBxi and Bcl-3 instead potentiate NF-kappaB transactivation in the nucleus. p100 and p105 are precursors of the p52 and p50 NF-kappaB subunits, respectively. There are two unique NF-kappaB signalling pathways, termed canonical (or classical) and noncanonical (or alternative) NF-kappaB pathways.
The canonical NF-kappaB pathway plays a major role in innate and adaptive immunity, and is triggered by many stimuli including proinflammatory cytokines (for example, TNF, IL-1), antigens, RANKL, and TLR ligands. NF-kappaB signalling initiated by different receptors requires the formation of proximal protein-protein interactions that are often receptor specific, but ultimately converge in the activation of the IkappaB kinase (IKK) complex, which mediates phosphorylation of the inhibitory IkappaB protein leading to its K48-polyubiquitination and degradation by the proteasome [20]. The IKK complex is comprised of the two catalytic subunits IKK1 and IKK2 (also known as IKKalpha and IKKbeta) and the regulatory subunit NF-kappaB essential modulator (NEMO - also known as IKKgamma) (Figure 1). Gene targeting experiments showed that IKK2 and NEMO, but not IKK1, are required for canonical NF-kappaB activation [21].
One of the best studied NF-kappaB signalling pathways is the TNF pathway. TNF stimulation results in the recruitment of TNF receptor-1-associated death domain (TRADD) protein and of receptor interacting protein 1 (RIP1), which function as adaptor proteins for the E3 ubiquitin ligases TNF receptor-associated factor (TRAF) 2 and TRAF5, which in turn bind the E3 ubiquitin ligases cellular inhibitor of apoptosis (cIAP) 1 and cIAP2 (Figure 1). On TNF stimulation, TNF-receptor bound RIP1 is rapidly modified by K63-linked polyubiquitin chains. TRAF2/5 and cIAP1/2 are good candidates for RIP1 ubiquitination, but the specific role of each is still unclear. The polyubiquitin chains on RIP1 are believed to create a scaffold to recruit the IKK and TAK1 complex via the ubiquitin-binding proteins NEMO and TAB1/2, respectively. The recent identification of a distinct E2/E3 enzyme complex that modifies NEMO with linear polyubiquitin chains and is essential for TNF-activated NF-kappaB signalling adds further complexity [22]. The exact role of protein-anchored polyubiquitin chains remains unclear, as it was recently suggested that unanchored polyubiquitin chains can directly activate the TAK1 complex [23].
Similar signalling principles apply to other receptors. For example, TLR4 stimulation by lipopolysaccharide induces the recruitment of Toll/IL-1 receptor adaptor protein (also referred to as Mal) and TRIF-related adaptor molecule (TRAM), which most probably serve as bridging factors to recruit myeloid differentiation primary response gene 88 (MyD88) and TIR domain-containing adaptor-inducing IFNbeta (TRIF), respectively. MyD88 in turn recruits members of the IL-1R-associated kinase (IRAK) family and TRAF6, leading to oligomerisation and selfubiquitination of TRAF6 [24]. TRIF also recruits TRAF6 [25] and RIP1 [26] via a direct interaction. Both pathways then activate TAK1 and IKK in a ubiquitination-dependent manner similar to the TNF pathway (Figure 1).
The noncanonical NF-kappaB pathway can be activated by the lymphotoxin beta receptor, BAFF receptor, CD40, and RANK (Figure 2). In this pathway, p100 is processed by the proteasome to p52, which together with the RelB NF-kappaB subunit regulates a distinct set of target genes that control B-cell development, secondary lymphoid organ development, and osteoclastogenesis [27] The noncanonical NF-kappaB pathway is strictly dependent on IKK1, which is activated upon phosphorylation by NF-kappaB inducing kinase (NIK). NIK is predominantly regulated at the post-translational level and is present at extremely low levels in most cell types. In unstimulated cells, NIK occurs in a cytoplasmic complex with TRAF2, TRAF3, and cIAP1/2, which K48-polyubiquitinates NIK, leading to its continuous degradation by the proteasome. Receptor ligation has been shown not only to remove TRAF3 from this complex by recruiting it to the receptor, but also to attract TRAF2 and cIAP1/2, which are essential for subsequent TRAF3 degradation. All this contributes to releasing NIK from its constitutive degradation, resulting in NIK accumulation and IKK1 phosphorylation [28,29] (Figure 2).
It should be mentioned that CD40, lymphotoxin beta receptor and RANK mediate the activation of both canonical and noncanonical NF-kappaB signalling pathways. Upon binding of their ligand, CD40 and RANK interact with several TRAF members, including TRAF1, TRAF2, TRAF3, TRAF5, and TRAF6, and this leads to the proteolysis of both TRAF2 and TRAF3, which represents an important step in the activation of the noncanonical pathway as described above. Specific TRAF molecules are associated with overlapping and distinct CD40-mediated functions. For example, in B cells TRAF6 is required for CD40-mediated JNK activation and IL-6 production, while TRAF2 is required for activation of NF-kappaB, and TRAF3 serves as a negative regulator of CD40 signalling [30,31].","[{'offsets': [[255, 267]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[269, 280]], 'text': ['IkappaBbeta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[282, 296]], 'text': ['IkappaBepsilon'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[298, 302]], 'text': ['p105'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[318, 328]], 'text': ['NF-kappaB1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[331, 335]], 'text': ['p100'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[351, 361]], 'text': ['NF-kappaB2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[398, 407]], 'text': ['IkappaBxi'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[412, 417]], 'text': ['Bcl-3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[479, 483]], 'text': ['p100'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[488, 492]], 'text': ['p105'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[515, 518]], 'text': ['p52'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[523, 526]], 'text': ['p50'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[866, 869]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[888, 893]], 'text': ['RANKL'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1345, 1349]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1354, 1358]], 'text': ['IKK2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1374, 1382]], 'text': ['IKKalpha'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1387, 1394]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1423, 1452]], 'text': ['NF-kappaB essential modulator'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1454, 1458]], 'text': ['NEMO'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1475, 1483]], 'text': ['IKKgamma'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1536, 1540]], 'text': ['IKK2'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1545, 1549]], 'text': ['NEMO'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1559, 1563]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1680, 1683]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1693, 1696]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1739, 1777]], 'text': ['TNF receptor-1-associated death domain'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1779, 1784]], 'text': ['TRADD'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1801, 1831]], 'text': ['receptor interacting protein 1'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1833, 1837]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1904, 1943]], 'text': ['TNF receptor-associated factor (TRAF) 2'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1948, 1953]], 'text': ['TRAF5'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1999, 2039]], 'text': ['cellular inhibitor of apoptosis (cIAP) 1'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2044, 2049]], 'text': ['cIAP2'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2065, 2068]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2101, 2105]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2162, 2167]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2168, 2169]], 'text': ['5'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2174, 2179]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2180, 2181]], 'text': ['2'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2206, 2210]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2303, 2307]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2365, 2369]], 'text': ['TAK1'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2413, 2417]], 'text': ['NEMO'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2422, 2426]], 'text': ['TAB1'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2427, 2428]], 'text': ['2'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2519, 2523]], 'text': ['NEMO'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2578, 2581]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2808, 2812]], 'text': ['TAK1'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2896, 2900]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[2962, 2996]], 'text': ['Toll/IL-1 receptor adaptor protein'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[3018, 3020]], 'text': ['Ma'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[3027, 3056]], 'text': ['TRIF-related adaptor molecule'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[3058, 3062]], 'text': ['TRAM'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[3122, 3170]], 'text': ['myeloid differentiation primary response gene 88'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[3172, 3177]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[3183, 3229]], 'text': ['TIR domain-containing adaptor-inducing IFNbeta'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[3231, 3235]], 'text': ['TRIF'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[3252, 3257]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[3332, 3337]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[3392, 3397]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[3404, 3408]], 'text': ['TRIF'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[3423, 3428]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[3438, 3442]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[3502, 3506]], 'text': ['TAK1'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[3567, 3570]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T83'}, {'offsets': [[3650, 3675]], 'text': ['lymphotoxin beta receptor'], 'type': 'Protein', 'id': 'T84'}, {'offsets': [[3677, 3690]], 'text': ['BAFF receptor'], 'type': 'Protein', 'id': 'T85'}, {'offsets': [[3692, 3696]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T86'}, {'offsets': [[3702, 3706]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T87'}, {'offsets': [[3736, 3740]], 'text': ['p100'], 'type': 'Protein', 'id': 'T88'}, {'offsets': [[3775, 3778]], 'text': ['p52'], 'type': 'Protein', 'id': 'T89'}, {'offsets': [[3804, 3808]], 'text': ['RelB'], 'type': 'Protein', 'id': 'T90'}, {'offsets': [[4027, 4031]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T91'}, {'offsets': [[4076, 4101]], 'text': ['NF-kappaB inducing kinase'], 'type': 'Protein', 'id': 'T92'}, {'offsets': [[4103, 4106]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T93'}, {'offsets': [[4109, 4112]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T94'}, {'offsets': [[4254, 4257]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T95'}, {'offsets': [[4295, 4300]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T96'}, {'offsets': [[4302, 4307]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T97'}, {'offsets': [[4313, 4318]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T98'}, {'offsets': [[4319, 4320]], 'text': ['2'], 'type': 'Protein', 'id': 'T99'}, {'offsets': [[4350, 4353]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T100'}, {'offsets': [[4464, 4469]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T101'}, {'offsets': [[4542, 4547]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T102'}, {'offsets': [[4552, 4557]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T103'}, {'offsets': [[4558, 4559]], 'text': ['2'], 'type': 'Protein', 'id': 'T104'}, {'offsets': [[4596, 4601]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T105'}, {'offsets': [[4649, 4652]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T106'}, {'offsets': [[4701, 4704]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T107'}, {'offsets': [[4722, 4726]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T108'}, {'offsets': [[4791, 4795]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T109'}, {'offsets': [[4797, 4822]], 'text': ['lymphotoxin beta receptor'], 'type': 'Protein', 'id': 'T110'}, {'offsets': [[4827, 4831]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T111'}, {'offsets': [[4951, 4955]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T112'}, {'offsets': [[4960, 4964]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T113'}, {'offsets': [[5011, 5016]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T114'}, {'offsets': [[5018, 5023]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T115'}, {'offsets': [[5025, 5030]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T116'}, {'offsets': [[5032, 5037]], 'text': ['TRAF5'], 'type': 'Protein', 'id': 'T117'}, {'offsets': [[5043, 5048]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T118'}, {'offsets': [[5092, 5097]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T119'}, {'offsets': [[5102, 5107]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T120'}, {'offsets': [[5279, 5283]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T121'}, {'offsets': [[5328, 5333]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T122'}, {'offsets': [[5350, 5354]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T123'}, {'offsets': [[5383, 5387]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T124'}, {'offsets': [[5406, 5411]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T125'}, {'offsets': [[5457, 5462]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T126'}, {'offsets': [[5497, 5501]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T127'}]",[],[],[],[],[]
28,PMC-1472690-04-Results,"Role of NFkappaB, NFIL-6 and NFAT binding in LPS-, TSST-1-, GP-, GP + LPS- and GP + TSST-1-induced IL-1RA expression by human PBMC
Because GP induced band shifts to NFkappaB, NFIL-6 and NFAT sites, but no TNFalpha, IL-6 or IFNgamma, we hypothesized that the activated transcription factors might bind to sites in the IL-1RA promoter. We investigated previoulsy described and newly discovered transcription factor binding sites of the IL-1RA promoter (Table 1) using the program OMIGA (v.1.1.3, Oxford Molecular, Oxford, UK). The LPS responsive kappaB consensus site of LRE-1 (between -84 and -93) [30] displayed band shifts, but no significant alterations of its binding activity, irrespective of the treatment (data not shown). A new kappaB3 site (-100 and -130) within the LRE-1 [30] showed increased binding induced by TSST-1 (+30% vs. control), but GP co-treatment up-regulated the LPS (+65% vs. control)- and the TSST-1 (+110% vs. control)-induced binding in a superadditive synergistic fashion, when compared to medium control as well as to LPS, TSST-1 or GP or the theoretical values of GP/LPS calc. or GP/TSST-1 calc. (all p < 0.05; Fig. 4). Binding to a new kappaB consensus site (between -266 and -280) was significantly elevated for GP + TSST-1 (p < 0.05; data not shown). The LPS-, TSST-1- and GP + LPS-induced binding to the new kappaB2/3 site (-288 and -302) was down-regulated by about 20-35% in comparison with medium control (p < 0.05; data not shown). The NFIL-6 site (-147 and -170) close to LRE-2 [31,32] showed an up-regulation of binding for all compounds and combinations vs. medium control, ranging from 25-110% (p < 0.05). Further, GP + TSST-1 induced an increased binding to the NFIL-6 site in comparison with TSST-1 (1.3fold) or GP (1.6fold; p < 0.05), (data not shown). A new binding site for NFATP2/3 was found more distal of the transcription start site, between -471 and -490, displaying again a substantial increase of binding for all compounds and combinations, when compared to medium control (p < 0.05). In addition, binding to the NFATP2/3 site following both, GP + LPS (1.4fold of GP) and GP + TSST-1 (1.5fold of GP, 1.25fold of TSST-1) was elevated (p < 0.05; Fig. 5), but only in an additive synergistic manner, i.e. the experimental results were not different from the theoretical values (calc.).","[{'offsets': [[18, 24]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[29, 33]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[51, 57]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[84, 90]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[99, 105]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[205, 213]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[215, 219]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[223, 231]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[317, 323]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[434, 440]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[822, 828]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[918, 924]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1052, 1058]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1113, 1119]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1249, 1255]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1294, 1300]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1662, 1668]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1736, 1742]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2131, 2137]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2166, 2172]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T20'}]",[],[],[],[],[]
29,PMC-3218875-09-Negative_regulation_of_NF-+%A6B_signalling_in_RA,"TNF receptor-associated factor 1
TRAF1 is a unique member of the TRAF protein family because it lacks a RING finger domain and therefore lacks ubiquitin ligase activity. Accumulating data support a role for TRAF1 as both a negative and a positive modulator of NF-kappaB signalling by certain TNF family receptors, possibly in a cell-type-dependent manner [71,72]. Expression of TRAF1 is inducible by TNF and overexpression of TRAF1 inhibits TNF-induced NF-kappaB activation. TRAF1-deficient T cells are hyper-responsive to TNF, with enhanced proliferation and activation of the NF-kappaB signalling pathway. TRAF1 also functions as a negative regulator of CD40-induced NF-kappaB activation. TRAF1-deficient dendritic cells, however, show attenuated responses to secondary stimulation by TRAF2-dependent factors, suggesting a positive regulatory role in these cells. The mechanism by which TRAF1 modulates NF- kappaB activation is still unclear. Most probably, TRAF1 competes with TRAF family members for binding to the receptor or other signalling proteins. Alternatively, TRAF1 might recruit A20 with which it can physically interact [73]. A genome-wide association study examining more than 300,000 SNPs among approximately 1,500 autoantibody-positive RA cases and 1,800 controls identified a genetic variation at the TRAF1-complement component 5 locus as an important RA risk locus [74]. Subsequent work indicates that TRAF1 is more likely to be the causative locus [75]. Recent work in a Korean population also demonstrates genetic association of the TRAF1 region with RA [76].","[{'offsets': [[0, 32]], 'text': ['TNF receptor-associated factor 1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[33, 38]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[143, 152]], 'text': ['ubiquitin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[207, 212]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[378, 383]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[400, 403]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[426, 431]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[441, 444]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[475, 480]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[523, 526]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[608, 613]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[656, 660]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[691, 696]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[787, 792]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[889, 894]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[960, 965]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1073, 1078]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1093, 1096]], 'text': ['A20'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1320, 1325]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1422, 1427]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1555, 1560]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T21'}]",[],[],[],[],[]
30,PMC-3585731-01-Introduction,"Necroptosis is a form of regulated cell death that displays all the major hallmarks of necrosis [1]. A growing number of studies have implicated necroptosis in a wide range of animal models of human disease, including brain, heart and retinal ischemia-reperfusion injury, acute pancreatitis, brain trauma, retinal detachment, and Huntington's disease [2], [3]. Importantly, several recent studies have linked necroptosis to models of inflammation including intestinal inflammation and systemic inflammatory response syndrome (SIRS) [4], [5], [6]. The discovery of a regulated form of necrotic death could uncover molecular targets amenable to pharmacological intervention for the treatment of various conditions.
A complex consisting of two related Ser/Thr kinases, RIP1 and RIP3, plays a critical role in the initiation of necroptosis in multiple systems [7], [8], [9]. A recent genome wide siRNA screen for mediators of necroptosis induced by the pan-caspase inhibitor zVAD.fmk in mouse fibrosarcoma L929 cells, revealed a broad and diverse cellular network of 432 genes that may regulate this process [10]. These data provided important confirmation of the highly regulated nature of necroptosis and revealed the first insight into the full repertoire of mediators of this form of cell death. However, the specific signaling pathways activated during necroptosis and their connections to RIP1 and RIP3 remain poorly understood. Several recent studies [10], [11], [12], [13], [14] have suggested that JNK kinase activation plays an important role during necroptosis in L929 cells downstream from RIP1 kinase. For example, the transcription factor c-Jun, a key cellular target of JNK activity, was one of the hits in the genome wide siRNA screen [10]. Activation of JNK in L929 cells has been linked to autocrine TNFalpha synthesis, activation of oxidative stress and induction of autophagy, all of which contribute to necroptosis. Importantly, RIP1 kinase dependent activation of JNK and TNFalpha production has recently been described to be independent of its role in necroptosis [15]. Curiously, Akt kinase, a key pro-survival molecule and a well-established inhibitor of apoptotic cell death, has also recently been linked to necroptosis in L929 cells [16], where insulin-dependent activation of Akt was suggested to promote necroptosis by suppressing autophagy. This conclusion was unexpected, since several reports from different groups, including ours, have established that autophagy promotes, rather than suppresses, zVAD.fmk-induced necroptosis in L929 cells [11], [14], [17]. This raised the possibility that Akt controls more general mechanisms that contribute to the execution of necroptosis. Furthermore, the key question of whether insulin-dependent Akt activity solely provides an environment conducive for necroptosis or if Akt activation is an intrinsic component of necroptosis signaling that is linked to RIP1 kinase has not been explored.
In this study, we expanded these observations to delineate the specific contributions and molecular ordering of the Akt and JNK pathways downstream from RIP1 kinase during necroptosis. Our data reveal that Akt is activated through RIP1 kinase-dependent Thr308 phosphorylation during necroptosis in multiple cell types. Furthermore, we found that downstream Akt signaling through mTORC1 and S6 contributes to the activation of necroptosis and TNFalpha production. We found that the Akt pathway serves as a critical link between RIP1 kinase and JNK activation in L929 cells. Further data suggested that in multiple other cell types including FADD deficient Jurkat cells, RAW and J774.1 macrophage cell lines, and mouse lung fibroblasts Akt provides a key link to TNFalpha production, but is dispensible for cell death per se. Overall, our results reveal a specific and novel role for the Akt pathway in regulated necrosis and necrosis-associated inflammatory signaling.","[{'offsets': [[766, 770]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[775, 779]], 'text': ['RIP3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1391, 1395]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1400, 1404]], 'text': ['RIP3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1598, 1602]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1649, 1654]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1814, 1822]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1946, 1950]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1990, 1998]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[2269, 2276]], 'text': ['insulin'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[2748, 2755]], 'text': ['insulin'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[2926, 2930]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[3114, 3118]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[3192, 3196]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[3351, 3353]], 'text': ['S6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[3403, 3411]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[3488, 3492]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[3601, 3605]], 'text': ['FADD'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[3722, 3730]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T19'}]",[],[],[],[],[]
31,PMC-3586680-10-Caption-Figure_2,"p53 and WWOX in GBM cell apoptosis. (A) Full-length p53 possesses two N-terminal transactivation acidic domains, a proline-rich domain, a central DNA-binding region, and a C-terminal domain, containing a nuclear localization signal, an oligomerization domain, and a basic region. N-terminal deletion mutants of p53 are also shown. (B) Three likely scenarios are proposed for WWOX and p53 to regulate GBM cell death. First, ectopic WWOX fails to induce apoptosis of GBM cells expressing endogenous wild type p53. It appears that ectopic WWOX binds and functionally antagonizes p53, and both proteins nullify each other's function in inducing apoptosis. Second, no physical interactions between mutant p53 proteins and WWOX are expected in GBM cells. Thus, ectopic WWOX induce apoptosis in mutant p53-expressing cells. Finally, whether WWOX binds p53 isoforms is unknown. Also, whether ectopic WWOX induction of apoptosis in GBM cells expressing p53 isoforms remains to be established. TAD, transactivation domain; PrD, proline domain; NLS, nuclear localization signal; OD, oligomerization domain; BR, basic region.","[{'offsets': [[0, 3]], 'text': ['p53'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[8, 12]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[52, 55]], 'text': ['p53'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[311, 314]], 'text': ['p53'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[375, 379]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[384, 387]], 'text': ['p53'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[431, 435]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[507, 510]], 'text': ['p53'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[536, 540]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[576, 579]], 'text': ['p53'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[700, 703]], 'text': ['p53'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[717, 721]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[763, 767]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[795, 798]], 'text': ['p53'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[834, 838]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[845, 848]], 'text': ['p53'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[892, 896]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[944, 947]], 'text': ['p53'], 'type': 'Protein', 'id': 'T18'}]",[],[],[],[],[]
32,PMC-3312845-16-Results,"Neutrophil infiltration
Recent studies have reported that neutrophils infiltrate the brain under certain pathological conditions [26]. Indeed, we have reported massive neutrophil infiltration in layer III/IV of the PC 1 day after SE [20]. In the present study, 1 day-post-SE animals of the saline-infused group showed infiltration of MPO-positive neutrophils into the PC. Similarly, 1 day-post-SE animals of the sTNFp55R-infused group showed neutrophil infiltration into the PC 1 day after SE (Figure 6A). The number of neutrophils/area in the PC region (including the vasogenic edema region and the non-vasogenic edema region) of sTNFp55R-infused animals was significantly lower than that of the saline-infused group (Figure 6D, p < 0.05). However, there was no difference in neutrophil infiltration per unit area of vasogenic edema between the saline- and sTNFp55R-infused groups (Figure 6D). Furthermore, neutrophil infiltration showed a direct proportion to the area of vasogenic edema, with a linear coefficient of correlation of 0.8631 (p < 0.05, Figure 6E). Therefore, our findings indicate that SE-induced neutrophil infiltration into the PC may be correlated to TNF-alpha-mediated vasogenic edema formation.","[{'offsets': [[413, 420]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[632, 639]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[859, 866]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1171, 1180]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
33,PMC-3589482-03-Experimental_Procedures,"Real-time Quantitative PCR (qPCR)
The RNeasy Mini Kit (Qiagen) was used to isolate total RNA from cells. For cDNA synthesis, 1 microg of total RNA was reverse transcribed using TaqMan(R) Reverse Transcription Reagents (Applied Biosystems). qPCR was performed using TaqMan(R) Gene Expression 20X primers for Serpinb2/SerpinB2 (Mm00440905_m1), Cebpb (Mm00843434_s1) and beta-actin (Mm00607939_s1) (Applied Biosystems).","[{'offsets': [[307, 315]], 'text': ['Serpinb2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[316, 324]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[342, 347]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[368, 378]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
34,PMC-1359074-04-Results,"EMSA and ChIP Assays Show that Sox6 Directly Binds to the epsilony Promoter
Sox6 might repress the epsilony promoter, either through direct physical contact with the promoter or by regulating intermediates affecting the epsilony promoter. To investigate whether Sox6 is directly associated with the epsilony promoter, we first performed electrophoretic mobility shift assays (EMSA) using a c-Myc-tagged Sox6 in a reticulocyte lysate-based transcription/translation in vitro system. The probes used are listed in Figure 3A. The 36-base pair (bp) WT probe corresponds to the critical region of the epsilony promoter defined in our promoter deletion analyses. This probe contains two consensus Sox/Sox6 binding sites. Also included in our EMSA are three mutated probes that are, either truncated (M1), or mutated (M2 and M3) in Sox/Sox6 binding sites (Figure 3A). Sox6 is able to physically associate with the 36-bp region (Figure 3B) within the epsilony promoter defined by the deletion analysis experiments (Figure 2C). The 36-bp probe was shifted by the tagged Sox6 protein. Moreover, both c-Myc and Sox6 antibodies supershift the band, indicating that the binding is Sox6-specific. To rule out the possibility that the c-Myc tag itself binds to the probe, an HA-tagged Sox6 was used in another EMSA that confirmed these results (Figure 3C).
Next, nuclear extracts from MEL cells were used in EMSA employing the same 36-bp probe. MEL cells, a murine erythroleukemic cell line, express adult beta globins, but not epsilony [33]. Sox6 directly binds to this DNA sequence in MEL cells (Figure 3D). The intact consensus Sox/Sox6 binding sites of the DNA probe are required for the binding, as shown in the competition assay (Figure 3E). Ablation of putative Sox/Sox6 binding sites (M1 and M3) abolish their ability to compete in EMSA (Figure 3E). The M2 mutant probe may compete partially with WT binding.
To investigate the functional significance of the intact Sox/Sox6 binding sites, the epsilony promoter reporter constructs with mutagenized Sox/Sox6 binding sites were co-transfected with the Sox6 overexpression vector into GM979 cells. Consistent with the EMSA results, the mutant epsilony promoter reporter constructs (with either one or both Sox/Sox6 binding sites mutagenized) do not result in significant promoter repression in transfection studies (Figure 3F). Thus, both sites are required for maximal repression of epsilony by Sox6, but not to the same degree.
We also tested whether Sox6 binds to the epsilony promoter in vivo using chromatin immunoprecipitation (ChIP) (Figure 4). The Sox6-containing complex was immunoprecipitated from MEL cells or from liver cells of 15.5 dpc WT mice using Sox6 antibody. Figure 4 shows that the epsilony proximal promoter is readily immunoprecipitated with Sox6 antibody in both MEL cells and liver cells. Normal IgG was used as a negative control (Figure 4A). The above data (Figures 3 and 4) clearly indicate that Sox6 acts as a repressor of the epsilony gene by directly binding to the epsilony promoter, probably as a dimer.","[{'offsets': [[31, 35]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[58, 66]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[76, 80]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[99, 107]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[220, 228]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[262, 266]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[299, 307]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[390, 395]], 'text': ['c-Myc'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[403, 407]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[596, 604]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[861, 865]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[943, 951]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1061, 1065]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1090, 1095]], 'text': ['c-Myc'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1100, 1104]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1168, 1172]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1220, 1225]], 'text': ['c-Myc'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1260, 1262]], 'text': ['HA'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1270, 1274]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1491, 1503]], 'text': ['beta globins'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1513, 1521]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1528, 1532]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1987, 1995]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2094, 2098]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2184, 2192]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2425, 2433]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2437, 2441]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2494, 2498]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2512, 2520]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2597, 2601]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2705, 2709]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2744, 2752]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2806, 2810]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2965, 2969]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2997, 3005]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3038, 3046]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T36'}]",[],[],[],[],[]
35,PMC-3317373-02-2._Methods_and_Materials,"2.1. Primary Culture and Identification of Mouse Astrocytes
Nrf2 knockout ICR mice were kindly provided by Dr. Thomas W. Kensler (Johns Hopkins University, Baltimore, MD, USA). Primary astrocytes were obtained from postnatal 2-day-old Nrf2 wide type (WT) and knockout (KO) mice (6 mice for each genotype). Following decapitation, the cortices were dissected out, and the meninges and associated blood vessels were removed. The tissue was roughly chopped with a scalpel blade, incubated in 0.5% trypsin for 10 minutes at 37degreesC, and agitated every few minutes. After digestion, the tissue was rinsed twice in DMEM with 10% FBS, followed by a mechanical dissociation in DMEM with 20% FBS and 5 units/mL penicillin, 5 mug/mL streptomycin (complete culture medium). After incubation for 1 h, the supernatant was transferred to a new flask or dish (Costar, USA) for depleting the residual epithelial cells. Then the cells were cultivated at 37degreesC with 5% CO2. And the complete culture medium was half-changed twice a week. Astrocytes expanded for about 7 days to reach confluence. Then the flasks or dishes were shaken at 150 rpm for 4 h to deplete the microglia and less adherent cells from the cultures. After shaking, the resulting cultures were mainly astrocytes, which were determined by immunoreactivity for GFAP (sc-166481, Santa Cruz Biotechnology, CA, USA). Cells passaged for 2-3 generations were used in the following studies.",[],[],[],[],[],[]
36,PMC-3291650-19-Caption-Figure_3,"A20 deficiency in myeloid cells protects against IAV lung infection.
A20myel-WT and A20myel-KO mice were infected intranasally with a sublethal dose of IAV and weight loss was monitored (A). At day 4, 7 and 10 post infection (p.i.) viral titers in the lung were measured and expressed as mean TCID50 (B). The dashed line represents the detection limit. ND, not detectable. BAL was isolated from IAV infected mice at 4, 7 and 10 days p.i. and KC, MIP-2, MCP-1, IL-6 and IFNalpha protein levels were analyzed by ELISA and multiplexing technologies (C). Absolute numbers of resident alveolar macrophages, neutrophils and monocytes in BAL were analyzed by flow cytometry at 4, 7 and 10 days p.i. (D). Numbers are averages +/- SEM of at least 5 mice per group and are representative of 2 independent experiments. *p<0.05; **p<0.01.","[{'offsets': [[442, 444]], 'text': ['KC'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[446, 451]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[453, 458]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[460, 464]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
37,PMC-1472690-18-Caption-Figure_1,"A, GP led to DNA binding of NFAT, NFkappaB and NFIL-6. Human PBMC were incubated with medium control or GP (1 and 100 mug) for 1 h at 37degreesC. Nuclear extracts were incubated with a 32P-labeled NFAT, NFkappaB, NFIL-6 or NFkappaB-IL-8 oligonucleotide probe corresponding to the IFNgamma, TNFalpha, IL-6 and IL-8 gene promoters (Table 1). Arrows with the black head indicate migrational location of the NFAT-DNA, NFkappaB-DNA, NFIL-6-DNA or NFkappaB-IL-8-DNA complex compared to free probe (no shift). Arrow with the open head indicates a supershift of NFkappaB-IL-8-DNA-anti-p65 and -p50, respectively. An autoradiogram from a representative experiment is shown (n = 7). B, Decreased DNA binding of NFkappaB following GP + TSST-1, compared to TSST-1, GP, or TSST-1/GP. Human PBMC were incubated with medium control, LPS, TSST-1, GP (100 mug), GP + TSST-1 and GP + LPS for 1 h at 37degreesC. An autoradiogram from a representative experiment is shown. Schematic representation of NFkappaB-DNA binding activity following GP (1 and 100 mug) or TSST-1 treatment (250 ng) as well as simultaneous administration of both compounds and the theoretical value (GP/TSST-1 calc.). Medium control levels were set equal to 1+/- SEM and significances (* = p < 0.05) are shown with respect to medium control (n = 4).","[{'offsets': [[28, 32]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[47, 53]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[197, 201]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[213, 219]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[232, 236]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[280, 288]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[290, 298]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[300, 304]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[309, 313]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[404, 408]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[428, 434]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[451, 455]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[563, 567]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[577, 580]], 'text': ['p65'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[586, 589]], 'text': ['p50'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[725, 731]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[745, 751]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[760, 766]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[823, 829]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[850, 856]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1043, 1049]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T21'}]",[],[],[],[],[]
38,PMC-2817507-12-3._Results,"3.4. Activation of TLR4-Mediated NF-Kappa-B Signaling
Activation of TLR4 induces the phosphorylation of inhibitor of kappa-B (IkappaB), which dissociates IkappaB with NF-kappa-B (NFkappaB). Then, NFkappaB translocates into the nucleus and activates and regulates the transcription of genes related to inflammatory responses. To detectd the activation of TLR4-mediated NFkappaB signaling, the phosphorylation of inhibitor of kappa-B (p-IkappaB) and activity of NFkappaB were measured by methods of Western Blots and EMSA. Results showed that the p-IkappaB increased at 6 hours after ICH (P < .05), peaked on 3 days after ICH, and maintained a high level on 7 days after ICH (P < .05, Figure 5). As expected, the activity of NFkappaB was also increased in the same manner as that of the p-IkappaB (Figure 4).","[{'offsets': [[19, 23]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[68, 72]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[354, 358]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
39,PMC-1064895-19-Discussion,"IL-17 was first described as a T cell product with proinflammatory properties [5,22]. RA is characterized by hyperplasia of synovial lining cells and an intense infiltration by mononuclear cells [23]. Proinflammatory cytokines such as IL-1 and TNF-alpha are abundant in rheumatoid synovium, whereas the T cell-derived cytokines, especially IL-4 and interferon-gamma, have often proved difficult to detect in RA synovium [24]. Although T cells may have a role in the augmentation of rheumatoid synovial inflammation, the lack of T cell-derived cytokines has limited its importance. In this respect, IL-17 is appealing because it has been described as a T cell-derived cytokine with proinflammatory properties.
In our studies, we tried to evaluate how IL-17 production is regulated in RA PBMC, and which signaling pathway it used. Levels of IL-17 were found to be higher in RA synovial fluid than in OA synovial fluid [15]. However, there are few data available on the agents that stimulate IL-17 production in RA, although the highest level of IL-17 production can be achieved by anti-CD3/anti-CD28 stimulation in healthy individuals [25]. In our experiments, PHA as mitogens, as well as anti-CD3/anti-CD28 for signaling through the T cell receptor, increased IL-17 production from RA PBMC in a dose-dependent manner. We found, by a cell proliferation assay (data not shown), that this upregulation of IL-17 might be due to increased cellular activity rather than to cellular proliferation.
IL-17 is produced mainly by activated CD4+ T cells, especially for Th1/Th0 cells, not the Th2 phenotype [26]. However, it can also be produced by CD8+ T cells via an IL-23 triggering mechanism in Gram-negative pulmonary infection [14]. In addition, IL-17 production was significantly augmented by T cells recognizing type II collagen in a collagen-induced arthritis model [27]. A complex interaction between cells in inflamed RA joints might produce a variety of proinflammatory cytokines and chemokines, which also activate other cells in the joints. For example, IL-17 stimulates rheumatoid synoviocytes to secrete several cytokines such as IL-6, IL-8 and tumor necrosis factor-stimulated gene 6 as well as prostaglandin E2 in vitro [12,28,29]. There are as yet few data available on the agents that stimulate IL-17 production in RA, although some cytokines (IL-15 and IL-23) have been known to regulate IL-17 production [13,14]. We therefore investigated the in vitro production of IL-17 in RA PBMC responding to a variety of cytokines/chemokines and mitogens as well as T cell receptor (TCR) ligation using anti-CD3/anti-CD28. Our studies demonstrated that IL-15 and MCP-1 as well as TCR ligation significantly increased the production of IL-17 in RA PBMC. Adding IL-15 or MCP-1 to TCR ligation augmented IL-17 production more markedly. In contrast, IL-1 and TNF-alpha, which are known to have proinflammatory properties and to be increased in RA joints, did not affect IL-17 production. Our data were consistent with a recent report that IL-15 triggered in vitro IL-17 production in PBMC, but TNF-alpha did not do so [13]. Although there were no data that MCP-1 directly induces T cell activation, it might exert effects indirectly on T cells through the activation of monocytes/macrophages in PBMC cultures. As reported for normal individuals [25], T cell activation through anti-CD3/anti-CD28 also increases IL-17 induction in RA PBMC.
Although the signaling pathway for the induction of cytokines/chemokines by IL-17 has been documented widely [8,30,31], no data have been available on how IL-17 production can be regulated by certain signaling pathways. By using signal transduction inhibitors, we therefore examined which signaling pathway was mainly involved in the induction of IL-17 in RA PBMC.
We identified that anti-CD3-induced IL-17 production in RA PBMC was significantly hampered by the PI3K inhibitor LY294002 and the NF-kappaB inhibitor PDTC to comparable levels of basal production without stimulation. We also found that anti-CD3-induced IL-17 production was downregulated by the addition of SB203580, a p38 MAPK inhibitor. It is interesting that a series of evidence supports crosstalk between NF-kappaB and p38. In myocytes, IkappaB kinase-beta is activated by p38 [32], and the activated p38 can stimulate NF-kappaB by a mechanism involving histone acetylase p300/CREB-binding protein [33]. Our results revealed that p38 MAPK activation was not affected by LY294002, whereas NF-kappaB binding activity was decreased by LY294002, which provided the evidence for a p38 MAPK pathway independent of PI3K activation. The direct relationship between p38 and NF-kappaB for IL-17 production needs to be studied in future experiments.
The search for a downstream pathway of PI3K seemed to have a maximal response of Akt activation at 1 hour and a gradual loss of activity at 2 hours. The fact that Akt is phosphorylated upon anti-CD3 stimulation suggests the possible involvement of PI3K in the induction of IL-17 in RA. In view of the fact that NF-kappaB was also activated by anti-CD3/anti-CD28, IL-15 or mitogens in our experiments, it is most likely that the NF-kappaB pathway is also actively involved in the induction of IL-17 in RA PBMC. In contrast, the AP-1 signal transduction pathway, another important signaling pathway for cytokines/chemokines, was not activated in our experiments (data not shown). Although PI3K and its downstream kinase Akt in association with NF-kappaB have been reported to deliver activating signals in many cell types, the data on the signal inducing IL-17 are lacking. Our data clearly demonstrated that PI3K/Akt and resultant NF-kappaB activation could be an important arbitrator of the upregulation of IL-17 in RA, on the basis of our experiments showing simultaneous blocking of NF-kappaB binding activity in the IL-17 promoter by PDTC and LY294002. Considering its proinflammatory activities and successful induction of anti-IL-17 for ameliorating arthritis in animal models [2,6,34-36], understanding the IL-17 signaling pathway is an important element of developing new targeted therapies in RA.","[{'offsets': [[0, 5]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[235, 239]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[244, 253]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[340, 344]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[349, 365]], 'text': ['interferon-gamma'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[598, 603]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[750, 755]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[839, 844]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[989, 994]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1043, 1048]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1093, 1097]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1159, 1162]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1201, 1205]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1259, 1264]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1401, 1406]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1490, 1495]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1528, 1531]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1636, 1639]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1656, 1661]], 'text': ['IL-23'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1739, 1744]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2055, 2060]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2133, 2137]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2139, 2143]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2148, 2187]], 'text': ['tumor necrosis factor-stimulated gene 6'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2302, 2307]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2351, 2356]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2361, 2366]], 'text': ['IL-23'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2396, 2401]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2475, 2480]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2615, 2619]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2651, 2656]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2661, 2666]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2733, 2738]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2758, 2763]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2767, 2772]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2799, 2804]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2844, 2848]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2853, 2862]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2964, 2969]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3033, 3038]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3058, 3063]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3088, 3097]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3151, 3156]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3385, 3389]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3405, 3410]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3509, 3514]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3588, 3593]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3780, 3785]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3822, 3825]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3834, 3839]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4051, 4056]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4240, 4259]], 'text': ['IkappaB kinase-beta'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4375, 4379]], 'text': ['p300'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4380, 4400]], 'text': ['CREB-binding protein'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4682, 4687]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4823, 4826]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[4905, 4908]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[5015, 5020]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[5099, 5103]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[5105, 5110]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[5234, 5239]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[5269, 5273]], 'text': ['AP-1'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[5460, 5463]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[5595, 5600]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[5654, 5657]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[5749, 5754]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[5861, 5866]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[5974, 5979]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[6055, 6060]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T69'}]",[],[],[],[],[]
40,PMC-3589482-15-Results,"Sequence Conservation within the Human and Murine SerpinB2 Proximal Promoters
To look for potential cis-acting elements that might mediate transcription of the murine SerpinB2 gene and the response to LPS, we aligned the murine and human SerpinB2 5' flanking regions. We reasoned that the presence of evolutionarily conserved, potential transcription factor binding sites in this region might play a role in the regulation of SerpinB2 gene expression [52]. The presence of several repetitive sequence elements delineated five broadly homologous regions (A-E) between the human and murine promoters (Fig. 2C). The proximal promoter (Region E), which contains the essential LPS response element, exhibited the greatest homology. Further analysis of Region E revealed that several of the cis-acting regulatory elements defined in the human SerpinB2 proximal promoter are conserved in the murine SerpinB2 promoter (Fig. 3). Specifically, a TATA consensus sequence is located 23 to 29bp upstream from the transcription initiation site, similar to the position of the TATA box of the human SERPINB2 gene [53]; [54]. A putative CCAAT enhancer binding protein (C/EBP) site is present at -192/-203, two potential activator protein 1 (AP-1) binding sites are found at nucleotides -88/-94 and -100/-106, and a putative cyclic AMP response element (CRE) is present at -172/-177. Both of the AP-1 sites are identical in sequence to those identified in the human SERPINB2 promoter, and the CRE differs in the identity of a single central nucleotide [37]; [55]. A consensus E box (-538/-533), as well as potential binding sites for PU.1 (-412/-407) and Oct-1 (-296/-288) were also identified within the proximal promoter region (Fig. S2). Further upstream, a retinoic acid response element at -1349/-1340, a PAUSE-1 silencer element at -1540/-1528 and a NF-kappaB p65 binding site at -1342/-1351 (Fig. S2) are also well conserved [16]; [30]; [56].","[{'offsets': [[50, 58]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[167, 175]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[238, 246]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[426, 434]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[837, 845]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[892, 900]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1084, 1092]], 'text': ['SERPINB2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1449, 1457]], 'text': ['SERPINB2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1617, 1621]], 'text': ['PU.1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1638, 1643]], 'text': ['Oct-1'], 'type': 'Protein', 'id': 'T10'}]",[],[],[],[],[]
41,PMC-3342329-03-Results,"Decrease of NF-kappaB Activity in Tumor Tissue of CCR5-/- Mice
The activation of NF-kappaB plays a critical role in cancer cell survival, especially melanoma cancer cells and in CCR5 expression. To evaluate whether the tumor inhibition was related with the inactivation of NF-kappaB in melanoma, the DNA binding activity of NF-kappaB was determined by electromobility shift assay (EMSA) in melanoma tissue. The constitutively activated DNA binding activity was reduced in the CCR5-/- mice tumor tissue (Figure 2A). Moreover, the translocation of p50 and p-p65 into the nucleus through the inhibition of phosphorylation of IkappaB was also prevented in the tumor tissues of CCR5-/- mice (Figure 2B). Immunofluorescence analysis also confirmed that the intensity of nuclear staining for p50 had decreased in the tumor tissues of CCR5-/- mice (Figure 2C).","[{'offsets': [[50, 54]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[178, 182]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[476, 480]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[546, 549]], 'text': ['p50'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[556, 559]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[673, 677]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[785, 788]], 'text': ['p50'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[827, 831]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
42,PMC-3589482-31-Caption-Figure_8,"C/EBP-beta is necessary for SerpinB2 proximal promoter activity.
(A) The SerpinB2 proximal promoter is significantly activated in LPS-stimulated Cebpb+/+ MEFs and not in Cebpb-/- MEFs. Murine SerpinB2 gene promoter activity measured in Cebpb+/+ and Cebpb-/- MEFs expressing the pGLmP-539 SerpinB2 promoter-luciferase reporter in the presence or absence of LPS (100 ng/mL). Cells were co-transfected with the pGLmP-539 SerpinB2 promoter-luciferase reporter and beta-galactosidase reporter plasmids, and luciferase units normalized to beta-galactosidase activity. (B) C/EBP-beta gene schematic depicting gene structure and phospho-acceptor sites. (C) Phosphorylation of C/EBP-beta at Serine 64 negatively regulates LPS-stimulated SerpinB2 promoter activity. Cebpb-/- MEFs were co-transfected with expression plasmids encoding wild-type C/EBP-beta or the indicated C/EBP-beta phospho-acceptor mutants, along with the pGLmP-539 SerpinB2 promoter-luciferase reporter and beta-galactosidase reporter plasmids, and stimulated with LPS for 4 hrs. Luciferase activity was quantified and normalized to beta-galactosidase activity. The western blot (below the graphs) confirms the expression of the respective C/EBP-beta phospho-acceptor mutants. The C/EBP-betaT217A -transfected MEFs express both the 38 kDa and 35 kDa isoforms of C/EBP-beta. The results represent the mean and SEM of at least three independent experiments performed in triplicate. (*, p<0.05, one-way ANOVA).","[{'offsets': [[0, 10]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[28, 36]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[73, 81]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[145, 150]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[170, 175]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[192, 200]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[236, 241]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[249, 254]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[288, 325]], 'text': ['SerpinB2 promoter-luciferase reporter'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[418, 455]], 'text': ['SerpinB2 promoter-luciferase reporter'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[460, 487]], 'text': ['beta-galactosidase reporter'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[502, 512]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[533, 551]], 'text': ['beta-galactosidase'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[566, 576]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[668, 678]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[728, 736]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[756, 761]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[834, 844]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[862, 897]], 'text': ['C/EBP-beta phospho-acceptor mutants'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[924, 961]], 'text': ['SerpinB2 promoter-luciferase reporter'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[966, 993]], 'text': ['beta-galactosidase reporter'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1039, 1049]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1092, 1110]], 'text': ['beta-galactosidase'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1199, 1234]], 'text': ['C/EBP-beta phospho-acceptor mutants'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1240, 1255]], 'text': ['C/EBP-betaT217A'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1321, 1331]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T26'}]",[],[],[],[],[]
43,PMC-3317373-11-3._Results,"3.1. Depletion of Nrf2 Aggravated the Cell Death in Astrocytes after Scratch Injury
Cell death was detected by microscope and CCK-8 analysis at 24 h after scratch. The detachment from culture plate, cell lost, and cytoplasmic process distortion were mostly observed in both sides of scratch line in group KO TBI. CCK-8 assay also showed lower OD value of group KO TBI (0.38 +/- 0.064) than that of group WT TBI (0.98 +/- 0.098) (P < 0.01), which also suggested more cell death in group KO TBI (Figure 1). There was no difference between two sham-operated groups.",[],[],[],[],[],[]
44,PMC-3312845-10-Methods,"Quantification of data
The fluorescence intensities of SMI-71/p65-Thr435 phosphorylation or GFPA/p65-Thr435 phosphorylation were measured using a computer-assisted image analysis program (The University of Texas ImageTool program V. 3.0 and AxioVision Rel. 4.8 software). After regions were outlined, 30 areas/rat (300 mum2/area) were randomly selected within the PC, and double immunofluorescent merge images were captured from the PC (15 sections from each animal). Merge images were digitally separated to red or green image, and converted to grayscale images, respectively (n = 36 per region examined, in non-SE, 12 hr post-SE and 1 day post-SE). The range of intensity values was obtained from the selected images. Based on the mean range of intensity values, each image was normalized by adjusting the black and white range of the image. Manipulation of the images was restricted to threshold and brightness adjustments to the whole image. Intensity measurements are represented as the mean number of a 256 gray scale (NIH Image 1.59 software and AxioVision Rel. 4.8 software). Values for background staining were obtained from the corpus callosum. Optical density values were then corrected by subtracting the average values of background noise obtained from 15 image inputs.","[{'offsets': [[62, 65]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[97, 100]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
45,PMC-3218875-05-Negative_regulation_of_NF-+%A6B_signalling_in_RA,"A20 protein
A20 (also known as TNFAIP3) is a ubiquitin-editing protein that negatively regulates NF-kappaB-dependent gene expression in response to different immune-activating stimuli, including TNF, IL-1 and antigens, and the triggering of TLRs and the nucleotide-binding oligomerisation domain-containing 2 receptor (reviewed in [37]). A20 is believed to inhibit NF-kappaB function by deubiquitinating specific NF-kappaB signalling molecules, such as RIP1, RIP2, TRAF6 and MALT1, which disrupts specific protein-protein interactions [38-41] (Figure 1). Recently, the disruption of interactions between E2 ubiquitin conjugating enzymes (Ubc13 and Ubc5hc) and E3 ubiquitin ligases (TRAF6, TRAF2 and cIAP1/2) were described as another important mechanism used by A20 to downregulate NF-kappaB signalling [42]. The association of A20 with its targets requires specific ubiquitin-binding adaptor proteins, including A20-binding inhibitor of NF-kappaB (ABIN) 1 and Tax1-binding protein 1 [43-46].
Next to its role in suppressing NF-kappaB activation, A20 is also a strong inhibitor of apoptosis, at least in some cell types. The mechanisms by which A20 regulates apoptotic signalling, however, are still elusive. A20-deficient mice spontaneously develop multiorgan inflammation and cachexia and die within 2 weeks of birth, illustrating the potent anti-inflammatory function of this molecule [46]. A20-deficient cells are also more susceptible to TNF-mediated apoptosis, confirming its role as an antiapoptotic protein. We recently showed that mice specifically lacking A20 in intestinal epithelial cells exhibit increased susceptibility to experimental colitis due to the hypersensitivity of their intestinal epithelial cells to TNF-induced apoptosis, confirming A20 as a major antiapoptotic protein in the intestinal epithelium [47]. Two independent studies showed that mice lacking A20 in B cells develop autoimmunity due to hyperactive NF-kappaB responses in B cells leading to unrestricted B-cell survival [48,49].
A20 expression has been observed in several cell types that play important roles in the pathophysiology of RA, such as fibroblasts, synoviocytes and lymphocytes. Interestingly, A20 expression is itself regulated by NF-kappaB [50], implicating A20 in the negative feedback regulation of NF-kappaB signalling. Recently, intra-articular injection of an A20-expressing adenovirus was shown to reduce the severity of synovial inflammation and joint destruction in a mouse model of collagen-induced arthritis, even in untreated joints, in both a prophylactic and therapeutic setting. A20 expression in synovial tissue was associated with inhibition of NF-kappaB activity and decreased levels of TNF, IL-1beta, IL-6, soluble RANKL, monocyte chemo-attractant protein 1, and IL-17, suggesting that A20 induces a protective effect in collagen-induced arthritis mice through suppression of NF-kappaB activation and NF- kappaB-dependent gene expression [51]. Because TNF and IL-1beta are known to mediate synovitis, pannus formation, and erosion of cartilage and bone in RA, the decreased serum levels of TNF and IL-1beta in A20-transduced mice might explain the beneficial effects in the clinical, pathological, and radiological findings. This study also demonstrated that A20 overexpression leads to a decrease in the number of activated osteoclasts in joint tissue. A20 might therefore minimise joint destruction through decreasing the osteoclast number and activity. It will be interesting to analyse in future the susceptibility of conditional knockout mice that lack A20 in specific cell types such as synovial fibroblasts, macrophages, dendritic cells, B cells or T cells.
Importantly, several SNPs in the human A20 locus have been associated with increased susceptibility to development of autoimmune pathologies (reviewed in [52]). Several genome-wide association studies also revealed a clear association between mutations in the A20 locus in the 6q23 chromosome and susceptibility to RA [52]. Although the identified variants are not located in a gene, they are thought to influence A20 as its nearest gene (~150 kb downstream of A20), probably by the presence of potential regulatory DNA elements in this region. As A20 is required for termination of TNF-induced signals, and TNF is the primary inflammatory cytokine in RA, these findings reveal A20 as a candidate susceptibility locus for RA. How these variants affect normal A20 activity and how they cause RA, however, remain unclear. Recently, Elsby and colleagues functionally evaluated in vitro the regulatory ability of RA-associated SNP variants on A20 promoter activity, and could show repressed A20 transcription for some of the SNPs investigated [53]. It will be of interest to identify the actual causal variants and to elucidate the functional consequences of these variants. In this context, knockin mice for the corresponding A20 SNPs, combined with mouse models for RA, will be very valuable tools.","[{'offsets': [[0, 3]], 'text': ['A20'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[12, 15]], 'text': ['A20'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[31, 38]], 'text': ['TNFAIP3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[45, 70]], 'text': ['ubiquitin-editing protein'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[97, 106]], 'text': ['NF-kappaB'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[195, 198]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[338, 341]], 'text': ['A20'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[453, 457]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[459, 463]], 'text': ['RIP2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[465, 470]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[475, 480]], 'text': ['MALT1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[638, 643]], 'text': ['Ubc13'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[648, 654]], 'text': ['Ubc5hc'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[682, 687]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[689, 694]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[699, 704]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[705, 706]], 'text': ['2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[762, 765]], 'text': ['A20'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[828, 831]], 'text': ['A20'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[913, 956]], 'text': ['A20-binding inhibitor of NF-kappaB (ABIN) 1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[961, 983]], 'text': ['Tax1-binding protein 1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1047, 1050]], 'text': ['A20'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1145, 1148]], 'text': ['A20'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1209, 1212]], 'text': ['A20'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1394, 1397]], 'text': ['A20'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1443, 1446]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1566, 1569]], 'text': ['A20'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1726, 1729]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1760, 1763]], 'text': ['A20'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1881, 1884]], 'text': ['A20'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2016, 2019]], 'text': ['A20'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2193, 2196]], 'text': ['A20'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2259, 2262]], 'text': ['A20'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2366, 2369]], 'text': ['A20'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2594, 2597]], 'text': ['A20'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2705, 2708]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2710, 2718]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2720, 2724]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2734, 2739]], 'text': ['RANKL'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2741, 2776]], 'text': ['monocyte chemo-attractant protein 1'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2805, 2808]], 'text': ['A20'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2971, 2974]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2979, 2987]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3109, 3112]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3117, 3125]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3129, 3132]], 'text': ['A20'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3278, 3281]], 'text': ['A20'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3373, 3376]], 'text': ['A20'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3577, 3580]], 'text': ['A20'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3723, 3726]], 'text': ['A20'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[3944, 3947]], 'text': ['A20'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4098, 4101]], 'text': ['A20'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4145, 4148]], 'text': ['A20'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4232, 4235]], 'text': ['A20'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4267, 4270]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4292, 4295]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[4324, 4332]], 'text': ['cytokine'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[4362, 4365]], 'text': ['A20'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[4443, 4446]], 'text': ['A20'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[4623, 4626]], 'text': ['A20'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[4671, 4674]], 'text': ['A20'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[4907, 4910]], 'text': ['A20'], 'type': 'Protein', 'id': 'T62'}]",[],[],[],[],[]
46,PMC-3291650-17-Caption-Figure_1,"A20 inhibits NF-kappaB and IRF3 activation in response to RIG-I stimulation.
(A) HEK293T cells were transfected with NF-kappaB (left), IRF3 (middle) or IRF7 dependent luciferase reporter (right) plasmids, together with plasmids expressing RIG-I (2CARD), IRF7 (right) and increasing amounts of A20. Luciferase activity in cell extracts was analyzed in a luminometer. Numbers are averages +/- SD of 3 samples per set-up. (B-D) A20myel-KO and wild type (A20myel-WT) BMDM were transfected with LMW poly(I:C) and analyzed at different time points (minutes) after the start of transfection for IkappaBalpha phosphorylation and degradation, and IRF3 phosphorylation by immunoblotting of total cell extracts (B). The band that is non-specifically recognized by the anti-IkappaBalpha antibody (indicated by an asterisk) can be used as a loading control. Nuclear translocation of NF-kappaB (p65) and IRF3 was analyzed by immunoblotting of cytoplasmic or nuclear fractions (C). Quantification of band density for nuclear p65 and IRF3 is shown in bar graphs (expressed as relative density compared to the first lane;  = time 0). IL-6, TNF and IFNbeta levels in the supernatant of cells used in (B) were determined by bioassay (IL-6) and ELISA (TNF and IFNbeta) as described in the 'materials and methods' section (D). Data are representative of 2 independent experiments.","[{'offsets': [[27, 31]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[58, 63]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[135, 139]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[152, 156]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[167, 177]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[254, 258]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[588, 600]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[638, 642]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[881, 884]], 'text': ['p65'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[890, 894]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1010, 1013]], 'text': ['p65'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1018, 1022]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1117, 1121]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1123, 1126]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1131, 1138]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1215, 1219]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1232, 1235]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1240, 1247]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T18'}]",[],[],[],[],[]
47,PMC-2817507-01-1._Introduction,"Intracerebral hemorrhage (ICH) represents 10%-15% of all strokes and occurs with increasing frequency as a complication of the thrombolytic treatment of ischemic stroke, which is associated with high mortality and severe disability in survivors [1, 2]. Local brain tissue deformation induces primary brain damage after ICH; more importantly, the excitotoxicity and inflammatory responses in the brain tissue induced by ICH result in further brain damage following ICH [3]. Both innate and adaptive immunological/inflammatory mechanisms have been clearly shown to participate in the progression of brain injury after ischemic stroke. Nevertheless, how the inflammatory responses in ICH are triggered and regulated remains to be elucidated.
TLRs are a family of transmembrane proteins and act as signal transduction molecules [4]. Activation of TLRs recruits downstream signaling proteins and results in transcription of genes encoding inflammation-associated molecules and cytokines [5, 6]. For example, combined with specific ligand, the activation of TLR4 induces the phosphorylation of inhibitor of kappa-B (IkappaB) and dissociates IkappaB from NF-kappa-B (NFkappaB). Then, NFkappaB trans-locates into the nucleus and activates and regulates the transcription of genes related to inflammatory responses [5, 6]. TLRs play a critical role in the induction of immunological/inflammatory responses and are implicated in several CNS diseases, such as infectious disease, autoimmune disease, and ischemic brain injury [7, 8]. Accumulating evidences demonstrate that TLR4, the first mammalian TLR recognized, contributes to the neuronal death, blood brain barrier damage, brain edema, and inflammatory responses in the brain injury induced by ischemia [8, 9]. However, little is known about TLR4 in the brain after ICH. In the present study, we detected the transcription of TLR4 gene and the activation of TLR4-mediated signaling in the rat brains subjected to experimental ICH. Our data firstly provided the knowledge about the distribution of TLR4 and the temporal profile of the activation of TLR4-mediated signaling in rat brain tissue after ICH.","[{'offsets': [[1052, 1056]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1563, 1567]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1787, 1791]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1871, 1875]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1903, 1907]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[2042, 2046]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[2093, 2097]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
48,PMC-3342329-22-Caption-Figure_5,"Induction of the infiltration of CD8+ T cells and NK cells into tumor, and increase in spleen of CCR5-/- mice.
A and B, Immunolfluorescence analysis was used to determine the expression levels of CD8 (CD8+ cytotoxic T-cell surface marker) and CD57 (NK cell marker) in tumor and spleen sections. The images shown are representative of three separate experiments performed in triplicate. Scale bars indicate 50 microm (A) and 100 microm (B). C and D, Analysis of lymphocyte phenotypes. The tumor and spleen tissues were separated at study termination (Day 31). Flow cytometry analysis was performed using FACSAria flow cytometry, and represent data were shown. Data are means +/- S.D. of four experimental animals.","[{'offsets': [[97, 101]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
49,PMC-3312845-12-Results,"TNF-alpha, and TNF receptor expression
In non-SE induced animals of the saline-infused groups, TNF-alpha immunoreactivity was weakly detected in PC neurons (data not shown). In 12 hr-post SE animals of the saline-infused group, most of the activated microglia showed strong TNF-alpha immunoreactivity (Figure 1A). This expression pattern was maintained up to 1 week after SE. In non-SE-induced animals of the saline-infused groups, TNFp55R and TNFp75R immunoreactivities were also weakly observed in astrocytes (data not shown). In 12 hr-post SE animals of the saline-infused group, TNFp55R immunoreactivity was observed in astrocytes (Figure 1B). Unlike TNFp55R, TNFp75R immunoreactivity was detected in endothelial cells as well as astrocytes (Figures 1C-E). One day to 1 week after SE, both TNFp55R and TNFp75R immunoreactivities were significantly reduced in astrocytes, not in endothelial cells, due to massive astroglial loss (data not shown) [5,7,8,20].","[{'offsets': [[0, 9]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[95, 104]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[274, 283]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[432, 439]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[444, 451]], 'text': ['TNFp75R'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[583, 590]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[655, 662]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[664, 671]], 'text': ['TNFp75R'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[794, 801]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[806, 813]], 'text': ['TNFp75R'], 'type': 'Protein', 'id': 'T10'}]",[],[],[],[],[]
50,PMC-1064895-07-Materials_and_methods,"Quantification of IL-17 mRNA by semiquantitative reverse transcription-polymerase chain reaction
PBMC were incubated with various concentrations of anti-CD3 in the presence or absence of inhibitors (LY294002, PDTC). After 16 hours of incubation, mRNA was extracted with RNAzol B (Biotex Laboratories, Houston, TX, USA) in accordance with the manufacturer's instructions. Reverse transcription of 2 mug of total mRNA was performed at 42degreesC using the Superscript(TM) reverse transcription system (Takara, Shiga, Japan). PCR amplification of cDNA aliquots was performed by adding 2.5 mM dNTPs, 2.5 U of Taq DNA polymerase (Takara) and 0.25 muM of sense and antisense primers. The reaction was performed in PCR buffer (1.5 mM MgCl2, 50 mM KCl, 10 mM Tris-HCl, pH 8.3) in a total volume of 25 mul. The following sense and antisense primers for each molecules were used: IL-17 sense, 5'-ATG ACT CCT GGG AAG ACC TCA TTG-3'; IL-17 antisense, 5'-TTA GGC CAC ATG GTG GAC AAT CGG-3'; glyceraldehyde-3-phosphate dehydrogenase (GAPDH) sense, 5'-CGA TGC TGG GCG TGA GTA C-3'; GAPDH antisense, 5'-CGT TCA GCT CAG GGA TGA CC-3'. Reactions were processed in a DNA thermal cycler (Perkin-Elmer Cetus, Norwalk, CT, USA) through cycles for 30 s of denaturation at 94degreesC, 1 min of annealing at 56degreesC for GAPDH and IL-17, followed by 1 min of elongation at 72degreesC. PCR rounds were repeated for 25 cycles each for both GAPDH and IL-17; this was determined as falling within the exponential phase of amplification for each molecule. The level of mRNA expression was presented as a ratio of IL-17 PCR product over GAPDH product.","[{'offsets': [[18, 23]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[605, 608]], 'text': ['Taq'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[870, 875]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[978, 1018]], 'text': ['glyceraldehyde-3-phosphate dehydrogenase'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1020, 1025]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1067, 1072]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1298, 1303]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1308, 1313]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1415, 1420]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1425, 1430]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1585, 1590]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1608, 1613]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
51,PMC-3320587-01-Introduction,"Mycobacterium tuberculosis (MTb), the causative agent of tuberculosis (TB), is the most common co-infection and cause of death in patients infected with human immunodeficiency virus type 1 (HIV-1) [1], [2]. Direct engagement of pathogen recognition receptors (PRRs) by MTb on mononuclear phagocytes activates signaling cascades that directly induce transcription from the proviral LTR (reviewed in [3]). Furthermore, inflammatory cytokines and chemokines produced by the human host in response to MTb infection activate signal transduction pathways in CD4 T cells and monocytic cells that also result in transcriptional activation of the HIV-1 LTR [4]-[6]. Activation of HIV-1 replication via these MTb-induced pathways ultimately leads to higher viral loads and, in turn, expedited CD4 T cell loss and progression to AIDS ([7], reviewed in [8]-[10]). Furthermore, the progressive immune compromise associated with HIV-1 infection itself is a major cause of latent MTb reactivation, as well as increased susceptibility to primary TB infection ([11]-[15], reviewed in [8]).
The primary PRR on monocytic cells triggered by MTb infection is toll-like receptor (TLR) 2 [16]-[20]. Engagement of TLR2 results in engagement of the adaptor protein MyD88 and the subsequent recruitment of several kinases, including IRAK1 and IRAK4, and the ubiquitin ligase TRAF6 ([21]-[23], reviewed in [10], [24]). TRAF6 activates IkappaB kinase (IKK) and mitogen-activated protein (MAP) kinases that, in turn, ultimately induce activation of specific transcription factor families, including the NF-kappaB and AP-1 families, which have been shown to associate with the HIV-1 LTR and to drive its transcription ([22], [25]-[27], reviewed in [10]).
Notably, HIV-1 comprises several subtypes, and the LTR of each subtype is unique with respect to the number and organization of activator binding sites. For example, HIV-1 subtype B, the most highly characterized viral subtype and the primary cause of infection in the Americas, Europe, Japan, and Australia, has two tandem NF-kappaB motifs in its LTR. By contrast, HIV-1 subtypes C and E, which have spread disproportionately in TB-burdened sub-Saharan Africa and southeast Asia, have three and one NF-kappaB binding sites, respectively [1], [28]-[30].
We previously showed that the most primordial member of the nuclear factor of activated T cells (NFAT) family, NFAT5 (also known as TonEBP), binds to a site within the HIV-1 LTR that is highly conserved across all HIV-1 subtypes, and is also conserved in HIV-2 and SIV LTRs. This NFAT5 site overlaps the core NF-kappaB binding motifs in the LTR and is required for constitutive replication of representative HIV-1 subtype B, C, and E isolates in human primary monocyte-derived macrophages (MDM) [31]. Given that NFAT5 has previously been shown to be transcriptionally activated by the MAP kinase p38, which is downstream of MyD88 signaling, [32], we speculated that NFAT5 may also be involved in MTb-induced activation of HIV-1 replication via a TLR-mediated pathway in monocytes and peripheral blood mononuclear cells (PBMC).
Here, we show that NFAT5 and its cognate binding site are of crucial importance for efficient MTb-induced stimulation of HIV-1 replication in human MDM and PBMC. Moreover, we demonstrate that MTb infection increases NFAT5 gene expression in human monocytes in a MyD88-dependent manner. Thus, these results expand the known stimuli of NFAT5 expression to the PRR-mediated innate immune response, and demonstrate that NFAT5 is a critical modulator of MTb-induced enhancement of HIV-1 replication.","[{'offsets': [[552, 555]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[783, 786]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1138, 1164]], 'text': ['toll-like receptor (TLR) 2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1190, 1194]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1240, 1245]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1307, 1312]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1317, 1322]], 'text': ['IRAK4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1349, 1354]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1392, 1397]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[2390, 2395]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[2411, 2417]], 'text': ['TonEBP'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2791, 2796]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2903, 2908]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2945, 2950]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[3125, 3130]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[3322, 3327]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[3368, 3373]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[3440, 3445]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[3522, 3527]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T20'}]",[],[],[],[],[]
52,PMC-3585731-17-Materials_and_Methods,"Cell Lines
L929 and FADD-deficient Jurkat cells were obtained from ATCC. Lung fibroblasts were a generous gift of Dr. Philip Tsichlis (Tufts University) [53]. J774A.1 (ATCC) cells and RAW264.7 (ATCC) cells were generous gifts of Junying Yuan (Harvard University) and Alexander Poltorak (Tufts University), respectively. Cells were maintained in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic mixture (Invitrogen). The mouse lung fibroblast media was additionally supplemented with L-glutamine, non-essential amino acids, and sodium pyruvate. Jurkat cells were maintained in RPMI1640, supplemented with 10% FetalPlex (Gemini) and 1% antibiotic-antimycotic.","[{'offsets': [[20, 24]], 'text': ['FADD'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
53,PMC-3291650-03-Results,"A20 negatively regulates IAV-induced gene expression in BMDM
To investigate the role of A20 in the IAV-induced proinflammatory and antiviral innate immune responses, we infected A20 deficient and control BMDM with IAV X-47 (H3N2). A20 mRNA levels were rapidly induced in wild type BMDM, but not in A20 deficient BMDM, upon viral infection (figure 2A). Furthermore, A20myel-KO BMDM show enhanced expression of IL-6 and IFNbeta mRNA after IAV infection compared to control cells (figure 2A). In accordance with these data, cell culture supernatant collected from these cells contained higher levels of TNF and IFNbeta (figure 2B).
Upon host infection with IAV, alveolar macrophages are an important source of cytokines and chemokines, attracting innate immune cells to the lung during the primary phase of infection. To test whether A20 directly controls IAV-induced gene expression in alveolar macrophages, we isolated these cells from lungs of A20myel-KO and control littermates and infected them in vitro with IAV X-47. Expression and secretion of the proinflammatory cytokines IL-6 and TNF, the type-I IFN IFNbeta and IFNalpha4 and the chemokines MCP-1 (ccl2) and KC (cxcl1) was significantly higher in IAV infected cells lacking A20 compared to infected wild type cells (figure 2C and figure S1). Taken together these results demonstrate that A20 negatively regulates IAV-induced proinflammatory and antiviral gene expression in alveolar macrophages, consistent with the inhibitory effect of A20 seen on RIG-I-induced NF-kappaB and IRF3 activation.","[{'offsets': [[409, 413]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[418, 425]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[600, 603]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[608, 615]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1079, 1083]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1088, 1091]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1108, 1115]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1120, 1129]], 'text': ['IFNalpha4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1149, 1154]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1156, 1160]], 'text': ['ccl2'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1166, 1168]], 'text': ['KC'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1170, 1175]], 'text': ['cxcl1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1507, 1512]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1535, 1539]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T14'}]",[],[],[],[],[]
54,PMC-3585731-05-Results,"Late Increase in Akt Thr308 Phosphorylation Contributes to the Induction of Necroptotic Cell Death
We next investigated if the delayed RIP1 kinase-dependent increase in Akt Thr308 phosphorylation functionally contributes to the execution of necroptotic cell death. Firstly, PDGF/zVAD.fmk, which cannot induce necroptosis (Fig. 2A), triggered only the initial, rapid Akt and JNK phosphorylation changes and not the delayed activation (Fig. 4A), indicating that late, rather than early Akt phosphorylation correlates with necroptosis. Secondly, we saw that the ability of the Akt inhibitor to protect cells from necroptosis rapidly declined after 6 hrs of stimulation with zVAD.fmk, TNFalpha or bFGF/zVAD.fmk and no protection was observed when the inhibitor was added at 9 hrs (Fig. 4B,C). This time frame coincides with the timing of the secondary Akt Thr308 phosphorylation. Finally, we terminated the bFGF signal one hour after addition of bFGF by the addition of PD173074. This allowed us to retain early Akt activation, but to suppress the secondary increase (Fig. 4D). Both pre-addition and delayed addition of PD173074 fully prevented necroptosis (Fig. 4E). Overall, these data, while correlative, indicate that early Akt activation is insufficient to promote necroptosis and are strongly supportive of an important role for the delayed activation of Akt in the induction of necroptotic cell death.","[{'offsets': [[135, 139]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[681, 689]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[693, 697]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[903, 907]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[942, 946]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
55,PMC-3342329-15-Materials_and_Methods,"Flow Cytometric Analysis
Lymphocytes were obtained from tumor and spleen tissues for phenotype analysis. Spleen and tumor lymphocytes were isolated from fresh spleen and tumor biopsies obtained from three mice per group. Spleen and tumor biopsies were briefly homogenized mechanically in PBS, filtered (100 microm cell strainer; BD PharMingen) and then placed in lysis buffer (ACK lysing buffer, LONZA) to remove red blood cells. One million splenocytes were washed once in PBS containing 1% bovine serum albumin (BSA) and re-suspended in 100 microl of PBS/BSA buffer. Meanwhile, one million cells obtained from tumor tissues were placed in RPMI medium, incubated to obtain suspension cell for 1hour at 37degreesC, centrifuged (1200 rpm, 3 min) and then washed in PBS. Next, the lymphocytes were incubated with various conjugated monoclonal antibodies, including CD4-APC, CD8-FITC and CD19-PE for 20min at 4degreesC, washed twice in PBS, and re-suspended in 400 microl of PBS. A flow cytometric analysis was performed on a FACSAria flow cytometry (BD Biosciences), and the data were analyzed using the WinMDI statistical software (Scripps, La Jolla, CA, USA). Forward and side scatter parameters were used to gate on lymphocytes.","[{'offsets': [[863, 866]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[885, 889]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
56,PMC-3585731-12-Discussion,"Altogether, our results suggest that Akt kinase is specifically engaged in the signaling downstream from RIP1 kinase, which exerts its activity through promoting a selective increase in Akt phosphorylation on Thr308. This provides a link connecting RIP1 kinase to downstream signaling and execution events during necroptosis in L929 cells, including JNK activation, autocrine TNFalpha synthesis and eventual cell death. According to our model, phosphorylation of Akt requires two distinct signals. The first input, which is induced by growth factors, leads to the plasma membrane localization of Akt. Expression of constitutively active membrane-targeted Myr-Akt overcomes this requirement. At the same time, expression of Myr-Akt is not sufficient for the induction of necroptosis or efficient activation of JNK and TNFalpha synthesis. A second, RIP1 kinase-dependent input is required for Thr308 phosphorylation of Akt, which in turn is required for necroptotic signaling. Necroptotic phosphorylation of Thr308 of Akt is sufficient to increase its activity towards a number of known substrates in L929 cells and our data reveal that the Akt effector pathway downstream of mTORC1 contributes to necroptosis, thereby identifying a new mediator of this form of cell death.
Our results raise some important mechanistic questions relevant to the specific regulation of Akt during necroptosis. First, what is the mechanism of the RIP1-dependent increase in Akt Thr308 phosphorylation? One possibility is that RIP1 kinase inhibits a phosphatase that targets Thr308. To our knowledge, PP2A is the only enzyme established to specifically dephosphorylate this residue [45]. However, we did not observe any effect of the PP2A inhibitor, okadaic acid, on Thr308 phosphorylation or activation of necroptosis in L929 cells. Another possibility is that the increase in Thr308 results from RIP1 kinase targeting PDK1, Akt or scaffolding factors that bring these two kinases together. Interestingly, we observed phosphorylation of Akt by recombinant RIP1 kinase in vitro on Thr146, 195/197, and 435 and Ser381 residues. Furthermore, mutating these residues to Ala in Myr-Akt leads to the loss of its ability to promote necroptosis. However, we were not able to confirm phosphorylation of these residues on endogenous Akt in L929 cells using either mass spectrometry or western blotting with a phospho-specific antibody raised against Thr435 peptide, suggesting that direct phosphorylation of Akt by RIP1 likely represents an in vitro artifact and does not reflect endogenous regulation. Second, what are the key substrates of Akt that promote necrotic death and TNFalpha synthesis? On the one hand, our data suggest new roles for Akt effector pathways mediated by mTORC1 in necroptotic control. On the other hand, we have observed only modest changes in mTORC1 activity under necroptotic conditions, suggesting that additional Akt substrates are likely to be involved. This warrants a re-evaluation of the roles of additional Akt substrates in necroptotic death, since no such connections have been established. Similarly, the mechanisms connecting mTORC1 to JNK remain to be elucidated. While there are some recent examples of mTORC1-dependent regulation of JNK, e.g. following ER stress [46], the exact mechanisms during necroptosis remain to be established. Given the activation of JNK by TNFalpha and the importance of mTORC1-dependent translational control in necroptosis, one possibility is that mTORC1 contributes to the translation of TNFalpha and forms a positive feed forward loop with JNK.
Akt's role as a key inhibitor of apoptosis is well documented, however, evidence of its contribution as a mediator of cell death under various circumstances has begun to emerge as well [45], [47]. Our data demonstrates a new mode of necrosis-specific regulation of Akt by RIP1 kinase. Importantly, while it is possible that necroptosis-specific targets of Akt exist, this regulation clearly involves a number of well established Akt targets including mTORC1, and potentially, GSK-3, FoxO1/4, and MDM2. Therefore, it may no longer be safe to assume that activation of Akt universally reflects pro-survival signaling nor that its inhibition will lead to more cell death. It is tempting to speculate that rather than serving a universally pro-survival role, the Akt pathway may function to promote cell fates alternative to apoptosis, ranging from survival to non-apoptotic cell death. The final decision between survival and death may depend on additional, Akt-independent inputs, such as the status of RIP1 kinase, expression of particular oncogenic factors [45] or excessive metabolic stress [47].
Another mechanism that should be considered in conjunction with the regulation of cell death by Akt is autophagy. Akt activation leads to the inhibition of autophagy through activation of mTOR [48]. The role of autophagy in cell death in general is very complex and it can both promote and inhibit necroptosis in various situations. Several studies suggested that activation of autophagy promotes necroptosis induced by zVAD.fmk in L929 cells [11], [14]. Others, including ourselves in unpublished data, have found that inihibition of autophagy promotes necroptosis by TNFalpha [49]. This suggests that the inhibition of autophagy by Akt or mTOR in our system may contribute to necroptosis induced by TNFalpha, however, it is more difficult to reconcile with the positive role of these proteins in zVAD-induced death. Clearly, further identification of the factors differentiating between pro-death and pro-survival autophagy in mammalian cells is required to better understand its role in the regulation necroptosis by Akt pathway.
Importantly, our data revealed that RIP1 kinase signaling to Akt is a general feature of necroptotic signaling that is observed in multiple cell types. At the same time, the significance of this connection varies in a cell type specific fashion. Importantly, in mouse lung fibroblasts, FADD-deficient Jurkat cells, and macrophages, Akt signaling contributed more prominently to an increase in TNFalpha synthesis, rather than cell death per se, unlike its role in L929 cells. A recent study [15] has demonstrated that, in addition to its role in necroptosis, RIP1 plays an important role in mediating the production of TNFalpha. These data emphasize the emerging complexity of necroptotic signaling mechanisms and highlight the major contribution of Akt to increased inflammatory signaling, specifically accompanying this form of regulated necrosis [5], [6], [10].
Robust inflammation is one of the most important consequences of necrotic cell death as well as its regulated subtype, necroptosis, both in vitro and in vivo [1], [5], [6], [50], [51]. Our results highlight an important notion that inflammation not only passively accompanies necroptosis in a variety of cellular systems by the virtue of rapid loss of plasma membrane integrity characteristic for necrotic cell death, but also that it is an intrinsic and regulated component of necroptosis due to the specific activation of TNFalpha synthesis by RIP1/Akt kinases. Therefore, this pathway may represent a new molecular target for the inhibition of pathologic inflammatory signaling. Initial in vivo data appears to support this notion. Two recent papers showed that the loss of control over RIP1/RIP3 kinase activities by FADD and caspase-8 in epithelial cells unleashes a feed forward cycle of necroptosis and TNFalpha production, resulting in the development of intestinal inflammation in mice and, possibly, in patients with Crohn's disease [4], [5]. This increased production of TNFalpha during necroptosis may also be important for acute necrotizing diseases, such as necrotizing pancreatitis and acute bacterial infections, where hyper-acute inflammation accompanying necrotic cell death is the primary cause of multiple organ failure and patient death. Along these lines, another recent paper by Duprez et al. has shown that RIP1 and RIP3 mediate the cellular damage introduced by TNF-induced SIRS [6]. The role of RIP1 kinase in acute and chronic inflammatory diseases warrants further investigation, as efficient and specific RIP1 kinase inhibitors may offer therapeutic benefit for treating these conditions.","[{'offsets': [[105, 109]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[249, 253]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[376, 384]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[655, 662]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[723, 730]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[817, 825]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[847, 851]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1426, 1430]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1505, 1509]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1876, 1880]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1898, 1902]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[2035, 2039]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2152, 2159]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2484, 2488]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2647, 2655]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[3377, 3385]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[3528, 3536]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[3858, 3862]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[4069, 4074]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[4075, 4076]], 'text': ['4'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[4082, 4086]], 'text': ['MDM2'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[4587, 4591]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[5253, 5261]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[5385, 5393]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[5753, 5757]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[6003, 6007]], 'text': ['FADD'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[6110, 6118]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[6275, 6279]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[6335, 6343]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[7105, 7113]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[7127, 7131]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[7371, 7375]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[7376, 7380]], 'text': ['RIP3'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[7402, 7406]], 'text': ['FADD'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[7411, 7420]], 'text': ['caspase-8'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[7491, 7499]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[7663, 7671]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[8012, 8016]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[8021, 8025]], 'text': ['RIP3'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[8102, 8106]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[8215, 8219]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T56'}]",[],[],[],[],[]
57,PMC-1064873-03-Materials_and_methods,"Isolation of CD4+ T cells
Peripheral blood mononuclear cells (PBMC) were prepared from heparinized blood samples by centrifugation over Ficoll-Hypaque density gradients (Pharmacia, Uppsala, Sweden). CD4+ T cells were purified from PBMC by positive selection using anti-CD4 mAb-coated magnetic beads (Miltenyi Biotec, Gladbach, Germany), according to the manufacturer's instructions. CD4+ T cells were isolated from ST samples, as previously described [27]. Briefly, fresh ST samples were fragmented and digested with collagenase and DNase for 1 hour at 37degreesC. After removing tissue debris, ST cell suspensions in culture medium (RPMI 1640 medium; Life Technologies, Gaithersburg, MD, USA) supplemented with 25 mM HEPES (2 mM L-glutamine, 2% nonessential amino acids, 100 IU/ml penicillin, and 100 mg/ml streptomycin; Life Technologies) with 10% heat-inactivated FCS (Life Technologies) were incubated at 37degreesC in six-well plates (Coster, Cambridge, MA, USA) for 45 min. Non-adherent cells were harvested and CD4+ T cells were purified by positive selection as already described.","[{'offsets': [[13, 16]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[199, 202]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[269, 272]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[383, 386]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1018, 1021]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
58,PMC-1064895-13-Results,"Increased IL-17 production in PBMC of patients with RA by anti-CD3 and/or anti-CD28, and PHA
Because IL-17 was already known from earlier reports to be produced mainly by activated T cells, we investigated the effect of different concentrations of anti-CD3 (1, 5 and 10 mug/ml) as a T cell activation, which showed a dose-dependent increase in IL-17 levels (data not shown). On the basis of this, we chose 10 mug/ml as a stimulation concentration for anti-CD3. As shown in Table 1, anti-CD3 significantly upregulated IL-17 production up to 3.7-fold, and the combination of anti-CD28 and anti-CD3 produced more IL-17 (approximately 1.3-1.5-fold) than anti-CD3 alone. Furthermore, when incubated with T cell mitogens such as PHA, increased IL-17 production was more pronounced than with anti-CD3 and anti-CD28 (588 +/- 85 versus 211 +/- 1 pg/ml; P < 0.05).","[{'offsets': [[10, 15]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[79, 83]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[89, 92]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[101, 106]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[344, 349]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[517, 522]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[578, 582]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[610, 615]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[723, 726]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[738, 743]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[803, 807]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T11'}]",[],[],[],[],[]
59,PMC-3589482-00-TIAB,"The Transcription Factor C/EBP-beta Mediates Constitutive and LPS-Inducible Transcription of Murine SerpinB2
SerpinB2 or plasminogen activator inhibitor type 2 (PAI-2) is highly induced in macrophages in response to inflammatory stimuli and is linked to the modulation of innate immunity, macrophage survival, and inhibition of plasminogen activators. Lipopolysaccharide (LPS), a potent bacterial endotoxin, can induce SerpinB2 expression via the toll-like receptor 4 (TLR4) by ~1000-fold over a period of 24 hrs in murine macrophages. To map the LPS-regulated SerpinB2 promoter regions, we transfected reporter constructs driven by the ~5 kb 5'-flanking region of the murine SerpinB2 gene and several deletion mutants into murine macrophages. In addition, we compared the DNA sequence of the murine 5' flanking sequence with the sequence of the human gene for homologous functional regulatory elements and identified several regulatory cis-acting elements in the human SERPINB2 promoter conserved in the mouse. Mutation analyses revealed that a CCAAT enhancer binding (C/EBP) element, a cyclic AMP response element (CRE) and two activator protein 1 (AP-1) response elements in the murine SerpinB2 proximal promoter are essential for optimal LPS-inducibility. Electrophoretic mobility shift (EMSA) and chromatin immunoprecipitation (ChIP) assays demonstrated that LPS induces the formation of C/EBP-beta containing complexes with the SerpinB2 promoter. Importantly, both constitutive and LPS-induced SerpinB2 expression was severely abrogated in C/EBP-beta-null mouse embryonic fibroblasts (MEFs) and primary C/EBP-beta-deficient peritoneal macrophages. Together, these data provide new insight into C/EBP-beta-dependent regulation of inflammation-associated SerpinB2 expression.","[{'offsets': [[25, 35]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[100, 108]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[109, 117]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[121, 159]], 'text': ['plasminogen activator inhibitor type 2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[161, 166]], 'text': ['PAI-2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[419, 427]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[447, 467]], 'text': ['toll-like receptor 4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[469, 473]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[561, 569]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[676, 684]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[970, 978]], 'text': ['SERPINB2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1189, 1197]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1393, 1403]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1434, 1442]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1500, 1508]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1546, 1556]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1609, 1619]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1700, 1710]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1759, 1767]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T19'}]",[],[],[],[],[]
60,PMC-1472690-25-Caption-Table_1,Sense strand of oligonucleotides used in EMSAs.,[],[],[],[],[],[]
61,PMC-3291650-06-Materials_and_Methods,"Ethics statement
All experiments on mice were conducted according to the national (Belgian Law 14/08/1986 and 22/12/2003, Belgian Royal Decree 06/04/2010) and European (EU Directives 2010/63/EU, 86/609/EEG) animal regulations. Animal protocols were approved by the ethics committee of Ghent University (permit number LA1400091, approval ID 2010/001). All efforts were made to ameliorate suffering of animals. Mice were anesthetized by intraperitoneal (i.p.) injection of a mixture of ketamine (12 mg/kg) and xylazine (60 mg/kg).",[],[],[],[],[],[]
62,PMC-3312845-18-Discussion,"The major findings in the present study are that TNF-alpha signaling showed cellular specific responses of NF-kappaB phosphorylation in the PC following SE, which may be related to vasogenic edema formation followed by neutrophil infiltration. BBB disruption has been reported in experimental and human epilepsy [12,13,15,16,28]. Leakage of serum-derived components into the extracellular space is associated with hyperexcitability and seizure onset [12,13,15,16,28]. Furthermore, dysfunction of the BBB leads to epileptogenesis and contributes to progression of epilepsy [12,13,15,16,28]. In the present study, TNF-alpha immunoreactivity was obviously observed in microglia in the PC following SE. TNF receptor expressions were also up-regulated in astrocytes (TNFp55R and TNFp75R) and endothelial cells (TNFp75R). Furthermore, blockade of TNF-alpha signaling by sTNFp55 infusion effectively (but not completely) reduced volumes of SE-induced vasogenic edema and neuronal damage in the PC. These findings indicate that TNF-alpha may participate in astroglial and endothelial responses to SE, which are relevant to SE-induced vasogenic edema formation [5-8]. Indeed, TNF-alpha signaling increases BBB permeability in various experimental disease models [29]. In the present study, sTNFp55 infusion could not completely prevent SE-induced vasogenic edema and neuronal damage in the PC. Therefore, our findings suggest that TNF-alpha signaling may not be a unique upstream event in vasogenic edema development.
p65 phosphorylation of NF-kappaB enhances its transactivation potential, and p65 phosphorylation occurs in either the cytoplasm or the nucleus [30]. In the present study, p65-Thr435 immunoreactivity was detected in endothelial cells, and its immunoreactivity showed an inverse correlation to the degree of SMI-71 expression. SMI-71, an endothelial barrier antigen, is a protein expressed by endothelial cells of rat BBB [31]. Under pathological conditions, SMI-71 expression is lost in endothelial cells [5,7,8,30,32]. Acute phases of the above pathological conditions are accompanied by opening of the BBB and development of vasogenic edema [33]. Indeed, neutralization of SMI-71 in vivo leads to widening of intercellular junctions between endothelial cells and swelling of perivascular astrocytic processes [34], although SMI-71 is not localized at endothelial cell junctions [35-38]. In the present study, SMI-71 immunoreactivity was significantly reduced in blood vessels 1 day after SE when vasogenic edema and neuronal damage were observed. Furthermore, sTNFp55R infusion effectively prevented SE-induced SMI-71 down-regulation. With respect to the phosphorylation of p65-Thr435 by TNF-alpha [39], our findings indicate that TNF-alpha-mediated p65-Thr435 phosphorylation in endothelial cells may play an important role in vasogenic edema induction via SMI-71 degradation or its posttranslational dysfunction influencing BBB permeability.
In our previous studies [5,8], dystrophin (an actin-binding protein [40]) immunoreactivity was detected in blood vessels and in astrocytic perivascular end-feet, and was down-regulated 12 hrs after SE prior to the appearance of vasogenic edema and down-regulation of SMI-71 immunoreactivity. With respect to this previous report, changes in SMI immunoreactivity would be causes/results of interaction between endothelial cells and perivascular astrocytes. In the present study, p65-Ser276, p65-Ser311, p65-Ser529, and p65-Ser536 phosphorylation was observed in astrocytes following SE. Furthermore, sTNFp55R infusion effectively inhibited p65-Ser276 and p65-Ser311phosphorylation in astrocytes following SE. Therefore, it is likely that enhanced p65-Ser276 and p65-Ser311 phosphorylation may be involved in TNF-alpha-mediated BBB disruption. However, sTNFp55R infusion could not prevent p65-Ser529 and p65-Ser536 phosphorylations from SE insults. Since p65-Ser529 and p65-Ser536 are phosphorylated by TNF-alpha and IL-1beta [41], it is likely that IL-1beta-mediated p65-Ser529/Ser536 phosphorylation may also play a role in SE-induced vasogenic edema. Therefore, our findings indicate that both TNF-alpha and IL-1beta may be synergists to play either a direct (by endothelial cells) or indirect (by astrocytes) role in the maintenance of BBB permeability.
Neutrophil infiltration into brain parenchyma is transiently observed during the acute phase of SE (4 - 36 hr after SE) and disappears thereafter [20]. SE rapidly increases synthesis and release of chemokines in various areas of the rodent brain [42]. Among them, MIP-2 is required for efficient neutrophil or lymphocyte recruitment to brain parenchyma [43]. In our previous study [20], neutrophil infiltration in the frontoparietal cortex was regulated by P2X7 receptor-mediated MIP-2 expression. In the PC, however, neither a P2X7 receptor agonist/antagonist nor IL-1Ra (an IL-1beta antagonist) infusion could not affect leukocyte infiltration. In the present study, sTNFp55R infusion effectively inhibited neutrophil infiltration in the PC by reducing vasogenic edema formation in a MIP-2-independent manner. With respect to the present and our previous reports, it is therefore likely that vasogenic edema induced by TNF-alpha can induce neutrophil infiltration and press injury to evoke neuronal-astroglial loss in the PC, unlike other brain regions.
In conclusion, our findings reveal that impairments of endothelial cell function via TNF-alpha mediated p65-Thr 435 NF-kappaB phosphorylation may be involved in SE-induced vasogenic edema, which is relevant to neutrophil infiltration and neuronal-astroglial loss.","[{'offsets': [[49, 58]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[612, 621]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[762, 769]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[774, 781]], 'text': ['TNFp75R'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[806, 813]], 'text': ['TNFp75R'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[841, 850]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[865, 871]], 'text': ['TNFp55'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1020, 1029]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1167, 1176]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1282, 1288]], 'text': ['TNFp55'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1422, 1431]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1509, 1512]], 'text': ['p65'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1586, 1589]], 'text': ['p65'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1680, 1683]], 'text': ['p65'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2571, 2578]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2684, 2687]], 'text': ['p65'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2698, 2707]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2741, 2750]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2760, 2763]], 'text': ['p65'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2985, 2995]], 'text': ['dystrophin'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3000, 3021]], 'text': ['actin-binding protein'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3432, 3435]], 'text': ['p65'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3444, 3447]], 'text': ['p65'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3456, 3459]], 'text': ['p65'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3472, 3475]], 'text': ['p65'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3554, 3561]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[3593, 3596]], 'text': ['p65'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3608, 3611]], 'text': ['p65'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3700, 3703]], 'text': ['p65'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3715, 3718]], 'text': ['p65'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3761, 3764]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3806, 3813]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3841, 3844]], 'text': ['p65'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3856, 3859]], 'text': ['p65'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3907, 3910]], 'text': ['p65'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3922, 3925]], 'text': ['p65'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3955, 3964]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3969, 3977]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[4002, 4010]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[4020, 4023]], 'text': ['p65'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[4149, 4158]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[4163, 4171]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[4574, 4579]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4767, 4780]], 'text': ['P2X7 receptor'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4790, 4795]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4875, 4881]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4886, 4905]], 'text': ['IL-1beta antagonist'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4980, 4987]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[5096, 5101]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[5231, 5240]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[5451, 5460]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[5470, 5473]], 'text': ['p65'], 'type': 'Protein', 'id': 'T59'}]",[],[],[],[],[]
63,PMC-3320587-13-Materials_and_Methods,"Statistical analysis
Where applicable, results are expressed as mean +/- SEM. Comparison between two groups was performed using the paired Student t-Test with the aid of Microsoft Excel software. p<=0.05 was considered significant.",[],[],[],[],[],[]
64,PMC-2817507-13-4._Discussion,"Intra-cerebral hemorrhage (ICH) represents 10-15% of all strokes, and occurs with increasing frequency as a complication of the thrombolytic treatment of ischemic stroke [1]. The mortality of ICH is higher than that of ischemic stroke. Only 31% are functionally independent at 3 months. Only 38% of the patients survive the 1st year [10]. Unfortunately, the method for treatment of this disease and protection of the brain tissue after ICH are not effective. Mass effect, ischemia, and toxicity of blood components after ICH induce brain tissue damage. In addition, there is increasing evidence that inflammatory processes are involved in cerebrovascular events. After ICH, inflammatory mediators from the blood might enter to the brain and induce an inflammatory reaction and the brain cells itself are also capable of producing many of these agents [11]. The inflammatory responses are responsible for the ICH induced brain injury, which could provide new therapeutic targets for ICH. Various constituents of the inflammatory response, including adhesion molecules, cytokines, leukocytes, immunoglobulins, and complement, may be important in the pathogenesis of ICH. However, how the inflammatory responses is activated and regulated in the brain tissue after ICH is unclear.
Transcription factor nuclear factor-kappa-B (NFkappaB) is an important nuclear transcription factor, which initiates transcription of genes associated with immune responses and inflammation [12, 13] and also plays a key role in regulating inflammation in brain pathologies. It has been reported that NFkappaB increased in the region of perihematoma after ICH [14]. NFkappaB activation occurs within minutes and persists for at least a week in response to ICH, which is associated with the expression of selected target genes [15]. Activation of NFkappaB initiates inflammatory responses and contributes to the pathobiology of perilesional cell death after ICH [16]. Inhibition of NFkappaB activity has been shown to have a therapeutic effect on experimental ICH, such as reduce inflammation, behavioral dysfunction, and neuronal damage produced by ICH [17]. The knowledge about how NFkappaB is activated in the brain subjected to ICH is critical for seeking a new neuroprotective method for ICH.
Toll-like receptors (TLRs) are a family of signal transduction molecules and play a critical role in the induction of innate and adaptive immunity [4]. TLR-mediated signaling pathways mainly stimulate the activation of NFkappaB [12, 13]. TLR4, the first mammalian TLR recognized, has been reported to be involved in several central nervous (CNS) system diseases, such as inflammatory or autoimmune CNS diseases and cerebral ischemic injury [7, 8]. Although previous reports indicated that the activation of NFkappaB was attributed to the oxidative stress or glutamate receptor activation induced by red blood cells and/or plasma constituents [17], very few studies have been directed to investigate the role and the relationship between TLR4-mediated NFkappaB signaling and ICH.
In the present study, we established the rat model of experimental ICH and detected the TLR4 mRNA and protein. Our data showed that transcription of TLR4 as well as the expression of TLR4 protein after ICH significantly elevated in brain tissue. These changes started as early as 6 hours after the ICH insult and maintained at a high level for 7 days afterward. The TLR4 protein, detected by immunohistochemistry, was consistently distributed in peri-hemorrhage areas, the hippocampus, cortex, thalamic nuclei, and some white matter tracts. These data indicated that increased expression of TLR4 may be related to the triggering of the inflammatory responses in the brain tissue after ICH.
Recent studies demonstrated that ICH initiates inflammatory responses, which are associated with secondary growth of hemorrhage and cell death [18]. It is now believed that TLR4-mediated-NFkappaB pathway activates and regulates immunological and inflammatory responses. To investigate the mechanisms underlying the increased inflammatory responses in the brain after ICH, in the present study, we evaluated the activation of TLR4-mediated NFkappaB signaling by detecting the p-IkappaB and the activity of NFkappaB in hemorrhagic brains. NFkappaB is an important transcription factor downstream in the TLR4-mediated signaling pathway. Activation of TLR4 stimulates IkappaBalpha phosphorylation and degradation, resulting in nuclear translocation of NFkappaB, which initiates transcription of genes associated with innate immune responses and inflammation [5, 6]. We observed that the levels of phosphorylation of IkappaB and the activity of NFkappaB were significantly increased in brain tissue after ICH. The temporal profile of the expression of p-IkappaB and the activation of NFkappaB was similar to that of the expression of TLR4. Our data suggest that ICH stimulates activation of the TLR4/NFkappaB signaling pathway, which is consistent with previous reports that activation of NFkappaB is regulated through the TLR4-mediated signaling pathway. TLR4 plays an important role in the recognition of microbial components [19, 20] and can also recognize endogenous molecules such as the degradation products of macromolecules, products of proteolytic cascades, intracellular components of ruptured cells, and products of genes that are activated by inflammation. For instance, HSP70, HSP32, HSP27, and enzymes involved in oxidative stress are found to be upregulated in the brain after ICH, which may be produced by injured neuronal cells or blood cells [21]. It may be speculated that these molecules produced in damaged brain or came from blood cells and constituents of plasma server as endogenous TLR4 ligands, activate TLR4-mediated NFkappaB signaling, and initiate the inflammatory responses in IHC brain. However, the specific endogenous ligands for TLR4 in hemorrhagic brain have not been determined and need to be identified through further research.
In conclusion, the present study demonstrated the temporal profile of the activation of TLR4-mediated NFkappaB signaling in brain tissue in a rat model of experimental ICH, which suggests that TLR4-mediated NFkappaB signaling participates in the pathogenesis of ICH, which may be a therapeutic target for the prevention of ICH-induced brain damage.","[{'offsets': [[2512, 2516]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[3011, 3015]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[3141, 3145]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[3202, 3206]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[3236, 3240]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[3419, 3423]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[3644, 3648]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[3916, 3920]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[4168, 4172]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[4344, 4348]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[4391, 4395]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[4407, 4419]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[4872, 4876]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[4933, 4937]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[5061, 5065]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[5094, 5098]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[5421, 5426]], 'text': ['HSP70'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[5428, 5433]], 'text': ['HSP32'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[5435, 5440]], 'text': ['HSP27'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[5745, 5749]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[5768, 5772]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[5901, 5905]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[6092, 6096]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[6197, 6201]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T24'}]",[],[],[],[],[]
65,PMC-3585731-27-Caption-Figure_2,"Akt contributes to necroptosis induced by zVAD.fmk and TNFalpha.
(A,B) Necroptosis was induced by zVAD.fmk or TNFalpha (full serum, A) or growth factors/zVAD.fmk (serum free, B) in the presence of inhibitors of Akt (Akt inhibitor VIII), JNK (SP600125), p38 (PD169316), and Erk (UO126). Cell viability was determined after 24 hrs. (C) L929 cells transfected with Akt1, Akt2, and Akt3 siRNAs for 72 hrs were treated with zVAD.fmk or TNFalpha for 9 hrs. Cell viability and Akt expression levels were determined after 24 hrs. In all graphs, average+/-SD was plotted.","[{'offsets': [[55, 63]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[110, 118]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[362, 366]], 'text': ['Akt1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[368, 372]], 'text': ['Akt2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[378, 389]], 'text': ['Akt3 siRNAs'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[431, 439]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T6'}]",[],[],[],[],[]
66,PMC-1472690-15-Methods,"Cytokine measurements
Supernatants of cell cultures were harvested 3, 6, 9, 12, 18, 24, 30, 36 and 48 hours after stimulation and stored at -80 degreesC until used and thawed only once. IFNgamma, TNFalpha, IL-1 and IL-6 were determined using an ELISA from Bender Systems (Vienna, Austria), IL-1RA and IL-8 by an ELISA from R&D Systems (Wiesbaden-Nordenstadt, Germany), and TGFbeta 1 using an ELISA as previously described [57]. Quantification of IL-2 as an indicator for the bioactivity of IL-1 was done as previously described [46]. Samples were diluted in the same buffer as that used for the standards. All cytokines were quantified using an ELISA plate reader (Anthos Labotec, Salzburg, Austria or Microplate Reader, BioRad). Cytokine amounts were all within the range of the standard curve. Only stimulation of PBMC observed in donors showing no spontaneous cytokine release was included in the statistics.","[{'offsets': [[186, 194]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[196, 204]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[206, 210]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[215, 219]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[290, 296]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[301, 305]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[373, 382]], 'text': ['TGFbeta 1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[446, 450]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[490, 494]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T9'}]",[],[],[],[],[]
67,PMC-2817507-06-2._Methods,"2.5. Western Blots
Cellular proteins were prepared from ICH cerebral hemispheres, electrophoresed with SDS-polyacrylamide gel and transferred onto Hybond ECL membranes (Amersham Pharmacia, Piscataway, NJ). The ECL membranes were incubated with the appropriate primary antibody (WuHan, BA1717) followed by incubation with peroxidase-conjugated secondary antibodies (Golden Bridge, PV-6001). The signals were detected with the ECL system (Amersham Pharmacia). The same membranes were probed with anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase, Biodesign, Saco, Maine) after being washed with stripping buffer. The signals were quantified by scanning densitometry and computer-assisted image analysis.","[{'offsets': [[499, 504]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[506, 546]], 'text': ['glyceraldehyde-3-phosphate dehydrogenase'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
68,PMC-3586680-06-Perspectives,"Whether WWOX affects TMZ sensitivity has never been determined. Binding proteins for WWOX and/or p53 are likely to affect apoptosis and TMZ sensitivity in GBM cells. WWOX binds MEK, and that PMA dissociates this complex for causing apoptosis of T leukemia cells (Lin et al., 2011). Thus, appropriate chemicals, which break apart the WWOX/MEK complex, are expected to cause GBM cell death. Preliminary studies from our screening of chemicals have selected certain small molecules that induce apoptosis of many types of cancer cells (Lu et al., unpublished). Indeed, specific inhibition of MEK by selumetinib enhances TMZ-induced cancer cell death in vivo (Holt et al., 2012). Serum factors can be utilized for blocking cancer growth. For example, serum complement C1q induces apoptosis of prostate cancer and neuroblastomas cells without participation of downstream proteins in the classical activation pathway (Hong et al., 2009). In this event, ectopic WWOX is activated for inducing apoptosis.
Failure of ectopic WWOX in inducing apoptosis of glioma cells possessing wild type p53 is unusual (Chiang et al., 2012). In most cases, we have shown that p53 functionally interacts with WWOX, and both proteins induce apoptosis in a synergistic manner (Chang et al., 2001, 2003, 2005a,b, 2007, 2010, 2012; Su et al., 2012). A likely scenario is that p53-binding proteins, which are present in GBMs, may interfere with the apoptotic function of WWOX and p53. Functional antagonism among tumor suppressors has never been documented in the literature. However, it is not surprising to find that many tumor suppressor proteins, e.g., p53, WWOX, Smad4, PTEN, PP2A, and etc., are significantly upregulated during the early stage of cancer progression (Lai et al., 2005; Chang et al., unpublished). Do these proteins act synergistically in blocking cancer progression but lose control eventually? Or, do they counteract each other's function, thus allowing cancer growth? Whether endogenous WWOX counteracts with the function of endogenous p53 is unknown and remains to be established.
One of the unique characteristics for malignant gliomas is their diffuse infiltration into distant brain tissue. Signal pathways, involving PI3K, Akt, mTOR, NF-kappaB, and autophagy, are believed to confer these migrating cells resistant to apoptotic death (Lefranc et al., 2005). Glioma cells possess CD44 as a receptor for interacting with brain matrix hyaluronan (Murai et al., 2004; Yoshida et al., 2012), and secrete hyaluronidases and metalloproteinases to facilitate their migration (Delpech et al., 2002; Junker et al., 2003; Hagemann et al., 2012). Also, lack of WWOX expression is expected to enhance cell migration. For example, loss of WWOX facilitates migration of ovarian cancer and osteosarcoma cells (Gourley et al., 2009; Del Mare et al., 2011). Ectopic expression of TIAF1 (TGF-beta-induced antiapoptotic factor), p53, and WWOX suppresses anchorage-independent growth and cell migration and causes apoptosis in cancer cells (Chang et al., 2012). We believe that glioma cells, with stem cell-like properties, migrate individually rather than collectively. This assumption is based upon our observations that mouse Wwox gene knockout cells (e.g., embryonic fibroblasts) migrate individually and aggressively. In contrast, wild type cells migrate collectively (Chou et al., unpublished). While a portion of WWOX is anchored on the cell membrane/cytoskeleton, WWOX-negative cells lose recognition by parental WWOX-positive cells, and this increases the mobility of WWOX-negative cells to move away from the WWOX-positive cells. Conceivably, WWOX-negative glioma cells migrate individually and turn away from WWOX-expressing brain cells to low WWOX expression areas. Apparently, the migratory behavior of WWOX-negative glioma cells may account for the diffuse invasion into distant brain tissue (Chou et al., unpublished).
Metabolic alterations have been shown in Wwox knockout mice, including postnatal lethality, bone metabolism defects, ataxia, steroidogenesis, and generation of osteosarcomas (Del Mare et al., 2011; Salah et al., 2012). In a Drosophila model, Wwox is shown to participate in pathways involving aerobic metabolism and oxidative stress for generation of ROS (O'Keefe et al., 2011). Under UV stress, functional Wwox gene expression induces ROS production in Drosophila. Cancer cells are known to overly utilize glycolysis for growth advantage - the so-called Warburg (Moncada et al., 2012). Conceivably, WWOX is likely to override glucose consumption in cancer cells and exerts generation of ROS to curb the cancer cell growth and invasion.
In summary, in this perspective article we have discussed the potential role of tumor suppressors p53 and WWOX in regulating TMZ sensitivity in GBM cells. We have shown the role of WWOX in controlling cell migration and metabolic alterations, and discussed the effects of WWOX deficiency and TMZ resistance in cancer cells.","[{'offsets': [[8, 12]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[85, 89]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[97, 100]], 'text': ['p53'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[166, 170]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[954, 958]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1015, 1019]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1079, 1082]], 'text': ['p53'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1151, 1154]], 'text': ['p53'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1183, 1187]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1346, 1349]], 'text': ['p53'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1440, 1444]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1449, 1452]], 'text': ['p53'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1626, 1629]], 'text': ['p53'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1631, 1635]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1637, 1642]], 'text': ['Smad4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1644, 1648]], 'text': ['PTEN'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1980, 1984]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2029, 2032]], 'text': ['p53'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2221, 2224]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2226, 2230]], 'text': ['mTOR'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2377, 2381]], 'text': ['CD44'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2647, 2651]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2723, 2727]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2860, 2865]], 'text': ['TIAF1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2907, 2910]], 'text': ['p53'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2916, 2920]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3206, 3210]], 'text': ['Wwox'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3397, 3401]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3449, 3453]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3498, 3502]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3554, 3558]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3596, 3600]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3630, 3634]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[3697, 3701]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3732, 3736]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3793, 3797]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3952, 3956]], 'text': ['Wwox'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[4153, 4157]], 'text': ['Wwox'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[4318, 4322]], 'text': ['Wwox'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[4511, 4515]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[4746, 4749]], 'text': ['p53'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[4754, 4758]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[4829, 4833]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[4920, 4924]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T44'}]",[],[],[],[],[]
69,PMC-3320587-04-Materials_and_Methods,"Viruses
HIV-1Bal, HIV-1Lai, HIV-193TH64, HIV-192TH51, HIV-192TH53, HIV-198CH01, and HIV-198IN22 were obtained from The Centralized Facility for AIDS Reagents, National Institute for Biological Standard and Control (NIBSC), United Kingdom. HIV-1KR25 was isolated in our laboratory as described before [33].",[],[],[],[],[],[]
70,PMC-1064873-15-Discussion,"CD4+ T cells orchestrate the Th1-type cell-mediated immune response in RA [22]. Activated CD4+ T cells stimulate macrophages, synovial fibroblasts, B cells, and osteoclasts through the expression of cell surface molecules and Th1 cytokines, thereby contributing to both the chronic inflammation and the joint destruction. CD4+ T cells require two signals to be activated; antigen receptor occupancy and CD28-mediated costimulation. In the ST lesion, the CD28 ligands, both CD80 and CD86, together with MHC class II antigens, are substantially expressed by antigen-presenting cells such as macrophages and dendritic cells [18-20]. The significance of CD28 engagement in the T-cell-mediated disease process has recently been proven by the clinical efficacy of its blocker cytotoxic T-cell-associated antigen 4 (CD152)-IgG in RA patients [23].
IL-10 plays a predominant role in limiting immune and inflammatory responses by regulating the function of both macrophages and Th1 cells [1]. IL-10 inhibits the tyrosine phosphorylation of the CD28 molecule and the subsequent phosphatidylinositol 3-kinase binding in T cells, and thereby directly acts on T cells [24]. In the present study, we found that PB CD4+ T cells from patients with active RA, in the presence of IL-10, are able to produce higher levels of IFN-gamma after CD3 and CD28 costimulation than normal CD4+ T cells. Despite high-level IL-10R1 expression and constitutive STAT3 activation, IL-10-induced tyrosine phosphorylation of STAT3 is suppressed in RA CD4+ T cells, in contrast to normal CD4+ T cells, where STAT3 phosphorylation is dose-dependently inducible by IL-10. Serum IL-6 from RA patients induces STAT3 but not STAT1 phosphorylation in normal CD4+ T cells, and exogenous IL-6 induces the resistance to IL-10 inhibition of IFN-gamma production. RA CD4+ T cells contain higher levels of SOCS1 but contain lower levels of SOCS3 transcripts in comparison with normal CD4+ T cells. These findings indicate that CD4+ T cells become resistant to the inhibitory effect of IL-10 before migration into the inflamed ST, and suggest that this resistance may be attributable to impaired IL-10-dependent STAT3 activation, in association with sustained STAT3 phosphorylation and SOCS1 induction.
IL-10-mediated inhibition of CD4+ T-cell cytokine production is principally dependent on its inhibition of macrophage antigen-presenting cell function [1]. However, this indirect inhibitory effect is thought to be restricted at the site of T-cell activation in RA, because macrophages in the ST express high levels of cytokines, CD80 and CD86 molecules, and MHC class II antigens [10,18-20]. More recently, IL-10 has been shown to induce the antigen-specific T-cell unresponsiveness by inhibiting CD28 tyrosine phosphorylation [33]. This direct effect also may be limited in active RA patients, because their PB CD4+ T cells showed a defective IL-10 inhibition of CD28-costimulated production of both IFN-gamma and IL-2.
Numerous cytokines, both proinflammatory and anti-inflammatory, have been detected in the ST of RA, and the balance between these opposing cytokine activities regulates disease severity [10]. Endogenous IL-10, produced mainly by macrophages and T cells, inhibits proinflammatory cytokine production by ST cells [12]. However, this regulatory activity seems to be restricted during chronic inflammation. The activation of both the extracellular stimulus-regulated kinase and p38 kinase pathways, induced by TNF-alpha and IL-1, inhibits the Jak1-STAT3 signaling pathway shared by IL-10 and IL-6 in adhered macrophages [13]. More importantly, IL-10-mediated STAT3 activation is mostly undetectable in RA synovial macrophages. This impaired IL-10 signaling is probably induced by chronic exposure to immune complexes in vivo, because both cell surface IL-10R1 expression and IL-10-induced Jak1 activation are suppressed in IFN-gamma-primed macrophages by a protein kinase C-dependent pathway following ligation of the IgG Fc gamma receptor [14]. Furthermore, dendritic cells from RA synovial fluids are resistant to the immunoregulatory effect of IL-10 due to decreased transport of intracellular IL-10R1 in the presence of proinflammatory cytokine stimuli such as TNF-alpha, IL-1, and granulocyte-macrophage colony-stimulating factor [15]. We have demonstrated that the resistance of RA CD4+ T cells to IL-10 may be associated with defective IL-10-dependent STAT3 activation, but not with IL-10R1 expression. Inhibitory effects of IL-10 on these inflammatory cell types are therefore differentially modulated at the signal transduction level under the inflammatory environment in RA.
In association with impaired IL-10-mediated STAT3 activation, STAT3 was found to be tyrosine phosphorylated persistently (up to 6 hours) in freshly isolated PB and ST CD4+ T cells from RA patients. STAT3 is activated by a variety of cytokines, notably the IL-6 family of cytokines (e.g. IL-6, IL-11, leukemia inhibitory factor, and oncostatin M) and growth factors, in addition to IL-10 [4]. Of these cytokines, IL-6 plays a predominant role in eliciting a systemic reaction such as the acute phase response in active RA, due mainly to its abundance in the blood circulation [27]. Consistent with this notion, IL-6 was the major STAT3-activating factor contained in the serum of active RA patients, and the responsiveness to IL-10 was suppressed in normal CD4+ T cells after 36 hours of incubation with IL-6. These results suggest that both the sustained STAT3 activation and the resistance to IL-10 inhibition found in RA CD4+ T cells may be induced after chronic exposure in vivo to high concentrations of serum IL-6. However, it is also possible that STAT3 activity could be constitutively induced in CD4+ T cells by their own IL-10 secretion, leading to the loss of sensitivity to exogenous IL-10, because RA CD4+ T cells in the ST are capable of producing significant levels of IL-10 [34].
CD4+ T cells isolated from the ST of RA also showed a defect in the IL-10-induced STAT3 signaling pathway. It is most probable that the resistance of CD4+ T cells to IL-10 can be even augmented after migration into the inflamed ST, because IL-6 is highly concentrated compared with the blood level [27]. In addition, the involvement of other essential proinflammatory cytokines in this process was suggested by our preliminary experiments demonstrating that IL-10-mediated IFN-gamma inhibition in CD4+ T cells was reduced by pretreatment with IL-1beta and TNF-alpha, although less effectively than by IL-6 (data not shown). Furthermore, IFN-gamma and IL-10 produced by CD4+ T cells themselves could be responsible for impaired IL-10 signaling in the ST, because T-cell infiltrates produce both cytokines [34,35]. In an autocrine fashion, IL-10 may persistently stimulate STAT3 activation and IFN-gamma can induce SOCS1 protein as a crosstalk inhibitor of IL-10 signaling [32]. The T-cell-inhibitory effect of IL-10 may therefore be modulated complicatedly upon exposure to an inflammatory environment in RA joints, where many cytokines are present substantially [10].
STAT3 activation has been implicated in the pathogenesis of RA. Active STAT3 is constitutively expressed in synovial fluid mononuclear cells from RA patients [36]. IL-6 is the major STAT3-activating factor present in synovial fluid, which has a crucial role in the activation of monocyte functions such as gene expression of the Fc gamma receptor type I and type III and of HLA-DR [31]. More recently, high levels of activated STAT3, thought to be induced mainly by IL-6, have been detected in the ST, and STAT3 activation has been shown to be involved in synovial fibroblast proliferation and IL-6 production [37]. In this regard, STAT3 is critical in the survival and expansion of growth factor-dependent synovial fibroblasts [38]. Furthermore, the significance of persistent STAT3 signaling in Th1-cell-dominated autoimmune arthritis has been suggested by studies of the gp130F759/F759 mice, in which the Src homology phosphatase-2 binding site of gp130 (the transmembrane glycoprotein beta subunit of the IL-6 family cytokine receptor), tyrosine 759, was mutated to phenylalanine [39]. In the gp130F759/F759 mice, T cells, particularly the CD4+ T-cell subset, are chronically activated and resistant to activation-induced cell death through gp130-mediated STAT3 activation.
The longevity of cytokine signals transduced by the JAK-STAT pathway is regulated by the SOCS family proteins [7]. We found that CD4+ T cells from patients with active RA expressed higher levels of SOCS1, but lower levels of SOCS3, compared with normal CD4+ T cells. SOCS1 prevents activation of JAK by directly binding to JAK, and SOCS3 inhibits the action of JAK by binding to the Src homology phosphatase-2-binding domain of receptors such as gp130 [40]. SOCS1 and SOCS3 are induced by various cytokines, including IL-6 and IL-10, as mediators of negative feedback and crosstalk inhibition [7]. Recent studies with mice lacking SOCS3 or SOCS1 revealed that SOCS3 is a negative regulator of IL-6 signaling but not of IL-10 signaling. Studies of conditional SOCS3-deficient mice have shown that SOCS3 deficiency, but not SOCS1 deficiency, results in sustained activation of STAT3 in response to IL-6 [8,41]. The analysis of SOCS3-deficient macrophages has indicated that SOCS3 is a crucial inhibitor of the IL-6-induced transcriptional response [42]. However, SOCS3 is dispensable for both the negative feedback inhibition and the immunoregulatory action of IL-10 in macrophages [41]. On the contrary, SOCS1 was found to directly inhibit IL-10-mediated signaling [43]. Increased SOCS1 expression in RA CD4+ T cells may therefore be associated with both the impaired responsiveness to IL-10 and to IL-10-mediated STAT3 activation, and defective SOCS3 expression may be responsible for persistent STAT3 activation in response to serum IL-6.
There is a possibility that SOCS1 induction may be associated with the ability of CD4+ T cells to produce IFN-gamma, because CD4+ T cells from active RA could produce high levels of IFN-gamma in the presence of IL-10, and because IFN-gamma has been known as a potent inducer of SOCS1 [32]. It is of interest in this regard to indicate that polarized Th1 and Th2 cells express high levels of SOCS1 and SOCS3 mRNA, respectively [44]. IL-12-induced STAT4 activation is inhibited by SOCS3 induction in Th2 cells, whereas IL-4-induced STAT6 signaling is diminished by SOCS1 induction in Th1 cells. SOCS1 and SOCS3 may thus have important roles as Th1-specific and Th2-specific, mutually exclusive, cross-talk repressors of the IL-4-STAT6 and the IL-12-STAT4 signaling pathways, respectively. Consistent with this notion, PB T cells from patients with allergic diseases significantly express high levels of SOCS3 transcripts, and the SOCS3 expression correlates well with serum IgE levels and disease pathology [45]. Higher SOCS1 expression with lower SOCS3 expression in PB CD4+ T cells from RA patients, compared with healthy controls, is therefore probably consistent with their systemic bias towards a Th1 phenotype, as has previously been demonstrated [46-49].","[{'offsets': [[0, 3]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[90, 93]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[322, 325]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[403, 407]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[454, 458]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[473, 477]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[482, 486]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[650, 654]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[770, 819]], 'text': ['cytotoxic T-cell-associated antigen 4 (CD152)-IgG'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[841, 846]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[984, 989]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1035, 1039]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1200, 1203]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1262, 1267]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1306, 1315]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1330, 1334]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1361, 1364]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1394, 1401]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1430, 1435]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1448, 1453]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1490, 1495]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1516, 1519]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1552, 1555]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1572, 1577]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1627, 1632]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1640, 1644]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1670, 1675]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1684, 1689]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1716, 1719]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1744, 1748]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1775, 1780]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1795, 1804]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1820, 1823]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1858, 1863]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1892, 1897]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1936, 1939]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1979, 1982]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2037, 2042]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2147, 2152]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2163, 2168]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2211, 2216]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2237, 2242]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2254, 2259]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2283, 2286]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2583, 2587]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2592, 2596]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2661, 2666]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2751, 2755]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2866, 2869]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2898, 2903]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2918, 2922]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2955, 2964]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2969, 2973]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[3178, 3183]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T96'}, {'offsets': [[3481, 3490]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T97'}, {'offsets': [[3495, 3499]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T98'}, {'offsets': [[3514, 3518]], 'text': ['Jak1'], 'type': 'Protein', 'id': 'T99'}, {'offsets': [[3519, 3524]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T100'}, {'offsets': [[3553, 3558]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T101'}, {'offsets': [[3563, 3567]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T102'}, {'offsets': [[3615, 3620]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T103'}, {'offsets': [[3630, 3635]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T104'}, {'offsets': [[3712, 3717]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T105'}, {'offsets': [[3823, 3830]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T106'}, {'offsets': [[3846, 3851]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T107'}, {'offsets': [[3860, 3864]], 'text': ['Jak1'], 'type': 'Protein', 'id': 'T108'}, {'offsets': [[3894, 3903]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T109'}, {'offsets': [[4118, 4123]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T110'}, {'offsets': [[4168, 4175]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T111'}, {'offsets': [[4236, 4245]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T112'}, {'offsets': [[4247, 4251]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T113'}, {'offsets': [[4257, 4305]], 'text': ['granulocyte-macrophage colony-stimulating factor'], 'type': 'Protein', 'id': 'T114'}, {'offsets': [[4359, 4362]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T115'}, {'offsets': [[4375, 4380]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T116'}, {'offsets': [[4414, 4419]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T117'}, {'offsets': [[4430, 4435]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T118'}, {'offsets': [[4461, 4468]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T119'}, {'offsets': [[4503, 4508]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T120'}, {'offsets': [[4685, 4690]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T121'}, {'offsets': [[4700, 4705]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T122'}, {'offsets': [[4718, 4723]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T123'}, {'offsets': [[4823, 4826]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T124'}, {'offsets': [[4854, 4859]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T125'}, {'offsets': [[4943, 4947]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T126'}, {'offsets': [[4949, 4954]], 'text': ['IL-11'], 'type': 'Protein', 'id': 'T127'}, {'offsets': [[4956, 4982]], 'text': ['leukemia inhibitory factor'], 'type': 'Protein', 'id': 'T128'}, {'offsets': [[4988, 5000]], 'text': ['oncostatin M'], 'type': 'Protein', 'id': 'T129'}, {'offsets': [[5037, 5042]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T130'}, {'offsets': [[5068, 5072]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T131'}, {'offsets': [[5266, 5270]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T132'}, {'offsets': [[5285, 5290]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T133'}, {'offsets': [[5381, 5386]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T134'}, {'offsets': [[5412, 5415]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T135'}, {'offsets': [[5459, 5463]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T136'}, {'offsets': [[5511, 5516]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T137'}, {'offsets': [[5550, 5555]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T138'}, {'offsets': [[5579, 5582]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T139'}, {'offsets': [[5670, 5674]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T140'}, {'offsets': [[5710, 5715]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T141'}, {'offsets': [[5760, 5763]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T142'}, {'offsets': [[5786, 5791]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T143'}, {'offsets': [[5851, 5856]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T144'}, {'offsets': [[5869, 5872]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T145'}, {'offsets': [[5939, 5944]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T146'}, {'offsets': [[5951, 5954]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T147'}, {'offsets': [[6019, 6024]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T148'}, {'offsets': [[6033, 6038]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T149'}, {'offsets': [[6101, 6104]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T150'}, {'offsets': [[6117, 6122]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T151'}, {'offsets': [[6191, 6195]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T152'}, {'offsets': [[6409, 6414]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T153'}, {'offsets': [[6424, 6433]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T154'}, {'offsets': [[6448, 6451]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T155'}, {'offsets': [[6494, 6502]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T156'}, {'offsets': [[6507, 6516]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T157'}, {'offsets': [[6552, 6556]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T158'}, {'offsets': [[6588, 6597]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T159'}, {'offsets': [[6602, 6607]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T160'}, {'offsets': [[6620, 6623]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T161'}, {'offsets': [[6678, 6683]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T162'}, {'offsets': [[6789, 6794]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T163'}, {'offsets': [[6822, 6827]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T164'}, {'offsets': [[6843, 6852]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T165'}, {'offsets': [[6864, 6869]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T166'}, {'offsets': [[6906, 6911]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T167'}, {'offsets': [[6960, 6965]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T168'}, {'offsets': [[7119, 7124]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T210'}, {'offsets': [[7190, 7195]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T211'}, {'offsets': [[7283, 7287]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T212'}, {'offsets': [[7301, 7306]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T213'}, {'offsets': [[7448, 7472]], 'text': ['Fc gamma receptor type I'], 'type': 'Protein', 'id': 'T214'}, {'offsets': [[7477, 7485]], 'text': ['type III'], 'type': 'Protein', 'id': 'T215'}, {'offsets': [[7546, 7551]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T216'}, {'offsets': [[7585, 7589]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T217'}, {'offsets': [[7625, 7630]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T218'}, {'offsets': [[7713, 7717]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T219'}, {'offsets': [[7751, 7756]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T220'}, {'offsets': [[7897, 7902]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T221'}, {'offsets': [[7993, 7998]], 'text': ['gp130'], 'type': 'Protein', 'id': 'T222'}, {'offsets': [[8070, 8075]], 'text': ['gp130'], 'type': 'Protein', 'id': 'T223'}, {'offsets': [[8081, 8157]], 'text': ['transmembrane glycoprotein beta subunit of the IL-6 family cytokine receptor'], 'type': 'Protein', 'id': 'T224'}, {'offsets': [[8216, 8221]], 'text': ['gp130'], 'type': 'Protein', 'id': 'T225'}, {'offsets': [[8263, 8266]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T226'}, {'offsets': [[8364, 8369]], 'text': ['gp130'], 'type': 'Protein', 'id': 'T227'}, {'offsets': [[8379, 8384]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T228'}, {'offsets': [[8526, 8529]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T229'}, {'offsets': [[8595, 8600]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T230'}, {'offsets': [[8622, 8627]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T231'}, {'offsets': [[8650, 8653]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T232'}, {'offsets': [[8664, 8669]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T233'}, {'offsets': [[8729, 8734]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T234'}, {'offsets': [[8843, 8848]], 'text': ['gp130'], 'type': 'Protein', 'id': 'T235'}, {'offsets': [[8855, 8860]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T236'}, {'offsets': [[8865, 8870]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T237'}, {'offsets': [[8915, 8919]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T238'}, {'offsets': [[8924, 8929]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T239'}, {'offsets': [[9028, 9033]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T240'}, {'offsets': [[9037, 9042]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T241'}, {'offsets': [[9057, 9062]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T242'}, {'offsets': [[9090, 9094]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T243'}, {'offsets': [[9116, 9121]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T244'}, {'offsets': [[9156, 9161]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T245'}, {'offsets': [[9193, 9198]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T246'}, {'offsets': [[9219, 9224]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T247'}, {'offsets': [[9272, 9277]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T248'}, {'offsets': [[9293, 9297]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T249'}, {'offsets': [[9322, 9327]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T250'}, {'offsets': [[9369, 9374]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T251'}, {'offsets': [[9405, 9409]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T252'}, {'offsets': [[9458, 9463]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T253'}, {'offsets': [[9556, 9561]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T254'}, {'offsets': [[9600, 9605]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T255'}, {'offsets': [[9636, 9641]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T256'}, {'offsets': [[9677, 9682]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T257'}, {'offsets': [[9700, 9703]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T258'}, {'offsets': [[9782, 9787]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T259'}, {'offsets': [[9795, 9800]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T260'}, {'offsets': [[9810, 9815]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T261'}, {'offsets': [[9842, 9847]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T262'}, {'offsets': [[9893, 9898]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T263'}, {'offsets': [[9931, 9935]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T264'}, {'offsets': [[9965, 9970]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T265'}, {'offsets': [[10019, 10022]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T266'}, {'offsets': [[10043, 10052]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T267'}, {'offsets': [[10062, 10065]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T268'}, {'offsets': [[10119, 10128]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T269'}, {'offsets': [[10148, 10153]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T270'}, {'offsets': [[10167, 10176]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T271'}, {'offsets': [[10215, 10220]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T272'}, {'offsets': [[10328, 10333]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T273'}, {'offsets': [[10338, 10343]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T274'}, {'offsets': [[10369, 10374]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T275'}, {'offsets': [[10383, 10388]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T276'}, {'offsets': [[10416, 10421]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T277'}, {'offsets': [[10454, 10458]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T278'}, {'offsets': [[10467, 10472]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T279'}, {'offsets': [[10500, 10505]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T280'}, {'offsets': [[10530, 10535]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T281'}, {'offsets': [[10540, 10545]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T282'}, {'offsets': [[10659, 10663]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T283'}, {'offsets': [[10664, 10669]], 'text': ['STAT6'], 'type': 'Protein', 'id': 'T284'}, {'offsets': [[10678, 10683]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T285'}, {'offsets': [[10684, 10689]], 'text': ['STAT4'], 'type': 'Protein', 'id': 'T286'}, {'offsets': [[10838, 10843]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T287'}, {'offsets': [[10865, 10870]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T288'}, {'offsets': [[10955, 10960]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T289'}, {'offsets': [[10983, 10988]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T290'}, {'offsets': [[11006, 11009]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T291'}]",[],[],[],[],[]
71,PMC-3320587-18-Results,"NF-kappaB and NFAT5 binding to the HIV-1 LTR can be specifically disrupted
To demonstrate that the impact of NFAT5 silencing on MTb-induced viral replication was a direct effect due to modulation of recruitment of NFAT5 to the HIV-1 LTR and not due to secondary, NFAT5-regulated effects, we set out to disrupt NFAT5 binding to the viral LTR in the context of HIV-1/MTb co-infection. This series of experiments also allowed us to dissect the relative importance of NFAT5 and NF-kappaB binding to the HIV-1 LTR in MTb regulation of HIV-1 replication.
To perform these experiments, we constructed a panel of infectious HIV-1Lai/Bal-env molecular clones where either the NFAT5 site was specifically disrupted or the two NF-kappaB binding sites were either individually or dually disrupted (Figure 3A). Specifically, we constructed a clone in which the NFAT5 binding site was mutated (named HIV-1Lai/Bal-env-N5-Mut) by changing the CC dinucleotide to TT in the core NFAT5 binding site and introduced substitution mutations into the NF-kappaB/NFAT5 shared binding element that we predicted would disrupt NF-kappaB binding but preserve NFAT5 binding. Specifically, we mutated two guanines (GG) in the kappaB I site and changed them to thymine and adenine (TA) (HIV-1Lai/Bal-env-kappaB I-mut) and also introduced the same GG to TA change in the second, more distal NF-kappaB site (kappaB II) in HIV-1Lai/Bal-env (HIV-1Lai/Bal-env-kappaB II-Mut). We also created a double NF-kappaB site mutant virus (HIV-1Lai/Bal-env-kappaB I+II-Mut) in order to test the impact of complete disruption of NF-kappaB binding to the HIV-1 LTR on MTb regulation.
To determine the specificity of these substitutions upon NFAT5 and NF-kappaB p50/p65 binding to the LTR, we performed a quantitative DNase I footprinting analysis using the wild-type LTR or mutant LTRs in combination with increasing concentrations of recombinant NFAT5 or NF-kappaB p50/p65 proteins. As shown in Figure 3B, the N5-Mut LTR could not bind NFAT5 (compare lanes 12-15 and lanes 17-20), but p50/p65 binding was not impaired (compare lanes 2-5 with lanes 7-10). By contrast, changing the GG dinucleotide to TA in either NF-kappaB binding motif, as predicted, inhibited p50/p65 binding at each site (compare lanes 2-5 with lanes 7-10 and lanes 12-15 of Figure 3C). As expected, mutation of both NF-kappaB sites (kappaB I+II-Mut) resulted in abrogation of p50/p65 binding to the LTR. However, recombinant NFAT5 binding to the single and the double NF-kappaB mutant LTRs was not impaired and indeed appeared enhanced (compare lanes 2-5 to lanes 7-20 of Figure 3D). Thus, binding of NFAT5 or NF-kappaB p50/p65 to their respective motifs can be specifically disrupted within an overlapping or shared binding site.","[{'offsets': [[14, 19]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[109, 114]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[214, 219]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[263, 268]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[310, 315]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[464, 469]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[629, 632]], 'text': ['env'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[899, 902]], 'text': ['env'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1129, 1134]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1267, 1270]], 'text': ['env'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1400, 1403]], 'text': ['env'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1418, 1421]], 'text': ['env'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1505, 1508]], 'text': ['env'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1691, 1696]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1711, 1714]], 'text': ['p50'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1715, 1718]], 'text': ['p65'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1767, 1774]], 'text': ['DNase I'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1897, 1902]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1916, 1919]], 'text': ['p50'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1920, 1923]], 'text': ['p65'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1987, 1992]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2036, 2039]], 'text': ['p50'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2040, 2043]], 'text': ['p65'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2213, 2216]], 'text': ['p50'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2217, 2220]], 'text': ['p65'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2398, 2401]], 'text': ['p50'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2402, 2405]], 'text': ['p65'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2447, 2452]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2623, 2628]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2642, 2645]], 'text': ['p50'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2646, 2649]], 'text': ['p65'], 'type': 'Protein', 'id': 'T31'}]",[],[],[],[],[]
72,PMC-3312845-09-Methods,"Volumetric analysis and cell counts
To measure vasogenic edema, the volume of anti-rat IgG positive region in PC was estimated according to the formula based on the modified Cavalieri method: V = sigmaa x tnom x 1/ssf, where a is area of the region of the delineated subfield measured by AxioVision Rel. 4.8 software, tnom is the nominal section thickness (of 30 mum in this study), and ssf is the fraction of the sections sampled or section sampling fraction (of 1/6 in this study). The subfield areas were delineated with a 2.5 x objective lens [5,7,8,18,25]. The volumes are reported as mm3. An optical fractionator was used to estimate cell numbers. The optical fractionator (a combination of performing counting with the optical dissector, with fractionator sampling) is a stereological method based on a properly designed systematic random sampling method that by definition yields unbiased estimates of population number. The sampling procedure is accomplished by focusing through the depth of the tissue (the optical dissector height, h; 15 mum in all cases for this study). The number of each cell type (C) in each of the subregions is estimated as: C = sigmaQ- x t/h x 1/asf x 1/ssf, where Q- is the number of cells actually counted in the dissectors that fell within the sectional profiles of the subregion seen on the sampled sections, and Asf is the areal sampling fraction calculated by the area of the counting frame of the dissector, a(frame) (of 50 x 50 mum2 in this study) and the area associated with each x, y movement, grid (x, y step) (of 250 x 250 mum2 in this study) {asf = (a(frame)/a(x, y step))}. The immunoreactive cells were counted with a 40x objective lens. The immunoreactive cells were counted with a 40x objective lens. All immunoreactive cells were counted regardless the intensity of labeling. Cell counts were performed by two different investigators who were blind to the classification of tissues. SE-induced PC atrophy is evident [8], so changes in cell number may be caused by an alterations in the volume of the PC. Therefore, the total number of cells was corrected by multiplying with appropriate correction factors (CF) representing the degree of shrinkage (or swelling) compared with the Non-SE.",[],[],[],[],[],[]
73,PMC-3291650-15-Materials_and_Methods,"RNA isolation, cDNA synthesis and qPCR
Total RNA was extracted using Aurum Total RNA mini kit (BioRad) and reverse transcribed into cDNA with iScript cDNA synthesis kit (BioRad) according to the manufacturer's instructions. qPCR was performed by using SYBR Green I master mix I (Roche) in the Lightcycler 480 detection system (Roche) with the following primers: HPRT: 5'-AGTGTTGGATACAGGCCAGAC-3' and 5'CGTGATTCAAATCCCTGAAGT-3'; IL-6: 5'-GAGGATACCACTCCCAACAGACC-3' and 5'-AAGTGCATCATCGTTGTTCATACA-3'; IFNbeta: 5'-TCAGAATGAGTGGTGGTTGC-3' and 5'-GACCTTTCAAATGCAGTAGATTCA-3'; A20: 5'-AAACCAATGGTGATGGAAACTG-3' and 5'-GTTGTCCCATTCGTCATTCC-3'; CCL2: 5'-TTAAAAACCTGGATCGGAACCAA-3' and 5'-GCATTAGCTTCAGATTTACGGGT-3'; CXCL1: 5'-GAGCCTCTAACCAGTTCCAG-3' and 5'-TGAGTGTGGCTATGACTTCG-3' and IFNalpha4: 5'-TGATGAGCTACTACTGGTCAGC-3' and 5'-GATCTCTTAGCACAAGGATGGC-3'. Primers were designed with PerlPrimer (http://perlprimer.sourceforge.net). Quantification was performed using the comparative CT method (deltadeltaCT). Results are expressed relative to HPRT values.","[{'offsets': [[428, 432]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[500, 507]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[572, 575]], 'text': ['A20'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[638, 642]], 'text': ['CCL2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[709, 714]], 'text': ['CXCL1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[778, 787]], 'text': ['IFNalpha4'], 'type': 'Protein', 'id': 'T6'}]",[],[],[],[],[]
74,PMC-1359074-12-Materials_and_Methods,"Histology.
18.5-dpc embryos were exsanguinated and peripheral blood smears were prepared from both mutant and WT mice. The slides were Wright-stained and read by DAF. For whole mount analysis, 14.5-dpc WT and mutant embryos, and postnatal day-10.5 mice were fixed in 10% formalin, paraffin-embedded, sectioned at 5 mum, and stained with hematoxylin and eosin. Liver samples (at 14.5 dpc and 18.5 dpc) were prepared in a similar manner. Images were obtained with Nikon Labophot-2 microscope. Objectives used were E Plan 40/0.65 160/0.17 Nikon (40x objective), E Plan 100/1.25 oil 160/0.17 Nikon (100x objective). The camera was a Nikon Coolpix 4300. Original images are available.",[],[],[],[],[],[]
75,PMC-3317373-06-2._Methods_and_Materials,"2.5. RT-PCR
Total RNA was isolated with Trizol (Invitrogen, CA, USA), and single-stranded cDNA was synthesized from 2 mug of total RNA with BU-Script RT-Kit (Biunique, Jiangsu, China) according to the manufacturer's protocol. The cDNA was stored in -20degreesC. Reverse transcription was conducted with GoTaq Green Master Mix (Promega, WI, USA) according to the manufacturer's protocol. Table 1 shows the primers and PCR parameters. PCR products were detected by agarose gel electrophoresis. The intensity of the bands was analyzed by ImageJ program. The level of beta-actin was used as an internal standard.","[{'offsets': [[564, 574]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
76,PMC-3589482-07-Experimental_Procedures,"Transient Transfection and Luciferase Assays (RAW264.7 Macrophages)
RAW 264.7 cells (2x107) growing in log phase were transfected with the indicated luciferase reporter plasmid (20 microg) along with the pRL-thymidine kinase (TK) (Promega) internal control reporter plasmid (2 microg) by electroporation using a Bio-Rad Gene Pulser with a Capacitance Extender (0.25 kV, 960 microFd). pGL3 control plasmid which encodes the SV40 promoter and enhancer was included as a positive control for transfection efficiency, and as an internal standard for promoter and enhancer activities. Transfected cells were transferred to 10 ml of pre-warmed media in 6-well tissue culture plates, divided into two identical cell pools and incubated 16 hrs in a 5% CO2 and 95% humidified air atmosphere at 37degreesC either in the presence or absence of 100 ng/ml LPS. Luciferase activity was measured using a Dual-Luciferase Reporter Assay System kit (Promega). Measurements represent the results of at least three independent experiments. Promoter activity is expressed as the number of firefly luciferase light units normalized either to pRL-TK renilla luciferase light units or to cellular protein concentration (where co-transfected C/EBP-beta or LPS affected pRL-TK activity). Protein concentration was determined using the Bio-Rad protein microassay reagent.","[{'offsets': [[27, 37]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[149, 159]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[208, 224]], 'text': ['thymidine kinase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[226, 228]], 'text': ['TK'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[848, 858]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[894, 904]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1076, 1086]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1124, 1126]], 'text': ['TK'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1135, 1145]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1217, 1227]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1248, 1250]], 'text': ['TK'], 'type': 'Protein', 'id': 'T11'}]",[],[],[],[],[]
77,PMC-3291650-01-Introduction,"Viruses are a class of highly diverse pathogens which depend on the host cell for their replication. The initiation of a protective innate antiviral immune response involves the action of specialized pattern recognition receptors (PRR), which detect conserved molecular structures of the invading pathogen. Triggering of PRRs induces the production of host proinflammatory cytokines (e.g. TNF, IL-6 and IL-1) and type I interferons (interferon-alpha (IFN-alpha) and IFN-beta) through activation of downstream signaling pathways that control various transcription factors such as NF-kappaB, AP-1, IRF3 and IRF7 [1], [2]. The presence of viral nucleic acids, such as viral RNA and DNA, viral replication intermediates and viral transcription products, can be sensed by specific intracellular PRRs [3]. Endosomal Toll-like receptors (TLRs) and cytoplasmic RNA helicase RIG-I-like receptors (RLRs) or Nod-like receptors (NLRs) detect the presence of viral single stranded (TLR7, TLR8, Nod2) or double stranded RNA (TLR3, RIG-I, MDA5). Intracellular DNA sensors that mediate antiviral immune responses to DNA viruses include TLR9, DAI [4] and the PYHIN domain containing proteins AIM2 [5], [6], [7] and IFI16 [8]. TLR mediated antiviral responses are restricted to specialized type I IFN producing plasmacytoid dendritic cells (pDC), while most other cell types, including conventional DC (cDC), macrophages and fibroblasts, depend on the cytosolic RNA and DNA sensors for the production of antiviral proteins [9].
Influenza A virus (IAV) is the etiological agent of a contagious acute respiratory disease that causes considerable mortality, which is generally believed to be due to an excessive host inflammatory response. Emergence of drug-resistant strains of influenza viruses with pandemic potential underscores the importance of developing novel antiviral strategies. In this context, understanding of the mechanisms that regulate IAV-induced immune responses is critical. IAV infection leads to the exposure in the host cell of single-stranded genomic RNA and double stranded RNA, the latter being an intermediate of viral replication. TLR3 and RIG-I have been implicated as sensors of IAV infection [10]-[12]. Both receptors contribute to the proinflammatory response to IAV, but the initiation of the innate antiviral immune response largely depends on RIG-I mediated signaling [13]. Interestingly, RIG-I deficient mice are highly susceptible to IAV [14], [15], whereas TLR3 deficient mice have a survival advantage to acute infection [16]. These results indicate that an imbalance between the beneficial and harmful effects of mediators released by immune cells is likely to contribute to the pathogenesis of influenza.
RIG-I contains a C-terminal DExD/H box helicase domain, which is required for ligand recognition, and two N-terminal CARD domains. Upon ligand binding, the CARD domains of RIG-I associate with the CARD domain of the MAVS (also termed IPS-1, VISA, Cardif) adaptor protein, which subsequently translocates to and inserts in the outer mitochondrial membrane via its C-terminal transmembrane domain [17]-[20]. Signaling downstream of MAVS requires the action of various ubiquitin modifying enzymes, which both positively and negatively regulate RIG-I mediated signal transduction [21]. K63-specific ubiquitin ligases (E3s), such as TRIM25 [22] and Riplet [23], [24], have been shown to directly promote RIG-I activation. In addition, well characterized ubiquitin ligases such as TRAF6 [25], [26] and TRAF3 [27] mediate respectively NF-kappaB and IRF3 activation upon RIG-I stimulation. On the other hand, deubiquitinating enzymes (DUBs), such as DUBA [28], CYLD [29], [30] and OTUB1/2 [31] have been shown to negatively regulate RLR signaling by specifically removing K63-linked polyubiquitin chains from several signaling molecules. Furthermore, various K48-specific ubiquitin ligases, such as AIP4 [32] and TRIAD3A [33] mark respectively MAVS and TRAF3 for proteasome mediated degradation, thus inhibiting further downstream signaling. Additionally, the attachment of K48-specific polyubiquitin chains to the IRF3 and IRF7 transcription factors by E3s such as RAUL [34], TRIM21 [35] and RBCK1 [36] further dampens antiviral signal transduction.
A20 is an ubiquitin-editing enzyme belonging to the OTU-domain family of DUBs. Interestingly, A20 also harbors atypical zinc finger dependent K48-specific E3 ubiquitin ligase activity. Both catalytic and noncatalytic mechanisms were previously shown to be involved in the negative regulation of proinflammatory signaling by A20 in response to multiple receptors such as TNF receptor I [37]-[39], TLR4 [40], and IL-1R [41]. The anti-inflammatory role of A20 is clearly demonstrated by the fact that A20 deficient mice die early after birth due to severe multi-organ inflammation and cachexia [37]. More recently, gene targeting of A20 in specific cell types was shown to be associated with autoimmunity and chronic inflammation [42]-[48], further illustrating that A20 is an important brake on the inflammatory response. The relevance of these findings for human disease has recently been illustrated through the identification of polymorphisms in the A20 locus that are associated with several autoimmune diseases and chronic inflammation [45]. In contrast to its well established function in the regulation of proinflammatory responses, the role of A20 in the regulation of antiviral immune responses is less well described and limited to a number of in vitro studies using overexpression or silencing in specific cell lines, indicating that A20 may regulate RIG-I- and TLR3-induced signaling to NF-kappaB and IRF-3 [49]-[52]. However, the precise in vivo role of A20 in the response to viral infection remains to be clarified. Using myeloid cell specific A20 knockout mice (A20myel-KO) that were recently generated in our lab and primary cells derived of these mice, we here provide evidence that A20 is a crucial negative regulator of IAV-induced proinflammatory and antiviral signaling in macrophages. Interestingly, A20myel-KO mice show enhanced survival and reduced morbidity in response to IAV lung infection compared to wild type mice. Protection against IAV in A20myel-KO mice is associated with increased cytokine and chemokine production, augmented recruitment of innate immune cells such as neutophils and alveolar macrophages, and enhanced viral clearance. These results suggest that boosting the innate immune response to IAV by targeting A20 activity in myeloid cells might have therapeutic potential.","[{'offsets': [[389, 392]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[394, 398]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[403, 407]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[433, 449]], 'text': ['interferon-alpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[451, 460]], 'text': ['IFN-alpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[466, 474]], 'text': ['IFN-beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[596, 600]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[605, 609]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[969, 973]], 'text': ['TLR7'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[975, 979]], 'text': ['TLR8'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[981, 985]], 'text': ['Nod2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1011, 1015]], 'text': ['TLR3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1017, 1022]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1024, 1028]], 'text': ['MDA5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1120, 1124]], 'text': ['TLR9'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1126, 1129]], 'text': ['DAI'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1175, 1179]], 'text': ['AIM2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1198, 1203]], 'text': ['IFI16'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2138, 2142]], 'text': ['TLR3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2147, 2152]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2357, 2362]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2403, 2408]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2474, 2478]], 'text': ['TLR3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2725, 2730]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2897, 2902]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2941, 2945]], 'text': ['MAVS'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2959, 2964]], 'text': ['IPS-1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2966, 2970]], 'text': ['VISA'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2972, 2978]], 'text': ['Cardif'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3155, 3159]], 'text': ['MAVS'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3266, 3271]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[3353, 3359]], 'text': ['TRIM25'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3369, 3375]], 'text': ['Riplet'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3424, 3429]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3500, 3505]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3521, 3526]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3567, 3571]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3588, 3593]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3667, 3671]], 'text': ['DUBA'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3678, 3682]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3750, 3753]], 'text': ['RLR'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3916, 3920]], 'text': ['AIP4'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3930, 3937]], 'text': ['TRIAD3A'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3961, 3965]], 'text': ['MAVS'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3970, 3975]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[4132, 4136]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[4141, 4145]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[4183, 4187]], 'text': ['RAUL'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4194, 4200]], 'text': ['TRIM21'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4210, 4215]], 'text': ['RBCK1'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4638, 4652]], 'text': ['TNF receptor I'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4664, 4668]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4679, 4684]], 'text': ['IL-1R'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[5628, 5633]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[5639, 5643]], 'text': ['TLR3'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[5679, 5684]], 'text': ['IRF-3'], 'type': 'Protein', 'id': 'T58'}]",[],[],[],[],[]
78,PMC-3342329-21-Caption-Figure_4,"Upregulation of IL-1Ra in the tumor and spleen of CCR5-/- mice.
A, Figure 4A indicates mouse cytokine array panel coordinates. Nitrocellulose membranes contain 40 different anti-cytokine antibodies printed in duplicate. B, Mouse cytokine array panel indicate the cytokine expression difference in tumor tissues of CCR5+/+ mice and CCR5-/- mice, especially IL-1Ra. Representative blot from three independent experiments is shown. Positive controls show the manufacturer's internal positive control samples on the membrane. C, Protein immune-arrays were performed using Mouse cytokine array in spleen tissues. There were differences in cytokines between CCR5+/+ mice and CCR5-/- mice, especially IL-1Ra. Representative blot from three independent experiments is shown. Positive controls show the manufacturer's internal positive control samples on the membrane. D and E, Immunolfluorescence analysis was used to determine the expression levels of IL-1Ra in tumor and spleen tissues. The reactive cell number was determined as the number of DAPI-stained, IL-1Ra antibody-positive cells that were counted. Values are the mean +/- S.D. of four experimental animals. * indicates statistically significant differences from CCR5+/+ mice. Scale bar indicates 50 microm. F and G, Expression of IL-1Ra was analyzed by western blotting in tumor and spleen tissues. Each band is representative of three independent experimental results. Data are means +/- S.D. of three experimental animals. * indicates significant difference from CCR5+/+ mice (p<0.05).","[{'offsets': [[16, 22]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[50, 54]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[314, 318]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[331, 335]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[356, 362]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[652, 656]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[669, 673]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[694, 700]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[945, 951]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1216, 1220]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1284, 1290]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1519, 1523]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
79,PMC-3585731-24-Materials_and_Methods,"TNFalpha ELISA
Mouse TNFalpha Quantikine ELISA assays (R&D Systems) were performed according to manufacturer's descriptions. Cell lysates were prepared from 3x106 cells plated and treated in a 10 cm2 dish.","[{'offsets': [[0, 8]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[21, 29]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
80,PMC-3589482-13-Results,"The SerpinB2 Gene is Highly Responsive to LPS
When RAW264.7 macrophages were exposed to LPS, SerpinB2 mRNA was detectable as early as 30 min following LPS challenge, reaching maximal levels at 24 hrs (Fig. 1A). A similar strong induction of LPS-inducible SerpinB2 mRNA expression has been reported previously in murine peritoneal macrophages and human peripheral blood mononuclear cells [4]; [32]. LPS-induced SerpinB2 expression involves both an increase in gene transcription and stabilization of the mRNA [5]; [29]; [42]-[44]. SerpinB2 protein expression was also induced as has been reported in other cell types [31], and detectable after 8 hrs of LPS treatment (Fig. 1).","[{'offsets': [[4, 12]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[93, 101]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[255, 263]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[410, 418]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[530, 538]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
81,PMC-1359074-18-Materials_and_Methods,"ChIP assay.
As described by Nouzova [53], in brief: Cells from MEL cells (4 x 107) or fetal liver cells from three 15.5-dpc WT mice were treated with 1% formaldehyde for 10 min at 37 degreesC, rinsed in ice-cold 1x Hanks' balanced salt solution with 0.1% EDTA containing protease inhibitors, collected by centrifugation at 4 degreesC, resuspended in a SDS lysis buffer containing protease inhibitors, and incubated on ice for 10 min. DNA-protein complexes were sonicated to 200 and 600 bp. One-tenth of the sample was set aside for input control, and the remaining sample was precleared with protein A-Sepharose (Amersham Biosciences, Piscataway, New Jersey, United States). Following preclearing, the samples were split into thirds: one sample treated with anti-Sox6, a second treated with normal rabbit IgG, and the third sample without Ab. The last two were used as negative controls. The chromatin-antibody complexes were eluted, and the DNA protein cross-links were reversed with 5 M NaCl at 65 degreesC for 4 h. Input DNA or immunoprecipitated DNA was used as a template in the PCR reaction. PCR amplification of the epsilony promoter was performed and yielded a 172-bp amplicon, corresponding to nucleotides -31 to +140 of the epsilony promoter (primers MHB1688, 5'CGAAGAATAAAAGGCCACCA3'; and MHB1689, 5'GCTTCACCACCAACCTCTTC3'). PCR was performed under the following conditions: 95 degreesC for 15 min followed by 30 cycles at 95 degreesC for 30 s, 60 degreesC for 30 s, and 72 degreesC for 45 s, ending with a final extension at 72 degreesC for 5 min.","[{'offsets': [[592, 601]], 'text': ['protein A'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[763, 767]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1123, 1131]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1234, 1242]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
82,PMC-1064873-09-Materials_and_methods,"Statistical analysis
Data are expressed as the mean value +/- standard error of the mean or box plots. The statistical significance of differences between two groups was determined by the Mann-Whitney U test or the Wilcoxon signed rank test. P < 0.05 was considered significant.",[],[],[],[],[],[]
83,PMC-3589482-30-Caption-Figure_7,"Differential recruitment of C/EBP-beta and C/EBP-betaT217 to the murine SerpinB2 promoter in vivo.
Transcription factor occupancy on the SerpinB2 proximal promoter in vivo was determined by chromatin immunoprecipitation (ChIP) assay. RAW264.7 macrophages were treated in the presence or absence of LPS for the indicated times and chromatin immunoprecipitation performed using antibodies against C/EBP-beta or p-C/EBP-beta (T217). Soluble chromatin (600-700 ng) was immunoprecipitated with antibodies against C/EBP-beta, p-C/EBP-beta (T217), RNA Polymerase II (RNAPII), or a rabbit IgG (rIgG) control. (A) Typical PCR pattern obtained in ChIP assays using murine SerpinB2 proximal promoter-specific primers, 338/-315 and -5/+19, as diagrammed in top. Recruitment of RNAPII to the SerpinB2 promoter suggests active transcription following LPS stimulation. Minimal background was detected using the rabbit IgG control, indicative of the specificity of the ChIP reaction. (B) qPCR analysis of chromatin immunoprecipitated with antibodies against C/EBP-beta, p-C/EBP-beta (T217), and the rIgG control. The data are represented relative to rIgG signal using the 2-deltadeltaCt method.","[{'offsets': [[28, 38]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[72, 80]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[137, 145]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[395, 405]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[409, 428]], 'text': ['p-C/EBP-beta (T217)'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[508, 518]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[520, 539]], 'text': ['p-C/EBP-beta (T217)'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[662, 670]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[779, 787]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1042, 1052]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1054, 1073]], 'text': ['p-C/EBP-beta (T217)'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1134, 1138]], 'text': ['rIgG'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
84,PMC-1359074-00-TIAB,"Sox6 Directly Silences Epsilon Globin Expression in Definitive Erythropoiesis
Sox6 is a member of the Sox transcription factor family that is defined by the conserved high mobility group (HMG) DNA binding domain, first described in the testis determining gene, Sry. Previous studies have suggested that Sox6 plays a role in the development of the central nervous system, cartilage, and muscle. In the Sox6-deficient mouse, p100H, epsilony globin is persistently expressed, and increased numbers of nucleated red cells are present in the fetal circulation. Transfection assays in GM979 (erythroleukemic) cells define a 36-base pair region of the epsilony proximal promoter that is critical for Sox6 mediated repression. Electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assays demonstrate that Sox6 acts as a repressor by directly binding to the epsilony promoter. The normal expression of Sox6 in wild-type fetal liver and the ectopic expression of epsilony in p100H homozygous fetal liver demonstrate that Sox6 functions in definitive erythropoiesis. The present study shows that Sox6 is required for silencing of epsilony globin in definitive erythropoiesis and suggests a role for Sox6 in erythroid cell maturation. Thus, Sox6 regulation of epsilony globin might provide a novel therapeutical target in the treatment of hemoglobinopathies such as sickle cell anemia and thalassemia.","[{'offsets': [[0, 4]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[23, 37]], 'text': ['Epsilon Globin'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[78, 82]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[261, 264]], 'text': ['Sry'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[303, 307]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[401, 405]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[430, 445]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[645, 653]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[693, 697]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[828, 832]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[880, 888]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[924, 928]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[984, 992]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1042, 1046]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1116, 1120]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1150, 1165]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1219, 1223]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1260, 1264]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1279, 1294]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T19'}]",[],[],[],[],[]
85,PMC-1359074-09-Materials_and_Methods,"Plasmid construction.
The epsilony promoter deletion reporter plasmid (E-luc) was generated by PCR amplification of the epsilony proximal promoter. A 2.2-kb fragment upstream of the epsilony globin initiation codon (ATG) was used, because it has been shown that all sequences required for epsilon gene silencing are located within a 3.7-kb EcoRI fragment containing about 2 kb of sequence upstream of the epsilon globin gene cap site [50]. Nucleotide numbering is relative to the transcription start site. The transcriptional start site is based on the longest cDNA in the Fantom (Functional Annotation of Mouse) database. The PCR primers contained XhoI and HindIII sites that were used to clone the epsilony promoter fragment upstream of the firefly luciferase gene in pGL3 Basic (Promega, Madison, Wisconsin, United States). A 2.5-kb SstI/XhoI fragment of muLCRbeta 9.3 (micro LCR; [31]) was then inserted upstream of the epsilony promoter in the above pGL3 Basic plasmid, resulting in a reporter construct in which luciferase expression is driven by the epsilony promoter. A series of deletion constructs of the epsilony promoter were generated similarly. Forward primers with an XhoI site include: MHB1457, 5'CCGCTCGAGTGCTAGGCAAACACTCA3' (-2077 to -2052); MHB1503, 5'CCGCTCGAGTCTCTACACTGTCACTCCCTG3' (-634 to -605); MHB1505, 5'CCGCTCGAGGGAGCCAAAAAAAGAATGC3' (-197 to -169); MHB1506, 5'CCGCTCGAGCTGACCAATGGCTTCAAAG3' (-85 to -58); MHB1532, 5'CCGCTCGAGAATGCAGAACAAAGGGTCAGA3' (-63 to -34); and MHB1507, 5'CCGCTCGAGGTCTGCGAAGAATAAAAGGC 3' (-37 to -9). All forward primers were used in combination with the reverse primer HindIII site: MHB1477, 5'CGGAAGCTTGGGAGGTTGCTGGTGA3' (+45 to +20).
Sox6-pcDNA3.1 [15] was used to overexpress Sox6. A truncated version of the Sox6 overexpression construct (Sox6-deltaHMG-pcDNA3.1) that lacks the HMG domain was generated, as described by others [32]. Mutagenesis of Sox/Sox6 consensus binding sites of the epsilony promoter were done by PCR. Forward primers used to generate these mutagenized epsilony promoter reporter constructs include: MHB1661, 5'CCGCTCGAGAATGCAGTGCCAAGGGTCAGAACATTGTCTGCGAAG3' (-63 to -19); MHB1662, 5'CCGCTCGAGAATGCAGAACAAAGGGTCAGATGAGTGTCTGCGAAGAA3' (-63 to -16); and MHB1663, 5'CCGCTCGAGAATGCATGCCAAGGGTCAGATGAGTGTCTGCGAAGAA 3' (-63 to -18).","[{'offsets': [[26, 34]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[120, 128]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[182, 197]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[289, 296]], 'text': ['epsilon'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[405, 419]], 'text': ['epsilon globin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[700, 708]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[751, 761]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[924, 932]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1018, 1028]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1057, 1065]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1115, 1123]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1689, 1693]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1732, 1736]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1765, 1769]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1796, 1800]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1945, 1953]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T16'}]",[],[],[],[],[]
86,PMC-3585731-15-Materials_and_Methods,"Antibodies
The following antibodies were used: phospho-Akt (Thr308) (clone C31E5E) rabbit mAb, phospho-Akt (Ser473) (clone D9E) XP rabbit mAb, Akt (pan) (clone C67E7) rabbit mAb, Akt1 (clone C73H10) rabbit mAb, Akt2 (clone D6G4) rabbit mAb, Akt3 (clone 62A8) rabbit mAb, phospho-JNK (Thr183/Tyr185) (81E11) rabbit mAb, SAPK/JNK rabbit pAb, phospho-c-Jun (Ser63) II rabbit pAb, c-Jun (60A8) rabbit mAb, alpha-tubulin (clone DM1A) mouse mAb, phospho-FoxO1 (Thr24)/FoxO3a (Thr32) rabbit pAb, FoxO1 (L27) rabbit pAb, phospho-FoxO4 (Ser193) rabbit pAb, FoxO4 rabbit pAb, phospho-MDM2 (Ser166) rabbit pAb, phospho-GSK-3alpha/beta (Ser21/9) rabbit pAb, phospho-p70 S6 Kinase (Thr389) (clone 108D2) rabbit mAb, phospho-S6 Ribosomal Protein (Ser235/236) (clone D57.2.2E) XP rabbit mAb, S6 Ribosomal Protein (clone 54D2) mouse mAb, phospho-4E-BP1 (Thr37/46) rabbit pAb, mTOR (clone 7C10) rabbit mAb, PDK1 rabbit pAb (all Cell Signaling), MDM2 rabbit pAb (Bioworlde).",[],[],[],[],[],[]
87,PMC-3589482-22-Results,"Phosphorylation of C/EBP-beta at Serine 64 negatively Regulates LPS-stimulated SerpinB2 Promoter Activity
Phosphorylation of C/EBP-beta is well recognized to modulate its transactivation potential [63]. To investigate C/EBP-beta phosphorylation sites that may be important for LPS-stimulated SerpinB2 proximal promoter activity (Fig. 8B), we co-expressed several C/EBP-beta phospho-acceptor mutants in which the critical threonine or serine residue was mutated to an alanine, along with the pGLmP-539 murine SerpinB2 luciferase reporter in Cebpb-/- MEFs. Re-expression of wild-type C/EBP-beta in Cebpb-/- MEFs significantly stimulated SerpinB2 luciferase reporter gene expression in the presence of LPS by ~3 fold (Fig. 8C, left), confirming the importance of C/EBP-beta to LPS-induced SerpinB2 gene transcription. Expression of the C/EBP-beta phospho-acceptor mutant, C/EBPbetaT217A, in Cebpb-/- MEFs did not significantly increase SerpinB2 promoter activity above that of wild-type C/EBP-beta (Fig. 8C, right); confirming that phosphorylation of C/EBP-beta at T217 is not a major factor in the regulation of SerpinB2 promoter activity in response to LPS.
C/EBP-beta contains additional phosphorylation sites, C/EBP-betaT188 and C/EBP-betaS64 (Fig. 8B), which may be involved in modulating C/EBP-beta-dependent SerpinB2 gene transcription. C/EBP-betaT188 is implicated in regulating DAPK1, an IFNgamma-inducible gene involved in the regulation of cell cycle and apoptosis [38], processes with which SerpinB2 has also been associated [17]. C/EBP-betaS64 is important for LPS-induced transcription of the cytokines IL-6 and MCP-1 [64]. Similarly, SerpinB2 is induced by LPS and regulated in a manner similar to cytokines [29]. Given the similarities in the functional significance of these phospho-specific isoforms of C/EBP-beta and SerpinB2, we investigated whether these phospho-acceptor sites may play a role in SerpinB2 gene expression. C/EBP-betaT188A-transfected MEFs exhibited SerpinB2 promoter activity similar to that of wild-type C/EBP-beta-transfected MEFs, whereas the expression of C/EBP-betaS64A potentiated SerpinB2 promoter activity in response to LPS (Fig. 8C, right). These data suggest that phosphorylation of C/EBP-beta at S64 acts to negatively regulate SerpinB2 proximal promoter activity.","[{'offsets': [[19, 29]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[79, 87]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[125, 135]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[218, 228]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[292, 300]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[363, 398]], 'text': ['C/EBP-beta phospho-acceptor mutants'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[508, 536]], 'text': ['SerpinB2 luciferase reporter'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[540, 545]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[582, 592]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[596, 601]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[635, 663]], 'text': ['SerpinB2 luciferase reporter'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[760, 770]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[786, 794]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[833, 867]], 'text': ['C/EBP-beta phospho-acceptor mutant'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[869, 883]], 'text': ['C/EBPbetaT217A'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[888, 893]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[933, 941]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[984, 994]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1048, 1058]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1110, 1118]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1157, 1167]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1291, 1301]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1312, 1320]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1384, 1389]], 'text': ['DAPK1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1394, 1402]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1413, 1417]], 'text': ['gene'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1500, 1508]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1614, 1618]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1623, 1628]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1646, 1654]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1818, 1828]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1833, 1841]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1915, 1923]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1941, 1956]], 'text': ['C/EBP-betaT188A'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1984, 1992]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2040, 2050]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2095, 2109]], 'text': ['C/EBP-betaS64A'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2122, 2130]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2229, 2239]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2275, 2283]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T40'}]",[],[],[],[],[]
88,PMC-3218875-02-Pathological_triggers_of_NF-+%A6B_signalling_in_RA,"Since NF-kappaB is central to the process of inflammation in RA, much research deals with the identification of the molecular triggers that activate NF-kappaB in RA. It is well accepted that proinflammatory cytokines such as TNF and IL-1 play an important role, and administration of TNF antagonists is an effective treatment for severe RA (reviewed in [9]). TNF and IL-1 are both very potent activators of NF-kappaB and it can be expected that NF-kappaB activation by these cytokines mediates most of their pro-inflammatory activities in RA (reviewed in [3]).
NF-kappaB activation by receptor activator of NF-kappaB (RANK), a TNF receptor family member, is important for osteoclastogenesis, and defects in proper RANK-NF-kappaB signalling are likely to be involved in RA pathology and other diseases associated with bone loss [7]. CD40 is another TNF receptor family member that is functionally expressed on a variety of cell types, including smooth muscle fibroblasts from normal and RA patients and RA synovial cells, B cells, macrophages, and dendritic cells, and can be upregulated by proinflammatory cytokines including TNF [10]. Binding of the CD40 ligand (CD154), which is transiently expressed on the surface of activated CD4+ T cells, triggers NF-kappaB activation resulting in fibroblast proliferation and secretion of proinflammatory cytokines and chemokines, which contributes to joint destruction. However, studies with antagonistic anti-CD40 or anti-CD154 antibodies led to the conclusion that CD40 signals may be important at the initial stages of arthritis induction, but are not required once disease is established and pathogenic antibodies are already present [11,12]. Enhanced expression of the TNF receptor family member B-cell activating factor (BAFF), allowing the survival of autoantibody- producing B lymphocytes, is also characteristic for RA, and antagonists of BAFF have been developed to counter RA [13]. Finally, lymphotoxin beta receptor signalling has been implicated in tertiary lymphoid organ formation at sites of chronic inflammation including RA [13].
Toll-like receptors (TLRs) have been implicated in a variety of autoimmune diseases and are potential candidates for inducing NF-kappaB-dependent inflammation in RA. In addition to microbial ligands, an increasing number of endogenous ligands - a group of proteins derived from host tissues and cells - have been reported as candidate activators of TLRs inducing so-called sterile inflammation (reviewed in [14,15]). TLRs are expressed in RA synovial tissues and various endogenous ligands are present within the inflamed joints of RA patients. Moreover, animal models using TLR knockout mice or strategies to block TLR signalling clearly identify TLR-dependent inflammation as being important in the pathogenesis of the disease.
High mobility group box chromosomal protein 1 (HMGB1), a highly conserved chromatin component that can be actively secreted by macrophages or passively released by necrotic cells, is one of the most putative endogenous TLR4 ligands involved in RA pathology. HMGB1 is increased in RA synovial tissue and HMGB1 neutralising antibodies or the antagonistic BoxA domain of HMGB1 protect against collagen-induced arthritis in mice [16]. Myeloid-related protein 8 and myeloid-related protein 14, damage-associated molecular pattern molecules belonging to the S100 family of calcium-binding proteins, are also abundantly present in RA synovial fluid, and have been suggested to be involved in TLR4-induced chronic inflammation in RA [17,18]. Other endogenous TLR ligands that may be involved in RA pathology are extracellular matrix components such as fibrinogen, fibronectin, biglycan, tenascin C, and hyal-uronic acid fragments (reviewed in [14,15]). Together, these studies suggest that several TLR ligands in the inflamed joint tissue may contribute to NF-kappaB activation and inflammatory gene expression in RA.","[{'offsets': [[225, 228]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[284, 287]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[359, 362]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[585, 616]], 'text': ['receptor activator of NF-kappaB'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[618, 622]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[714, 718]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[832, 836]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[848, 874]], 'text': ['TNF receptor family member'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1126, 1129]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1151, 1162]], 'text': ['CD40 ligand'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1164, 1169]], 'text': ['CD154'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1231, 1234]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1509, 1513]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1743, 1767]], 'text': ['B-cell activating factor'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1769, 1773]], 'text': ['BAFF'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1890, 1894]], 'text': ['BAFF'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1944, 1969]], 'text': ['lymphotoxin beta receptor'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2820, 2865]], 'text': ['High mobility group box chromosomal protein 1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2867, 2872]], 'text': ['HMGB1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2894, 2913]], 'text': ['chromatin component'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[3039, 3051]], 'text': ['TLR4 ligands'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[3078, 3083]], 'text': ['HMGB1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[3123, 3128]], 'text': ['HMGB1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3188, 3193]], 'text': ['HMGB1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3251, 3276]], 'text': ['Myeloid-related protein 8'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3281, 3307]], 'text': ['myeloid-related protein 14'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3505, 3509]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3676, 3687]], 'text': ['fibronectin'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3689, 3697]], 'text': ['biglycan'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3699, 3709]], 'text': ['tenascin C'], 'type': 'Protein', 'id': 'T30'}]",[],[],[],[],[]
89,PMC-1064895-05-Materials_and_methods,"CD4+ T-cell isolation by MACS
Anti-CD4 microbeads were used essentially as recommended by the manufacturer (Miltenyi) [19]. PBMC were resuspended in 80 mul of FBS staining buffer. Anti-CD4 microbeads (20 mul) were added and incubated for 15 min at 6-12degreesC. Saturating amounts of fluorochrome-conjugated antibodies were added for a further 10 min. Cells were diluted in 2.5 ml of FBS staining buffer, pelleted, resuspended in 500 mul and magnetically separated, usually on an AutoMACS magnet fitted with a MACS MS column. Flow-through and two 1 ml washes were collected as the negative fraction. Enriched cells were collected in two 0.5 ml aliquots from the column after removal from the magnet. Alternatively, cells stained with anti-CD4-phycoerythrin were washed, magnetically labeled with anti-phycoerythrin microbeads (20 mul added to 80 mul of cell suspension; 15 min, 6-12degreesC), and magnetically separated as described above. The purity of cells was assessed by flow cytometric analysis of stained cells on a FACS Vantage sorter. Most (more than 97%) of the isolated cells had the CD4 T cell marker.","[{'offsets': [[0, 3]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[35, 38]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[185, 188]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[739, 742]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1095, 1098]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
90,PMC-1064873-00-TIAB,"Resistance to IL-10 inhibition of interferon gamma production and expression of suppressor of cytokine signaling 1 in CD4+T cells from patients with rheumatoid arthritis
IL-10 has been shown to block the antigen-specific T-cell cytokine response by inhibiting the CD28 signaling pathway. We found that peripheral blood CD4+ T cells from patients with active rheumatoid arthritis (RA) were able to produce greater amounts of interferon gamma after CD3 and CD28 costimulation in the presence of 1 ng/ml IL-10 than were normal control CD4+ T cells, although their surface expression of the type 1 IL-10 receptor was increased. The phosphorylation of signal transducer and activator of transcription 3 was sustained in both blood and synovial tissue CD4+ T cells of RA, but it was not augmented by the presence of 1 ng/ml IL-10. Sera from RA patients induced signal transducer and activator of transcription 3 phosphorylation in normal CD4+ T cells, which was mostly abolished by neutralizing anti-IL-6 antibody. Preincubation of normal CD4+ T cells with IL-6 reduced IL-10-mediated inhibition of interferon gamma production. Blood CD4+ T cells from RA patients contained higher levels of suppressor of cytokine signaling 1 but lower levels of suppressor of cytokine signaling 3 mRNA compared with control CD4+ T cells, as determined by real-time PCR. These results indicate that RA CD4+ T cells become resistant to the immunosuppressive effect of IL-10 before migration into synovial tissue, and this impaired IL-10 signaling may be associated with sustained signal transducer and activator of transcription 3 activation and suppressor of cytokine signaling 1 induction.","[{'offsets': [[14, 19]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[34, 50]], 'text': ['interferon gamma'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[80, 114]], 'text': ['suppressor of cytokine signaling 1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[118, 121]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[170, 175]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[264, 268]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[319, 322]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[424, 440]], 'text': ['interferon gamma'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[455, 459]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[501, 506]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[532, 535]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[587, 608]], 'text': ['type 1 IL-10 receptor'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[647, 697]], 'text': ['signal transducer and activator of transcription 3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[746, 749]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[818, 823]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[855, 905]], 'text': ['signal transducer and activator of transcription 3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[932, 935]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[994, 998]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1033, 1036]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1051, 1055]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1064, 1069]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1093, 1109]], 'text': ['interferon gamma'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1128, 1131]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1185, 1219]], 'text': ['suppressor of cytokine signaling 1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1240, 1274]], 'text': ['suppressor of cytokine signaling 3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1302, 1305]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1379, 1382]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1444, 1449]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1507, 1512]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1556, 1606]], 'text': ['signal transducer and activator of transcription 3'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1622, 1656]], 'text': ['suppressor of cytokine signaling 1'], 'type': 'Protein', 'id': 'T31'}]",[],[],[],[],[]
91,PMC-3342329-01-Introduction,"Chemokines are small soluble molecules that are best known for their potent ability to induce cancer cell growth by inflammation. Many types of cancer cells express chemokines and chemokine receptors [1]. The accumulated evidence indicates that the chemokine (C-C motif) ligand 5 (CCL5) and C-C chemokine receptor (CCR5), which are potent chemotactic factors for inflammatory cells, may be significantly involved in the proliferation and metastasis of several cancers. Intermediate and strong CCR5 expression is significantly associated with nonmetastatic development of colorectal cancer [2], melanoma [3], hepatoma [4], glioblastoma, Hodgkin lymphoma [5], as well as oral and prostate cancer cells [6]. Local production of the CCL5 is also important in the progression of breast cancer [7], and also correlates with poor prognosis [8]. Meanwhile, CCR5 disruption has been demonstrated to inhibit experimental tumor growth and metastasis of pancreatic cancer [9]. In addition, host absence of CCR5 potentiates the delay of tumor growth [10], and CCR5 inhibitors prevented cancer cell growth, such as prostate cancer [11], breast cancer, hepatoma cells [4], and lung cancer [12]. These data suggest that the deficiency of inflammatory chemokine receptor CCR5 may function as a suppressive receptor in cancer progression. However, more studies are required to describe how CCR5 deficiency acts in the inhibition of tumor development.
Interleukin-1 receptor antagonist (IL-1Ra), a member of the IL-1 family, is a naturally occurring cytokine that competitively blocks the IL-1 receptor [13]. Because IL-1Ra has been shown to inhibit tumor progression by promoting antitumor immune responses and by enhancing the activity of chemotherapy, numerous studies have examined the ability of IL-1Ra to block tumor progression. IL-1Ra expression was reduced in prostate [14], breast [15], and skin cancer [16]. It was also reported that endogenous IL-1Ra deficient mice developed aggressive tumors following exposure to carcinogens [17]. Meanwhile, proliferation of the melanoma cells that were transduced with IL-1Ra gene was reduced and inhibited melanoma development [18]. IL-1R blockade also reduced hepatic tumor growth [19]. Moreover, it has also been reported that IL-1Ra reduces fibrosarcoma development [20], B16 melanoma growth and metastasis [21], colon adenocarcinoma growth [22], and skin cancer development [23]. IL-1 knockout mice injected with melanoma failed to develop solid tumors [24]. It was also found that IL-1Ra, combined with temozolomide and docetaxel chemotherapy, demonstrated more significant antitumor activity against B16 melanoma cells in vivo [25]. These data indicate that IL-1Ra is important as a tumor growth suppressing cytokine.
NF-kappaB plays a crucial role in the suppression of apoptosis, as well as the induction of cell proliferation and inflammation, and is closely associated with cancer development [26]. Constitutive activation of NF-kappaB has been described in a great number of cancers including colon cancers, prostate cancers and melanoma [27], and was found to up-regulate anti-apoptotic genes and/or down regulate apoptotic gene expression [28]. Although NF-kappaB promotes tumor growth, it is required for the immune system to function normally [29]. Studies on c-Rel-deficient mice demonstrated that c-Rel is essential for IL-2, IL-3, GM-CSF, and IFNgamma expression in T lymphocytes [30]. C-Rel-deficient mice also have a tissue-specific deficiency of various cytokines and growth factors in T cells and macrophages affecting both innate and humoral immune responses in the host [31]. Therefore, NF-kappaB can be specially targeted to prevent cancer cell growth by (1) directly affecting apoptotic cancer cell death, (2) stimulating tumor killing lymphocytes infiltration or (3) increasing the production of tumor killing lymphokines. Activation of NF-kappaB is important in the regulation of CCR-mediated tumor growth and metastasis. It was reported that inhibition of NF-kappaB by dehydroxymethyl-epoxyquinomicin (DHMEQ) induces cell death of primary effusion lymphoma by inhibition of CCR5 expression [32]. Activation of NF-kappaB also increases CCL5-mediated oral cancer motility (5) and lung metastasis [33]. Thus, it is possible that inhibition of NF-kappaB could be involved in CCR5 mediated tumor development.
NF-kappaB transcription factor binding sites are present in the promoter region of proinflammatory cytokine genes, such as IL-1alpha, IL-6, GM-CSF, and KC [34]. On the other hand, the IL-1Ra is a negative regulator of the inflammatory response. Several studies have demonstrated the ability of IL-1Ra to abrogate the proinflammatory effects of IL-1. Smith et al. suggested that the regulation of IL-1Ra gene expression is a complex event involving the interactions of three different transcription factors; NF-kappaB/PU.1/GA-binding protein binding site [35]. Nuclear translocation of NF-kappaB (p65) was significantly enhanced and prolonged in IL-1Ra-deficient mice, compared to that in wild type mice [36]. Intracellular IL-1Ra (icIL-1Ra) was found to inhibit IL-1 by blocking NF-kappaB signal transduction pathways in inflammatory responses [37]. Because IL-1 has been shown to be an inducer of NF-kappaB activation [38], we hypothesized that the expression of IL-1Ra could play an important role in the autocrine activation of transcription factors NF-kappaB or vice versa. Thus, the aim of this study was to evaluate the roles of NF-kappaB and IL-1Ra in the chemokine receptor CCR5-mediated suppression of tumor development.","[{'offsets': [[249, 279]], 'text': ['chemokine (C-C motif) ligand 5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[281, 285]], 'text': ['CCL5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[291, 313]], 'text': ['C-C chemokine receptor'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[315, 319]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[493, 497]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[729, 733]], 'text': ['CCL5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[849, 853]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[994, 998]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1047, 1051]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1254, 1258]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1372, 1376]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1433, 1466]], 'text': ['Interleukin-1 receptor antagonist'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1468, 1474]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1531, 1539]], 'text': ['cytokine'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1598, 1604]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1782, 1788]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1817, 1823]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1937, 1943]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2100, 2106]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2261, 2267]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2518, 2524]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2696, 2702]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2746, 2754]], 'text': ['cytokine'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3307, 3312]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3346, 3351]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3369, 3373]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3375, 3379]], 'text': ['IL-3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3381, 3387]], 'text': ['GM-CSF'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[4135, 4139]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[4196, 4200]], 'text': ['CCL5'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[4332, 4336]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[4488, 4497]], 'text': ['IL-1alpha'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[4499, 4503]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[4505, 4511]], 'text': ['GM-CSF'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[4517, 4519]], 'text': ['KC'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[4549, 4555]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[4659, 4665]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[4761, 4767]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[4882, 4886]], 'text': ['PU.1'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4961, 4964]], 'text': ['p65'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[5010, 5016]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[5074, 5094]], 'text': ['Intracellular IL-1Ra'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[5096, 5104]], 'text': ['icIL-1Ra'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[5329, 5335]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[5514, 5520]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[5528, 5546]], 'text': ['chemokine receptor'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[5547, 5551]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T58'}]",[],[],[],[],[]
92,PMC-1472690-00-TIAB,"beta-(1->3)-D-glucan modulates DNA binding of nuclear factors kappaB, AT and IL-6 leading to an anti-inflammatory shift of the IL-1beta/IL-1 receptor antagonist ratio
Background
beta-1 to 3-D-glucans represent a pathogen-associated molecular pattern and are able to modify biological responses. Employing a comprehensive methodological approach, the aim of our in vitro study was to elucidate novel molecular and cellular mechanisms of human peripheral blood immune cells mediated by a fungal beta-1 to 3-D-glucan, i.e. glucan phosphate, in the presence of lipopolysaccharide (LPS) or toxic shock syndrome toxin 1 (TSST-1).
Results
Despite an activation of nuclear factor (NF)kappaB, NFinterleukin(IL)-6 and NFAT similar to LPS or TSST-1, we observed no significant production of IL-1beta, IL-6, tumor necrosis factor alpha or interferon gamma induced by glucan phosphate. Glucan phosphate-treated leukocytes induced a substantial amount of IL-8 (peak at 18 h: 5000 pg/ml), likely due to binding of NFkappaB to a consensus site in the IL-8 promoter. An increase in IL-1receptor antagonist(RA) production (peak at 24 h: 12000 pg/ml) by glucan phosphate-treated cells positively correlated with IL-8 levels. Glucan phosphate induced significant binding to a known NFIL-6 site and a new NFAT site within the IL-1RA promoter, which was confirmed by inhibition experiments. When applied in combination with either LPS or TSST-1 at the same time points, we detected that glucan phosphate elevated the LPS- and the TSST-1-induced DNA binding of NFkappaB, NFIL-6 and NFAT, leading to a synergistic increase of IL-1RA. Further, glucan phosphate modulated the TSST-1-induced inflammatory response via reduction of IL-1beta and IL-6. As a consequence, glucan phosphate shifted the TSST-1-induced IL-1beta/IL-1RA ratio towards an anti-inflammatory phenotype. Subsequently, glucan phosphate decreased the TSST-1-induced, IL-1-dependent production of IL-2.
Conclusion
Thus, beta-1 to 3-D-glucans may induce beneficial effects in the presence of pro-inflammatory responses, downstream of receptor binding and signaling by switching a pro- to an anti-inflammatory IL-1RA-mediated reaction. Our results also offer new insights into the complex regulation of the IL-1RA gene, which can be modulated by a beta-1 to 3-D-glucan.","[{'offsets': [[77, 81]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[127, 135]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[136, 160]], 'text': ['IL-1 receptor antagonist'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[585, 613]], 'text': ['toxic shock syndrome toxin 1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[615, 621]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[684, 703]], 'text': ['NFinterleukin(IL)-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[708, 712]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[731, 737]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[780, 788]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[790, 794]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[796, 823]], 'text': ['tumor necrosis factor alpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[827, 843]], 'text': ['interferon gamma'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[941, 945]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1035, 1039]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1065, 1088]], 'text': ['IL-1receptor antagonist'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1089, 1091]], 'text': ['RA'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1193, 1197]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1305, 1311]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1416, 1422]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1508, 1514]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1548, 1554]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1559, 1563]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1602, 1608]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1650, 1656]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1704, 1712]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1717, 1721]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1770, 1776]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1785, 1793]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1794, 1800]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1892, 1898]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1908, 1912]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1937, 1941]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2148, 2154]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2245, 2251]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T34'}]",[],[],[],[],[]
93,PMC-3585731-03-Results,"RIP1 Kinase-dependent Activation of Akt Contributes to Necroptosis
Given our observation that growth factors are important for zVAD.fmk induced death, we examined the contribution of several pathways, including MAPK pathways and Akt, which are known to be activated following growth factor receptor activation (Fig. 2A). Inhibition of Akt (Akt inhibitor VIII) strongly protected the cells from growth factor-sensitive necroptosis induced by zVAD.fmk [16] as well as cell death triggered by bFGF or IGF-1/zVAD.fmk under serum free conditions (Fig. 2B). Inhibition of Akt also protected the cells from growth-factor insensitive death by caused by TNFalpha (Fig. 2A). Consistent with previous reports, the JNK inhibitor SP600125 protected the cells from both zVAD.fmk and TNFalpha induced death (Fig. 2A,B and Fig. S2A) [12], [14]. In contrast, inhibition of two other MAPKs, p38 and ERK, previously reported not to be activated during necroptosis [14], did not protect from either zVAD.fmk or TNFalpha induced death (Fig. 2A).
Next, we used two approaches to further validate the role of Akt in necroptotic cell death. First, two additional Akt inhibitors, a highly specific, allosteric kinase inhibitor MK-2206 [25] and triciribine (TCN) [26], which blocks membrane translocation of Akt, both attenuated cell death (Fig. S2B). Secondly, simultaneous knockdown of Akt isoforms Akt1 and Akt2 using siRNAs protected cells from necroptosis induced by both zVAD.fmk and TNFalpha (Fig. 2C). No expression of Akt3 was seen in L929 cells (Fig. S2C) and, consistently, Akt3 siRNA had no additional effect on necroptosis. Our results confirmed that Akt plays a key role in necroptosis induced by multiple stimuli in L929 cells.
To understand the activation of Akt and JNK under necroptotic conditions, we examined the changes in Akt and JNK phosphorylation at 9 hrs post zVAD.fmk and TNFalpha stimulation. This time point was chosen because it reflects the early stage of cell death in our system (Fig. S3A, B). Following stimulation with either zVAD.fmk or TNFalpha we observed a robust increase in Akt phosphorylation at a known major activation site, Thr308 (Fig. 3A). Interestingly, we did not observe concomitant phosphorylation changes in the second major activation site of Akt, Ser473. We also observed an increase in the phosphorylation of both the p46 and p54 isoforms of JNK and its major substrate c-Jun (Fig. 3A). These data indicate that both Akt and JNK are activated under necroptotic conditions.
The RIP1 kinase inhibitor, Nec-1, completely prevented the increase in Thr308 Akt phosphorylation, while Nec-1i did not (Fig. 3A, Fig. S1D). Similarly, Nec-1 prevented the induction of JNK phosphorylation in response to zVAD.fmk and substantially reduced this change after TNFalpha addition. We observed some changes in total protein levels of JNK and c-Jun following necroptotic stimulation. Some of these changes, e.g. zVAD.fmk-induced increase in c-Jun, were also attenuated by Nec-1. Importantly, Nec-1 did not alter the basal phosphorylation levels of either Akt or JNK (Fig. 3A). This established that Akt Thr308 and JNK phosphorylation during necroptosis is RIP1 dependent.
Interestingly, we discovered that the phosphorylation of Akt Thr308, JNK and Jun are late events following zVAD.fmk stimulation (Fig. 3B) that coincide with the onset of necroptosis at 6 hr post-stimulation (Fig. S3A). To better understand the contributions of growth factors and RIP1 kinase to necroptotic regulation of Akt, we next analyzed the time course of these phosphorylation changes under serum free conditions. We found that the addition of bFGF alone or in combination with zVAD.fmk led to a substantial rapid and transient increase in both Thr308 and Ser473 phosphorylation of Akt as well as JNK and c-Jun at 15 minutes, reflecting the expected response to growth factor stimulation (Fig. 3C). Significantly, the combination of bFGF/zVAD.fmk, but not bFGF alone, also caused a robust, second, delayed increase in the phosphorylation of Thr308, but not Ser473, of Akt as well as a delayed increase in the phosphorylation of JNK and Jun. Furthermore, Nec-1 had no significant effect on the early increase in both Akt and JNK/c-Jun phosphorylation triggered by both bFGF and bFGF/zVAD, while Nec-1, but not its inactive analog Nec-1i (Fig. S1E), efficiently blocked the bFGF/zVAD increase at 6-9 hr (Fig. 3D), suggesting that only the delayed activation of Akt and JNK is specific for necroptosis and dependent on RIP1 kinase activity. Similarly, IGF/zVAD, which also promoted cell death under serum free conditions, produced a delayed increase in Thr308 phosphorylation on Akt, while IGF alone caused solely an early, transient increase in phosphorylation (Fig. S3C). We confirmed the kinetics of the Akt Thr308 and Ser473 phosphorylation changes using a quantitative ELISA assay, which also showed a robust delayed necroptosis-specific RIP1-dependent increase in Akt Thr308 phosphorylation (Fig. S3D, E). Taken together, these results indicate that the observed delayed increases in Akt and JNK phosphorylation, preceding the onset of cell death, represent specific consequences of necroptotic signaling downstream from RIP1 kinase.","[{'offsets': [[0, 4]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[490, 494]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[498, 503]], 'text': ['IGF-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[645, 653]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[769, 777]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[991, 999]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1375, 1379]], 'text': ['Akt1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1384, 1388]], 'text': ['Akt2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1464, 1472]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1501, 1505]], 'text': ['Akt3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1559, 1569]], 'text': ['Akt3 siRNA'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1873, 1881]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2047, 2055]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2347, 2350]], 'text': ['p46'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2355, 2358]], 'text': ['p54'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2399, 2404]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2506, 2510]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2580, 2583]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2775, 2783]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2854, 2859]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2952, 2957]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3167, 3171]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3463, 3467]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3634, 3638]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3795, 3800]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3923, 3927]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3946, 3950]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[4218, 4223]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[4258, 4262]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[4267, 4271]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[4362, 4366]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[4506, 4510]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[4930, 4934]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[5214, 5218]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T37'}]",[],[],[],[],[]
94,PMC-1472690-19-Caption-Figure_2,"NFkappaB p65/p50 and NFATc2/c1 were involved in GP-induced DNA binding. In order to determine whether the DNA binding proteins activated by GP were related to NFkappaB and NFAT, an immuno(dot) blot was performed. A representative dot blot showing staining of negative and positive controls (recombinant proteins NFkappaB p52, c-rel; nuclear extracts of PMA-treated Jurkat cells positive for NFkappaB p50, p65 and for NFATc1, c2) in the upper panel and staining of nuclear extracts of GP-treated PBMC (positive for NFkappaB p65, p50 and NFAT c2, c1) in the lower panel is shown (n = 3).","[{'offsets': [[9, 12]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[13, 16]], 'text': ['p50'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[21, 27]], 'text': ['NFATc2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[28, 30]], 'text': ['c1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[172, 176]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[321, 324]], 'text': ['p52'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[326, 331]], 'text': ['c-rel'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[400, 403]], 'text': ['p50'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[405, 408]], 'text': ['p65'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[417, 423]], 'text': ['NFATc1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[425, 427]], 'text': ['c2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[523, 526]], 'text': ['p65'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[528, 531]], 'text': ['p50'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[536, 543]], 'text': ['NFAT c2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[545, 547]], 'text': ['c1'], 'type': 'Protein', 'id': 'T15'}]",[],[],[],[],[]
95,PMC-3342329-13-Materials_and_Methods,"Immunofluorescence
Sections were treated with 10% bovine serum albumin in PBS for 1 h at room temperature, incubated overnight at 4degreesC with p50 (1:250, Santa Cruz Biotechnology, Santa Cruz, CA), p65 (1:250, Santa Cruz Biotechnology, Santa Cruz, CA), Bax (1:200 dilution), cleaved caspase-3 (1:100), CD8 (1:10), CD57 (1:50) and IL-1Ra (1:500) antibodies, followed by incubation in anti-mouse IgG conjugated with Alexa 488 (1:100 dilution, Molecular Probes, Eugene, OR, USA) and anti-rabbit IgG conjugated with Alexa 568 (1:100 dilution, Molecular Probes) for 40 min at room temperature. Finally, the sections were rinsed, mounted on slides, and cover-slipped for fluorescence microscopy and photography using ApoTome microscopy (Carl Zeiss, Thornwood, NY, USA).","[{'offsets': [[145, 148]], 'text': ['p50'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[200, 203]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[332, 338]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
96,PMC-3320587-11-Materials_and_Methods,"Western blot
Whole cell extracts were collected with lysis buffer containing 150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1% Triton, 10% glycerol, and 1 tablet of Complete EDTA-free Protease Inhibitor Cocktail (Roche) per 25 ml of buffer. Extracts were boiled for 5 min in 1x Laemmli sample buffer with 5% v/v 2-mercaptoethanol and proteins were separated by SDS-PAGE. The gel was transferred to a nitrocellulose Trans-Blot Transfer Membrane (BioRad). The blot was then blocked for 1 h at 37degreesC in a solution of 4% BSA (Sigma) and 0.1% Tween-20 (BioRad) in a buffer containing 50 mM Tris and 150 mM NaCl at pH 7.6 (BSA/TBST). Primary incubation was carried out with a1:200 dilution of rabbit anti-NFAT5 antibody (H-300) (Santa Cruz Biotechnology) and a 1:500 dilution of goat anti-Lamin-B1 antibody (sc-6217; Santa Cruz Biotechnology) in BSA/TBST for 2 h at room temperature. The blot was washed 3x5 min in TBST and incubated in 1:6000 donkey anti-goat-HRP (Santa Cruz Biotechnology) or goat anti-rabbit-HRP (BioRad) as appropriate for 1 h. The blot was again washed 3x5 min in TBST and developed with SuperSignal West Pico Chemiluminescent Reagent (Pierce).","[{'offsets': [[512, 515]], 'text': ['BSA'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[835, 838]], 'text': ['BSA'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
97,PMC-3317373-04-2._Methods_and_Materials,"2.3. Cell Death Measurement by CCK-8 Assay
1 x 103/well cells were seeded to 96-well culture plates and cultivated for 24 h to adhere. Then the cell was scrated as mentioned above. Astrocyte cell death was assessed by cell counting kit-8 (CCK-8) (Dojindo, Japan) assay 24 h after scratch according to the manufacturer's protocol. Briefly, 10 muL CCK-8 was added into every well and incubated for 1 h. Then OD value was read at 450 nm using a Bio-Rad ELISA microplate reader (Bio-Rad Laboratories, CA, USA). All measurements were performed in sextuplicate. Results were expressed as mean of OD value at 450 nm +/- SD.",[],[],[],[],[],[]
98,PMC-1472690-13-Methods,"Preparation of nuclear extracts and electrophoretic mobility shift assays (EMSA)
Nuclear extracts of purified PBMCs were prepared according to a technique described by Trede et al. [27] and modified for our experimental setup [56]. The intensity of shifted bands was normalized to bands of unstimulated controls. Competition experiments with labeled and unlabeled mutated oligos of the cytokine promoter binding sites (see above) were carried out in order to prevent non-specific binding to nuclear proteins. For such experiments, an excess (5-50x) of unlabeled oligos was added to the nuclear extracts. For specificity of binding, supershift assays for NFkappaB with a combined p65/50 antibody were performed (data not shown). To exclude non-specific reactions, a 30-fold molar excess of Oct-1 DNA (unrelated DNA, Table 1) was used, which did not compete with specific binding.","[{'offsets': [[679, 682]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[683, 685]], 'text': ['50'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[789, 794]], 'text': ['Oct-1'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
99,PMC-1359074-10-Materials_and_Methods,"Quantitation of globin mRNA.
RNA was first reverse transcribed to cDNA. Primers for cDNA PCR amplification of globin genes were obtained from Primerbank [51]. All primers were searched against the NCBI database to confirm specificity. For epsilony globin: MHB1666, 5'TGGCCTGTGGAGTAAGGTCAA3'; and MHB1667, 5'GAAGCAGAGGACAAGTTCCCA3'. For zeta globin: MHB1668, 5'CTACCCCCAGACGAAGACCTA3'; and MHB1669, 5'CTTAACCGCATCCCCTACGG3'. For betaH1 globin: MHB1672, 5'TGGACAACCTCAAGGAGACC3'; and MHB1673, 5'ACCTCTGGGGTGAATTCCTT3'. For betamaj/min globin: MHB1674: 5'ATGGCCTGAATCACTTGGAC3'; and MHB1675, 5'ACGATCATATTGCCCAGGAG3'. Using the SYBR green supermix kit with ROX (Bio-Rad, Hercules, California, United States), PCR amplification was run on an ABI7000 (Applied Biosystems, Foster City, California, United States) at the University of Arizona core facility. All PCR was performed in a 25-mul reaction with 12.5 mul SYBR green supermix. GAPDH mRNA levels were used as control for input RNA. Standard curve analyses were performed to test the efficiency of the amplifications. Triplicates were done for each PCR reaction. Relative quantitative values were calculated in the ABI Prism 7000 SDS Software (Applied Biosystems) and normalized to GAPDH in Microsoft Excel (Redmond, Washington, United States).","[{'offsets': [[239, 254]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[336, 347]], 'text': ['zeta globin'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[428, 441]], 'text': ['betaH1 globin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[521, 528]], 'text': ['betamaj'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[529, 539]], 'text': ['min globin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[929, 934]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1232, 1237]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
100,PMC-3291650-13-Materials_and_Methods,"Flow cytometry
Lungs were dissected and incubated with collagenase type IV (1 mg/ml; Sigma) and DNAse (100 U/ml; Roche) at 37degreesC for 30 min. Subsequently, samples were filtered through a 70 microm and 40 microm nylon mesh. For the preparation of BAL, trachea were canulated and airway lumen was flushed 4 times with HBSS with 1 mM EDTA. Cells were stained with monoclonal antibodies directed against MHC-II (I-A/I-E) FITC (M5/114.15.2), CD11c PerCP-Cy5.5 (N418), F4/80 APC (BM8), CD62L PE (MEL-14), Granzyme B FITC (NGZB) from eBiosciences and CD3 Molecular Complex Horizon v450 (17A2), Ly6C Horizon v450 (AL-21), Ly6G PE (1A8), CD11b APC-Cy7 (M1/70), CD8alpha PerCP (53-6.7), IFNgamma Alexa 647 (XMG1.2) and CD16/32 (2.4G2) from BD Pharmingen. Samples were acquired on a LSRII Cytometer and analyzed using FACSDiva software (BD Biosciences). Propidium iodide was used to discriminate between live and dead cells.","[{'offsets': [[55, 74]], 'text': ['collagenase type IV'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[485, 490]], 'text': ['CD62L'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[504, 514]], 'text': ['Granzyme B'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[549, 552]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[619, 623]], 'text': ['Ly6G'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[657, 665]], 'text': ['CD8alpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[682, 690]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[714, 718]], 'text': ['CD16'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
101,PMC-3320587-02-Materials_and_Methods,"Ethics statement
In our studies we used unidentified human discarded blood cells (peripheral blood mononuclear cells, PBMC), which we obtained from the Blood Bank of Children's Hospital in Boston.",[],[],[],[],[],[]
102,PMC-1472690-06-Results,"Inhibition of transcription factors led to reduced IL-1RA levels
Pharmacological inhibitors were used to demonstrate that the transcription factor sites within the IL-1RA promoter are relevant for the induction of IL-1RA by GP. As expected, an inhibition of NFkappaB via CAPE [35] and CyA, NFAT via CyA and NFIL-6 via CHX [36] could not be overruled by GP, leading to a down-regulated binding activity of the transcription factors to the IL-1RA sites, and a reduction of IL-1RA mRNA and IL-1RA protein levels (Fig. 7). The extent of reduction in NFATP2/3 binding is exemplarily shown in an autoradiogram (Fig. 7A, left side) and graphically summarized (n = 4, Fig. 7A, right side). The results for the NFkappaB and NFIL-6 binding sites were similar (data not shown). Because the highest IL-1RA amount was found at 24 h, mRNA was examined following 1 h inhibition and 18 h of GP. A representative gel demonstrating a decrease in IL-1RA mRNA after inhibition with CAPE, CyA and CHX is displayed in Fig. 7B (n = 4). In addition, corresponding IL-1RA protein levels after 24 h of GP are shown in Fig. 7C (n = 3). Altogether, NFkappaB inhibition by CAPE was more pronounced at the binding activity and the transcription, whereas CyA and CHX mainly led to a decreased IL-1RA release.","[{'offsets': [[51, 57]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[164, 170]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[214, 220]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[290, 294]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[307, 313]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[438, 444]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[471, 477]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[487, 493]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[787, 793]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[928, 934]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1040, 1046]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1262, 1268]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
103,PMC-3585731-26-Caption-Figure_1,"bFGF and IGF-1 promote necroptosis in concert with zVAD.fmk.
(A) L929 cells were treated with TNFalpha or zVAD.fmk under normal serum (10% FBS) or serum free conditions. Cell viability was determined after 24 hr using the CellTiter-Glo Viability assay. The concentrations of all necroptosis-inducing agents are listed in the Materials and Methods section or indicated in the figures. (B) Cells were treated with zVAD.fmk, the indicated growth factors, and Nec-1 under serum free conditions for 24 hrs followed by measurement of cell viability. (C) Cells under serum free conditions were treated with FGF, zVAD.fmk, or both for 24 hrs followed by viability assay. (D) Cell death was induced by zVAD.fmk or TNFalpha under full serum condition in the presence of 2 microM PD173074 and 20 microM PD166866. In all graphs, average+/-SD was plotted.","[{'offsets': [[0, 4]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[9, 14]], 'text': ['IGF-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[94, 102]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[705, 713]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
104,PMC-3312845-07-Methods,"Double immunofluorescence study
Sections were incubated with 3% bovine serum albumin in PBS for 30 min at room temperature. Sections were then incubated in a mixture of goat anti-TNF-alpha IgG (1:1000, R&D systems, Minneapolis, MN)/mouse anti-OX-42 IgG (1:100, Serotec, Cambridge, UK), mouse anti-GFAP IgG (1:1000, an astroglial marker, Millipore Corporation, Billerica, MA)/rabbit anti-TNFp55R IgG (1:1000, Abcam, Cambridge, UK), mouse anti-GFAP IgG/rabbit anti-TNFp75R IgG (1:1000, Abcam, Cambridge, UK), mouse anti-SMI-71 IgM (1:1000, Covance, Berkeley, CA)/rabbit anti-TNFp75R IgG, mouse anti-GFAP IgG/rabbit anti-NF-kappaB (p65-Ser276, p65-Ser311, p65-Ser529, and p65-Thr435) IgG (1:100, Abcam, Cambridge, UK), mouse anti-SMI-71 IgM/rabbit anti-p65-Thr435 NF-kappaB IgG, mouse anti-SMI-71 IgM/rabbit anti-GLUT-1 IgG (1:100, Abcam, Cambridge, UK), or mouse anti-GFAP IgG/rabbit anti-MIP-2 IgG (1:100) in PBS containing 0.3% triton X-100 overnight at room temperature. After washing three times for 10 minutes with PBS, sections were also incubated in a mixture of FITC- and Cy3-conjugated secondary antisera (Amersham, San Francisco, CA), diluted 1:200, for 2 hr at room temperature. The sections were washed three times for 10 min with PBS, and mounted on gelatin-coated slides. For nuclei counterstaining, we used Vectashield mounting medium with DAPI (Vector, Burlingame, CA). All images were captured using an AxioImage M2 microscope and AxioVision Rel. 4.8 software.","[{'offsets': [[71, 84]], 'text': ['serum albumin'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
105,PMC-3320587-16-Results,"MTb increases NFAT5 mRNA levels in human MDM
Given that macrophages, which are the primary target of MTb infection, are also a major reservoir of HIV-1 as infection progresses [40], we next investigated whether MTb is able to directly enhance NFAT5 mRNA expression in primary human MDM. We prepared MDM from five normal donors, stimulated the cells with the MTb lysate or left them unstimulated, and measured NFAT5 gene expression levels by quantitative real-time PCR at 24 and 48 hours. We also investigated whether HIV-1 infection is capable of inducing NFAT5 mRNA synthesis by infecting MDM with live or heat-inactivated R5-tropic representatives of subtype B (HIV-1Bal), C (HIV-198IN22), or E (HIV-192TH64). As shown in Figure 2A, stimulation with MTb lysate significantly increased NFAT5 mRNA levels at 24 (p<0.05) and 48 (p<0.01) hours, whereas infection with viable or heat-inactivated HIV-1 isolates did not increase NFAT5 mRNA levels (Figure 2A). Thus, MTb specifically enhances NFAT5 mRNA expression in human MDM, and this response continues to increase for at least 48 hours post-stimulation (Figure 2A).","[{'offsets': [[14, 19]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[243, 248]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[409, 414]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[556, 561]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[787, 792]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[925, 930]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[988, 993]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
106,PMC-3589482-05-Experimental_Procedures,"Western Blot Assays
Whole cell lysates were prepared in RIPA buffer (10 mM Tris, 150 mM NaCl, 1%Triton X-100, 0.5% NP-40, 0.5% deoxycholate, 0.1% SDS), proteins were separated on 4-12% Bis-Tris NuPAGE gels (Invitrogen), and transferred to PVDF membranes. Membranes were subsequently blocked with 5% milk in PBS-T (1X PBS, 0.1% Tween-20), and incubated with primary antibodies overnight. Affinity purified rabbit anti-mouse SerpinB2 antibodies were prepared after immunization with a purified recombinant GST-murine SerpinB2 fusion protein produced in E. coli as in [35]. Other antibodies used for western blot assays include: C/EBP-beta (sc-150) (Santa Cruz Biotechnologies), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and alpha/beta tubulin (Cell Signaling Technology, Inc.).","[{'offsets': [[504, 538]], 'text': ['GST-murine SerpinB2 fusion protein'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[626, 636]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[676, 716]], 'text': ['glyceraldehyde-3-phosphate dehydrogenase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[718, 723]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
107,PMC-2817507-04-2._Methods,"2.3. Detection of TLR4 mRNA by the Method of RT-PCR
Briefly, total RNA samples were isolated from peri-hemorrhage regions in left basal ganglia using Simply P Total RNA isolation Kit (BioFlux, HZ, China) according to the manufacturer's instructions. The quantity of total RNA was determined on a Nanodrop (ND-1000 Spectrophotometer) by measuring optical density at A260 and A280 nm wavelength. Then, the concentrations of mRNA were adjusted to 1.0 g/mL. RNA was reverse-transcribed into cDNA in 20 muL reaction system using Superscript First-Strand Synthesis Kit for RT-PCR (promega Inc) under conditions described by the supplier. One microliter of cDNA was used to amplify the TLR4 gene fragment with 1x PCR buffer, 1.5 mM MgCl2, 200 muM of each dNTP, 200 muM of primers, and 2u Taq DNA polymerase. The house keep gene (beta-actin) was used as an internal control. The PCR primer sequences were designed according to the TLR4 and beta-actin gene sequences reported in GenBank. TLR4 (145 bp): forward: 5'-AGCTTTGGTCAGTTGGCTCT-3'; reverse: 5'-CAGGATGACACCATTGAAGC-3'; beta-actin (701 bp): forward: 5'-GCCAACCGTGAAAAAGATG-3'; reverse: 5'-CCAGGATAGAGCCACCAAT-3'. Reaction cycles were performed at the following condition: 94degreesC 2 min, 94degreesC 40 s, 55degreesC 40 s, and 72degreesC 60 s. The reaction was stopped after 31 cycles. PCR products were electrophoresed through agarose gel. Image Acquisition and Analysis software were used to determine band densities. The abundance of TLR4 mRNA was expressed as the ratio of TLR4 mRNA to beta-actin mRNA.","[{'offsets': [[18, 22]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[679, 683]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[781, 799]], 'text': ['Taq DNA polymerase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[801, 820]], 'text': ['The house keep gene'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[822, 832]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[923, 927]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[932, 942]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[979, 983]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1068, 1078]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1486, 1490]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1526, 1530]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1539, 1549]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
108,PMC-3342329-07-Discussion,"In the present study, we found that tumor weight and volume were much smaller in the CCR5-/- mice compared to the CCR5+/+ mice inoculated with B16 melanoma cells (Figure 1A and 1B). The tumor growth inhibition in the CCR5-/- mice was associated with the inhibition of constitutively activated NF-kappaB and elevation of IL-1Ra in the tumor tissue. This anti-tumor activity was also associated with decreased expression of NF-kappaB target anti-apoptotic, cell proliferative, and tumor promoting genes (Bcl-2 and C-IAP1) but with increased expression of their target apoptotic genes; cleaved caspase-3 and 9, and Bax (Figure 3A-D). In the tumor and the spleen, the number of cytotoxic CD8+ T cells, CD57+ natural killer cells, and the levels of IL-1Ra were increased (Figure 4 and 5). These findings suggest that melanoma growth was inhibited in the CCR5-/- mice, and that the elevation of IL-1Ra, accompanied with decreased NF-kappaB, is significant in the inhibition of melanoma growth in CCR5-/- mice.
NF-kappaB regulates the expression of over 200 genes that control the immune system, cancer cell growth and inflammation [39]. Because of its abilities to induce the expression of a large array of inflammatory mediators and its roles as core transcription factors in diverse immune responses, NF-kappaB has been recognized as a major factor responsible for cytokine-associated cancer development or anti-tumor immunity. In the melanoma tumor tissues of the CCR5-/- mice, the expression of NF-kappaB target cell death genes (Bax, caspase-3 and 9) and the DNA binding activity of NF-kappaB, were significantly inhibited, but the expression of cell death inhibitory NF-kappaB target genes, such as Bcl-2 and cIAP were enhanced. In addition, CCR5-/- prevented the phosphorylation of IkappaB, accompanied with the inhibition of the p50 and p65 translocation into the nucleus (Figure 2A-C). Many tumors, including melanoma, have increased levels of NF-kappaB [40], which is likely acting as a survival factor for melanoma growth. Thus, the inhibitions of NF-kappaB activity and the expression of target genes are critical in the inhibition of tumor growth in CCR5-/- mice. Although the mechanism is not clear as to how CCR5-/- downregulates NF-kappaB, it is noteworthy that NF-kappaB is activated or inactivated by many cytokines.
Numerous studies showed that cytokine affect tumor growth by regulating NF-kappaB. Inflammatory cytokines, including IL-1, IL-6 and IL-8, activate NF-kappaB pathways in tumor cells [41]. The interleukin 10 (IL-10) is well known as an anti-tumor factor as well as an anti-inflammatory factor [42], [43]. IL-10 inhibits constitutively activated NF-kappaB both in vitro [44] and in vivo [45]. Inhibition of NF-kappaB by the IL-10 contributes to the anti-tumor effects through the activation of caspase-3 and apoptosis in Colon26-bearing mice [43]. Similarly, several studies have demonstrated the ability of IL-1Ra to abrogate the proinflammatory effects of IL-1 [46]. It has been reported that IL-1 induces the activation of NF-kappaB in several cancers, and increases cell cycle progression, and the suppression of apoptotic cell death leading to tumor promotion. The results of various studies over the past 10 years indicate that the major function of IL-1Ra is to regulate the pleiotropic effects of IL-1 by competitively blocking its functions [47]. The ability of IL-1 to induce its own antagonist is of interest in understanding the regulation and dysregulation of IL-1 signaling in normal and diseased tissue. Up-regulation of the receptor antagonist represents a mechanism for turning off IL-1 signaling and creating a temporary state of refractoriness. The elevated expression of IL-1Ra, without any change of IL-1 in tumors, suggests that the IL-1-signaling system may be dysregulated by IL-1Ra in tumors. IL-1Ra has been shown to inhibit tumor progression in prostate, breast, and skin cancer [14], [15], [16]. Intracellular IL-1Ra (icIL-1Ra) inhibits IL-6 and IL-8 production in Caco-2 cells by blocking NF-kappaB pathways [37]. We found that the levels of IL-1Ra were significantly elevated in the tumor tissues of CCR5-/- mice inoculated with B16 melanoma cells. Taken together, these data indicate IL-1Ra could be critically involved in the tumor growth inhibition of CCR5-/- mice through the inactivation of NF-kappaB in the present study.
CCR5 increases tumor growth in a local model and inhibits the efficacy of a dendrite cell vaccine in CCR5+/+ mice compared with CCR5-/- mice [10]. Cheng J and Sung RS examined the effect of CCR5 on the immune response to adenovirus vectors and graft function in an islet transplant model. They found that CCR5 absence does not prevent the local immune response to adenovirus transduction [48]. Additionally, Tan MC et al. suggested that disruption of CCR5/CCL5 signaling, either by reducing CCL5 production by tumor cells or by systemic administration of a CCR5 inhibitor (TAK-779), reduced Treg (regulatory T cells) migration to tumors so that tumors are smaller in control mice [9]. These data support the important premise that inhibition of tumor growth in CCR5-/- mice could be related with the inhibition of immune escape. Similar to this finding, we found that the CCR5+/+ mice injected with melanoma cells apparently have a lower number of cytotoxic T cells (CD8+positive T Lymphocytes cells) and natural killer cells (CD57 positive NK cells), as well as dendrite cells, in spleen tissues compared to those without melanoma cells. But the lymphocytes of the CCR5-/- mice did not decrease when injected with melanoma cells. These differences of the immune response between the CCR5+/+ mice and the CCR5-/- mice, involving tumor immune tolerance, may be connected with the inhibition of cancer progression. Taken together, in the cytokine array experiment, the level of MIP-1alpha (which has a potent activity of T cell and B cell migration) was increased in the CCR5-/- mice compared with those in the CCR5+/+ mice. Thus, relatively increased tumor associated cytotoxic lymphocytes could play an important role in inhibiting the tumor growth in CCR5-/- mice.
Activation of NF-kappaB could modulate subcellular localization of NK cells and pathogenesis [49]. Inhibition of NF-kappaB activity prevented NK cell depletion, and thus increased anti-tumor activity by decreasing IL-6 production [50]. Thus, the decreased NF-kappaB and elevated IL-1Ra could also be associated in the infiltration of cytotoxic lymphocytes into tumor, resulting in tumor growth inhibition. In contrast, IL-23, a tumor growth promoting cytokine, increased NF-kappaB and immune cell infiltration in oral tumor [51]. These data indicate that NF-kappaB could be involved in the cytokine mediated anti-tumor activities of immune cells. It is also noteworthy that IL-1Ra inhibited melanoma tumor growth by increasing the number of myeloid suppressor cells in tumor [25]. The 3-methylcholatrene-induced tumor incidence was reduced in IL-1alpha knockout mice, but increased in IL-1Ra mice with concomitant maturation of NK cells and anti-tumor immunity [52]. These data indicate that the decrease of NF-kappaB, and thus increase of IL-1Ra could be significant in tumor growth inhibition of CCR5-/- mice.
Our data thus show significant clinical implications of CCR5, because CCR5 is a G protein-coupled receptor and it is amenable to use as a small molecule for the inhibition of CCR5. Several such compounds have already been shown to be safe in clinical trials for use in certain diseases such as HIV [53]. Thus, we believe CCR5 is a cancer target that warrants continued investigation. In summary, this study showed that melanoma cells growth was inhibited via modulation of NF-kappaB/IL-1Ra pathways in CCR5-/- mice.","[{'offsets': [[85, 89]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[114, 118]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[217, 221]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[320, 326]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[512, 518]], 'text': ['C-IAP1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[744, 750]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[849, 853]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[889, 895]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[990, 994]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1461, 1465]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1742, 1746]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1831, 1834]], 'text': ['p50'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1839, 1842]], 'text': ['p65'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2157, 2161]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2217, 2221]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2452, 2456]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2520, 2534]], 'text': ['interleukin 10'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2536, 2541]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2632, 2637]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2750, 2755]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2934, 2940]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[3282, 3288]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[3717, 3723]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3826, 3832]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3950, 3970]], 'text': ['Intracellular IL-1Ra'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3972, 3980]], 'text': ['icIL-1Ra'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3991, 3995]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[4097, 4103]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[4156, 4160]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[4241, 4247]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[4311, 4315]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[4384, 4388]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4485, 4489]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4512, 4516]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4574, 4578]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4689, 4693]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[4835, 4839]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[4840, 4844]], 'text': ['CCL5'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[4875, 4879]], 'text': ['CCL5'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[4941, 4945]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[5145, 5149]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[5256, 5260]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[5550, 5554]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[5668, 5672]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[5689, 5693]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[5860, 5870]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[5953, 5957]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[5993, 5997]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[6136, 6140]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[6364, 6368]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[6429, 6435]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[6824, 6830]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[6993, 7002]], 'text': ['IL-1alpha'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[7035, 7041]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[7190, 7196]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[7248, 7252]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[7318, 7322]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[7332, 7336]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[7437, 7441]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[7583, 7587]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[7745, 7751]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[7764, 7768]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T82'}]",[],[],[],[],[]
109,PMC-3218875-01-Introduction,"Rheumatoid arthritis (RA) is the most common inflammatory arthritis, affecting up to 1% of the adult population. RA is characterised by a symmetrical polyarthritis in which chronic inflammation of joints is associated with a progressive destruction of cartilage and bone, leading to functional decline and disability. Infiltration of cells of the innate and adaptive immune system into the joint space drives the local production of proinflammatory T-helper type 1 and T-helper type 17 cytokines, chemokines, and matrix metalloproteinases by infiltrating monocytes and synovial cells. Proliferation of synovial fibroblasts leads to the formation of pannus tissue, which invades and degrades articular cartilage and subchondral bone.
The aetiology of RA is still not understood, but it is well accepted that activation of NF-kappaB-dependent gene expression plays a key role in the development of RA and many other autoimmune diseases. NF-kappaB represents a family of structurally related and evolutionarily conserved proteins (p100 or NF-kappaB2, p105 or NF-kappaB1, p65 or RelA, RelB, c-Rel) that function as homodimers or heterodimers [1], and that regulate the expression of a large number of genes - such as TNF, IL-1, IL-6, cyclo-oxygenase-2, chemokines, inducible nitric oxide synthase, and matrix metalloproteinases - that are involved in RA. In addition, TNF and IL-1 are themselves very potent activators of NF-kappaB (reviewed in [2,3]).
NF-kappaB activation can be detected in cultured synovial fibroblasts and synovial tissue from RA patients, and animal models of inflammatory arthritis also demonstrate the active role of NF-kappaB in the development and progression of RA (reviewed in [4]). The time course of NF-kappaB activation appears to precede the onset of disease, and blockade of NF-kappaB by different means decreases disease severity [5,6].
Next to its role in proinflammatory gene expression, NF-kappaB is also essential for osteoclastogenesis, mainly by mediating the effects of receptor activator of NF-kappaB ligand (RANKL). Defects in the regulation of osteoclastogenesis are the major cause of bone erosion in osteolytic diseases such as RA [7].
Finally, recent discoveries revealing a genetic association with several genes relevant to NF-kappaB signalling, including CD40, TRAF1, TNFAIP3, and c-REL, further highlight the importance of NF-kappaB activation in RA pathogenesis [8].","[{'offsets': [[1028, 1032]], 'text': ['p100'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1036, 1046]], 'text': ['NF-kappaB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1048, 1052]], 'text': ['p105'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1056, 1066]], 'text': ['NF-kappaB1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1068, 1071]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1075, 1079]], 'text': ['RelA'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1081, 1085]], 'text': ['RelB'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1087, 1092]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1213, 1216]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1224, 1228]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1230, 1247]], 'text': ['cyclo-oxygenase-2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1261, 1292]], 'text': ['inducible nitric oxide synthase'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1364, 1367]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2007, 2045]], 'text': ['receptor activator of NF-kappaB ligand'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2047, 2052]], 'text': ['RANKL'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2301, 2305]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2307, 2312]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2314, 2321]], 'text': ['TNFAIP3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2327, 2332]], 'text': ['c-REL'], 'type': 'Protein', 'id': 'T19'}]",[],[],[],[],[]
110,PMC-1359074-06-Results,"The Expression Pattern of Sox6 Suggests a Role in Definitive Erythropoiesis
The observation that Sox6-deficient mice ectopically express epsilony globin in liver, where definitive erythroid cells mature, suggests that Sox6 is an important regulator in definitive erythropoiesis. To determine the temporal and spatial expression pattern of Sox6, Northern blot and in situ hybridization assays were employed. As shown in Figure 6A, Sox6 is detectable by Northern blot beginning at 10.5 dpc, coincident with the temporal onset of definitive erythropoiesis in the liver. Furthermore, in situ hybridization shows that Sox6 is highly transcribed in 12.5-dpc liver, but not in yolk sac blood islands at 7.5 dpc (Figure 6B). Therefore, Sox6 expression is temporally and spatially coincident with definitive, but not primitive, erythropoiesis. These data, taken together with the observation that epsilony globin is highly expressed in the liver cells of 14.5-dpc p100H mutant mice (Figure 5), demonstrate that Sox6 functions in definitive erythropoiesis.","[{'offsets': [[26, 30]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[97, 101]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[137, 152]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[218, 222]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[339, 343]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[430, 434]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[613, 617]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[728, 732]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[888, 903]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1002, 1006]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T10'}]",[],[],[],[],[]
111,PMC-3317373-13-3._Results,"3.3. Expression of Proinflammatory Cytokines Was Elevated in Nrf2 Knockout Astrocytes after Scratch Injury
As we all know, TNF-alpha, IL-1beta, and IL-6 are regulated by NF-kappaB and reflect the endogenous activity of NF-kappaB. It has been revealed that these proinflammatory cytokines are increased after TBI in animals [2, 8]. And our previous study has proved that higher levels of such proinflammatory cytokines were observed in the brain of Nrf2-deficient mice after TBI [5]. But it is still ambiguous about the relationship between these cytokines and Nrf2 in astrocytes after TBI. Here, we tested the levels of TNF-alpha, IL-1beta, and IL-6 in cultured astrocytes at 24 h after scratch injury by RT-PCR and ELISA. It was shown that the mRNA levels of TNF-alpha, IL-1beta, and IL-6 were increased after scratch in both WT and KO astrocytes when compared with their sham counterparts, respectively. Moreover, the mRNA levels of these cytokines in group KO TBI were much higher than those in group WT TBI (1.66 +/- 0.085 versus 1.39 +/- 0.110 for TNF-alpha, 1.34 +/- 0.064 versus 0.73 +/- 0.088 for IL-1beta, and 1.28 +/- 0.102 versus 0.99 +/- 0.073 for IL-6. P < 0.01) (Figures 3(a)-3(d)). The results of ELISA revealed that the protein level of TNF-alpha was upregulated after scratch injury in WT and KO astrocytes when compared with their sham counterparts. And it was also higher in group KO TBI than in group WT TBI (3.67 +/- 0.156 versus 2.31 +/- 0.087, P < 0.01) (Figure 4(a)). Similar tendency was observed in protein level of IL-6 and IL-1beta. For IL-6, it was 36.07 +/- 0.786 for group KO TBI while 25.76 +/- 0.536 for group WT TBI (P < 0.01) (Figure 4(b)). For IL-1beta, it was 190.75 +/- 6.339 for group KO TBI while 154.50 +/- 5.348 for group WT TBI (P < 0.01) (Figure 4(c)).","[{'offsets': [[134, 142]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[148, 152]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[631, 639]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[645, 649]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[771, 779]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[785, 789]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1105, 1113]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1160, 1164]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1542, 1546]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1551, 1559]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1565, 1569]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1680, 1688]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
112,PMC-3589482-10-Experimental_Procedures,"Electrophoretic Mobility Shift Assays
Radiolabelled, double-stranded oligonucleotide probes for gel shift assays were prepared using T4 polynucleotide kinase and [gamma-32P]-ATP. RAW 264.7 nuclear extracts were prepared by the detergent lysis method [41]. DNA binding reactions (25 microl) containing 10 mM HEPES pH 7.9, 10 microg/ml BSA, 2 mM DTT, 30% glycerol, 20% Ficoll-400, 1 microg poly (dI-dC), 6 microg of nuclear extracts and 10,000 to 20,000 cpm (0.05 to 0.2 ng) of radiolabelled probe were performed for 20 minutes at room temperature. Binding reaction products were resolved by electrophoresis at room temperature on 5% polyacrylamide gels (29:1 acrylamide:bis-acrylamide (Bio-Rad)) in 1x TBE at 10V/cm. For supershift assays, nuclear extracts were pre-incubated 2 hrs on ice with 4 microg of specific C/EBP antibody. Antibodies were purchased from Santa Cruz: anti-C/EBP-alpha (sc-61), anti-C/EBP-beta (sc-150), anti-C/EBP-delta (sc-151) and anti-C/EBP-epsilon (sc-158).","[{'offsets': [[133, 157]], 'text': ['T4 polynucleotide kinase'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
113,PMC-3586680-04-p53_Isoforms,"At least nine isoforms of p53 have been identified due to alternative mRNA splicing, multiple gene promoters, and alternative initiation sites of translation (Ghosh et al., 2004; Ray et al., 2006; Figure 2). In cancers, aberrant expression of p53 isoforms occurs frequently (Bourdon et al., 2005; Bourdon, 2007). Full-length p53, delta133p53, and p53beta are localized mainly in the nucleus, and only few of them are in cytoplasm. p53gamma and delta133p53beta are localized in the nucleus and cytoplasm. delta133p53gamma is localized in the cytoplasm (Bourdon et al., 2005). Co-transfection of p53 and p53beta increases p53-mediated apoptosis, whereas co-expression of p53 with delta133p53 suppresses p53-mediated apoptosis (Bourdon et al., 2005). delta133p53 differentially regulates gene expression in p53-dependent and -independent manners (Aoubala et al., 2011). Co-expression of delta133p53beta or delta133p53gamma with p53 does not affect p53 transcriptional activity on p21 and Bax promoters, as well as apoptosis.","[{'offsets': [[26, 29]], 'text': ['p53'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[243, 246]], 'text': ['p53'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[325, 328]], 'text': ['p53'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[330, 341]], 'text': ['delta133p53'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[347, 354]], 'text': ['p53beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[431, 439]], 'text': ['p53gamma'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[444, 459]], 'text': ['delta133p53beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[504, 520]], 'text': ['delta133p53gamma'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[594, 597]], 'text': ['p53'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[602, 609]], 'text': ['p53beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[620, 623]], 'text': ['p53'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[669, 672]], 'text': ['p53'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[678, 689]], 'text': ['delta133p53'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[701, 704]], 'text': ['p53'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[748, 759]], 'text': ['delta133p53'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[804, 807]], 'text': ['p53'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[884, 899]], 'text': ['delta133p53beta'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[903, 919]], 'text': ['delta133p53gamma'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[925, 928]], 'text': ['p53'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[945, 948]], 'text': ['p53'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[977, 980]], 'text': ['p21'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[985, 988]], 'text': ['Bax'], 'type': 'Protein', 'id': 'T22'}]",[],[],[],[],[]
114,PMC-3342329-05-Results,"Upregulation of IL-1Ra in the Tumor and Spleen of CCR5-/- Mice
To investigate the difference in the cytokine levels between the tumor and spleen tissues of the CCR5+/+ and CCR5-/- mice, we conducted a cytokine array assay using a Mouse Proteome Array (Figure 4A). Among 40 tested cytokines, the levels of IL-1Ra, MIG, MIP-1alpha increased about 686, 9 and 25-fold respectively, in CCR5-/- mice compared to CCR5+/+ mice. Using this technique, no other cytokines were found to be different between the CCR5-/- mice and the CCR5+/+ mice (Figure 4B). Similar altered cytokine levels were found in the spleens of CCR5-/- mice (Figure 4C). Since the IL-1Ra level was the most significantly elevated, the expression of IL-1Ra in tumor and spleen tissues was analyzed by immunofluorescence and western blotting. The expression of IL-1Ra was upregulated in tumor and spleen tissues of the CCR5-/- mice (Figure 4D-G).","[{'offsets': [[16, 22]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[50, 54]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[160, 164]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[172, 176]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[305, 311]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[313, 316]], 'text': ['MIG'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[318, 328]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[381, 385]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[406, 410]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[500, 504]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[521, 525]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[608, 612]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[644, 650]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[712, 718]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[822, 828]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[880, 884]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T16'}]",[],[],[],[],[]
115,PMC-3312845-19-Caption-Figure_1,Expression of TNF-alpha and TNF receptor in the PC 12 hr-post SE. (A) TNF-alpha immunoreactivity in Ox-42-positive microglia (arrows). (B) TNFp55R expression in astrocytes (arrows). (C-D) TNFp75R expression in astrocytes as well as endothelial cells (arrows). Bar = 25 (A-D) mum.,"[{'offsets': [[14, 23]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[70, 79]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[139, 146]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[188, 195]], 'text': ['TNFp75R'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
116,PMC-3589482-17-Results,"The C/EBP Element is Bound by an LPS-induced Nuclear Factor from RAW 264.7 Macrophages
Nuclear factor binding to the putative C/EBP element (-203/-192) was investigated by electrophoretic mobility shift assay (EMSA) using nuclear extracts from untreated and LPS-treated RAW 264.7 macrophages. Three different double stranded oligonucleotide probes were used for EMSA, representing (1) the putative SerpinB2 C/EBP element (-203/-192), (2) a mutant SerpinB2 element containing the same mutation as in pGLmP-539mC/EBP and (3) the rat albumin promoter distal element 1 (DEI) region containing a high affinity C/EBP binding site. Four bands of different mobilities, representing DNA-nuclear protein complexes were detected (Fig. 5A). Three of these bands (I, II, III) represent complexes with single stranded DNA (Fig. 5A) while the uppermost (slowest migrating) complex was induced by LPS. The LPS-inducible complex was not detected using the mutant C/EBP oligonucleotide probe and could be abolished by an excess of unlabeled double-stranded oligonucleotide, carrying either the same sequence (Fig. 5B, lanes 4 and 5) or the sequence of a known C/EBP binding site from the rat albumin promoter (Fig. 5B, lanes 8 and 9), but not by the mutated oligonucleotide (Fig. 5B, lanes 6 and 7). Together these data indicate that the putative SerpinB2 C/EBP site at -203/-192 binds a LPS-inducible complex that is likely to contain a member of the C/EBP family of transcription factors.","[{'offsets': [[398, 406]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[447, 455]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[531, 538]], 'text': ['albumin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1174, 1181]], 'text': ['albumin'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1329, 1337]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
117,PMC-1064873-11-Results,"Increased expression of cell surface IL-10R1 on RA CD4+ T cells
The functional receptor complex of IL-10 consists of two subunits, the primary ligand-binding component IL-10R1 and the accessory component type 2 IL-10R [1]. IL-10R1 expression plays a critical role in cellular responses to IL-10 [29]. To examine whether the resistance to IL-10 inhibition in RA CD4+ T cells was due to limited receptor expression, the cell surface expression of IL-10R1 on PB CD4+ T cells from active RA patients and from healthy controls was determined by flow cytometric analysis. As shown in Fig. 3a,3b, the intensity of IL-10R1 expression on CD4+ T cells was significantly increased in RA patients compared with in healthy controls. These results suggest that the intracellular signal transduction pathway of IL-10 may be impaired in CD4+ T cells of active RA.","[{'offsets': [[37, 44]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[51, 54]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[99, 104]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[168, 175]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[204, 217]], 'text': ['type 2 IL-10R'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[223, 230]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[289, 294]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[338, 343]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[361, 364]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[445, 452]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[459, 462]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[607, 614]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[629, 632]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[796, 801]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[821, 824]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T15'}]",[],[],[],[],[]
118,PMC-3320587-21-Results,"MTb induces NFAT5 gene expression via the MyD88-dependent signaling cascade
To begin to decipher the cellular mechanisms underlying NFAT5-dependent, MTb-induced HIV-1 replication, we next investigated the requirement for specific signaling molecules in the TLR pathway that are required for MTb stimulation of NFAT5 gene expression. We began by examining the requirement of TLR2 ligation in enhancing NFAT5 mRNA levels. When THP-1 cells were treated with the TLR2-specific agonist Pam3Cys for 16 hours, NFAT5 mRNA levels were significantly increased in Pam3Cys-stimulated cells as compared to mock-stimulated control cells (Figure 7A). As a positive control for this experiment we also infected THP-1 cells with CDC1551 (Figure 7A). Notably, MTb infection enhanced NFAT5 mRNA levels to a greater extent than Pam3Cys stimulation, suggesting that additional PRRs may be triggered during actual MTb infection, augmenting its stimulatory effect on NFAT5 gene expression (Figure 7A).
The adaptor molecule MyD88 transmits signals upon TLR2 ligation (reviewed in [53]). To confirm that this protein and, therefore, that this TLR-dependent pathway is important for MTb induction of NFAT5 gene expression, we constructed a THP-1 cell line that constitutively expresses a lentivirally-delivered short hairpin (sh)RNA targeting MyD88. Real-time PCR analysis demonstrated that MyD88 mRNA levels in these cells were constitutively and significantly reduced in comparison to control THP-1 cells transduced with a lentivirus expressing control GFP shRNA (data not shown). These MyD88 knockdown THP-1 cells were then infected with MTb (CDC1551) and NFAT5 mRNA levels were examined. Since TNF is a MyD88-dependent gene [21], [54], [55], as a positive control we measured TNF mRNA levels. For a negative control, we measured mRNA levels of the MyD88-independent gene CD86 [55], [56]. As shown in Figure 7B, knockdown of MyD88 specifically inhibited MTb-induced NFAT5 and TNF mRNA levels and had no impact on CD86 mRNA levels. Thus, MTb regulation of NFAT5 is dependent upon MyD88.
To futher dissect the pathway mediating MTb upregulation of NFAT5 transcription, we also constructed THP-1 cells transduced with lentivirally-delivered shRNAs targeting IRAK1 or TRAF6, two signaling molecules downstream of MyD88. As shown in Figures 7C and 7D, knockdown of both IRAK1 and TRAF6 significantly inhibited MTb induced NFAT5 mRNA levels. As expected, MTb-induced TNF gene expression was also significantly reduced (Figures 7C-7D), consistent with a role for IRAK1 and TRAF6 in TNF gene expression secondary to MTb infection as previously reported. Although CD86 gene expression did not depend on MyD88 (Figure 7B), abrogation of IRAK1 and TRAF6 gene expression significantly reduced CD86 mRNA levels, indicating that CD86 expression is IRAK1- and TRAF6-dependent, but MyD88-independent in MTb-infected monocytes (Figures 7C-7D). Taken together, these results clearly demonstrate that MTb upregulation of NFAT5 gene expression in human monocytic cells requires activation of MyD88 and the MyD88-associated adaptor molecules IRAK1 and TRAF6.","[{'offsets': [[12, 17]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[42, 47]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[132, 137]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[310, 315]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[374, 378]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[401, 406]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[459, 463]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[503, 508]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[765, 770]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[944, 949]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1000, 1005]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1029, 1033]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1174, 1179]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1285, 1306]], 'text': ['short hairpin (sh)RNA'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1317, 1322]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1365, 1370]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1529, 1538]], 'text': ['GFP shRNA'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1563, 1568]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1633, 1638]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1672, 1675]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1681, 1686]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1754, 1757]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1826, 1831]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1849, 1853]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1902, 1907]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1943, 1948]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1953, 1956]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1990, 1994]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2032, 2037]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2056, 2061]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2123, 2128]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2232, 2237]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2241, 2246]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2286, 2291]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2342, 2347]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2352, 2357]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2394, 2399]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2438, 2441]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2533, 2538]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2543, 2548]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2552, 2555]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2632, 2636]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2671, 2676]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2704, 2709]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2714, 2719]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2758, 2762]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2792, 2796]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2811, 2816]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[2822, 2827]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[2843, 2848]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2979, 2984]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[3049, 3054]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[3063, 3068]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[3098, 3103]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[3108, 3113]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T55'}]",[],[],[],[],[]
119,PMC-3291650-18-Caption-Figure_2,"A20 negatively regulates IAV-induced gene expression in BMDM and alveolar macrophages.
(A-B) BMDM isolated from A20myel-WT and A20myel-KO animals were infected with IAV (moi 1). At different hours post infection (hours p.i.) cells were lysed and IL-6, IFNbeta and A20 mRNA expression was analyzed by qPCR (A). 18 hours post infection cell culture supernatant was analyzed for TNF and IFNbeta protein levels by ELISA and multiplexing technologies (B). (C-D) Alveolar macrophages were mock treated or infected with IAV (moi 1) for 18 hours. IL-6 and IFNbeta mRNA expression was determined by qPCR (C). Cell culture supernatant was analyzed for IL-6 and IFNbeta protein levels by ELISA and multiplexing technologies (D). Error bars represent mean values (+/- SEM) of 2-3 samples. Results are representative for 2 independent experiments. ***p<0,001.","[{'offsets': [[246, 250]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[252, 259]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[376, 379]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[384, 391]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[539, 543]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[548, 555]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[642, 646]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[651, 658]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
120,PMC-1064895-00-TIAB,"Increased interleukin-17 production via a phosphoinositide 3-kinase/Akt and nuclear factor ?B-dependent pathway in patients with rheumatoid arthritis
Inflammatory mediators have been recognized as being important in the pathogenesis of rheumatoid arthritis (RA). Interleukin (IL)-17 is an important regulator of immune and inflammatory responses, including the induction of proinflammatory cytokines and osteoclastic bone resorption. Evidence for the expression and proinflammatory activity of IL-17 has been demonstrated in RA synovium and in animal models of RA. Although some cytokines (IL-15 and IL-23) have been reported to regulate IL-17 production, the intracellular signaling pathways that regulate IL-17 production remain unknown. In the present study, we investigated the role of the phosphoinositide 3-kinase (PI3K)/Akt pathway in the regulation of IL-17 production in RA. Peripheral blood mononuclear cells (PBMC) from patients with RA (n = 24) were separated, then stimulated with various agents including anti-CD3, anti-CD28, phytohemagglutinin (PHA) and several inflammatory cytokines and chemokines. IL-17 levels were determined by sandwich enzyme-linked immunosorbent assay and reverse transcription-polymerase chain reaction. The production of IL-17 was significantly increased in cells treated with anti-CD3 antibody with or without anti-CD28 and PHA (P < 0.05). Among tested cytokines and chemokines, IL-15, monocyte chemoattractant protein-1 and IL-6 upregulated IL-17 production (P < 0.05), whereas tumor necrosis factor-alpha, IL-1beta, IL-18 or transforming growth factor-beta did not. IL-17 was also detected in the PBMC of patients with osteoarthritis, but their expression levels were much lower than those of RA PBMC. Anti-CD3 antibody activated the PI3K/Akt pathway; activation of this pathway resulted in a pronounced augmentation of nuclear factor kappaB (NF-kappaB) DNA-binding activity. IL-17 production by activated RA PBMC is completely or partly blocked in the presence of the NF-kappaB inhibitor pyrrolidine dithiocarbamate and the PI3K/Akt inhibitor wortmannin and LY294002, respectively. However, inhibition of activator protein-1 and extracellular signal-regulated kinase 1/2 did not affect IL-17 production. These results suggest that signal transduction pathways dependent on PI3K/Akt and NF-kappaB are involved in the overproduction of the key inflammatory cytokine IL-17 in RA.","[{'offsets': [[10, 24]], 'text': ['interleukin-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[68, 71]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[263, 282]], 'text': ['Interleukin (IL)-17'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[494, 499]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[590, 595]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[600, 605]], 'text': ['IL-23'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[638, 643]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[707, 712]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[827, 830]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[860, 865]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1034, 1038]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1040, 1058]], 'text': ['phytohemagglutinin'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1060, 1063]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1116, 1121]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1262, 1267]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1357, 1361]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1366, 1369]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1421, 1426]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1428, 1462]], 'text': ['monocyte chemoattractant protein-1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1467, 1471]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1484, 1489]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1521, 1548]], 'text': ['tumor necrosis factor-alpha'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1550, 1558]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1560, 1565]], 'text': ['IL-18'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1569, 1600]], 'text': ['transforming growth factor-beta'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1610, 1615]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1783, 1786]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1920, 1925]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2074, 2077]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2150, 2169]], 'text': ['activator protein-1'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2174, 2213]], 'text': ['extracellular signal-regulated kinase 1'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2214, 2215]], 'text': ['2'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2231, 2236]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2323, 2326]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2409, 2414]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T35'}]",[],[],[],[],[]
121,PMC-2817507-10-3._Results,"3.2. Expression of TLR4 Protein Increased in Brain Tissue after ICH
To investigate the increased TLR4 at the protein level, the expression of TLR4 protein was measured in brain tissue by the method of Western Blots using specific antibodies for TLR4. Our results showed that a low level of TLR4 protein was detectable in the saline control group. The expression of TLR4 significantly increased starting from 6 hours after ICH (P < .05), peaked on the 3rd day after ICH, and then decreased but still maintained at a high level on the 7th day after ICH (P < .05, Figure 2). This observation of TLR4 protein was consistent with the temporal profile of the TLR4 mRNA after ICH.","[{'offsets': [[19, 23]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[97, 101]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[142, 146]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[245, 249]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[290, 294]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[365, 369]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[592, 596]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[653, 657]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
122,PMC-1472690-02-Results,"Binding activities of NFkappaB, NFIL-6 and NFAT from human PBMC to the TNFalpha, IL-6 and IFNgamma promoters following an in vitro stimulation (1 h) with LPS, TSST-1, GP, GP + LPS and GP + TSST-1
GP induced band shifts, indicating binding of NFkappaB as well as of NFIL-6 to the corresponding DNA oligonucleotides (kappa consensus, kappa1, kappa2, kappa3 sites from the TNFalpha promoter; kappa consensus from the IL-8 promoter; NFIL-6consensus from the IL-6 promoter; Table 1; Fig. 1A). The extent of the band shifts induced by GP was not statistically different when compared to LPS or TSST-1 (Fig. 1B). A supershift, conducted for an NFkappaB consensus site from the IL-8 promoter, demonstrated a GP-induced predominant binding of NFkappaB p65 and to a lesser degree of p50 (Fig. 1A). Accordingly, an immunoblot of nuclear extracts from GP-treated PBMC showed a strong binding of NFkappaB p65 and a weaker reaction of p50, whereas p52 was negative (Fig. 2). Simultaneous co-treatment of PBMC with GP did not change the LPS-induced NFkappaB binding to oligos from the TNFalpha promoter significantly (Fig. 1B), but substantially decreased the TSST-1-induced NFkappaB binding when compared to TSST-1 or GP (100 mug) and thus differed completely from the theoretical value of GP/TSST-1 calc. (n = 4; p < 0.05 vs. GP/TSST-1 calc. and p = 0.07 vs. TSST-1; Fig. 1B). GP was also able to induce band shifts indicative of binding of particular variants of NFAT to an oligo from the IFNgamma promoter (Fig. 1A). An immunoblot for two NFAT subunits demonstrated a GP-induced binding of NFATc2 and to a lesser degree of NFATc1 (Fig. 2).","[{'offsets': [[32, 38]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[43, 47]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[71, 79]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[81, 85]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[90, 98]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[159, 165]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[189, 195]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[265, 271]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[370, 378]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[414, 418]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[454, 458]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[588, 594]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[670, 674]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[743, 746]], 'text': ['p65'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[773, 776]], 'text': ['p50'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[892, 895]], 'text': ['p65'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[921, 924]], 'text': ['p50'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[934, 937]], 'text': ['p52'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1070, 1078]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1145, 1151]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1194, 1200]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1279, 1285]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1316, 1322]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1346, 1352]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1451, 1455]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1477, 1485]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1528, 1532]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1579, 1585]], 'text': ['NFATc2'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1612, 1618]], 'text': ['NFATc1'], 'type': 'Protein', 'id': 'T29'}]",[],[],[],[],[]
123,PMC-3312845-03-Methods,"Intracerebroventricular drug infusion
Rats were divided into two groups: vehicle (saline)-treated and soluble TNFp55 receptor (sTNFp55R, 50 mug/ml; Sigma-Aldrich Co., St. Louis, MO)-treated groups. The dosage of sTNFp55R was determined as the highest dose that induced SE of comparable severity in 100% of animals with 5% mortality in the preliminary study. Animals were anesthetized (Zolretil, 50 mg/kg, i.m.; Virbac Laboratories, France) and placed in a stereotaxic frames. For the osmotic pump implantation, holes were drilled through the skull to introduce a brain infusion kit 1 (Alzet, Cupertino, CA) into the right lateral ventricle (1 mm posterior; 1.5 mm lateral; - 3.5 mm depth; flat skull position with bregma as reference), according to the atlas of Paxinos and Watson [24]. The infusion kit was sealed with dental cement and connected to an osmotic pump (1007D, Alzet, Cupertino, CA). The pump was placed in a subcutaneous pocket in the dorsal region. Animals received 0.5 mul/hr of vehicle or compound for 1 week. Therefore, the dose of sTNFp55R was 0.6 mug/day per each animal. The compounds began to be immediately infused after surgery. Since the volume of vasogenic edema peaked at 2-3 days after SE in our previous studies [5-8,20], we chose this time point. Thus, our experimental schedules at least inhibit the function of TNF-alpha from 3 days prior to SE to 4 days after SE when the volume of vasogenic edema peaked.","[{'offsets': [[110, 125]], 'text': ['TNFp55 receptor'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[128, 135]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[213, 220]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1052, 1059]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1344, 1353]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
124,PMC-3218875-07-Negative_regulation_of_NF-+%A6B_signalling_in_RA,"Cylindromatosis protein
Cylindromatosis (CYLD) protein was originally identified as a tumour suppressor involved in familial cylindromatosis [63]. CYLD is also involved, however, in diverse physiological processes ranging from immunity and inflammation to cell cycle progression, spermatogenesis, and osteoclastogenesis (reviewed in [64]). CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB signalling initiated by TNFR, RANK and T-cell receptor stimulation (reviewed in [64]) (Figure 1), by deubiquitina-ting several NF-kappaB signalling proteins including NEMO, TRAF2, TRAF6, TRAF7, RIP1 and TAK1. Many of these are also targeted by A20 and it is still not clear why the cell needs A20 as well as CYLD to control NF-kappaB activation. As A20 is only expressed in many cell types upon stimulation, it has been suggested that this protein mainly regulates later phases of NF-kappaB signalling, whereas CYLD would regulate constitutive and early signalling. In addition, their relative activity might also be cell-type dependent [64].
Interestingly, CYLD has been shown to negatively regulate RANK signalling and osteoclastogenesis in mice [65]. Mice with a genetic deficiency of CYLD have aberrant osteoclast differentiation and develop severe osteoporosis. Osteoclast precursors of these mice are hyper-responsive to RANKL-induced differentiation and produce more and larger osteoclasts. CYLD expression is markedly upregulated under conditions of RANKL-induced osteoclastogenesis and is recruited to ubiquitinated TRAF6 via the ubiquitin-binding adaptor protein p62 (also known as sequestosome 1) [65], followed by the CYLD-mediated deubiquitination of TRAF6. In this context, it is worth mentioning that transgenic mice expressing a mutated form of p62 also display abnormal osteoclastogenesis and develop progressive bone loss [66]. These findings suggest that CYLD-mediated inhibi-tion of RANK-induced NF-kappaB signalling plays a key role in the negative regulation of osteoclastogenesis and indicate CYLD as a potential genetic factor involved in the pathology of bone disorders such as RA.","[{'offsets': [[0, 15]], 'text': ['Cylindromatosis'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[24, 39]], 'text': ['Cylindromatosis'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[41, 45]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[147, 151]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[340, 344]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[350, 373]], 'text': ['deubiquitinating enzyme'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[440, 444]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[577, 581]], 'text': ['NEMO'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[583, 588]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[590, 595]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[597, 602]], 'text': ['TRAF7'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[604, 608]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[613, 617]], 'text': ['TAK1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[654, 657]], 'text': ['A20'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[703, 706]], 'text': ['A20'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[718, 722]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[759, 762]], 'text': ['A20'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[921, 925]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1068, 1072]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1111, 1115]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1198, 1202]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1337, 1342]], 'text': ['RANKL'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1408, 1412]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1468, 1473]], 'text': ['RANKL'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1535, 1540]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1549, 1558]], 'text': ['ubiquitin'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1583, 1586]], 'text': ['p62'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1602, 1616]], 'text': ['sequestosome 1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1640, 1644]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1674, 1679]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1771, 1774]], 'text': ['p62'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1884, 1888]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1913, 1917]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2026, 2030]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T35'}]",[],[],[],[],[]
125,PMC-3585731-19-Materials_and_Methods,"siRNA Knockdown
siRNAs were purchased from Dharmacon. Mouse ribosomal S6 protein (L-040893-00 and L-045791-00), mouse Akt1 (L-040709-00), mouse Akt2 (L-040782-00), mouse Akt3 (L-040891-00), mouse mTOR (L-065427-00), mouse PDK1 (L-040658-00), non-coding control (D-001810-10-05), mouse Mapk8 (J-040128-05), mouse Mapk9 (J-040134-05), mouse Jun (L-043776-00). siRNA were transfected using RNAiMAX reagent (Invitrogen), according to manufacturer's recommendations. After 72 hr, cells were treated with zVAD.fmk or TNFalpha for 9 hr (RNA or Western blot) or 24 hr (cell viability).","[{'offsets': [[118, 122]], 'text': ['Akt1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[144, 148]], 'text': ['Akt2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[170, 174]], 'text': ['Akt3'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[222, 226]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[285, 290]], 'text': ['Mapk8'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[312, 317]], 'text': ['Mapk9'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[511, 519]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
126,PMC-3312845-14-Results,"NF-kappaB phosphorylation
It is well established that TNF-alpha is one of the major stimuli toward phosphorylation of NF-kappaB. To confirm TNF-alpha-mediated signaling following SE, we performed an immunohistochemical study using five phospho-NF-kappaB antibodies. Compared to non-SE animals (data not shown), 12 hr-post SE animals of the saline-infused group showed p65-Ser276, p65-Ser311, p65-Ser529, and p65-Ser536 phosphorylation in astrocytes (not endothelial cells). sTNFp55R infusion effectively reduced p65-Ser276 and p65-Ser311 phosphorylation (p < 0.05, respectively), while it could not affect p65-Ser529 or p65-Ser536 phosphorylation (Figures 3 and 4A). In contrast, p65-Thr435 phosphorylation was increased in endothelial cells (not astrocytes) within the PC of saline-infused animals 12 hr after SE (Figure 5A). In addition, sTNFp55R infusion effectively alleviated SE-induced p65-Thr435 phosphorylation in endothelial cells, compared to saline infusion (p < 0.05, Figure 5B).","[{'offsets': [[54, 63]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[140, 149]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[368, 371]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[380, 383]], 'text': ['p65'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[392, 395]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[408, 411]], 'text': ['p65'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[475, 482]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[512, 515]], 'text': ['p65'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[527, 530]], 'text': ['p65'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[606, 609]], 'text': ['p65'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[620, 623]], 'text': ['p65'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[680, 683]], 'text': ['p65'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[841, 848]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[892, 895]], 'text': ['p65'], 'type': 'Protein', 'id': 'T14'}]",[],[],[],[],[]
127,PMC-1064895-09-Materials_and_methods,"Gel mobility-shift assay of NF-kappaB binding site
Nuclear proteins were extracted from about 5 x 106 PBMC. Oligonucleotide probes encompassing the NF-kappaB binding site of the human IL-17 promoter (5'-ATG ACC TGG AAA TAC CCA AAA TTC-3') were generated by 5'-end labeling of the sense strand with [gamma-32P]dATP (Amersham Pharmacia) and T4 polynucleotide kinase (TaKaRa). Unincorporated nucleotides were removed by NucTrap probe purification columns (Stratagene, La Jolla, CA, USA). Nuclear extracts (2 mug of protein) were incubated with radiolabeled DNA probes (10 ng; 100,000 c.p.m.) for 30 min at room temperature in 20 mul of binding buffer consisting of 20 mM Tris-HCl, pH 7.9, 50 mM KCl, 1 mM dithiothreitol, 0.5 mM EDTA, 5% glycerol, 1 mg/ml BSA, 0.2% Nonidet P40 and 50 ng/mul poly(dI-dC). Samples were subjected to electrophoresis on nondenaturing 5% polyacrylamide gels in 0.5 x Tris-borate-EDTA buffer (pH 8.0) at 100 V. Gels were dried under vacuum and exposed to Kodak X-OMAT film at -70degreesC with intensifying screens. Rabbit polyclonal antibodies against NF-kappaB subunits p50, p65 and c-Rel were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).","[{'offsets': [[184, 189]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1095, 1098]], 'text': ['p50'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1100, 1103]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1108, 1113]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
128,PMC-1064873-16-Conclusion,"CD4+ T cells from active RA patients are characterized by their resistance to IL-10 inhibition of IFN-gamma production, due to constitutive STAT3 phosphorylation and impaired IL-10-mediated STAT3 activation. The defective STAT3 signaling is possibly associated with SOCS1 predominance over SOCS3. These abnormalities in active RA are thought to be induced mainly after chronic exposure to high concentrations of IL-6. The limited efficacy of IL-10 treatment of RA patients [50] may be explained in part by the unresponsiveness to IL-10 of inflammatory cells, including T cells. On the contrary, the therapeutic efficacy of anti-IL-6 receptor antibody has been reported in RA patients [51], and one of the effects of this therapy may be to normalize T cells through the inhibition of IL-6-dependent STAT3 activation. More specific therapy targeting STAT3 activation will be awaited; for example, the induction of the SOCS3 gene, the efficacy of which has been demonstrated in animal models [37].","[{'offsets': [[1, 3]], 'text': ['D4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[78, 83]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[98, 107]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[140, 145]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[175, 180]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[190, 195]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[222, 227]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[266, 271]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[290, 295]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[412, 416]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[442, 447]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[530, 535]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[628, 641]], 'text': ['IL-6 receptor'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[783, 787]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[798, 803]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[848, 853]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[916, 921]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T17'}]",[],[],[],[],[]
129,PMC-1359074-02-Results,"Persistent Expression of the Embryonic Globin, epsilony, in Sox6-Deficient Mice
The epsilony globin gene was initially identified as an upregulated transcript in the p100H mouse using subtractive hybridization to identify Sox6 downstream targets. This initial observation was confirmed in an independent knock-out allele of Sox6 [13] using real-time polymerase chain reaction (PCR) (unpublished data). Real-time PCR was used to quantitate the expression levels of other globin genes in p100H mutant and WT mouse livers at two developmental stages, 15.5 dpc and 18.5 dpc. As shown in Figure 1, the epsilony gene is expressed at high levels at both time points in mutant mice, in contrast to the decline in expression observed in WT mice. No difference was seen between WT and heterozygous mice (unpublished data). Interestingly, the expression levels of the other two embryonic globin genes (zeta and betah1) are also higher in p100H homozygous mice, compared with WT mice, but to a much lesser extent than seen for epsilony globin at 18.5 dpc (Figure 1). Moreover, the expression level of adult beta globin is also somewhat higher in p100H homozygous mice than in WT mice at 18.5 dpc (Figure 1). Perinatal lethality of mutant mice (presumably from the heart defect [14]) precludes us from evaluating postnatal globin expression. The graphs in Figure 1 illustrate real time PCR results that were performed in triplicate (standard deviation of the data is shown by error bars). Because all of the assays were performed at the same time with the same internal control, the levels shown are relative levels and are thus comparable across all samples and are in agreement with previously published results for WT fetal mice [29]. We note that the level of epsilony expression in the livers of 15.5 dpc and 18.5 dpc homozygous mutant mice is statistically equivalent to the level of betamaj/min expression in the livers of 15.5 dpc and 18.5 dpc homozygous WT mice.","[{'offsets': [[39, 45]], 'text': ['Globin'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[47, 55]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[60, 64]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[84, 99]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[222, 226]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[324, 328]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[597, 605]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[891, 895]], 'text': ['zeta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[900, 906]], 'text': ['betah1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1015, 1030]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1095, 1106]], 'text': ['beta globin'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1751, 1759]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1877, 1884]], 'text': ['betamaj'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1885, 1888]], 'text': ['min'], 'type': 'Protein', 'id': 'T14'}]",[],[],[],[],[]
130,PMC-3291650-08-Materials_and_Methods,"Viral infection and determination of viral titers
Mouse adapted IAV X-47 (H3N2; PR8xA/Victoria/3/75) was propagated in MDCK cells. For viral inoculation, mice were anesthetized by i.p. injection with ketamine (12 mg/kg) and xylazine (60 mg/kg) and 50 microl X-47 diluted in PBS was administered intranasally. For lethal and sublethal infection, mice received respectively 2-LD50 or 0.05-LD50 X-47. To determine pulmonary viral titers, median tissue culture infectious dose (TCID50) was measured as follows: lungs were homogenized with a Polytron homogenizer (Kinematica) in PBS. Eight-fold serial dilutions of lung homogenates were incubated on MDCK cells for 5 days in DMEM supplemented with trypsin (1 microg/ml), 2 mM L-glutamine, 0.4 mM sodium pyruvate and antibiotics. For read-out, 0.5% chicken red blood cells (RBC) were added and end-point dilution of hemagglutination was monitored. TCID50 titers were then calculated according to the method of Reed and Muench [85].",[],[],[],[],[],[]
131,PMC-2817507-09-3._Results,"3.1. TLR4 mRNA Increased in Brain Tissue after ICH
TLR4 mRNA levels were detected by Rt-PCR. The low level of TLR4 mRNA was observed in normal rat brain tissue. In the saline control group, the TLR4 mRNA slightly increased, but was not significantly different from normal group. However, the TLR4 mRNA after ICH significantly increased starting from 6 hours after ICH (P < .05), peaked on the 3rd day after ICH, and then decreased on the 7th day after ICH (P < .05), but still maintained a higher level compared with saline control (P < .05, Figure 1).","[{'offsets': [[5, 9]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[51, 55]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[110, 114]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[194, 198]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[292, 296]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
132,PMC-1064873-05-Materials_and_methods,"Flow cytometric analysis for IL-10R1 expression
A sample of 5 x 105 cells of PBMC was resuspended in PBS with 1% FCS. PBMC were incubated with saturating concentrations of anti-IL-10R1 mAb (IgG1; R&D systems, Minneapolis, MN, USA) or with isotype-matched control mAb (Immunotech), followed by incubation with FITC-conjugated goat anti-mouse IgG1 polyclonal antibody (Santa Cruz Biotechnologies, Santa Cruz, CA, USA). Cells were then incubated with phycoerythrin-conjugated anti-CD4 mAb (Becton Dickinson). Cells were washed well with 1% FCS/PBS between incubations. Analysis was performed on a FACScan flow cytometer (Becton Dickinson).","[{'offsets': [[29, 36]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[177, 184]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[478, 481]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
133,PMC-3585731-07-Results,"Akt and mTORC1 Control the Activation of JNK during Necroptosis
JNK is a well-established regulator of TNFalpha synthesis in a variety of systems [13], [14], [15], [34]. Therefore, the ability of Akt and mTORC1 inhibitors to block the increase in TNFalpha mRNA lead us to examine their role in the activation of JNK during necroptosis. Knockdown of Akt isoforms Akt1 and Akt2 or inhibition of Akt prominently suppressed the necroptosis dependent increase in JNK and c-Jun phosphorylation (Fig. 6E, S6D,E) suggesting that Akt may provide a link between RIP1 and JNK activation. Importantly, inhibition of Akt only inhibited the delayed, but not the early, increase in bFGF/zVAD.fmk induced JNK and c-Jun phosphorylation (Fig. S6F). Knockdown of mTOR, rapamycin and the p70S6K inhibitor PF-4708671 also attenuated the necroptosis-associated increase in JNK and c-Jun phosphorylation (Fig. 6F, S6E,G, Fig. S5D). Overall, these data suggested that the Akt-mTORC1-S6K axis, acting downstream from RIP1 kinase, is required for the increase in JNK activity during necroptosis in L929 cells.","[{'offsets': [[103, 111]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[247, 255]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[362, 366]], 'text': ['Akt1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[371, 375]], 'text': ['Akt2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[466, 471]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[552, 556]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[667, 671]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[697, 702]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[768, 774]], 'text': ['p70S6K'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[859, 864]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[959, 962]], 'text': ['S6K'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[992, 996]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
134,PMC-1064895-15-Results,"Inhibition of IL-17 production by signal transduction inhibitors and anti-rheumatic drugs
Having observed the increased IL-17 production in RA PBMC, it was important to know which signal transduction pathways were involved. As illustrated in Fig. 3, an significant decrease in anti-CD3-induced IL-17 production was observed when co-incubated with NF-kappaB inhibitor, PDTC and dexamethasone in comparison with anti-CD3 alone (38 +/- 5 and 54 +/- 11 versus 98 +/- 19 pg/ml, respectively; P < 0.05).
LY294002 and wortmannin, as an inhibitor of PI3K, also markedly inhibited the anti-CD3-induced IL-17 production in RA PBMC (98 +/- 19 versus 38 +/- 10 pg/ml [P < 0.005] and 48 +/- 4 pg/ml [P < 0.05], respectively).
The calcineurin inhibitors cyclosporin A and FK506 also downregulated the IL-17 secretion as well as the mitogen-activated protein kinase (MAPK) p38 inhibitor SB203580 did, whereas rapamycin and PD98059 had no effect on IL-17 levels (Fig. 3). To evaluate the possibility of non-specific inhibition by the drug at high concentrations, we observed the dose response of PDTC and LY294002 for the inhibition of IL-17 production in PBMC. There were dose-dependent inhibitions of IL-17 production with chemical inhibitors (Fig. 4a). The other inhibitors in addition to PDTC and LY294002 showed the same pattern of inhibition. Cytotoxic effects on PBMC by the chemical inhibitors at experimental concentrations were not observed (Fig. 4b).","[{'offsets': [[14, 19]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[120, 125]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[294, 299]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[593, 598]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[717, 728]], 'text': ['calcineurin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[787, 792]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[933, 938]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1120, 1125]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1187, 1192]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T9'}]",[],[],[],[],[]
135,PMC-1359074-08-Discussion,"In this report, we show that Sox6 is a novel factor in the complicated regulation mechanism of globin genes. In the Sox6 null mouse, there is a transient effect on the embryonic globin genes, zeta and betaH1, and a persistent upregulation of the epsilony globin gene. Sox6 directly regulates and binds to the proximal promoter of epsilony gene and represses the epsilony-globin gene in definitive erythropoiesis.
Sox6 belongs to group D of the Sox family of proteins that includes Sox5, 12, 13, and 23 [34]. Group D Sox proteins contain a coiled-coiled domain that mediates homo- and heterodimerization [6,35]. Functionally, dimerization of Sox5 and Sox6 has been shown to greatly increase the binding efficiency of the two Sox proteins to DNA that contains adjacent Sox sites [6]. In addition, Sox6 binds more strongly to an HMG-box dimer motif than to a single HMG-box motif [5]. Therefore, it appears that target genes for group D Sox proteins, such as Sox6, probably harbor pairs of HMG binding sites with a configuration compatible with binding of D-Sox protein dimers. Indeed, in the present study, the defined Sox6 target sequence of the epsilony promoter contains two Sox/Sox6 consensus sites (Figure 3A). Functionally, both sites are essential for Sox6 binding to the epsilony promoter and repression of its activity (Figure 3E and 3F). These observations suggest that Sox6 binds to this sequence of the epsilony promoter either as a homodimer or as a heterodimer with other Sox proteins. Because Sox proteins recognize a short 6-bp core-binding sequence that allows for considerable degeneracy, the specificity of their actions is thought to rely upon interactions with other transcription factors [36]. In our EMSAs, we had to run the electrophoresis on a 4%-6% gel for at least 4-8 h to detect the Sox6-associated band, suggesting that Sox6 is part of a high molecular weight complex. A few other epsilony globin repressors have been reported to bind to DNA sequences near the Sox/Sox6 consensus sites, including the DRED complex [37] and COUP-TF [38]. Sox6 might interact with these factors and form a large repression complex. Identification of other components of the Sox6-containing complex associated with the epsilony promoter will shed light on its mechanism of repression.
Sox proteins bind and bend linear DNA by partial intercalation in the minor groove, and can also bind to four-way junctions [2-4]. Therefore, one attractive model to explain how Sox6 proteins control gene expression is that they function as architectural factors bound to DNA, influencing local chromatin structure by bending DNA and by assembling multiprotein transcriptional complexes. By changing the local chromatin structure, Sox6 could either interfere with binding of other activators to the promoter or facilitate binding of other repressors. Another example of a repressor that interferes with an activator on the epsilony promoter is DRED. DRED interferes with EKLF, an activator, in binding to the epsilony promoter [39]. Two HMG architectural proteins (distantly related to the Sox family of transcription factors), HMG-I and HMG-Y, were demonstrated to bind to the human adult beta globin silencers (silencers I and II) and cause bending of the DNA, facilitating the binding of other repressors [40].
Sox6 expression is temporally and spatially coincident with definitive (but not primitive) erythropoiesis (Figure 6), and Sox6 represses epsilony globin expression both in vivo (Figure 1) and in vitro (Figure 2). Moreover, in situ hybridization clearly shows that the persistent expression of epsilony globin in p100H mutant mice is due to defects in the silencing mechanism of definitive erythropoiesis that takes place in the liver (Figure 5). Taken together, these data demonstrate that Sox6 functions in definitive erythropoiesis to silence epsilony globin expression.
The expression level of epsilony globin in homozygous Sox6 null mice at 15.5 dpc and 18.5 dpc is statistically equivalent to the level of betamaj/min expression in the livers of 15.5-dpc and 18.5-dpc homozygous WT mice (Figure 1). This demonstrates that ectopic expression of the epsilony globin gene is quite robust in homozygous mutant mice. The expression levels of two other embryonic globin genes (zeta and betah1) are also higher in p100H homozygotes, compared with WT. Like epsilony, levels of zeta and betah1 are dramatically higher in mutant mice at 15.5 dpc. However, unlike epsilony globin, zeta and betah1 decline in expression by day 18.5 dpc (Figure 1), suggesting that epsilony is regulated differently than zeta and betah1. It is possible that Sox6 has a general effect on embryonic globin genes (and erythrocyte maturation) in addition to a specific role in silencing epsilony.
Although most p100H mutant mice die just after being born, a rare few survive longer. None have been observed to live longer than 2 wk after birth [14]. We examined a single archived sample of liver RNA from a mutant mouse on postnatal day 13.5 for globin gene expression and detected high levels of epsilony globin in this RNA sample, compared with undetectable epsilony RNA in WT control mice. At this point in development, the levels of zeta and betah1 RNA were undetectable both in mutant and WT; however, adult beta-like globin RNA levels were moderately elevated in the mutant RNA compared with WT (unpublished data), similar to what we observe at 18.5 dpc (Figure 1). These findings suggest that Sox6 continues to function postnatally to silence epsilony globin expression and has a unique function in the regulation of epsilony-globin. The mechanism by which Sox6 regulates the other embryonic globin genes remains to be elucidated.
Sox6 has other effects in erythropoiesis, including a delay in enucleation/maturation in p100H mutant mice. This may be the result of indirect effects, such as stress-induced proliferation (resulting from cardiac defects) and/or anemia. Severe anemia can lead to rapid premature release of red cells, prior to their complete maturation. However, the hematocrit of 18.5-dpc mutant mice is only 20% lower than that of WT (unpublished data), and this mild anemia is probably not sufficient to explain the extent of nucleated red cells. Alternatively, Sox6 itself may play a role in red cell terminal differentiation, as it has been shown to be an important factor in cardiac [15], neuronal [10], astrocytic [11], and cartilage differentiation programs [32,41-44].
The restoration of normal enucleation of red cells in Sox6-deficient mouse by postnatal day 10.5 may result from functional compensation of other Sox proteins (expressed at later developmental stages), since functional redundancy is a recurring theme with Sox proteins [13,45,46]. Moreover, erythropoiesis has already shifted from fetal liver to bone marrow by postnatal day 10.5. The accompanying change in the microenvironment of red cell production may permit normal enucleation. Identification of Sox6 downstream target genes and its interacting proteins will shed light on the role of Sox6 in red cell terminal differentiation and the enucleation process.
Recently, in vivo and in vitro analyses suggest that reactivation of human epsilon-globin would be therapeutically beneficial to adults with sickle cell disease [47], providing a rationale for detailed investigations into the molecular basis of epsilon-globin gene silencing. The present study identifies a novel repressor, Sox6, which binds to the epsilony proximal promoter, potentially as part of a larger repression complex. Because murine Sox6 and its human counterpart are 94% identical at the amino acid level [48], it is possible that human Sox6 may also be important in human epsilon globin silencing. There is significant sequence homology between the human and mouse epsilon promoter regions, and the human promoter contains at least two potential Sox6 binding sites. Indeed, the existence of a silencer of the human epsilon globin gene has been proposed [49,50]. Thus, elucidation of the Sox6 repression mechanism and identification of other components of the Sox6-containing complex may further our understanding of epsilon globin regulation and potentially reveal additional molecular targets for the treatment of sickle cell anemia and beta thalassemias.","[{'offsets': [[29, 33]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[116, 120]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[192, 196]], 'text': ['zeta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[201, 207]], 'text': ['betaH1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[246, 261]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[268, 272]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[330, 343]], 'text': ['epsilony gene'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[362, 377]], 'text': ['epsilony-globin'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[413, 417]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[481, 485]], 'text': ['Sox5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[487, 489]], 'text': ['12'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[491, 493]], 'text': ['13'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[499, 501]], 'text': ['23'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[641, 645]], 'text': ['Sox5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[650, 654]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[795, 799]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[956, 960]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1117, 1121]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1145, 1153]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1257, 1261]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1277, 1285]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1378, 1382]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1413, 1421]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1810, 1814]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1848, 1852]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1909, 1924]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2029, 2033]], 'text': ['DRED'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2051, 2055]], 'text': ['COUP'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2056, 2058]], 'text': ['TF'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2065, 2069]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2183, 2187]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2227, 2235]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2471, 2475]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2724, 2728]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2916, 2924]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2937, 2941]], 'text': ['DRED'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2943, 2947]], 'text': ['DRED'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2964, 2968]], 'text': ['EKLF'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3002, 3010]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3121, 3126]], 'text': ['HMG-I'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3131, 3136]], 'text': ['HMG-Y'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3206, 3217]], 'text': ['silencers I'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3222, 3224]], 'text': ['II'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3307, 3311]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3429, 3433]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3444, 3459]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3600, 3615]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3797, 3801]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3852, 3867]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3904, 3919]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[3934, 3938]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4018, 4025]], 'text': ['betamaj'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4026, 4029]], 'text': ['min'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4160, 4175]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4283, 4287]], 'text': ['zeta'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4292, 4298]], 'text': ['betah1'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[4361, 4369]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[4381, 4385]], 'text': ['zeta'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[4390, 4396]], 'text': ['betah1'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[4465, 4480]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[4482, 4486]], 'text': ['zeta'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[4491, 4497]], 'text': ['betah1'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[4564, 4572]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[4603, 4607]], 'text': ['zeta'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[4612, 4618]], 'text': ['betah1'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[4640, 4644]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[4765, 4773]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[5075, 5090]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[5138, 5146]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[5215, 5219]], 'text': ['zeta'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[5224, 5230]], 'text': ['betah1'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[5291, 5307]], 'text': ['beta-like globin'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[5478, 5482]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[5528, 5543]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[5602, 5617]], 'text': ['epsilony-globin'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[5642, 5646]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[5716, 5720]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[6264, 6268]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[6531, 6535]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[6978, 6982]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[7067, 7071]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[7213, 7227]], 'text': ['epsilon-globin'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[7383, 7397]], 'text': ['epsilon-globin'], 'type': 'Protein', 'id': 'T83'}, {'offsets': [[7462, 7466]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T84'}, {'offsets': [[7487, 7495]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T85'}, {'offsets': [[7582, 7586]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T86'}, {'offsets': [[7687, 7691]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T87'}, {'offsets': [[7723, 7737]], 'text': ['epsilon globin'], 'type': 'Protein', 'id': 'T88'}, {'offsets': [[7816, 7823]], 'text': ['epsilon'], 'type': 'Protein', 'id': 'T89'}, {'offsets': [[7966, 7980]], 'text': ['epsilon globin'], 'type': 'Protein', 'id': 'T90'}, {'offsets': [[8038, 8042]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T91'}, {'offsets': [[8110, 8114]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T92'}, {'offsets': [[8167, 8181]], 'text': ['epsilon globin'], 'type': 'Protein', 'id': 'T93'}]",[],[],[],[],[]
136,PMC-3342329-17-Materials_and_Methods,"Statistical Analysis
The data were analyzed using the GraphPad Prism 4 ver. 4.03 software (GraphPad Software, La Jolla, CA). Data are presented as mean +/- SD. Difference between CCR5-/- mice and CCR5+/+ mice were compared using t test. A value of p<0.05 was considered to be statistically significant. Survival data were presented by Kaplan-Meier survival estimates and compared and calculated by Log-rank (Mantel-Cox) Test in GraphPad Prism.","[{'offsets': [[179, 183]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[196, 200]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
137,PMC-1359074-14-Materials_and_Methods,"Cell culture and transfection.
GM979 cells (Coriell Cell Repositories, Camden, New Jersey, United States) were cultured in Ham's F12 with 2 mM L-glutamine supplemented with heat-inactivated 10% fetal calf serum (Ivitrogen, Carlsbad, California, United States), penicillin (100 units/ml), streptomycin 100 mug/ml), and L-glutamine (2 mM). MEL cells were cultured in DMEM supplemented as above (without heat inactivating the serum). GM979 cells (4 x 105) in log phase of growth were transfected with plasmids by FuGENE6 (Roche, Indianapolis, Indiana, United States). Cells were transfected with epsilony promoter reporter constructs (500 ng) along with either empty vector or Sox6 overexpression vector (1000 ng). In assays of dosage effect, we used 200 ng, 500 ng, and 1000 ng). pRL-CMV 15ng (Promega) was used as a control for transfection efficiency.","[{'offsets': [[593, 601]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[674, 678]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
138,PMC-1472690-17-Methods,"Statistical analysis
The Kolmogorow-Smirnov test was used to evaluate, whether cytokine amounts and binding activities to transcription factors were normally distributed. Correlation coefficients and corresponding significances were analyzed by the Pearson test (normal distribution) or the Spearman test (non-normal distribution). To compare experimental data to a theoretical value (for example GP + TSST-1 vs GP/TSST-1 calc.) we calculated the sum of the individual effects and added these values into Fig. 1B, 3, 4, 5, and 6. Significances of differences between experimental data (for example GP vs LPS) as well as between experimental data and theoretical values (for example GP + TSST-1 vs GP/TSST-1 calc.) were analysed using the Student's t-test (normal distribution) or the Wilcoxon Signed-Rank test (non-normal distribution), (SPSS for Windows; SPSS Science Software, Erkrath, Germany).","[{'offsets': [[402, 408]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[415, 421]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[687, 693]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[700, 706]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
139,PMC-3317373-08-2._Methods_and_Materials,"2.7. Enzyme-Linked Immunosorbent Assay (ELISA)
Cells of four groups were homogenized as mentioned above. The supernatant was collected, and total protein was determined by Coomassie Plus Protein Assay Reagent (Pierce, IL, USA). Levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta), and interleukin-6 (IL-6) protein were quantified using ELISA kits specific for mouse according to the manufacturer's instructions (Bender MedSystems Inc. CA, USA). Briefly, prepared the standard and created the standard dilution for building standard curve. Then samples and biotinconjugate were added to microwell strips. After incubated for 2 h at room temperature, the microwell strips were washed 3 times with wash buffer, and streptavidin-HRP were added to all wells. After incubated for 1 h, microwell strips were washed 3 times followed by adding TMB substrate. After incubated for about 10-30 min, the stop solution was added. The colour intensity was measured at 450 nm using a Bio-Rad ELISA microplate reader (Bio-Rad Laboratories, CA, USA). The concentration of protein was determined according to the standard curve and expressed as pg/mg of total protein.","[{'offsets': [[279, 297]], 'text': ['interleukin-1 beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[299, 307]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[314, 327]], 'text': ['interleukin-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[329, 333]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
140,PMC-3586680-03-p53_and_Functions,"Activated p53 mediates apoptosis, cell cycle arrest, senescence, DNA repair, or metabolism (Lane and Levine, 2010). The primary structures of p53 and its isoforms are depicted (Figure 2). p53 induces cell cycle arrest by transactivating genes such as cyclin-dependent kinase inhibitor p21, or microRNA miR34. p53 induces apoptosis by transactivating proapoptotic genes such as BAX, PUMA, SCOTIN, and FAS, and inhibiting the antiapoptotic gene BCL-2 (Lane and Levine, 2010). p53 triggers pro-survival or cell death response, depending upon cell types, the intensity of the stress signal, and the extent of cellular damage (Menendez et al., 2009). Also, p53 plays a role in controlling cell motility via regulating the expression of smooth muscle alpha-actin (Comer et al., 1998), collagens IIalpha1 and VIalpha1 (Sun et al., 1999), and many others.","[{'offsets': [[10, 13]], 'text': ['p53'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[142, 145]], 'text': ['p53'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[188, 191]], 'text': ['p53'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[285, 288]], 'text': ['p21'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[302, 307]], 'text': ['miR34'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[309, 312]], 'text': ['p53'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[377, 380]], 'text': ['BAX'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[382, 386]], 'text': ['PUMA'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[388, 394]], 'text': ['SCOTIN'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[400, 403]], 'text': ['FAS'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[443, 448]], 'text': ['BCL-2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[474, 477]], 'text': ['p53'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[652, 655]], 'text': ['p53'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[731, 756]], 'text': ['smooth muscle alpha-actin'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[779, 797]], 'text': ['collagens IIalpha1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[802, 810]], 'text': ['VIalpha1'], 'type': 'Protein', 'id': 'T16'}]",[],[],[],[],[]
141,PMC-3320587-06-Materials_and_Methods,"Quantitative DNase I footprinting
Recombinant NFAT5 (amino acids 175-471) with an N-terminal 6x His tag was expressed in E. coli BL21(DE3) cells (Stratagene; www.stratagene.com) and purified under native conditions using Ni-NTA agarose (Qiagen). Recombinant p50 and p65 were purchased (Active Motif, www.activemotif.com). Quantitative DNase I footprinting was performed as previously described [31].","[{'offsets': [[13, 20]], 'text': ['DNase I'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[46, 51]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[258, 261]], 'text': ['p50'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[266, 269]], 'text': ['p65'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[335, 342]], 'text': ['DNase I'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
142,PMC-3589482-09-Experimental_Procedures,"Transient Transfection and Luciferase Assays (MEF Cells)
Cebpb-/- MEFs (1x105) [34] were transfected with the indicated luciferase reporter plasmid (400 ng) along with a beta-actin-beta-galactosidase reporter plasmid (200 ng) by electroporation using the Invitrogen Neon(TM) system (1 pulse, 1350 V, 30 msec). Transfected cells were transferred to pre-warmed media in 24 well plates and incubated for 48 hrs prior to incubation with LPS (100 ng/ml) for 4 hrs where indicated. In some experiments, plasmids encoding C/EBP-beta or C/EBP-beta phospho-acceptor mutants (T188A, T217A, S64A) [38]-[40] or control vector were co-transfected (0.6-1.0 microg total DNA). Luciferase activity was determined and normalized to that of beta-galactosidase [38] using the Luciferase Assay System and beta-Galactosidase Enzyme Assay System Kits, respectively (Promega). Each experiment was repeated at least three times, and triplicate samples were employed for each sample. Expression of the C/EBP-beta phospho-acceptor mutant proteins was checked for equal expression by western blot.","[{'offsets': [[27, 37]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[57, 62]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[120, 130]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[170, 180]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[181, 199]], 'text': ['beta-galactosidase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[515, 525]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[529, 564]], 'text': ['C/EBP-beta phospho-acceptor mutants'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[566, 571]], 'text': ['T188A'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[573, 578]], 'text': ['T217A'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[580, 584]], 'text': ['S64A'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[662, 672]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[723, 741]], 'text': ['beta-galactosidase'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[757, 767]], 'text': ['Luciferase'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[785, 803]], 'text': ['beta-Galactosidase'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[977, 1011]], 'text': ['C/EBP-beta phospho-acceptor mutant'], 'type': 'Protein', 'id': 'T15'}]",[],[],[],[],[]
143,PMC-3342329-08-Materials_and_Methods,"Ethics Statement
All experiments were approved and carried out according to the Guide for the Care and Use of Animals [Animal Care Committee of Chungbuk National University, Korea (CBNUA-045-0902-01)].",[],[],[],[],[],[]
144,PMC-3585731-20-Materials_and_Methods,"Western Blot
For Western blot, 4x105 adherent cells (1x106 Jurkat cells) were seeded into 35 mm2 dishes. After 24-48 hr, cells were stimulated with 30 microM zVAD.fmk or 10 ng/ml mouse TNFalpha. For treatments under serum free conditions, cells were serum starved for 24 hr prior to the addition of growth factors, 20 microM zVAD.fmk or 10 ng/ml mouse TNFalpha. Cells were harvested in 1xRIPA buffer (Cell Signaling) supplemented with 50 microg/ml phenylmethanesulfonylfluoride. After brief sonication, cell lysates were spun down for 15 min at 14,000xrpm. Protein concentrations were measured using the Pierce 660 nm Assay Reagent (Pierce). Equal amounts of proteins were boiled for 5 min at 95degreesC. Western blotting was performed according to standard protocols. Briefly, SDS-PAGE gels were transferred to PVDF membrane, blocked in 3% milk or 5% bovine serum albumin (BSA) in TBST buffer for 30 min at room temperature. Primary antibodies were incubated in 5%BSA/TBST overnight at 4degreesC. Secondary antibodies were incubated in TBST for 30 min at room temperature. Luminata (Millipore) ECL reagents were used to develop the signals. In some cases, membranes were stripped using OneMinute stripping buffer (GM Biosciences) and reprobed with new antibodies.","[{'offsets': [[185, 193]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[352, 360]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
145,PMC-1472690-26-Caption-Figure_8,"Cartoon of the sense strand of the IL-1RA promoter. Relative locations of previously (LRE-1) [30-33] and newly described (boxed), positively (black) and negatively (gray) regulatory transcription factor binding sites are depicted.","[{'offsets': [[35, 41]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
146,PMC-2817507-08-2._Methods,"2.7. Statistical Analysis
All data were presented as mean +/- SEM. The measurements were analyzed by one-way analysis of variance (ANOVA) or Student's t-test. The P < .05 level of probability was used as the criteria of significance.",[],[],[],[],[],[]
147,PMC-1064895-10-Materials_and_methods,"Cell viability (Trypan blue dye exclusion assay)
For cell viability assays, the trypan blue dye exclusion method was used to evaluate the potential of direct cytotoxic effect of inhibitors on cells. After incubation for 24 hours, the cells were harvested and the percentage cell viability was calculated with the formula 100 x (number of viable cells/number of both viable and dead cells) [21].",[],[],[],[],[],[]
148,PMC-3585731-28-Caption-Figure_3,"RIP1 kinase-dependent phosphorylation of Akt and JNK during necroptosis.
(A) L929 cells were treated with zVAD.fmk or TNFalpha for 9 hr, followed by western blotting with indicated antibodies. (B,C) L929 cells were treated with zVAD.fmk (B) or bFGF/zVAD.fmk (serum free conditions, C) and samples were collected at the indicated time points for western blot. (D) Nec-1 was added to the cells stimulated with bFGF or bFGF/zVAD (serum free conditions) for 15 min or 9 hr followed by western blot with the indicated antibodies.","[{'offsets': [[0, 4]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[118, 126]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[244, 248]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[408, 412]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[416, 420]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
149,PMC-3317373-01-1._Introduction,"Brain damage following traumatic injury is a result of direct (primary injury) and indirect (secondary or delayed injury) mechanisms. The secondary injury mechanism involves the initiation of an acute inflammatory response, including breakdown of blood-brain barrier (BBB), brain edema, infiltration of peripheral blood cells, and activation of resident immunocompetent cells, as well as the release of numerous immune mediators such as interleukins and chemotactic factors [1]. And the subsequent inflammation leads to secondary damage not only in brain but also in other organs [2-4].
Nuclear factor erythroid 2-related factor2 (Nrf2) is a transcription factor that regulates many kinds of antioxidant genes. Several studies have demonstrated that Nrf2 regulates the inflammation in the brain after traumatic brain injury (TBI). It was also showed that TBI could induce more aggravated damage in Nrf2 knockout mice than in wildtype mice [5]. On the contrary, such inflammation can be extenuated through elevating the level of Nrf2 by its inducers, such as sulforaphane (SFN) [6]. It is well documented that astrocytes play a critical role in maintaining normal brain physiology and responding to injury or disease. In fact, all the aforementioned studies are performed in vivo. Little is known about the relationship between Nrf2 and inflammation in astrocytes after TBI. Therefore, here we analysed the influence of Nrf2 on the expression of proinflammatory cytokines in primary cultured astrocytes from transgenic mice after scratch injury.",[],[],[],[],[],[]
150,PMC-3589482-25-Caption-Figure_2,"Deletion reporter gene analysis of LPS and PMA-responsive regions in the murine SerpinB2 promoter.
(A) Schematic representation of the murine SerpinB2 promoter and 5' deletion luciferase reporter constructs. The murine 5' flanking region from -4480 to +92 was inserted upstream of the luciferase reporter gene and 5' deletions were generated using restriction enzyme sites or with specific oligonucleotide PCR primers. Construct names indicate the most 5' nucleotide of murine SerpinB2 5' flanking sequence. (B) RAW 264.7 macrophages were transiently transfected with the indicated murine SerpinB2 promoter-luciferase reporter constructs and control plasmids. Cells were either left untreated or treated with 100 ng/ml LPS or 40 ng/ml PMA for 16 hrs. Shown is the relative luciferase reporter gene activity following treatment. The results represent the mean and SEM of four independent experiments. (C) DNA sequence conservation between the human and murine SerpinB2 5' flanking regions. Schematic representation of the human and murine SerpinB2 5' flanking regions with regions of nucleotide sequence identity indicated by the same colored boxes. Homologous regions are interrupted by repetitive sequence elements in both 5' flanking regions. Alu = Alu repeat, ID4 =  ID4 short interspersed nuclear repeat (SINE), L1 =  L1 long interspersed nuclear element (LINE), L2 =  L2 LINE, MIR = MIR SINE, MLT1L = MLT1L long terminal repeat (LTR), (TATG)n = TATG tetranucleotide repeat, tis = transcription initiation site.","[{'offsets': [[80, 88]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[142, 195]], 'text': [""SerpinB2 promoter and 5' deletion luciferase reporter""], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[285, 295]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[477, 485]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[589, 626]], 'text': ['SerpinB2 promoter-luciferase reporter'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[773, 783]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[959, 967]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1038, 1046]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
151,PMC-3312845-21-Caption-Figure_3,"Effect of sTNFp55R infusion on NF-kappaB phosphorylation in astrocytes 12 hr after SE. In 12 hr-post SE animals of the saline-infused group (A, C, E and G), astrocytes show p65-Ser276 (A), p65-Ser311 (C), p65-Ser529 (E), and p65-Ser536 (G) phosphorylation (arrows). sTNFp55R infusion (B, D, F and H) effectively reduces p65-Ser276 (B) and p65-Ser311 (D) phosphorylation, while it does not affect p65-Ser529 (F) and p65-Ser536 (H) phosphorylation (arrows). Bar = 12.5 mum.","[{'offsets': [[11, 18]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[173, 176]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[189, 192]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[205, 208]], 'text': ['p65'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[225, 228]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[267, 274]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[320, 323]], 'text': ['p65'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[339, 342]], 'text': ['p65'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[396, 399]], 'text': ['p65'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[415, 418]], 'text': ['p65'], 'type': 'Protein', 'id': 'T10'}]",[],[],[],[],[]
152,PMC-1359074-17-Materials_and_Methods,"EMSA.
Single-stranded complementary oligonucleotides were annealed and end-labeled with [gamma-32P] ATP with T4 polynucleotide kinase. EMSA was performed with 5 mug of nuclear proteins from MEL cells or 3 mul of in vitro-translated Sox6 along with the reticulocyte lysate in binding buffer: 100 mM NaCl, 10% glycerol, 200 ng/mul BSA, 50 ng/mul poly (dI-dC) or poly (dG-dC), 10 mM HEPES (pH 7), 0.1 mM EDTA, 0.25 mM DTT, 0.6 mM MgCl2. For competition or supershift assays, the indicated unlabelled oligonucleotide competitor (200-fold molar excess) or antibody (3 mul) was added 30 min to 60 min prior to addition of radiolabeled probe. Following addition of the radiolabeled probe, the samples were incubated for 30 min or 60 min at room temperature and loaded on a 4% or 6% (w/v) polyacrylamide gel. Electrophoresis was performed at a constant 19 mAmp for 4-8 h at room temperature, and the gels were dried prior to autoradiography. Antibodies used for supershift analyses included c-Myc, HA, and Sox6 antibodies (described as above). The DNA sequences of the oligonucleotides are as follows (only forward oligos are listed): For the 36-bp WT probe: 5'AATGCAGAACAAAGGGTCAGAACATTGTCTGCGAAG3' (MHB1556); for mutant probe 1 (M1): 5'AACAAAGGGTCAGAACATTGTCTGCGAAG3' (MHB1644); for mutant probe 2 (M2): 5'AATGCAGAACAAAGGGTCAGAtgagTGTCTGCGAAG3' (MHB1648); for mutant probe 3 (M3): 5'AATGCAGtgccAAGGGTCAGAACATTGTCTGCGAAG3' (MHB1650).","[{'offsets': [[109, 133]], 'text': ['T4 polynucleotide kinase'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[232, 236]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[329, 332]], 'text': ['BSA'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[983, 988]], 'text': ['c-Myc'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[990, 992]], 'text': ['HA'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[998, 1002]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T6'}]",[],[],[],[],[]
153,PMC-3291650-20-Caption-Figure_4,"A20 deficiency in myeloid cells protects against lethal IAV infection.
A20myel-WT (n = 11) and A20myel-KO (n = 11) mice were intranasally infected with a lethal dose of IAV and survival (p<0.001) (A) and weight loss +/- SEM (B) was monitored for respectively 21 and 15 days p.i. BAL fluid was collected from wild type (A20myel-WT) and A20myel-KO mice 6 days following infection with a lethal dose IAV and KC, MIP-2, MCP-1, IL-6 and IFNalpha protein levels were determined (C). Absolute numbers of alveolar macrophages, neutrophils and monocytes in BAL were analyzed by flow cytometry at 6 days p.i. (D). Numbers are averages +/- SEM of at least 5 mice per group. Data are representative of 2 independent experiments. *p<0.05; **p<0.01, ***p<0.001.","[{'offsets': [[405, 407]], 'text': ['KC'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[409, 414]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[416, 421]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[423, 427]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[432, 440]], 'text': ['IFNalpha'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
154,PMC-3320587-09-Materials_and_Methods,"Stable THP-1 cells expressing shRNA
The lentiviral plasmid pLKO.1 expressing shRNA targeting human MyD88 was purchased from Open Biosystems (www.openbiosystems.com) and was validated in our laboratory. shRNA targeting human IRAK1 (forward primer 5'-CCGGAGCAGCTGTCCAGGTTTCGTCTCATAAAACCTGGACAGCTGCTCCTTTTTG-3', reverse primer 5'-AATTCAAAAAGGAGCAGCTGTCCAGGTTTTATGAGACGAAACCTGGACAGCTGCT-3' mRNA (IRAK1 mRNA target sequence is underlined) and human TRAF6 (forward primer 5'-CCGGAGAAACCTGTTGTGATTCGTCTCATAAATCACAACAGGTTTCTCCTTTTTG-3', reverse primer 5'-AATTCAAAAAGGAGAAACCTGTTGTGATTTATGAGACGAATCACAACAGGTTTCT-3' (TRAF6 mRNA target sequence is underlined) were designed in our laboratory and were cloned into the pLKO.1 plasmid. Lentiviruses encoding shRNA sequences were generated by transfecting the packaging cell line HEK-293T with the shRNA-encoding pLKO.1 plasmids in combination with the packaging plasmid psPAX2 and the envelope plasmid pMD2.G using Effectene transfection reagent (Qiagen, www.qiagen.com). Supernatants were collected 48 hours post-transfection, clarified by centrifugation, and stored at -80degreesC. THP-1 cells were transduced with the lentiviral particles by culturing the cells with supernatants from the virus-producing cells in the presence of 8 microg/ml polybrene (Millipore, www.millipore.com) and spinoculation for two hours at 2000 RPM. Successfully transduced cells were selected and expanded by treatment with 0.8 microg/ml puromycin.","[{'offsets': [[30, 35]], 'text': ['shRNA'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[77, 82]], 'text': ['shRNA'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[99, 104]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[224, 229]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[392, 397]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[444, 449]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[607, 612]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
155,PMC-3585731-34-Caption-Figure_9,"Model of RIP1, Akt and JNK dependent signaling in necroptotic L929 cells.
Akt phosphorylation at Thr308 during necroptosis requires inputs from both growth factors and RIP1 kinase. Downstream from Akt, JNK activation leads to TNFalpha synthesis. Activation of Akt during necroptosis also leads the phosphorylation of several known Akt substrates, such as mTOR, which contribute to the execution of necroptotic death in L929 cells.","[{'offsets': [[9, 13]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[168, 172]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[226, 234]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
156,PMC-3585731-23-Materials_and_Methods,"ELISAOne Assay
ELISAOne assays (TGRBio, Hindmarsh, Australia) were performed according to manufacturer's protocol with the following modifications. Cell lysates were prepared in RIPA buffer as described for Western blots. Five microliters of samples were diluted in 45 microL of ELISAOne lysis buffer prior to analysis. Primary antibodies to phopsho-Thr308 and phopsho-Ser473 were incubated with the samples for 2 hr at room temperature. Primary antibody to pan-Akt was incubated overnight at 4degreesC. Signals for phospho-antibodies were normalized based on pan-Akt values.",[],[],[],[],[],[]
157,PMC-1064895-18-Results,"Activation of the NF-kappaB and activator protein-1 (AP-1) pathway in the IL-17 promoter region
To investigate further the intracellular signaling pathway activated by anti-CD3 plus anti-CD28, concanavalin A, PHA and IL-15, and responsible for inducing IL-17 expression, we performed an electrophoretic mobility-shift assay (EMSA) of NF-kappaB recognition sites in the promoters of IL-17. As shown in Fig. 7a, nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-kappaB to IL-17 promoters in comparison with that of controls (lane 1). A supershift assay demonstrated shifted bands in p65 and p50 (lanes 3 and 4) not in c-Rel (lane 5). In normal PBMC the same pattern was observed, but the degree of NF-kappaB activation by anti-CD3 plus anti-CD28 was less intense than that in RA PBMC (Fig. 7b). To confirm the link between PI3K activity and NF-kappaB, we performed EMSA to determine the NF-kappaB binding activity after treatment with both LY294002 and PDTC. Both agents block NF-kappaB DNA-binding activity in the IL-17 promoter (Fig. 7c). Western blotting for IkappaB-alpha showed inhibition of degradation of IkappaB-alpha by LY294002 and PDTC at the same time (Fig. 7c). In contrast, the AP-1 pathway was not activated by stimulation with anti-CD3 plus anti-CD28 (data not shown), demonstrating that NF-kappaB is the main intracellular signaling pathway in IL-17 production by activated PBMC from patients with RA.","[{'offsets': [[32, 51]], 'text': ['activator protein-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[53, 57]], 'text': ['AP-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[74, 79]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[187, 191]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[209, 212]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[217, 222]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[253, 258]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[382, 387]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[475, 479]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[536, 541]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[647, 650]], 'text': ['p65'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[655, 658]], 'text': ['p50'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[682, 687]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[805, 809]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1079, 1084]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1126, 1139]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1176, 1189]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1256, 1260]], 'text': ['AP-1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1326, 1330]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1425, 1430]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T20'}]",[],[],[],[],[]
158,PMC-3585731-14-Materials_and_Methods,"DNA
Cloning of Myr-Akt1, containing c-terminal FLAG tag, has been described [52]. Myr-Akt1-FLAG was amplified by PCR and subcloned into the BglII and EcoRI sites of pMSCV-puro retroviral vector (Invitrogen). Mutant versions of Myr-Akt1 were generated using the same strategy.","[{'offsets': [[15, 23]], 'text': ['Myr-Akt1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[82, 95]], 'text': ['Myr-Akt1-FLAG'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[227, 235]], 'text': ['Myr-Akt1'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
159,PMC-1064895-04-Materials_and_methods,"Production of IL-17 by T cell receptor activation, cytokines or chemokines
PBMC were prepared from heparinized blood by Ficoll-Hypaque (SG1077) density-gradient centrifugation. Cell cultures were performed as described previously [18]. In brief, the cell suspensions were adjusted to a concentration of 106/ml in RPMI 1640 medium supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine. Cell suspension (1 ml) was dispensed into 24-well multi-well plates (Nunc, Roskilde, Denmark), and incubated for 24 hours at 37degreesC in 5% CO2. Subsequently, various concentrations of cyclosporin A (10-500 ng/ml) were added to the medium and cells were incubated for 24 hours. To each well was added FK506, rapamycin, curcumin, PDTC, LY294002, SB203580, PD98059, dexamethasone or wortmannin. After incubation for 24 hours (unless otherwise stated), cell-free media were collected and stored at -20degreesC until assayed. All cultures were set up in triplicate, and results are expressed as means +/- SEM.","[{'offsets': [[14, 19]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
160,PMC-3320587-00-TIAB,"Regulation ofMycobacterium tuberculosis-Dependent HIV-1 Transcription Reveals a New Role for NFAT5 in the Toll-Like Receptor Pathway
Tuberculosis (TB) disease in HIV co-infected patients contributes to increased mortality by activating innate and adaptive immune signaling cascades that stimulate HIV-1 replication, leading to an increase in viral load. Here, we demonstrate that silencing of the expression of the transcription factor nuclear factor of activated T cells 5 (NFAT5) by RNA interference (RNAi) inhibits Mycobacterium tuberculosis (MTb)-stimulated HIV-1 replication in co-infected macrophages. We show that NFAT5 gene and protein expression are strongly induced by MTb, which is a Toll-like receptor (TLR) ligand, and that an intact NFAT5 binding site in the viral promoter of R5-tropic HIV-1 subtype B and subtype C molecular clones is required for efficent induction of HIV-1 replication by MTb. Furthermore, silencing by RNAi of key components of the TLR pathway in human monocytes, including the downstream signaling molecules MyD88, IRAK1, and TRAF6, significantly inhibits MTb-induced NFAT5 gene expression. Thus, the innate immune response to MTb infection induces NFAT5 gene and protein expression, and NFAT5 plays a crucial role in MTb regulation of HIV-1 replication via a direct interaction with the viral promoter. These findings also demonstrate a general role for NFAT5 in TLR- and MTb-mediated control of gene expression.","[{'offsets': [[93, 98]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[436, 473]], 'text': ['nuclear factor of activated T cells 5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[475, 480]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[621, 626]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1045, 1050]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1052, 1057]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1063, 1068]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1105, 1110]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1186, 1191]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1225, 1230]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1392, 1397]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T11'}]",[],[],[],[],[]
161,PMC-1064873-08-Materials_and_methods,"Western blot analysis
CD4+ T cells were stimulated for 20 min by the indicated concentrations of IL-10 and IL-6 at a density of 5 x 105 cells in 0.5 ml culture medium with 10% FCS. To examine the effect of serum IL-6 on STAT phosphorylation, normal CD4+ T cells were stimulated for 20 min with 30% active RA serum in culture medium with 40 mug/ml neutralizing goat anti-IL-6 polyclonal antibody (IgG; Techne, Princeton, NJ, USA) or control goat IgG (Techne). Whole cell lysates were prepared by placing cells in 100 mul SDS lysing buffer (62.5 mM Tris-HCl [pH 6.8], 2% SDS, 10% glycerol, 50 mM dithiothreitol, 0.1% bromphenol blue). Then 20 mul protein samples were fractionated on 10% SDS-polyacrylamide gels and were transferred to nitrocellulose membranes (Amersham, Buckinghamshire, UK), and the membrane was blocked with 5% skim milk in Tris-buffered saline with 0.1% Tween 20.
Tyrosine phosphorylation of STAT1 and STAT3 was detected using commercial available kits (Cell Signaling Technology, Beverly, MA, USA) according to the manufacturer's instructions. Briefly, the membrane was incubated with the antibodies (rabbit IgG) anti-STAT1 antibody, anti-phosphorylated tyrosine 701 of STAT1 antibody, anti-STAT3 antibody, and anti-phosphorylated tyrosine 705 of STAT3 antibody, diluted as recommended at 1/2000 with Tris-buffered saline with 0.1% Tween 20 with 5% BSA. Antibody binding was detected by horseradish peroxidase-conjugated anti-rabbit IgG antibody diluted at 1/4000 with Tris-buffered saline with 0.1% Tween 20 with 5% BSA, and was revealed using the chemiluminescence system. Protein bands were quantified by densitometry using NIH-Image analysis, and STAT phosphorylation was compared with the total amount of STAT protein. IFN-gamma-stimulated Hela cells were used as a positive control for STAT1 phosophorylation.","[{'offsets': [[22, 25]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[97, 102]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[107, 111]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[212, 216]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[249, 252]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[370, 374]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[911, 916]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[921, 926]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1138, 1143]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1190, 1195]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1211, 1216]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1267, 1272]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1671, 1675]], 'text': ['STAT'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1744, 1753]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1812, 1817]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T15'}]",[],[],[],[],[]
162,PMC-3589482-21-Results,"C/EBP-beta Promotes LPS-inducible Murine SerpinB2 Proximal Promoter Activity
Since C/EBP-beta binds to the SerpinB2 proximal promoter in an LPS-inducible manner both in vitro and in vivo, we wanted to address the question of whether C/EBP-beta was an essential factor for driving transcription from the SerpinB2 promoter in cells in response to LPS. The ability of endogenous C/EBP-beta to direct transcription from the SerpinB2 proximal promoter was examined by transfection of the pGLmP-539 murine SerpinB2 luciferase reporter construct into Cebpb+/+ and Cebpb-/- MEFs. We found that LPS-stimulated SerpinB2 promoter activity was significantly increased in Cebpb+/+ MEFs and abrogated in Cebpb-/- MEFs (Fig. 8A), indicating that endogenous C/EBP-beta is required for LPS-induced SerpinB2 proximal promoter activity.","[{'offsets': [[0, 10]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[41, 49]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[83, 93]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[107, 115]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[233, 243]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[303, 311]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[376, 386]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[420, 428]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[500, 528]], 'text': ['SerpinB2 luciferase reporter'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[544, 549]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[557, 562]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[601, 609]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[659, 664]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[690, 695]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[742, 752]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[781, 789]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T16'}]",[],[],[],[],[]
163,PMC-3320587-22-Discussion,"The transcription factor NFAT5 is the most evolutionarily divergent member of the Rel family of NFAT proteins [57]. Unlike the other NFAT proteins (NFATp, NFATc, NFAT3, and NFAT4), NFAT5 binds DNA as an obligate dimer in a fashion resembling NF-kappaB proteins [58], is calcineurin independent, and does not cooperate with the basic region-leucine zipper proteins Fos and Jun in gene activation ([59], [60], reviewed in [61]-[63]). To date, osmotic stress, integrin activation, and T cell-stimulation have been shown to regulate NFAT5 activity [59], [64], [65]. Based on our demonstration here that the host innate immune response to MTb infection induces MyD88-dependent upregulation of NFAT5 gene expression, we have expanded this list to include MTb as an additional stimulus. We have linked this observation to MTb-stimulated HIV-1 gene expression by showing that MTb enhances the replication of HIV-1 subtypes B and C via a direct interaction between NFAT5 and the viral promoter. Thus, HIV-1 has co-opted NFAT5, which is induced as part of the innate immune response to TB, for enhanced viral transcription/replication.
NF-kappaB is activated after MTb engagement of PRRs [20], [66]. Multiple studies of HIV-1 activation have shown that initial recruitment of the NF-kappaB p50/p65 heterodimer to the HIV-1 proviral enhancer region is crucial for HIV gene transcription (reviewed in [67], [68]). Upon interaction with the viral LTR, NF-kappaB rapidly induces hyperacetylation of histones associated with nucleosome 1 (nuc-1) at the HIV-1 transcription start site, resulting in recruitment of the pTEFb complex, which is required for RNA pol II processivity ([69], reviewed in [68], [70]).
In this report we directly examined the relative roles of NFAT5 and NF-kappaB p50/p65 in HIV-1 replication under conditions of activation by MTb co-infection, when NF-kappaB levels in the nucleus are elevated. We found that specific disruption of the NFAT5 binding site(s) in R5-tropic subtype B or subtype C infectious molecular clones significantly reduced virus replication in PBMC or MDM co-infected with a clinical isolate of MTb. Thus, NF-kappaB binding to the viral LTR is not sufficient to compensate for the loss of NFAT5 binding to the LTR under conditions of MTb co-infection. Reciprocally, an intact NFAT5 site could not compensate for disruption of the two NF-kappaB sites. Thus, both factors are required for MTb-induced HIV-1 replication.
Intriguingly, both in the absence and presence of MTb co-infection, disruption of NF-kappaB site II consistently resulted in greater suppression of virus replication than disruption of NF-kappaB site I. Consistent with these findings, synthetic reporter assays have previously shown that these two sites have distinct roles in driving transcription. The downstream NF-kappaB site I binding site, which is directly upstream of three highly conserved Sp binding sites, appears to enhance Sp protein recruitment to the LTR [71]-[73]. Because NF-kappaB site I overlaps the NFAT5 binding site, it is possible that loss of NF-kappaB binding to this site is mitigated, at least in part, by increased NFAT5 binding to the mutated site. This hypothesis is consistent with our quantitative DNase I footprinting analysis that shows that specific disruption of NF-kappaB site I results in enhanced binding of NFAT5 to the LTR.
HIV-1 subtype C now makes up greater than 50% of all HIV-1 infections worldwide, and its prevalence is especially high in regions of endemic TB [1], [2], [28], [52], Most HIV-1 subtype C isolates possess three NF-kappaB binding sites in the LTR [30]. Our analysis of MTb whole lysate-stimulated, LTR-driven reporter gene expression from representative B, C, and E LTRs showed that LTRs derived from subtype C isolates were superior in driving reporter gene expression as compared to LTRs derived from subtype B or E isolates. Other studies have found that, in response to TNF, subtype C LTRs drive reporter gene transcription more strongly than other subtype LTRs [38], [39]. In the co-infection model utilized in this report, in which clinical isolates of both MTb and HIV-1 subtype C were used to infect freshly prepared human peripheral blood cells, we found that specific disruption of NFAT5 binding to the LTR significantly impaired viral replication during MTb co-infection, indicating that even the presence of three intact NF-kappaB binding sites, which is typical for HIV-1 subtype C isolates [30], cannot compensate for loss of NFAT5 recruitment to the viral LTR in the context of MTb co-infection.
Given that the NF-kappaB and NFAT5 binding motifs overlap, how do NF-kappaB and NFAT5 function at this overlapping or shared site in the LTR to drive viral transcription in response to MTb infection? Because NFAT5 expression continues to rise for at least 48 hours post-MTb infection (Figure 2A), one possibility is that the host factors NF-kappaB and NFAT5 associate with the LTR at different stages after viral activation. While NF-kappaB presence in the nucleus declines in the hours post MTb infection [74], [75], NFAT5 levels escalate. Thus, NFAT5, which is pivotal for HIV-1 transcription in unstimulated cells [31], may, after Mtb infection, perpetuate viral transcriptional initiation begun by NF-kappaB and, with Tat levels also elevated, promote high levels of sustained HIV-1 transcription. Indeed, in response to hypertonic stress, NFAT5 binds to the aldose reductase (AR) promoter and induces rapid hyperacetylation of histones H3 and H4 [76]. Furthermore, hypertonic stress of mouse renal collecting duct epithelial cells results in NFAT5 and NF-kappaB complex formation at NF-kappaB-dependent gene promoters [77]. Thus, there are precedents for imagining that NFAT5 could function at the HIV-1 LTR by inducing histone remodeling in a manner similar to NF-kappaB ([69], reviewed in [68], [70]) or by directly interacting with NF-kappaB in a cooperative manner.
In conclusion, we have demonstrated that NFAT5 is required for the replication of R5-tropic subtype B and subtype C HIV-1 isolates in response to MTb-co-infection of human PBMC and MDM. Functional NF-kappaB interaction with the viral LTR is also required, but fully intact NF-kappaB binding elements are unable to compensate for the loss of NFAT5 recruitment to the viral promoter. In addition, we have demonstrated that MTb infection or stimulation with the TLR2 ligand PAM3Cys, induces NFAT5 gene expression in human monocytes. Furthermore, we have shown that MTb stimulation of NFAT5 depends on TLR pathway signaling molecules, including MyD88, IRAK1, and TRAF6. Taken together, the findings presented here enhance the general understanding of the innate immune response to MTb infection by showing that NFAT5 is a major mediator of TLR-dependent gene expression; its importance for gene regulation is likely applicable to other MTb- and TLR-regulated genes. Moreover, these data provide molecular insights into MTb regulation of HIV-1 transcription, thereby elucidating several new targets for therapeutic interventions aimed at controlling TB/HIV-1 co-infection.","[{'offsets': [[25, 30]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[148, 153]], 'text': ['NFATp'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[155, 160]], 'text': ['NFATc'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[162, 167]], 'text': ['NFAT3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[173, 178]], 'text': ['NFAT4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[181, 186]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[270, 281]], 'text': ['calcineurin'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[364, 367]], 'text': ['Fos'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[372, 375]], 'text': ['Jun'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[529, 534]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[656, 661]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[688, 693]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[956, 961]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1011, 1016]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1280, 1283]], 'text': ['p50'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1284, 1287]], 'text': ['p65'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1753, 1758]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1773, 1776]], 'text': ['p50'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1777, 1780]], 'text': ['p65'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2220, 2225]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[3142, 3147]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3229, 3236]], 'text': ['DNase I'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3346, 3351]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3936, 3939]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[4254, 4259]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[4502, 4507]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[4653, 4658]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[4781, 4786]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[4925, 4930]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[5091, 5096]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[5120, 5125]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[5295, 5298]], 'text': ['Tat'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[5417, 5422]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[5436, 5452]], 'text': ['aldose reductase'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[5454, 5456]], 'text': ['AR'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[5620, 5625]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[5748, 5753]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[5989, 5994]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[6145, 6154]], 'text': ['NF-kappaB'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[6289, 6294]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[6407, 6411]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[6436, 6441]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[6529, 6534]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[6589, 6594]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[6596, 6601]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[6607, 6612]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[6755, 6760]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T60'}]",[],[],[],[],[]
164,PMC-1472690-23-Caption-Figure_6,"Decreased IL-1beta/IL-1RA ratio following GP + TSST-1 when compared to TSST-1. Time course (48 h) of the IL-1beta/IL-1RA ratio following incubation of human PBMC with LPS, TSST-1, GP + LPS, GP/LPS calc., GP + TSST-1 or GP/TSST-1 calc. LPS and GP + LPS treatments resulted in generating more IL-1beta than IL-1RA up to 24 h. When comparing LPS or GP/LPS calc. vs GP + LPS we did not find significant alterations in the IL-1beta/IL-1RA ratio over 48 h. With respect to TSST-1 or GP/TSST-1 calc. vs GP + TSST-1 we observed a pronounced anti-inflammatory action of GP, as demonstrated by an about 10-100 fold reduced ratio at 18 h and 24 h, i.e. a higher production of IL-1RA than of IL-1beta (* = p < 0.05). Data are shown as mean +/- SEM (n = 3).","[{'offsets': [[10, 18]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[19, 25]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[47, 53]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[71, 77]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[105, 113]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[114, 120]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[172, 178]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[209, 215]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[222, 228]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[291, 299]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[305, 311]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[418, 426]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[427, 433]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[467, 473]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[480, 486]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[501, 507]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[665, 671]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[680, 688]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T18'}]",[],[],[],[],[]
165,PMC-3218875-13-Caption-Figure_2,"Noncanonical NF-kappaB signalling. CD40 and RANK can activate the noncanonical NF-kappaB pathway that is dependent on NF-kappaB inducing kinase (NIK) expression levels. In unstimulated cells NIK forms a cytosolic complex with the ubiquitin ligases TRAF2, TRAF3 and cIAP1/2, which facilitates the K48-linked polyubiquitination and proteasomal degradation of NIK, keeping NIK levels low. Upon ligand binding, TRAF3 is recruited to the receptor, where TRAF2 directs nondegradative K63-linked polyubiquitination of cIAP1/2, resulting in their activation. Subsequently cIAP1/2 directs its K48-linked polyubiquitination to TRAF3, rather than NIK. As a result, TRAF3 is degraded and NIK is stabilised, resulting in increased NIK levels in the cell. NIK then phosphorylates and activates IKK1, which mediates NF-kappaB p100 phosphorylation. This is followed by K48-linked polyubiquitination and partial proteasomal degradation of p100 to p52, which forms a heterodimer with RelB to activate transcription. Next to TRAF3, TRAF1 has also been identified as a negative regulator of this pathway, most probably by competing with other TNF receptor-associated factors. cIAP, cellular inhibitor of apoptosis; IKK, IkappaB kinase; NF, nuclear factor; RANK, receptor activator of NF-kappaB; TRAF, TNF receptor-associated factor; TNF, tumour necrosis factor.","[{'offsets': [[35, 39]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[44, 48]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[118, 143]], 'text': ['NF-kappaB inducing kinase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[145, 148]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[191, 194]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[248, 253]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[255, 260]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[265, 270]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[271, 272]], 'text': ['2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[357, 360]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[370, 373]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[407, 412]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[449, 454]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[511, 516]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[517, 518]], 'text': ['2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[564, 569]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[570, 571]], 'text': ['2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[617, 622]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[636, 639]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[654, 659]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[676, 679]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[718, 721]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[742, 745]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[780, 784]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[811, 815]], 'text': ['p100'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[922, 926]], 'text': ['p100'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[930, 933]], 'text': ['p52'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[966, 970]], 'text': ['RelB'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1006, 1011]], 'text': ['TRAF3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1013, 1018]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1236, 1240]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1242, 1273]], 'text': ['receptor activator of NF-kappaB'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1313, 1316]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1318, 1340]], 'text': ['tumour necrosis factor'], 'type': 'Protein', 'id': 'T34'}]",[],[],[],[],[]
166,PMC-3589482-29-Caption-Figure_6,"C/EBP-beta is essential for constitutive and LPS-induced SerpinB2 mRNA expression.
(A) Endogenous SerpinB2 mRNA expression is abrogated in Cebpb-/- MEFs compared to Cebpb+/+ MEFs in the absence and presence of LPS. qPCR analysis of murine SerpinB2 mRNA expression in untreated Cebpb+/+ and Cebpb-/- MEFs, and after simulation with LPS (100 ng/ml) for the indicated times. (B) Endogenous SerpinB2 expression is abrogated in C/EBP-beta-deficient inflammatory macrophages. Thioglycollate-elicited peritoneal macrophages (TG macs) were infected with human and murine specific lentiviral shRNAs. Human CEBPB shRNA serves as the non-silencing control since it does not target the murine Cebpb sequence [38]. Lentiviral transduced macrophages were stimulated with LPS (100 ng/ml) for 4 hrs. Left: Western blot analysis shows effective knockdown of endogenous C/EBP-beta following infection with murine Cebpb shRNA and not human CEBPB shRNA. Right: qPCR analysis of murine SerpinB2 mRNA expression in the lentiviral transduced peritoneal macrophages. The results represent the mean and SEM of two independent experiments performed in duplicate or triplicate. (*, p<0.05, two-way ANOVA).","[{'offsets': [[0, 10]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[57, 65]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[98, 106]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[139, 144]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[165, 170]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[239, 247]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[277, 282]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[290, 295]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[387, 395]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[423, 433]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[681, 686]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[852, 862]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[965, 973]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T13'}]",[],[],[],[],[]
167,PMC-3317373-03-2._Methods_and_Materials,"2.2. In Vitro Model of TBI Established by Scratch Injury
Astrocyte scratch injury was performed as in a previous report [7]. Astrocytes were planted in 6-well plates and grown to confluence. The cell monolayer was scratched with a sterile 26G syringe needle, resulting in the formation of a 0.5 mm wide gap. Immediately after scratch, cells were washed twice with sterile PBS, cultured with complete culture medium, and named as TBI group. Cells, which did not received scratch, were used as blank control and named as sham group.",[],[],[],[],[],[]
168,PMC-2817507-03-2._Methods,"2.2. Induction of Intracerebral Hemorrhage
Since most intracerebral hemorrhages occur in the basal ganglia clinically, in the present study, rat model of ICH was induced in left basal ganglia. Rats were anesthetized with intra-peritoneal sodium pentobarbital (60 mg/kg). The body (rectal) temperature was maintained at 37degreesC during the surgery using a feedback-controlled heating system. The rats were positioned in a stereotactic frame, and the scalp was incised along the midline. Using a sterile technique, a 1 mm burr hole was opened in the skull on the left coronal suture 3 mm lateral to the midline. A blunt 26-gauge needle was inserted into the left basal ganglia under stereotactic guidance (coordinates: 0.2 mm anterior, 6.0 mm ventral, and 3.0 mm lateral to the midline). Then, a 75 muL of autologous whole blood was infused at a rate of 20 muL/min with the use of a microinfusion pump. After the completion of the infusion, the needle was withdrawn quickly, cyanoacrylate glue was placed around the burr hole, and the skin incision was closed with sutures. For the normal saline control rats, only 75 muL normal saline was injected.",[],[],[],[],[],[]
169,PMC-3585731-02-Results,"Basic Fibroblast Growth Factor Promotes Necroptosis in L929 Cells
It has been established that mouse fibrosarcoma L929 cells undergo necroptotic cell death following stimulation with TNFalpha [10], [17]. In addition, inhibition of caspase-8 activity alone, either through siRNA knockdown or by using the pan-caspase inhibitor, zVAD.fmk, is sufficient to trigger necroptosis in these cells [10], [14]. Interestingly, while necroptosis was initially identified as a back-up form of cell death triggered by pro-apoptotic stimuli in the presence of apoptosis inhibitors [17], recent analysis of physiological cell death during mouse development has suggested that the loss of apoptotic regulators, such as caspase-8 and FADD [18], [19], [20], leads to robust induction of necroptosis and death of E10.5 embryos even though apoptosis is not normally induced in wild type embryos. These data are reminiscent of the observations in L929 cells where the loss of caspase activity in healthy cells is sufficient to trigger necroptosis and prompted us to explore the extrinsic or intrinsic cellular factors that promote necroptosis once caspase-8 activity, which cleaves and inactivates RIP1 kinase and the RIP1 deubiquitinase CYLD [21], [22], is removed in L929 cells. Consistent with a previous report [16], we found that serum starvation of L929 cells prevented necroptosis in response to zVAD.fmk (Fig. 1A). The addition of growth factors, such as bFGF, restored zVAD.fmk induced death under serum free conditions (Fig. 1B). Interestingly, this does not reflect a generic requirement for growth factor signaling, as only some growth factors (bFGF and IGF-1, but not EGF and PDGF) promoted death (Fig. 1B). Furthermore, growth factor-dependent necroptosis required the inhibition of caspase activity, as bFGF alone did not induce cell death (Fig. 1C). In contrast, TNFalpha triggered necroptosis equally efficiently in the absence of serum (Fig. 1A), suggesting that either growth factors and zVAD.fmk or TNFalpha are required for necroptotic death in L929 cells.
Previously we described the development of 7-Cl-O-Nec-1 (Nec-1) as a potent and selective inhibitor of RIP1 kinase and necroptosis (Fig. S1A) [23], [24]. Recently, its selectivity has been further validated against a panel of more than 400 human kinases [15]. This inhibitor efficiently blocked growth factor/zVAD.fmk-induced necroptosis under serum free conditions in L929 cells and both zVAD.fmk and TNFalpha-induced necroptosis under full serum conditions (Fig. 1B, S1B). To further validate the role of RIP1, we used an inactive analog, 7-Cl-O-Nec-1i (Nec-1i) (Fig. S1A), which contains an extra N-methyl group that leads to almost complete loss of RIP1 kinase inhibitory activity in vitro [23]. Nec-1i was unable to protect L929 cell death under serum condtions treated with zVAD.fmk or TNFalpha (Fig. S1B) or serum free conditions treated with bFGF/zVAD.fmk (Fig. S1C). This confirms that RIP1 kinase is responsible for necroptosis in L929 cells under both serum and serum free conditions.
We next examined whether bFGF contributes to zVAD.fmk-induced necroptosis under normal serum conditions (10% FBS). We used two bFGF receptor tyrosine kinase inhibitors (PD173074 and PD166866), and determined that inhibition of bFGF signaling strongly inhibited zVAD.fmk-induced necroptosis under normal serum conditions (Fig. 1D). In contrast, neither bFGF receptor inhibitor was able to attenuate TNFalpha-induced necroptosis (Fig. 1D), consistent with growth factors being dispensable for this pathway (Fig. 1A). Overall, these data suggest that the induction of necroptosis by zVAD.fmk is promoted by bFGF under both serum and serum free conditions. The induction of necroptosis, however, is not a simple consequence of growth factor signaling since not all growth factors allowed death to occur. Instead, specific signaling events mediated by particular growth factors appear to contribute to necroptotic death.","[{'offsets': [[0, 30]], 'text': ['Basic Fibroblast Growth Factor'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[183, 191]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[231, 240]], 'text': ['caspase-8'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[702, 711]], 'text': ['caspase-8'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[716, 720]], 'text': ['FADD'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1126, 1135]], 'text': ['caspase-8'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1176, 1180]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1196, 1215]], 'text': ['RIP1 deubiquitinase'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1216, 1220]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1441, 1445]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1635, 1639]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1644, 1649]], 'text': ['IGF-1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1659, 1662]], 'text': ['EGF'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1796, 1800]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1857, 1865]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1997, 2005]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2159, 2163]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2458, 2466]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2563, 2567]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2709, 2713]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2848, 2856]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2906, 2910]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2951, 2955]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3077, 3081]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3179, 3208]], 'text': ['bFGF receptor tyrosine kinase'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3279, 3283]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3404, 3417]], 'text': ['bFGF receptor'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3450, 3458]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3656, 3660]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T29'}]",[],[],[],[],[]
170,PMC-3320587-10-Materials_and_Methods,"MTb culture
The MTb clinical strain CDC1551 was prepared by adding 100 microl of frozen bacteria stock into 10 ml of Middlebrook 7H9 medium (Difco BD, www.bd.com) supplemented with albumin dextrose complex (ADC) and 0.05% Tween 80 (Sigma-Aldrich, www.sigmaaldrich.com). The cultures were grown to an OD650 of 0.4 at 37degreesC to ensure that they were in the logarithmic growth phase. Bacteria were then plated, washed with PBS, resuspended in PBS, and passed through a 5 microm filter to ensure that the bacteria were in a single cell suspension. Bacterial cell numbers were determined by measurement of OD650 before further dilution with RPMI 1640 medium for cell infection studies at 10:1 PBMC: bacilli or 1:1 MDM: bacilli and THP-1:bacilli. Colony-forming unit (CFU) analysis was performed and on days 4 and 7 the average CFU counts were 6x103 and 5x104, respectively, confirming that mycobacteria levels increased over the course of infection of primary MDM.",[],[],[],[],[],[]
171,PMC-3342329-12-Materials_and_Methods,"Immunohistochemistry
All specimens were fixed in formalin and embedded in paraffin for examination. Sections (4 microm thick) were stained with H&E and analyzed by immunohistochemistry. The paraffin-embedded sections were deparaffinized and rehydrated, washed in distilled water, and then subjected to heat-mediated antigen retrieval. Endogenous peroxidase activity was quenched by incubation in 3% hydrogen peroxide in methanol for 15 min, followed by clearing in PBS for 5 min. The sections were blocked for 30 min with 3% normal horse serum diluted in PBS, blotted, and incubated with primary mouse anti-mouse proliferating cell nuclear antigen (PCNA, 1:200 dilution) monoclonal antibodies in blocking serum for 4 h at room temperature. Thereafter, the slides were washed three times for 5 min each in PBS and incubated with biotinylated anti-mouse and anti-rabbit antibodies for 2 h. The slides were washed in PBS, followed by the addition of the avidin biotin peroxidase complex (ABC kit; Vector Laboratories, Burlingame, CA, USA). The slides were washed and the peroxidase reaction was developed with diaminobenzidine (DAB) and peroxide, followed by counterstaining with hematoxylin, mounting in aqua-mount, and evaluation under a light microscope (magnificationx200; Olympus, Tokyo, Japan). A negative control was included in all experiments by omitting the primary antibody. For the detection of apoptotic cell death in the tumor tissues, the paraffin-embedded sections were incubated in a mixture of the labeling solution (540 microl) and enzyme solution (60 microl) for 1 h at 37degreesC, and then washed three times in 0.1 M PBS for 5 min each, according to the manufacturer's instructions. Next, the sections were incubated with 4',6-diamidino-2-phenylindole (DAPI) for 15 min at 37degreesC. Finally, the sections were rinsed, mounted on slides, and cover-slipped for fluorescence microscopy (DAS microscope).",[],[],[],[],[],[]
172,PMC-1064873-14-Results,"High expression of SOCS1 mRNA in RA CD4+ T cells
IL-6 induces two potent inhibitors of JAKs (SOCS1 and SOCS3 proteins) that not only act as mediators of negative feedback inhibition, but also play a major role in crosstalk inhibition by opposing other cytokine-signaling pathways [7]. SOCS3 has recently been shown to specifically inhibit STAT3 activation induced by IL-6 but not by IL-10, thereby regulating the divergent action of IL-6 and IL-10 [8,9]. On the contrary, SOCS1 is able to partially inhibit IL-10-mediated STAT3 activation and cellular responses, as well as IFN-gamma-mediated STAT1 activation [32]. To determine whether SOCSs were involved in the defective IL-10-induced STAT3 activation of RA CD4+ T cells, the levels of SOCS1 and SOCS3 mRNA expression in PB CD4+ T cells from active RA patients and from healthy controls were compared by semiquantitative real-time PCR. The RA CD4+ T cells contained higher levels of SOCS1 but lower levels of SOCS3 transcripts than did control CD4+ T cells (Fig. 6a). Constitutive expression of SOCS1 mRNA in RA CD4+ T cells was comparable with the expression in normal CD4+ T cells stimulated by 10 ng/ml IL-6 (Fig. 6b), supporting its functional significance. Defective IL-10-induced STAT3 activation therefore appears to be due at least in part to an abundance of SOCS1 in RA CD4+ T cells.","[{'offsets': [[19, 24]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[36, 39]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[49, 53]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[93, 98]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[103, 108]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[285, 290]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[339, 344]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[367, 371]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[383, 388]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[433, 437]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[442, 447]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[472, 477]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[507, 512]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[522, 527]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[574, 583]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[593, 598]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[674, 679]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[688, 693]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[711, 714]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[739, 744]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[749, 754]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[777, 780]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[896, 899]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[936, 941]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[962, 967]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[997, 1000]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1048, 1053]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1065, 1068]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1123, 1126]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1159, 1163]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1225, 1230]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1239, 1244]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1320, 1325]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1332, 1335]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T34'}]",[],[],[],[],[]
173,PMC-3320587-15-Results,"Specific disruption of NFAT5 binding impairs LTR-driven transcription in THP-1 cells in response to MTb stimulation
Although the transcription factor NFAT5 binds to a core NF-kappaB binding motif in the HIV-1 LTR enhancer region of subtype B, when two thymines (TT) are changed to cytosines (CC) in the proximal NF-kappaB binding motif (named N5-Mut) (bottom of Figure 1B), the binding of NFAT5 can be disrupted while leaving binding of NF-kappaB unperturbed [31]. We examined the requirement of NFAT5 for MTb-induced LTR activity by transfecting a wild-type and NFAT5 mutant LTR reporter construct into THP-1 cells, followed by stimulation with an MTb lysate. As shown in Figure 1B, in the absence of MTb lysate stimulation the activity of the NFAT5 binding site-mutant LTR was significantly reduced (p<0.05) in comparison to the wild-type LTR. When the NFAT5 binding site-mutant LTR was examined in THP-1 cells stimulated with the MTb lysate, its activity was reduced to an even more significant extent (p<0.01).
To determine whether MTb lysate stimulation directly enhances NFAT5 expression in THP-1 cells, we stimulated cells for 8 or 24 hours or left them unstimulated and examined NFAT5 protein levels by western blot. As shown in Figure 1C, we found that NFAT5 protein levels steadily increased in response to MTb lysate stimulation, revealing that TLR engagement by MTb results in enhanced levels of NFAT5, consistent with its playing a role in MTb-induced activation of the HIV-1 LTR.","[{'offsets': [[23, 28]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[150, 155]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[389, 394]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[496, 501]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1077, 1082]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1187, 1192]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1262, 1267]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1408, 1413]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
174,PMC-3312845-06-Methods,"Immunohistochemistry
Free-floating sections were first incubated with 10% normal goat serum for 30 min at room temperature. They were then incubated in rabbit anti-MPO IgG (1:100, Thermo fisher scientific) or rabbit anti-MIP-2 IgG (1:200, Invitrogen, Carlsbad, CA) in PBS containing 0.3% Triton X-100 (Sigma-Aldrich Co., St. Louis, MO) and 2% normal goat serum(Sigma-Aldrich Co., St. Louis, MO) overnight at room temperature. After washing three times for 10 min with PBS, the sections were incubated sequentially, in goat anti-rabbit or horse anti-mouse IgG (Vector, Burlingame, CA) and ABC complex (Vector, Burlingame, CA), diluted 1:200 in the same solution as the primary antiserum. Between the incubations, the tissues were washed with PBS three times for 10 min each. To confirm vasogenic edema, some tissue sections were reacted for serum-proteins using horse anti-rat IgG (Vector, Burlingame, CA) as a primary antibody. The sections were visualized with 3,3'-diaminobenzidine (DAB, Sigma-Aldrich Co., St. Louis, MO) in 0.1 M Tris buffer and mounted on the gelatin-coated slides. The immunoreactions were observed under the Axioscope microscope (Carl Zeiss, Munchen-Hallbergmoos). For negative controls, rat hippocampal tissues were incubated with 1 mug of the antibody that was preincubated with 1 mug of purified peptide for 1 hr at room temperature or incubated with pre-immune serum instead of the primary antibody. For negative controls, tissues were incubated with pre-immune serum instead of primary antibody.",[],[],[],[],[],[]
175,PMC-1472690-05-Results,"GP modulated the TSST-1-induced IL-1beta/IL-1RA ratio towards an anti-inflammatory phenotype
In a simplified approach, IL-1beta and IL-1RA might represent two sides of a coin, i.e. pro- or anti-inflammatory action. Therefore, we applied the IL-1beta/IL-1RA ratio as an indicator of the degree of inflammation. Both, LPS and GP + LPS treatments resulted in generating more IL-1beta than IL-1RA at early time points, i.e. up to 24 h. Comparing LPS vs. GP + LPS, we did not find substantial alterations over a time course of 48 h in the IL-1beta/IL-1RA ratio, only a - non-significant - 2.5fold higher ratio at 6 h. With respect to TSST-1 or the theoretical value of GP/TSST-1 calc. vs. GP + TSST-1, we observed a pronounced anti-inflammatory action of GP, as demonstrated by an about 10-100 fold reduced ratio at 18 h and 24 h of incubation, i.e. a higher production of IL-1RA than of IL-1beta (n = 3; both p < 0.05; Fig. 6). A biological relevance of this result was suggested by a decrease of the IL-1 dependent release of IL-2 from murine EL-4 cells following GP + TSST-1 when compared to TSST-1 or GP/TSST-1 calc. (data not shown in detail, n = 4; p < 0.07).","[{'offsets': [[17, 23]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[32, 40]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[41, 47]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[119, 127]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[132, 138]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[241, 249]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[250, 256]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[372, 380]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[386, 392]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[534, 542]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[543, 549]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[629, 635]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[667, 673]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[689, 695]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[868, 874]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[883, 891]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[997, 1001]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1023, 1027]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1066, 1072]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1090, 1096]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1103, 1109]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T21'}]",[],[],[],[],[]
176,PMC-3320587-26-Caption-Figure_4,"MTb-induced HIV-1 replication in PBMC depends on binding of NFAT5 and NF-kappaB to the LTR.
Specific disruption of the NF-kappaB or NFAT5 binding sites in the HIV-1 subtype B LTR inhibits R5-tropic virus replication in human PBMC after co-infection with MTb. PBMC from four normal donors were infected with 1000 TCID50 HIV-1Lai/Bal-env-WT or the mutants HIV-1Lai/Bal-env-kappaB I-Mut, HIV-1Lai/Bal-env-kappaB II-Mut, HIV-1Lai/Bal-env-kappaB I+II-Mut, or HIV-1Lai/Bal-env-N5-Mut and either; (A) left untreated, or (B) co-infected with MTb isolate CDC1551 (10:1 cells:bacilli). Viral p24 levels in culture supernatants were measured at days 4, 7 and 12 post-infection. (C) Histograms show viral p24 levels at day 12 in the MTb uninfected (grey bars) and MTb co-infected (black bars) PBMC cultures. Replication of the mutant viruses was compared to wild-type virus replication under the same experimental conditions (without and with MTb co-infection, respectively). *, p<0.05; **, p<0.01, as compared to HIV-1Lai/Bal-Env-WT.","[{'offsets': [[60, 65]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[332, 335]], 'text': ['env'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[367, 370]], 'text': ['env'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[398, 401]], 'text': ['env'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[430, 433]], 'text': ['env'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[467, 470]], 'text': ['env'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[582, 585]], 'text': ['p24'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[693, 696]], 'text': ['p24'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
177,PMC-3585731-30-Caption-Figure_5,"mTORC1 contributes to the regulation of necroptosis.
(A) L929 cells were treated with zVAD.fmk or TNFalpha for 9 hr and harvested for western blot. (B) Cell under serum free condition were treated with bFGF or bFGF/zVAD.fmk for the indicated amounts of time, followed by western blotting using the indicated antibodies. (C) Necroptosis was induced by zVAD.fmk or TNFalpha in L929 cell in the presence of inhibitors of Akt(Akt inh. VIII) and mTOR (rapamycin, Torin-1 and PI-103). (D) L929 cells with mTOR siRNA knockdown were harvested for western blot or treated with zVAD.fmk or TNFalpha for 24 hrs. Cell viability was determined 24 hr after activation of necroptosis. In all graphs, average+/-SD was plotted.","[{'offsets': [[98, 106]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[202, 206]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[210, 214]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[363, 371]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[580, 588]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
178,PMC-3585731-11-Results,"Model of RIP1, Akt and JNK Dependent Signaling in Necroptotic L929 Cells
In this study we investigated RIP1 kinase-dependent signaling pathways using mouse fibrosarcoma L929 cells that die by necroptosis when treated with the pan-caspase inhibitor zVAD.fmk. Altogether, our results suggest that Akt kinase is specifically engaged in signaling downstream from RIP1 kinase, which leads to a selective increase in its phosphorylation on Thr308, but not Ser473. According to our model (Fig. 9), necroptosis-associated phosphorylation of Akt requires two distinct signals. The first input, which is induced by growth factors, leads to the plasma membrane localization of Akt. Expression of a constitutively membrane-targeted Akt construct, Myr-Akt, overcomes the requirement for growth factors. At the same time, expression of Myr-Akt alone is not sufficient for the induction of necroptosis. A second, RIP1 kinase-dependent input is required for Thr308 phosphorylation of Akt in response to caspase inhibition and is essential for the propagation of the necroptotic signal.
Using Akt inhibitors, knockdown of Akt isoforms, and the expression of Akt mutants, we showed that necroptotic activation of Akt is indispensable for this form of cell death in L929 cells. We also investigated downstream Akt-dependent pathways that contribute to necroptosis. First, we demonstrated that selective necroptotic phosphorylation of Thr308 of Akt is sufficient to increase its activity towards a number of known substrates and Akt effector pathways such as the mTORC1 pathway, which, in turn, contributes to cell death. Second, our data suggested that Akt activation provides a pivotal link connecting RIP1 kinase to known downstream signaling and execution events in necroptotic L929 cells, namely, JNK activation and autocrine TNFalpha synthesis, a critical event in necroptosis in L929 cells [15].
In order to further test our model, we examined Akt phosphorylation after inhibition of a downstream kinase in the pathway, JNK. However, we found that SP600125, which protected L929 cells from death and inhibited TNFalpha production (Fig. 2A,B S2A S10A), inhibited both basal and post-treatment phosphorylation levels of Akt at both Ser473 and Thr308 (Fig. S10B). It has been published that SP600125 is a somewhat non-specific inhibitor that may inhibit the p110delta subunit of PI3K [41] and PDK1 [42]. Both of these off-target effects could inhibit basal Akt phosphorylation levels, precluding the use of SP600125 in this system.
Therefore, to examine the role of JNK, we switched to a more specific JNK inhibitor, JNK inhibitor VIII [43], and siRNAs against JNK1 and JNK2 (Fig. S10B-G). As expected, specific inhibition or knockdown of JNK1/2 allowed phosphorylation of Akt on Thr308 while inhibiting the phosphorylation of c-Jun at Ser63 (Fig. S10B,E), agreeing with our model. It did not, however, lead to a reduction in TNFalpha production or cell death (Fig. S10C,D,F,G), suggesting that earlier data with SP600125 protection (Fig. 2) could reflect off-target effects of this molecule, rather than JNK inhibition. Previous reports also suggested a critical role for c-Jun in necroptosis and autocrine TNFalpha synthesis [13], [14], [15] and we confirmed these conclusions using c-Jun siRNA knockdown (Fig. S10H-J). Notably, in this case, Thr308 phosphorylation was reduced after the induction of necroptosis. Thus, autocrine TNFalpha production, dependent on c-Jun, may create a feedback loop that contributes to the delayed activation of Akt. It is also important to note that we observed an overall increase in the protein level of c-Jun after treatment of L929 cells with zVAD.fmk or TNFalpha, which was both Akt and mTOR-dependent (Fig. 6E,F). These new data led us to an unexpected, but important conclusion that c-Jun is critical for necroptosis, while JNK activity may serve as a useful marker of pathway activation, but may be either redundant (e.g. phosphorylation of c-Jun on a site other than Ser63 may occur [44]) or dispensable functionally. In addition, researchers need to use caution when using SP600125 due to potantial off-target effects.","[{'offsets': [[9, 13]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[103, 107]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[359, 363]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[735, 742]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[822, 829]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[898, 902]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1684, 1688]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1811, 1819]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[2097, 2105]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[2342, 2359]], 'text': ['p110delta subunit'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[2377, 2381]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[2645, 2649]], 'text': ['JNK1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2654, 2658]], 'text': ['JNK2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2723, 2727]], 'text': ['JNK1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2728, 2729]], 'text': ['2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2811, 2816]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2910, 2918]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[3157, 3162]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[3192, 3200]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[3269, 3274]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[3416, 3424]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[3450, 3455]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[3625, 3630]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3678, 3686]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3809, 3814]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3968, 3973]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T26'}]",[],[],[],[],[]
179,PMC-1472690-12-Methods,"Oligonucleotides (Oligos) and 5'-32-P-Labeling
The complementary double-stranded (ds) oligonucleotides (oligos) from the TNFalpha, IL-8, IFNgamma and IL-6 promoters were synthesised from single stranded (ss) oligos (illustrated in Table 1), (TIB Molbiol, Berlin, Germany) and 32P-labeled with 5'gamma-P-ATP (3,000 Ci/mmol, Amersham, Braunschweig, Germany) using the Ready-To-Go-Polynucleotide-Kinase Kit (PNK Kit, Pharmacia LKB, Freiburg, Germany) according to the manufacturer's instructions. To test the binding specificity of the oligos, mutated oligos were used as an additional control. Mutations in the P2 site of the IFNgamma promoter [29] and in the kappa consensus sequence of the TNFalpha promoter [55] have been reported to interfere with sequences, which seem to be crucial for the binding of NFAT and NFkappaB proteins, respectively. Afterwards, the ds oligos were purified via gel filtration using Probe Quant G-50 Micro Columns (Pharmacia) according to the manufacturer's instructions.","[{'offsets': [[121, 129]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[131, 135]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[137, 145]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[150, 154]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[624, 632]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[690, 698]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[805, 809]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
180,PMC-3586680-00-TIAB,"Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas
Tumor suppressor p53 are frequently mutated in glioblastomas (GBMs) and appears to contribute, in part, to resistance to temozolomide (TMZ) and therapeutic drugs. WW domain-containing oxidoreductase WWOX (FOR or WOX1) is a proapoptotic protein and is considered as a tumor suppressor. Loss of WWOX gene expression is frequently seen in malignant cancer cells due to promoter hypermethylation, genetic alterations, and translational blockade. Intriguingly, ectopic expression of wild type WWOX preferentially induces apoptosis in human glioblastoma cells harboring mutant p53. WWOX is known to physically bind and stabilize wild type p53. Here, we provide an overview for the updated knowledge in p53 and WWOX, and postulate potential scenarios that wild type and mutant p53, or isoforms, modulate the apoptotic function of WWOX. We propose that triggering WWOX activation by therapeutic drugs under p53 functional deficiency is needed to overcome TMZ resistance and induce GBM cell death.","[{'offsets': [[17, 21]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[26, 29]], 'text': ['p53'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[96, 99]], 'text': ['p53'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[242, 277]], 'text': ['WW domain-containing oxidoreductase'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[278, 282]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[284, 287]], 'text': ['FOR'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[291, 295]], 'text': ['WOX1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[372, 376]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[567, 571]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[650, 653]], 'text': ['p53'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[655, 659]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[712, 715]], 'text': ['p53'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[775, 778]], 'text': ['p53'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[783, 787]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[849, 852]], 'text': ['p53'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[902, 906]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[935, 939]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[978, 981]], 'text': ['p53'], 'type': 'Protein', 'id': 'T18'}]",[],[],[],[],[]
181,PMC-1359074-05-Results,"The Persistent Expression of epsilony Globin in Sox6-Deficient Mice Is Due to a Defect in the epsilony-Gene-Silencing Mechanism in Definitive Erythroid Cells
Normally, the epsilony globin gene is exclusively expressed in primitive erythrocytes and silenced in definitive erythrocytes. To determine whether the persistent expression of epsilony globin is due to residual primitive erythrocytes or is due to ectopic expression of epsilony globin in definitive erythrocytes, we examined the spatial pattern of epsilony globin transcripts in mouse embryos by in situ hybridization (Figure 5). As expected, epsilony globin is not expressed in the WT 14.5-dpc liver, the site of definitive erythropoiesis in the fetus. In contrast, abundant ectopic epsilony mRNA expression is seen in the liver of 14.5-dpc mutants (Figure 5 A-D). However, the expression of betamaj/min globin is equally abundant in both WT and p100H mutant mice (Figure 5 E and F). These data demonstrate that the persistent high levels of epsilony are due to ectopic expression in the definitive erythroid cells that mature in the fetal liver, suggesting that there is an intrinsic defect of the epsilony silencing mechanism in Sox6-null mice.","[{'offsets': [[29, 44]], 'text': ['epsilony Globin'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[48, 52]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[94, 102]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[172, 187]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[335, 350]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[428, 443]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[507, 522]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[602, 617]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[743, 751]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[852, 859]], 'text': ['betamaj'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[860, 870]], 'text': ['min globin'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1002, 1010]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1159, 1167]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1191, 1195]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T14'}]",[],[],[],[],[]
182,PMC-3589482-04-Experimental_Procedures,"DNA Sequence Analysis
The DNA sequence of the murine SerpinB2 promoter was determined by sequencing the pUC-based plasmids pDB9406, pDB9402-41 and pDB9402-42, in addition to plasmids prepared from pDB9402-41 and pDB9402-42 containing deletions introduced by exonuclease III digestion. Plasmids pDB9406, pDB9402-41 and pDB9402-42 containing genomic DNA isolated from a lambdaFIXII (Stratagene) genomic library prepared from a 129 mouse strain, were kindly provided by Dr. Dominique Belin, University of Geneva. pDB9406 contains a 4.4 kb EcoRI/SpeI genomic fragment spanning the transcription initiation site; pDB9402-41 and pDB9402-42 contain a 1.2 kb EcoRI genomic fragment, located immediately upstream of the pDB9406 EcoRI fragment, cloned in opposite orientations. Subcloned inserts were verified by restriction enzyme digestion and DNA sequencing. The nucleotide sequence of the 4480 bp murine SerpinB2 gene 5' flanking region was determined using the ABI PRISM dye terminator cycle sequencing ready reaction kit (Perkin-Elmer) and a PE 373A sequencer (Perkin-Elmer). This sequence was deposited in GenBank/EMBL/DDBJ Data Bank with Accession No. AF339731.","[{'offsets': [[53, 61]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[258, 273]], 'text': ['exonuclease III'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[898, 906]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
183,PMC-1064895-01-Introduction,"Rheumatoid arthritis (RA) is characterized by infiltrations of macrophages and T cells into the joint, and synovial hyperplasia. Proinflammatory cytokines released from these cells are known to be important in the destruction of joints in RA [1]. The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-alpha) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2].
A little over a decade ago, the primacy of T cells in the pathogenesis of autoimmune disease such as RA was undisputed because they are the largest cell population infiltrating the synovium. However, a series of studies demonstrated paucity of T cell-derived cytokines such as IL-2 and interferon-gamma in the joints of RA, whereas macrophage and fibroblast cytokines including IL-1, IL-6, IL-15, IL-18 and TNF-alpha were abundant in rheumatoid synovium. This paradox has questioned the role of T cells in the pathogenesis of RA [3]. Because we have already demonstrated the enhanced proliferation of antigen specific T cells, especially to type II collagen, and the skewing of T helper type 1 (Th1) cytokines in RA [4], the role of T cells needs to be elucidated in different aspects.
IL-17 is one of the inflammatory cytokines secreted mainly by activated T cells, which can induce IL-6 and IL-8 by fibroblasts [5]. This cytokine is of interest for two major reasons: first, similarly to TNF-alpha and IL-1, IL-17 has proinflammatory properties; second, it is produced by T cells [6]. Recent observations demonstrated that IL-17 can also activate osteoclastic bone resorption by the induction of RANKL (receptor activator of nuclear factor kappaB [NF-kappaB] ligand), which is involved in bony erosion in RA [7]. It also stimulates the production of IL-6 and leukemia inhibitory factor by synoviocytes, and of prostaglandin E2 and nitric oxide by chondrocytes, and has the ability to differentiate and activate the dendritic cells [8-10]. Levels of IL-17 in synovial fluids were significantly higher in patients with RA than in patients with osteoarthritis (OA), and it was produced by CD4+ T cells in the synovium [11,12].
IL-15, secreted from activated macrophages, has been reported to be an important trigger of IL-17 production in RA peripheral blood mononuclear cells (PBMC) by cyclosporine and steroid sensitive pathways [13]. Recently, Happel and colleagues also showed that IL-23 could be an efficient trigger of IL-17 production from both CD4+ and CD8+ T cells [14].
Although the contribution of IL-17 in joint inflammation in RA has been documented in earlier studies [12,15,16], the intracellular signal transduction pathway for IL-17 production remains uncertain. In the present study we used various stimuli to investigate IL-17 production in PBMC of patients with RA and its signaling transduction pathway.
We found that the intracellular signaling pathway involving phosphoinositide 3-kinase (PI3K)/Akt and NF-kappaB might be involved in the overproduction of the key inflammatory cytokine IL-17 in RA. These results might provide new insights into the pathogenesis of RA and future directions for new therapeutic strategies in RA.","[{'offsets': [[307, 340]], 'text': ['tumor necrosis factor (TNF)-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[346, 364]], 'text': ['interleukin (IL)-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[783, 787]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[792, 808]], 'text': ['interferon-gamma'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[884, 888]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[890, 894]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[896, 901]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[903, 908]], 'text': ['IL-18'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[913, 922]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1292, 1297]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1390, 1394]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1399, 1403]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1496, 1505]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1510, 1514]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1516, 1521]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1631, 1636]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1704, 1709]], 'text': ['RANKL'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1711, 1773]], 'text': ['receptor activator of nuclear factor kappaB [NF-kappaB] ligand'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1858, 1862]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1867, 1893]], 'text': ['leukemia inhibitory factor'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2057, 2062]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2194, 2197]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2232, 2237]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2324, 2329]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2491, 2496]], 'text': ['IL-23'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2530, 2535]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2557, 2560]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2566, 2569]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2614, 2619]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2749, 2754]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2845, 2850]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3023, 3026]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3114, 3119]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T33'}]",[],[],[],[],[]
184,PMC-3312845-17-Results,"MIP-2 expression
MIP-2 is a powerful chemokine that contributes to recruitment of neutrophils [27]. MIP-2 is undetectable or present at low levels under physiological conditions, and shows transient increases under pathological conditions via TNF-alpha and/or interleukin-1beta (IL-1beta)-dependent mechanisms [14]. Thus, it would be plausible that TNF-alpha-mediated MIP-2 expression may provoke SE-induced neutrophil infiltrations. To confirm this hypothesis, we investigated MIP-2 expression in the PC. Consistent with our previous study [20], some MIP-2-positive astrocytes were observed in the core and periphery of the vasogenic edema lesions, but not in the non-vasogenic edema region (Figure 6B and 6C). Although the number of MIP-2 positive cells per unit area in the PC region of sTNFp55R-infused animals was significantly lower than that of the saline-infused group due to reduction of the area of vasogenic edema, there was no difference in the number of MIP-2 positive cells per unit area of vasogenic edema between sTNFp55R-infused animals and saline-infused animals (Figure 6F). Furthermore, the number of MIP-2-positive cells showed a direct proportion to the unit area of vasogenic edema with a linear coefficient of correlation of 0.682 (p < 0.05, Figure 6G). Therefore, together with reduction in neutrophil infiltration in the PC region of sTNFp55R-infused animals, our findings provide evidence that TNF-alpha may regulate SE-induced neutrophil infiltration at least in the PC via vasogenic edema formation and not via direct TNF-alpha-mediated MIP-2 expression in astrocytes.","[{'offsets': [[0, 5]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[17, 22]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[37, 46]], 'text': ['chemokine'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[100, 105]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[243, 252]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[260, 277]], 'text': ['interleukin-1beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[279, 287]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[349, 358]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[368, 373]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[478, 483]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[552, 557]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[735, 740]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[791, 798]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[967, 972]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1030, 1037]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1121, 1126]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1361, 1368]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1421, 1430]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1547, 1556]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1566, 1571]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T20'}]",[],[],[],[],[]
185,PMC-3218875-11-Conclusions,"The NF-kappaB family of transcription factors plays crucial roles in the inflammatory processes in RA leading to cartilage and bone destruction. Keeping NF-kappaB activation under control can thus be very important for the design of specific therapeutics. The existence of multiple negative regulators ensuring a tight regulation of the NF-kappaB pathway, however, raises the question of the specific role of each of these regulators and the relationship between them. In addition, given the number of miRNAs in humans and the multiple mRNAs they target, intense complexity can be expected. How all these regulatory signals are themselves regulated will be an important question in order to clarify how NF-kappaB signalling is organised, and, more importantly, how this knowledge may lead to new treatments for inflammatory diseases such as RA.",[],[],[],[],[],[]
186,PMC-3291650-12-Materials_and_Methods,"Western blotting
For total lysates, cells were lysed at 4degreesC for 15 min in lysis buffer (200 mM NaCl, 1% NP-40, 10 mM Tris-HCl pH 7.5, 5 mM EDTA, 2 mM DTT) supplemented with protease and phosphatase inhibitors. Nuclear and cytoplasmic lysates were prepared by resuspending cells in B1 (10 mM Hepes pH 7.5, 10 mM KCl, 1 mM MgCl2, 5% glycerol, 0.5 mM EDTA and 0.1 mM EGTA supplemented with protease and phosphatase inhibitors) for 15 min at 4degreesC. Next, NP-40 detergent was added to a final concentration of 0.65% and cells were centrifuged at 500 g for 5 min. The nuclear fraction containing pellet was lyzed in B2 (20 mM Hepes pH 7.5, 1% NP-40, 400 mM NaCl, 10 mM KCl, 1 mM MgCl2, 20% glycerol, 0.5 mM EDTA and 0.1 mM EGTA supplemented with protease and phosphatase inhibitors) for 15 min at 4degreesC. The lysates were subsequently separated by SDS-PAGE and analyzed by western blotting and ECL detection (Perkin Elmer Life Sciences). Immunoblots were revealed with anti-A20, anti-IkappaBalpha, anti-p65, and anti-histon H1 (Santa Cruz), anti-IRF3 (Invitrogen), anti-phospho-IRF3 and anti-phospho-IkappaBalpha (Cell Signaling) and anti-actin (MP Biomedicals). The density of the bands was quantified (fold induction) with the ImageJ (http://rsbweb.nih.gov/ij) Gel analyzer tool. All intensities were calculated relative to the first lane ( = time 0).",[],[],[],[],[],[]
187,PMC-3312845-11-Methods,"Data analysis
Data obtained from volumetric analysis, cell counts, and quantitative measurements were analyzed using Student's t-test to determine statistical significance. Linear regression analysis was also performed to determine correlations with SMI-71/p65-Thr435 phosphorylation, and the number of MPO cells/vasogenic edema areas.","[{'offsets': [[257, 260]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
188,PMC-3312845-23-Caption-Figure_5,"Effect of sTNFp55R infusion on p65-Thr435 phosphorylation in endothelial cells following SE. (A-B) Inhibition of p65-Thr435 phosphorylation by sTNFp55R infusion 12 hr after SE. p65-Thr435 phosphorylation is rarely observed in astrocytes (arrows). (C) Endothelial p65-Thr435 phosphorylation in non-SE animals. (D-E) Endothelial p65-Thr435 phosphorylation in saline-infused animals 1 day after SE. p65-Thr435 phosphorylation is enhanced, while SMI-71 expression is reduced in GLUT-1-positive endothelial cells (arrows). (F-G) Endothelial p65-Thr435 phosphorylation in sTNFp55R-infused animal 1 day after SE. sTNFp55R infusion effectively reduces p65-Thr435 and preserves SMI-71 expression in GLUT-1-positive endothelial cells (arrows). Bars = 12.5 (A-D) and 25 (E-G) mum.","[{'offsets': [[11, 18]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[31, 34]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[113, 116]], 'text': ['p65'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[144, 151]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[177, 180]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[263, 266]], 'text': ['p65'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[327, 330]], 'text': ['p65'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[396, 399]], 'text': ['p65'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[474, 480]], 'text': ['GLUT-1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[536, 539]], 'text': ['p65'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[567, 574]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[607, 614]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[644, 647]], 'text': ['p65'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[690, 696]], 'text': ['GLUT-1'], 'type': 'Protein', 'id': 'T14'}]",[],[],[],[],[]
189,PMC-3320587-20-Results,"NFAT5 is important for enhancement of HIV-1 subtype C replication in response to MTb infection
As shown in Figure 1, the subtype C LTR was the most active of the HIV-1 LTR subtypes in the reporter assays. Subtype C LTRs generally have three functional NF-kappaB sites in their LTRs, and subtype C is the predominant viral subtype in the African and Asian HIV-1 epidemics where MTb co-infection is extremely common [1], [2], [28], [52]. We thus next extended our analysis of the role of NFAT5 in MTb/HIV-1 co-infection to a subtype C isolate. We first constructed an infectious molecular clone of the HIV-1 subtype C primary isolate HIV-198IN22, which has two NFAT5 binding sites in its LTR and three NF-kappaB sites (Figure 6A). We disrupted the two NFAT5 binding sites by changing the TT of each site to CC to create a mutant virus that we named HIV-198IN22-N5-Mut. Bulk PBMC from four normal donors were infected overnight with 1000 TCID50 of wild-type HIV-198IN22 or HIV-198IN22-N5-Mut and the cultures were then co-infected with MTb CDC1551 or left infected with virus alone. At day 11 post-viral infection, wild-type HIV-198IN22 replication was greater, but not significantly so, as compared to replication of HIV-198IN22 NFAT5-Mut (Figure 6B). However, in the context of MTb co-infection, wild-type HIV-198IN22 replication was significantly increased (p<0.05) at day 11 over HIV-198IN22 NFAT5-Mut replication (Figure 6C), indicating that the absence of NFAT5 binding sites was particularly detrimental to virus replication in the presence of MTb co-infection. Thus, even when three functional NF-kappaB binding sites are present in the LTR, as in the HIV-1 subtype C infectious clone studied here, disruption of NFAT5 binding to the LTR impairs virus replication in response to MTb co-infection.","[{'offsets': [[0, 5]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[486, 491]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1718, 1723]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
190,PMC-3589482-27-Caption-Figure_4,"Identification of cis-acting elements required for the LPS-responsiveness of the murine SerpinB2 promoter.
(A) Schematic representation of the -539/+92 region of the murine SerpinB2 promoter with the location of candidate cis-acting regulatory elements indicated with boxes. The location of the 5' ends of the -539, -189 and -87 reporter constructs is also shown. Positions of murine SerpinB2 proximal promoter-specific primers, 338/-315 and -5/+19 used in ChIP assays are indicated. (B) RAW 264.7 macrophages were transiently transfected with the indicated murine SerpinB2 promoter-luciferase reporter constructs and either left untreated or treated with 100 ng/ml LPS for 16 hrs. The results show relative luciferase activity following LPS treatment and represent the mean and SEM of 4-7 independent experiments.","[{'offsets': [[88, 96]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[173, 181]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[384, 392]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[565, 602]], 'text': ['SerpinB2 promoter-luciferase reporter'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[708, 718]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
191,PMC-1064873-10-Results,"Resistance to IL-10 inhibition of IFN-gamma production in RA CD4+ T cells
The CD28 costimulatory pathway is crucial for effective antigen-specific T-cell cytokine production, and IL-10 can directly suppress this response by inhibiting CD28 tyrosine phosphorylation and binding of phosphatidylinositol 3-kinase [24]. To evaluate the responsiveness of RA CD4+ T cells to IL-10, purified PB CD4+ T cells from three patients with active RA and from three healthy controls were stimulated by immobilized anti-CD3 antibody and anti-CD28 antibody with or without diluted concentrations of IL-10 for 36 hours, and IFN-gamma production was measured by ELISA. As shown in Fig. 1, IFN-gamma production by activated normal CD4+ T cells was mostly inhibited at concentrations as low as 1 ng/ml IL-10. However, RA CD4+ T cells were able to produce significant amounts of IFN-gamma in the presence of 1 ng/ml IL-10, and the maximal but not complete inhibition by IL-10 was obtained at 10-100 ng/ml.
We thus compared the levels of IFN-gamma production by CD4+ T cells after CD3 and CD28 costimulation in the presence of 1 ng/ml IL-10 in RA patients with active disease (multiple inflammatory joints, CRP level >= 10 mg/l) and inactive disease (in remission, CRP level < 10 mg/l) [26] and in healthy controls. There were no statistically significant differences in IFN-gamma production without IL-10 among these three groups (Fig. 2a), but the inhibitory effect of IL-10 on IFN-gamma production was significantly limited in the active RA group as compared with the inactive RA group and healthy controls (percentage decrease: active RA, 2.9 +/- 14.4%; inactive RA, 45.6 +/- 14.4%; controls, 65.8 +/- 7.9%) (Fig. 2b). As a consequence, CD4+ T cells from active RA patients produced higher levels of IFN-gamma in the presence of 1 ng/ml IL-10 than did normal CD4+ T cells (Fig. 2a).
In addition, we compared IL-2 production by CD4+ T cells after CD3 and CD28 costimulation in the presence of IL-10 in active RA patients and in healthy controls. Similarly, IL-2 production was not affected by 1 ng/ml IL-10 in RA patients (percentage decrease, -2.1 +/- 13.8%), while it was significantly reduced in healthy controls (61.1 +/- 13.7%; P < 0.05). Taken together, these results indicate that RA CD4+ T cells become less susceptible to the immunoregulatory effect of IL-10 during the active phase.","[{'offsets': [[14, 19]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[34, 43]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[61, 64]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[78, 82]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[179, 184]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[235, 239]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[353, 356]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[369, 374]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[388, 391]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[504, 507]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[526, 530]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[582, 587]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[606, 615]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[670, 679]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[711, 714]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[781, 786]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[800, 803]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[857, 866]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[894, 899]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[948, 953]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1015, 1024]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1039, 1042]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1058, 1061]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1066, 1070]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1112, 1117]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1348, 1357]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1377, 1382]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1448, 1453]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1457, 1466]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1718, 1721]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1781, 1790]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1818, 1823]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1840, 1843]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1889, 1893]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1908, 1911]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1935, 1939]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1973, 1978]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2037, 2041]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2081, 2086]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2271, 2274]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2342, 2347]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T41'}]",[],[],[],[],[]
192,PMC-1472690-21-Caption-Figure_4,"GP modulated LPS- and TSST-1-induced binding to a new NFkappaB3 site in the IL-1RA promoter. Binding was enhanced for GP + LPS and GP + TSST-1, when compared to LPS, TSST-1, GP, GP/LPS calc. or GP/TSST-1 calc., respectively (* = p < 0.05; ** = p < 0.01). Medium control levels were set equal to 1 +/- SEM (n = 6). DNA binding was assessed by EMSA (see methods).","[{'offsets': [[22, 28]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[76, 82]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[136, 142]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[166, 172]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[197, 203]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
193,PMC-3589482-16-Results,"A C/EBP, CRE and Two AP-1 Sites in the Murine SerpinB2 Gene Proximal Promoter are Essential for Optimal LPS-inducible Transcription
To investigate regulatory elements between -539 and -189 essential for LPS-inducible transcription, several candidate binding sites for transcription factors previously reported to mediate LPS-inducible transcription in other genes [57] were targeted by nucleotide substitution designed to disrupt transcription factor binding to the pGLmP-539 murine SerpinB2 promoter-luciferase reporter gene construct (Fig. 4A). As shown in Fig. 4B, mutation of the consensus E box (-538/-533), PU.1 (-412/-407), or the variant Oct-1 (-296/-288) site did not decrease LPS-induced promoter activity. In contrast, mutation of the C/EBP site (-203/-192) completely eliminated promoter activity, similar to the levels observed for the -189 SerpinB2 promoter deletion construct. Others have also recently implicated this C/EBP site in LPS-induced activation of the SerpinB2 gene [58].
Considering the conserved sequence and position of the CRE and two AP-1 sites in the murine SerpinB2 promoter and their demonstrated involvement in the PMA-responsiveness of the human SERPINB2 promoter [37], these sites were also mutated by nucleotide substitution to investigate whether they played a role in the LPS response of the murine SerpinB2 promoter. As shown in Fig. 4B, mutation of the CRE at -177/-172 or either of the two AP-1 sites at -106/-100 and -94/-88, completely or significantly reduced LPS-inducible luciferase activity from the murine SerpinB2 promoter. These data show that the C/EBP element, as well as the CRE and both AP-1 cis-acting elements are critical for LPS-inducible transcription from the SerpinB2 proximal promoter.","[{'offsets': [[46, 54]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[483, 525]], 'text': ['SerpinB2 promoter-luciferase reporter gene'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[854, 862]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[978, 986]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1090, 1098]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1182, 1190]], 'text': ['SERPINB2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1339, 1347]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1520, 1530]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1556, 1564]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1722, 1730]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T10'}]",[],[],[],[],[]
194,PMC-3218875-06-Negative_regulation_of_NF-+%A6B_signalling_in_RA,"A20-binding inhibitors of NF-kappaB
ABIN-1, ABIN-2 and ABIN-3 (also known as TNIP-1, TNIP-2, and TNIP-3) were identified as ubiquitously expressed A20 interacting proteins and were shown to inhibit NF-kappaB activation by TNF and several other inflammatory stimuli upon overexpression. Because ABINs contain a specific ubiquitin-binding motif, they have been proposed to target A20 to polyubiquitinated substrates [43,44]. Similar to A20, ABIN-1 and ABIN-3 expression is NF-kappaB dependent, implicating a potential role for the A20/ABIN complex in the negative feedback regulation of NF-kappaB activation (reviewed in [54]). Unexpectedly, both ABIN-1-deficient and ABIN-2-deficient mice exhibit only slightly increased or normal NF-kappaB responses, respectively, possibly reflecting redundant NF-kappaB inhibitory activities of multiple ABINs [55,56]. Functional ABIN-3 is expressed in humans, but mice only express a truncated and inactive form lacking the crucial ubiquitin-binding domain [57]. As for A20, ABIN-1 also strongly inhibits TNF-induced apoptosis [58], and ABIN-1 deficient mice die embryonically due to TNF-dependent foetal liver apoptosis [56].
Using oligonucleotide microarray analysis, ABIN-1 was identified among TNF-induced genes in human synoviocytes, and high levels of ABIN-1 mRNA were detected in RA tissue biopsies, indicating a potential role for ABIN-1, together with A20, in the negative feedback regulation of NF-kappaB signalling and the pathogenesis of RA [59]. In a recent study, inhibition of TLR responses by immunoreceptor tyrosine-based activation motif (ITAM)-coupled receptors was shown to depend on the expression of the NF-kappaB inhibitory proteins ABIN-3 and A20. Moreover, this protective effect of the ITAM was strongly suppressed in inflammatory arthritis synovial macrophages [60]. Interestingly, ABIN-1 polymorphisms have been associated with psoriasis and systemic lupus erythematosus in humans [61,62]. A high degree of overlap between systemic lupus erythematosus and RA susceptibility loci might be expected as the two diseases show some clinical overlap in joint involvement, autoantibody production, systemic features and response to treatments such as B-cell depletion (rituximab). It will therefore be interesting to investigate whether SNPs that have been reported to be associated with systemic lupus erythematosus are also associated with RA.","[{'offsets': [[0, 3]], 'text': ['A20'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[36, 42]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[44, 50]], 'text': ['ABIN-2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[55, 61]], 'text': ['ABIN-3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[77, 83]], 'text': ['TNIP-1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[85, 91]], 'text': ['TNIP-2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[97, 103]], 'text': ['TNIP-3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[147, 150]], 'text': ['A20'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[222, 225]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[378, 381]], 'text': ['A20'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[434, 437]], 'text': ['A20'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[439, 445]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[450, 456]], 'text': ['ABIN-3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[529, 532]], 'text': ['A20'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[645, 651]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[666, 672]], 'text': ['ABIN-2'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[865, 871]], 'text': ['ABIN-3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[920, 947]], 'text': ['truncated and inactive form'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1006, 1009]], 'text': ['A20'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1011, 1017]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1041, 1044]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1073, 1079]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1120, 1123]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1206, 1212]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1234, 1237]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1294, 1300]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1375, 1381]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1397, 1400]], 'text': ['A20'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1692, 1698]], 'text': ['ABIN-3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1703, 1706]], 'text': ['A20'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1845, 1851]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T31'}]",[],[],[],[],[]
195,PMC-3342329-04-Results,"Induction of Apoptotic Cell Death and Inhibition of the Expression of Anti-apoptotic Proteins in CCR5-/- Mice
To see whether inhibition of NF-kappaB activity results in the induction of apoptotic cell death and expression of NF-kappaB target apoptotic cell death regulatory protein, the levels of apoptotic cell death and expression of apoptotic cell death regulatory proteins were assessed. Apoptotic cell death in the tumor sections were evaluated in the CCR5+/+ and CCR5-/- mice that were inoculated with melanoma cells. TUNEL staining revealed a higher frequency of apoptotic cell death in the tumor tissues of the CCR5-/- mice than that of the CCR5+/+ mice (Figure 3A). Immunohistochemical and immunofluorescence showed that high levels of cleaved caspase-3 and Bax were found more frequently in the CCR5-/- mice than in the CCR5+/+ mice (Figure 3B and 3C). Consistent with the immunohistochemical data, Western blot analysis of tumor proteins showed greater increased levels of cleaved caspase-3, cleaved caspase-9, cleaved PARP and Bax, whereas the levels of Bcl-2 and C-IAP1 were significantly decreased in CCR5-/- mice tissues (Figure 3D).","[{'offsets': [[97, 101]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[457, 461]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[469, 473]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[619, 623]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[649, 653]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[805, 809]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[830, 834]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1076, 1082]], 'text': ['C-IAP1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1115, 1119]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T9'}]",[],[],[],[],[]
196,PMC-3312845-02-Methods,"Experimental animals
This study utilized progeny of Sprague-Dawley (SD) rats (male, 9 - 11 weeks old) obtained from Experimental Animal Center, Hallym University, Chunchon, South Korea. The animals were provided with a commercial diet and water ad libitum under controlled temperature, humidity and lighting conditions (22 +/- 2degreesC, 55 +/- 5% and a 12:12 light/dark cycle with lights). Animal protocols were approved by the Institutional Animal Care and Use Committee of Hallym University. Procedures involving animals and their care were conducted in accord with our institutional guidelines that comply with NIH Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23, 1996). In addition, we have made all efforts to minimize the number of animals used and their suffering.",[],[],[],[],[],[]
197,PMC-3585731-18-Materials_and_Methods,"Cell Viability Experiments
Cells were seeded into white clear bottom 96 well plates at the density of 1x104 cells/well and treated as described for western blot experiments. Cell viability was determined using CellTiter-Glo Cell Viability Assay (Promega). Experiments were performed in duplicate or triplicate. Viability of the control untreated cells was set as 100%. Relative viability of cells, induced to undergo necroptosis and treated with the compound relative to the control compound-treated cells, was determined and plotted to exclude the possible effects of non-specific toxicity of the small molecules.",[],[],[],[],[],[]
198,PMC-3589482-23-Discussion,"Macrophages are key mediators of the innate immune response, and consequently provide the first line of defense against pathogens. Pro-inflammatory stimuli, such as the bacterial endotoxin LPS, stimulate macrophages to mount an anti-pathogenic response which involves massive induction of the pro-survival factor SerpinB2. SerpinB2 is transcriptionally induced by cross talk between the IKKbeta/NF-kappaB and p38MAPK signaling modules in response to LPS [16]. Here we report that SerpinB2 gene transcription in response to LPS is conferred by the SerpinB2 proximal promoter and is greatly dependent upon C/EBP-beta. LPS-induced C/EBP-beta was shown to specifically bind the C/EBP response element in the SerpinB2 proximal promoter in vitro and in vivo, and loss of C/EBP-beta abrogates constitutive SerpinB2 gene transcription and the response to LPS.
The murine SerpinB2 proximal promoter region between nucleotides -539 and +92 mediated both PMA- and LPS-inducible gene transcription, with induction by PMA being less intense and more transient than that by LPS. Inspection of the murine SerpinB2 proximal promoter sequence shows that a CRE and two AP-1-like elements, demonstrated to mediate PMA-stimulated transcription of the human SERPINB2 gene [37], also are present in the murine SerpinB2 proximal promoter between nucleotides -189 and -87. These sites may therefore also play a role in mediating PMA-inducible transcription of the murine SerpinB2 gene. In contrast to the pattern of incremental increases in PMA-induced transcriptional activity conferred by regions of the murine SerpinB2 promoter containing these sites, most of the LPS-inducible response is dependent upon cis-acting regulatory sequences in the region between nucleotides -189 and -539. LPS responsiveness absolutely required the C/EBP binding site located in the region between nucleotides -189 and -539, with the downstream CRE and AP-1-like elements also being critical. Of note, there are previous reports of combinatorial interactions between C/EBP-beta and CRE binding proteins (CREB) and AP-1 [63], and C/EBP-beta has been reported to physically interact with AP-1, and NF-kappaB to promote gene expression of inflammatory mediators [63]; [66]. Additionally, CREB has been shown to control transcription of the C/EBP-beta gene [67].
In this study, C/EBP-beta was found to be a major requirement for both constitutive and LPS-induced SerpinB2 gene transcription. In a previous microarray expression profiling study, SerpinB2 was identified as gene whose induction in C/EBP-beta-deficient peritoneal macrophages by LPS and IFNgamma was severely impaired compared to wild-type macrophages [68]. Our qPCR results validate this finding, as we found that both constitutive and LPS-inducible SerpinB2 mRNA expression is significantly abrogated in C/EBP-beta-shRNA transduced peritoneal macrophages, emphasizing the link between C/EBP-beta and SerpinB2 gene transcription. While C/EBP proteins can act as either homodimers or heterodimers [63], we identified C/EBP-beta as the only LPS-inducible C/EBP isoform to bind the SerpinB2 C/EBP response element, suggesting a predominant role for C/EBP-beta in LPS-induced SerpinB2 gene expression. C/EBP-beta, like SerpinB2, plays an important role in inflammation, as it is upregulated by LPS and a host of other inflammatory cytokines [59]; [62]. Furthermore, C/EBP-beta-null mice are susceptible to bacterial infection [69]; [70] and SerpinB2 has been demonstrated to protect from bacterial and viral-induced cell death [14]-[16]; [25]. Thus the regulation of SerpinB2 gene expression by C/EBP-beta is consistent with its functional role in inflammation.
Phosphorylation of C/EBP-beta at several different amino acid residues has been shown to modulate transactivation of its target genes [63]; . C/EBP-beta phosphorylated on T217 has been reported to rescue macrophages from apoptosis induced by Bacillus anthracis lethal toxin (LT) [65], an activity that has also been attributed to SerpinB2 [16]. However, expression of a C/EBP-beta phospho-acceptor site mutant, C/EBPbetaT217A, in Cebpb-/- MEFs did not increase SerpinB2 proximal promoter activity over that of wild-type C/EBP-beta, even though recruitment of C/EBP-betaT217 to the SerpinB2 promoter was observed to decrease following LPS stimulation of RAW264.7 cells. These data indicate that the T217 phospho-acceptor site is not important for the regulation of SerpinB2 gene expression. Similarly, expression of the C/EBP-beta phospho-acceptor site mutant, C/EBP-betaT188A, did not affect SerpinB2 promoter activity differently from that of wild-type. In contrast, expression of C/EBP-betaS64A significantly enhanced LPS-induced SerpinB2 promoter activity, indicating that phosphorylation of C/EBP-beta at S64 negatively regulates LPS-induced SerpinB2 promoter activity. Since C/EBP-beta S64 is constitutively phosphorylated in both RAW264.7 cells and MEFs [73], it is likely that dephosphorylation at this site may be a critical event during LPS-induced transcription of SerpinB2 to increase its promoter activity. Roy and colleagues demonstrated that Mixed lineage kinase-3 (MLK3)-driven dephosphorylation of C/EBP-beta S64 was important for IFNgamma-regulated signaling pathways [73]. Our data suggest that MLK3-driven dephosphorylation of S64 may also be involved in LPS-signaling pathways.
In recent years it has become apparent that persistent infection is integrally linked to chronic inflammation and cancer, and immune cells such as macrophages can either promote or attenuate cancer progression [2]; [74]-[76]. SerpinB2 expression has been associated with both inflammation and cancer, and is a favorable or unfavorable prognostic indicator depending on cancer type [77]. The presence of SerpinB2 has been shown to modulate cytokine profiles which can affect immune cell polarization [27]; [28]; [77]; [78]. Interestingly C/EBP-beta has also been shown to modulate cytokine secretion from immune cells, thereby modifying their phenotype [27]; [79]-[81]. Our study has demonstrated that C/EBP-beta plays an important role in mediating both constitutive and LPS-induced transcription of the SerpinB2 gene, which may have implications for the inflammatory phenotype of infiltrating immune cells in the tumor microenvironment.
In summary, our studies show that the C/EBP site (-203/-195) in the murine SerpinB2 proximal promoter is necessary to support both constitutive and LPS-induced SerpinB2 gene expression. Importantly, we were able to uncover a previously unknown role for C/EBP-betaS64 in negatively regulating SerpinB2 promoter activity. Taken together these data provide new insight into the regulation of inflammation-associated SerpinB2 gene expression.","[{'offsets': [[313, 321]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[323, 331]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[387, 394]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[480, 488]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[547, 555]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[604, 614]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[628, 638]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[704, 712]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[765, 775]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[799, 807]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[863, 871]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1090, 1098]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1237, 1245]], 'text': ['SERPINB2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1288, 1296]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1447, 1455]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1589, 1597]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2026, 2036]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2088, 2098]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2296, 2306]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2333, 2343]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2418, 2426]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2500, 2508]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2527, 2531]], 'text': ['gene'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2551, 2561]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2606, 2614]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2770, 2778]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2906, 2916]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2921, 2929]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3036, 3046]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3099, 3107]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3166, 3176]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3192, 3200]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3218, 3228]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[3235, 3243]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3382, 3392]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3457, 3465]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3583, 3591]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3611, 3621]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3697, 3707]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T100'}, {'offsets': [[3820, 3830]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T101'}, {'offsets': [[4008, 4016]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T102'}, {'offsets': [[4048, 4087]], 'text': ['C/EBP-beta phospho-acceptor site mutant'], 'type': 'Protein', 'id': 'T103'}, {'offsets': [[4089, 4103]], 'text': ['C/EBPbetaT217A'], 'type': 'Protein', 'id': 'T104'}, {'offsets': [[4108, 4113]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T105'}, {'offsets': [[4139, 4147]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T106'}, {'offsets': [[4198, 4208]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T107'}, {'offsets': [[4259, 4267]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T108'}, {'offsets': [[4442, 4450]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T109'}, {'offsets': [[4497, 4536]], 'text': ['C/EBP-beta phospho-acceptor site mutant'], 'type': 'Protein', 'id': 'T110'}, {'offsets': [[4538, 4553]], 'text': ['C/EBP-betaT188A'], 'type': 'Protein', 'id': 'T111'}, {'offsets': [[4570, 4578]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T112'}, {'offsets': [[4660, 4674]], 'text': ['C/EBP-betaS64A'], 'type': 'Protein', 'id': 'T113'}, {'offsets': [[4710, 4718]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T114'}, {'offsets': [[4773, 4783]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T115'}, {'offsets': [[4824, 4832]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T116'}, {'offsets': [[4858, 4868]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T117'}, {'offsets': [[5053, 5061]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T118'}, {'offsets': [[5134, 5156]], 'text': ['Mixed lineage kinase-3'], 'type': 'Protein', 'id': 'T119'}, {'offsets': [[5158, 5162]], 'text': ['MLK3'], 'type': 'Protein', 'id': 'T120'}, {'offsets': [[5192, 5202]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T121'}, {'offsets': [[5225, 5233]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T122'}, {'offsets': [[5291, 5295]], 'text': ['MLK3'], 'type': 'Protein', 'id': 'T123'}, {'offsets': [[5602, 5610]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T124'}, {'offsets': [[5779, 5787]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T125'}, {'offsets': [[5913, 5923]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T126'}, {'offsets': [[6077, 6087]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T127'}, {'offsets': [[6180, 6188]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T128'}, {'offsets': [[6389, 6397]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T129'}, {'offsets': [[6474, 6482]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T130'}, {'offsets': [[6606, 6614]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T131'}, {'offsets': [[6727, 6735]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T132'}]",[],[],[],[],[]
199,PMC-3317373-12-3._Results,"3.2. Disruption of Nrf2 Enhanced Upregulation of NF-kappaB DNA-Binding Activity after Scratch Injury
It has been reported that NF-kappaB is activated in brain after TBI [2]. Here, we studied the DNA-binding activity of NF-kappaB of astrocytes from Nrf2 WT or KO mice by EMSA at 24 h after scratch injury. Scratch injury induced activation of NF-kappaB in astrocytes of both genotypes, while higher NF-kappaB activity was observed in group KO TBI than in group WT TBI (2.67 +/- 0.173 versus 2.28 +/- 0.072, P < 0.01) (Figure 2).",[],[],[],[],[],[]
200,PMC-3342329-18-Caption-Figure_1,"Inhibition of tumor development in CCR5-/- mice.
A-C, Tumor images, volumes, and weights. B16 melanoma cells (5x105 cells/mouse) were inoculated s.c. into CCR5+/+ mice and CCR5-/- mice (n = 20). Tumor volumes were measured every day and tumor weights were measured at study termination (Day 31). The CCR5-/- mice had a significant reduction in tumor growth and volume as compared to CCR5+/+ mice. The results are expressed as mean +/- SD. * indicates significant difference from CCR5+/+ mice (P<0.05). D, The CCR5-/- mice demonstrated significantly higher survival rates compared to CCR5+/+ mice (by Log-rank Test). E. Tumor sections were analyzed by H&E stain and expression of proliferating cell nuclear antigen (PCNA) by immunohistochemistry. Data are means +/- S.D. of four experimental animals. * indicates significant difference from CCR5+/+ mice (P<0.05). Scale bar indicates 50 m.","[{'offsets': [[35, 39]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[155, 159]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[172, 176]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[300, 304]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[383, 387]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[479, 483]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[509, 513]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[583, 587]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[840, 844]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T9'}]",[],[],[],[],[]
201,PMC-3586680-01-Mechanisms_of_Resistance_to_Temozolomide_in_Glioblastomas,"Glioblastoma multiforme afflicts 12,500 new patients in the U.S. annually (Friedman et al., 2000; Stupp et al., 2009; Silber et al., 2012). Glioblastoma (GBM) is highly lethal, and the average survival expectancy is 14.6 months, and the overall 5-year survival rate for GBM is only 9.8% (Friedman et al., 2000; Stupp et al., 2009). High levels of resistance to current therapeutic modalities and cancer relapse are frequently seen in patients (Haar et al., 2012; Happold et al., 2012). The current standard therapy for GBM mainly includes maximum debulking surgery, radiation, and treatment with the monofunctional alkylating agent temozolomide (TMZ) (Friedman et al., 2000; Nishikawa, 2010). Multiple mechanisms are involved in the TMZ resistance, which may include cancer stem cells, microRNAs, drug efflux, DNA damage repair, tumor cells under hypoxia, histone deacetylation, epithelial-mesenchymal transition, STAT3 kinase, and many others (Haar et al., 2012; Happold et al., 2012; Johannessen and Bjerkvig, 2012; Kitange et al., 2012; Kohsaka et al., 2012; Zhang et al., 2012b).
Temozolomide induces generation of DNA lesions, including O6-methylguanine, N3-methyladenine, and N7-methylguanine (Goellner et al., 2011; Zhang et al., 2012b). The O6-methylguanine lesion is known to trigger autophagy, rather than apoptosis, to cause cell death (Kanzawa et al., 2003). Also, inhibition of antiapoptotic Bcl-2 by a pan-Bcl-2 inhibitor (-)-gossypol leads to autophagic death in gliomas and enhances the action of TMZ (Voss et al., 2010). However, a recent study demonstrated that TMZ-induced autophagy is pro-survival, and may block the eventual apoptosis in GBM cells (Knizhnik et al., 2013). Also, MAPO2 (C1orf201) gene participates in the O6-methylguanine lesion-induced apoptosis (Fujikane et al., 2012). MAPO2 gene encodes a novel 37-kDa protein. It is not determined whether this gene is involved in autophagy.
The O6-methylguanine lesion is a substrate for direct repair by O6-methylguanine-DNA methyltransferase (MGMT) (Pollack et al., 2006; Hegi et al., 2008; Fukushima et al., 2009; Zhang et al., 2012b). Without MGMT repair, O6-methylguanine initiates activation of mismatch repair-deficient (MMR) proteins or Rad3-related protein kinase that ultimately leads to apoptotic cell death (Caporali et al., 2004; Wang and Edelmann, 2006; Roos et al., 2007). High expression of MGMT or loss of MMR contributes significantly to TMZ resistance in many clinical cases (Pollack et al., 2006; Hegi et al., 2008; Sarkaria et al., 2008). The initiation of apoptotic signaling fails in the absence of the MMR system.
Sensitivity to TMZ is significantly associated with the methylation status of MGMT gene promoter in cells committed to differentiation (Villalva et al., 2012). An increase in MGMT gene promoter methylation, which blocks MGMT protein expression, prolongs cancer patient survival. Intriguingly, overexpressed microRNA-21 reduces Bax/Bcl-2 ratio and caspase-3 activity, thereby blocking TMZ-induced apoptosis (Shi et al., 2010). MicroRNA-21 is considered as a pro-survival factor for cancer cells (Li et al., 2012). Integrins play a role in the resistance of advanced cancers to radiotherapy and chemotherapy. alpha5beta1 integrin negatively regulates p53 signaling, and the event induces glioma cell resistance to TMZ (Janouskova et al., 2012). alpha5beta1 integrin is considered as a therapeutic target for high-grade brain tumors. The base excision repair enzyme alkylpurine-DNA-N-glycosylase (APNG), which repairs the cytotoxic lesions N3-methyladenine and N7-methylguanine, also participates in the TMZ resistance (Agnihotri et al., 2012). Upregulation of mitochondrial respiratory chain coupling to suppress the production of reactive oxygen species (ROS) regulated by cytochrome c oxidase contributes in part to TMZ resistance in gliomas (Oliva et al., 2011).
Reversal of TMZ resistance may be achieved by MGMT pseudosubstrates, O6-benzylguanine and lomeguatrib to sensitize tumors to TMZ (Zhang et al., 2012b). Methoxyamine-blocker of base excision repair contributes significantly to TMZ cytotoxicity particularly when O6-methylguanine adducts are repaired or tolerated (Goellner et al., 2011; Zhang et al., 2012b). Dual targeting of base excision repair and NAD(+) biosynthesis may reverse TMZ resistance in patients with resistant and recurrent GBM (Goellner et al., 2011). Interferon-beta (IFN-beta), levetiracetam (LEV), resveratrol, and valproic acid (VAP) increase the sensitivity of TMZ through MGMT-dependent or -independent mechanisms (Nakada et al., 2012). Resveratrol, a natural polyphenol, reverses TMZ resistance via an NF-kappaB-dependent mechanism (Huang et al., 2012). STAT3 inhibitor or STAT3 knockdown potentiates TMZ efficacy in resistant GBM cell lines (Kohsaka et al., 2012). Intratumoral hypoxia is common in GBMs and may be associated with the development of TMZ resistance. Induced hyperoxia can be utilized to reverse TMZ resistance in GBMs (Sun et al., 2012). Cancer stem cells are probably the key to failure in TMZ treatment. The concept of cancer stem cell survival from treatment with TMZ and other chemotherapeutic drugs has been more complicated than previously thought (Beier et al., 2011; Chen et al., 2012). CD133-positive cancer stem cells are expressed in both normal stem cells and cancer stem cells (Donovan and Pilkington, 2012). However, the role of CD133 as a marker for glioma cancer stem cells relative to its biological function has yet to be established.","[{'offsets': [[1405, 1410]], 'text': ['Bcl-2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1420, 1425]], 'text': ['Bcl-2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1700, 1705]], 'text': ['MAPO2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1707, 1715]], 'text': ['C1orf201'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1809, 1814]], 'text': ['MAPO2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1981, 2019]], 'text': ['O6-methylguanine-DNA methyltransferase'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[2021, 2025]], 'text': ['MGMT'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[2123, 2127]], 'text': ['MGMT'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[2383, 2387]], 'text': ['MGMT'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[2692, 2696]], 'text': ['MGMT'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2789, 2793]], 'text': ['MGMT'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2834, 2838]], 'text': ['MGMT'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2921, 2932]], 'text': ['microRNA-21'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2941, 2944]], 'text': ['Bax'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2945, 2950]], 'text': ['Bcl-2'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2961, 2970]], 'text': ['caspase-3'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[3040, 3051]], 'text': ['MicroRNA-21'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[3263, 3266]], 'text': ['p53'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[3924, 3928]], 'text': ['MGMT'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[4396, 4411]], 'text': ['Interferon-beta'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[4413, 4421]], 'text': ['IFN-beta'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[4522, 4526]], 'text': ['MGMT'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[4705, 4710]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[4724, 4729]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[5263, 5268]], 'text': ['CD133'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[5411, 5416]], 'text': ['CD133'], 'type': 'Protein', 'id': 'T30'}]",[],[],[],[],[]
202,PMC-1064895-08-Materials_and_methods,"Western blot analysis of Akt, phosphorylated Akt and IkappaB-alpha
PBMC were incubated with anti-CD3 (10 mug/ml) in the presence or absence of LY294002 (20 muM). After incubation for 1 hour, whole cell lysates were prepared from about 107 cells by homogenization in the lysis buffer, and centrifuged at 14,000 r.p.m. (19,000 g) for 15 min. Protein concentrations in the supernatants were determined with the Bradford method (Bio-Rad, Hercules, CA, USA). Protein samples were separated by 10% SDS-PAGE and transferred to a nitrocellulose membrane (Amersham Pharmacia Biotech, Uppsala, Sweden). For western hybridization, membrane was preincubated with 0.1% skimmed milk in TBS-T buffer (0.1% Tween 20 in Tris-buffered saline) at room temperature for 2 hours, then primary antibodies against Akt, phosphorylated Akt and IkappaB-alpha (Cell Signaling Technology Inc., Beverly, MA, USA), diluted 1:1000 in 5% BSA/TBS-T, were added and incubated overnight at 4degreesC. After washing four times with TBS-T, horseradish peroxidase-conjugated secondary antibodies were added and allowed to incubate for 1 hour at room temperature. After TBS-T washing, hybridized bands were detected with the enhanced chemiluminescence (ECL) detection kit and Hyperfilm-ECL reagents (Amersham Pharmacia).","[{'offsets': [[25, 28]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[45, 48]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[53, 66]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[790, 793]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[810, 813]], 'text': ['Akt'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[818, 831]], 'text': ['IkappaB-alpha'], 'type': 'Protein', 'id': 'T6'}]",[],[],[],[],[]
203,PMC-3585731-00-TIAB,"Akt Regulates TNFalpha Synthesis Downstream of RIP1 Kinase Activation during Necroptosis
Necroptosis is a regulated form of necrotic cell death that has been implicated in the pathogenesis of various diseases including intestinal inflammation and systemic inflammatory response syndrome (SIRS). In this work, we investigated the signaling mechanisms controlled by the necroptosis mediator receptor interacting protein-1 (RIP1) kinase. We show that Akt kinase activity is critical for necroptosis in L929 cells and plays a key role in TNFalpha production. During necroptosis, Akt is activated in a RIP1 dependent fashion through its phosphorylation on Thr308. In L929 cells, this activation requires independent signaling inputs from both growth factors and RIP1. Akt controls necroptosis through downstream targeting of mammalian Target of Rapamycin complex 1 (mTORC1). Akt activity, mediated in part through mTORC1, links RIP1 to JNK activation and autocrine production of TNFalpha. In other cell types, such as mouse lung fibroblasts and macrophages, Akt exhibited control over necroptosis-associated TNFalpha production without contributing to cell death. Overall, our results provide new insights into the mechanism of necroptosis and the role of Akt kinase in both cell death and inflammatory regulation.","[{'offsets': [[14, 22]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[47, 51]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[389, 419]], 'text': ['receptor interacting protein-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[421, 425]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[534, 542]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[597, 601]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[757, 761]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[923, 927]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[974, 982]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1103, 1111]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T10'}]",[],[],[],[],[]
204,PMC-1064873-01-Introduction,"IL-10 is a key cytokine in regulating inflammatory responses, mainly by inhibiting the production and function of proinflammatory cytokines. IL-10 binds to the IL-10 receptor (IL-10R) complex that is composed of two subunits, the primary ligand-binding component type 1 IL-10R (IL-10R1) and the accessory component type 2 IL-10R [1]. The interaction of IL-10 and IL-10R engages the Janus kinase (JAK) family tyrosine kinases Jak1 and Tyk2, which are constitutively associated with IL-10R1 and type 2 IL-10R, respectively [2]. IL-10 induces tyrosine phosphorylation and activation of the latent transcriptional factors signal transducer and activator of transcription (STAT) 3 and STAT1 [3]. Upon phosphorylation, STAT1 and STAT3 proteins form homodimers or heterodimers, rapidly translocate into the nucleus, and modulate gene transcription. Intriguingly, STAT3 is indispensable for both IL-10-derived anti-inflammatory and IL-6-derived proinflammatory responses [4]. Studies of cell-type-specific STAT3-deficient mice have shown that STAT3 activation is essential for IL-10-mediated anti-inflammatory reactions in macrophages and neutrophils [5], but is responsible for IL-6-mediated prevention of apoptosis in T cells [6]. The suppressor of cytokine signaling (SOCS) proteins have been identified as a family of endogenous JAK kinase inhibitors that can act in classic feedback inhibition loops, but their roles as the mediators of crosstalk inhibition by opposing cytokine signaling pathways have been clarified [7]. Recent studies indicate that SOCS3 plays a key role in regulating the divergent action of IL-10 and IL-6, by specifically blocking STAT3 activation induced by IL-6 but not that induced by IL-10 [8,9].
The synovial membrane of rheumatoid arthritis (RA) is characterized by an infiltrate of a variety of inflammatory cells, such as lymphocytes, macrophages, and dendritic cells, together with proliferation of synovial fibroblast-like cells. Numerous cytokines are overproduced in the inflamed joint, and macrophages and synovial fibroblasts are an important source of proinflammatory cytokines. Tumor necrosis factor alpha (TNF-alpha) and IL-1, two major macrophage products, are crucial in the process of chronic inflammation and joint destruction, and they give rise to effector components, including other inflammatory cytokines, chemokines, growth factors, matrix proteases, nitric oxide, and reactive oxygen species [10]. IL-6 is a pleiotropic cytokine produced substantially by activated fibroblasts, and its proinflammatory actions include simulating the acute-phase response, B-cell maturation into plasma cells, T-cell functions, and hematopoietic precursor cell differentiation [11].
However, anti-inflammatory cytokines and cytokine inhibitors are also present in large quantities in RA joints. IL-10, produced by macrophages and partly by T cells in the synovial tissue (ST), is best known as a negative regulator for macrophage and Th1 cells, but the expression level is insufficient to counterbalance the cascade of proinflammatory events [12]. In addition, the anti-inflammatory action of IL-10 appears to be modulated at the level of signal transduction during chronic inflammation. IL-10 signaling is impaired in macrophages upon chronic exposure to proinflammatory cytokines such as TNF-alpha and IL-1 and immune complexes [13,14]. Cell surface expression of IL-10R1 is decreased in synovial fluid dendritic cells due to the presence of TNF-alpha, IL-1, and granulocyte-macrophage colony-stimulating factor [15].
CD4+ T cells may be activated by arthritogenic antigens, in conjunction with CD28-mediated costimulatory signaling, in RA. The significance of this autoimmune process has been supported by the linkage of the MHC class II antigens HLA-DRB1*0404 and HLA-DRB1*0401 with disease susceptibility and severity [16,17], and by the high-level expression of MHC class II molecules and both CD28 ligands, CD80 and CD86, in the inflamed ST [18-20]. The continuing emergence of activated CD4+ T cells, even though few in number, may be crucial in sustaining the activation of macrophages and synovial fibroblasts through cell surface signaling by means of cell surface CD69 and CD11, as well as the release of proinflammatory Th1 cytokines such as interferon gamma (IFN)-gamma and IL-17 [21,22]. In addition, CD4+ T cells could stimulate B-cell production of autoantibodies such as rheumatoid factor and osteoclast-mediated bone destruction. Their obligatory role in RA synovitis was recently proved by successful treatment of active disease by selective inhibition of T-cell activation with fusion protein of cytotoxic T-cell-associated antigen 4 (CD152)-IgG, which can block the engagement of CD28 on T cells by binding to CD80 and CD86 with high avidity [23].
IL-10 efficiently blocks the antigen-specific T-cell cytokine response by inhibiting the CD28 signaling pathway [24], as well as indirectly by downregulating the function of antigen-presenting cells. To elucidate the resistance of CD4+ T cells to this direct inhibition in RA, we investigated the production of IFN-gamma after CD3 and CD28 costimulation in the presence of IL-10, the induction of STAT1 and STAT3 phosphorylation by IL-10, and the expression of SOCS1 and SOCS3 mRNA in peripheral blood (PB) CD4+ T cells from RA patients.","[{'offsets': [[1, 5]], 'text': ['L-10'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[141, 146]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[160, 174]], 'text': ['IL-10 receptor'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[176, 182]], 'text': ['IL-10R'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[263, 276]], 'text': ['type 1 IL-10R'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[278, 285]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[315, 328]], 'text': ['type 2 IL-10R'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[353, 358]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[363, 369]], 'text': ['IL-10R'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[425, 429]], 'text': ['Jak1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[434, 438]], 'text': ['Tyk2'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[481, 488]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[493, 506]], 'text': ['type 2 IL-10R'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[526, 531]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[618, 675]], 'text': ['signal transducer and activator of transcription (STAT) 3'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[680, 685]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[713, 718]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[723, 728]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[856, 861]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[888, 893]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[924, 928]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[998, 1003]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1035, 1040]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1069, 1074]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1171, 1175]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1549, 1554]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1610, 1615]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1620, 1624]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1651, 1656]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1679, 1683]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1708, 1713]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2114, 2141]], 'text': ['Tumor necrosis factor alpha'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2143, 2152]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2158, 2162]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2446, 2450]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2456, 2476]], 'text': ['pleiotropic cytokine'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2825, 2830]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3123, 3128]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3218, 3223]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3320, 3329]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3334, 3338]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3396, 3403]], 'text': ['IL-10R1'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3474, 3483]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3485, 3489]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3495, 3543]], 'text': ['granulocyte-macrophage colony-stimulating factor'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3550, 3553]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3627, 3631]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3780, 3793]], 'text': ['HLA-DRB1*0404'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3798, 3811]], 'text': ['HLA-DRB1*0401'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3930, 3934]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[3944, 3948]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[3953, 3957]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4025, 4028]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4206, 4210]], 'text': ['CD69'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4215, 4219]], 'text': ['CD11'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4285, 4301]], 'text': ['interferon gamma'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[4302, 4313]], 'text': ['(IFN)-gamma'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[4318, 4323]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[4346, 4349]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[4647, 4696]], 'text': ['cytotoxic T-cell-associated antigen 4 (CD152)-IgG'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[4732, 4736]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[4762, 4766]], 'text': ['CD80'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[4771, 4775]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[4800, 4805]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[4889, 4893]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[5031, 5034]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[5111, 5120]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[5135, 5139]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[5173, 5178]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[5197, 5202]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[5207, 5212]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[5232, 5237]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[5261, 5266]], 'text': ['SOCS1'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[5271, 5276]], 'text': ['SOCS3'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[5307, 5310]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T75'}]",[],[],[],[],[]
205,PMC-3291650-04-Results,"A20 deficiency in myeloid cells protects against IAV lung infection
To determine the role of A20 expression in myeloid cells during an IAV infection in vivo, we intranasally inoculated both A20myel-KO mice and control littermates with a sublethal dose of the mouse adapted IAV X-47 (H3N2) strain and monitored morbidity in terms of weight loss. A20myel-KO mice showed reduced weight loss compared to wild type control littermates and recovered faster from the viral challenge (figure 3A). Also, total protein concentration in BAL fluid, which reflects lung damage and vascular leakage, was increased significantly at 7 and 10 days post infection in both wild type and A20myel-KO mice, and was slightly lower in A20myel-KO mice (data not shown). Next, we measured pulmonary viral titers at 4, 7 and 10 days post infection. No differences in viral titers were observed in A20myel-KO mice versus wild type mice at day 4 and 7 post infection. However, after 10 days, almost no virus could be detected in the lungs of A20myel-KO mice while abundant infectious viral particles could still be isolated from lungs of all wild type mice (figure 3B). This indicates that loss of A20 in myeloid cells does not affect early viral replication but contributes to viral clearance at later stages during infection.
To verify if A20 deficiency in myeloid cells affects IAV-induced gene expression in the lung, we analyzed the levels of several chemokines and cytokines in the bronchoalveolar lavage (BAL) at day 4, 7 and day 10 following infection. Levels of KC and MIP-2 chemokines, as well as IL-6 were significantly higher at day 7 p.i. in BAL from IAV infected A20myel-KO mice compared to IAV infected wild type mice (figure 3C). Unlike our observations with in vitro stimulated primary macrophages we could not detect a significant increase in MCP-1 or IFNalpha production in the lungs of A20myel-KO animals (figure 3C). KC is the murine orthologue of IL-8 and serves together with MIP-2 as a chemoattractant for neutrophils, while MCP-1 is mainly known as a chemoattractant for monocytes, which eventually develop into macrophages upon entering the alveolar lumen [60]. Consistent with the higher KC and MIP-2 levels in A20myel-KO mice, the number of neutrophils (CD11b+ Ly6C+ Ly6G+ F4/80-) that were recruited in the bronchoalveolar spaces upon IAV infection was clearly higher throughout infection in A20myel-KO mice compared to control animals (figure 3D). Although we could detect a significant increase in monocyte (CD11b+ Ly6C+) recruitment at day 4 post infection, this was not evident at later time points after infection (figure 3D), which is consistent with the equal expression of MCP-1 in both groups of mice. The number of resident alveolar macrophages (autofluorescent+ CD11c+ F4/80+ CD11b-) was also elevated in A20myel-KO mice but did not differ significantly between IAV infected or mock infected mice (figure 3D). Elimination of IAV infected cells depends on the clonal expansion of virus specific cytotoxic CD8+ T cells (CTL) [61], [62], [63]. To test whether A20 expression in myeloid cells regulates the antiviral CTL response, total CD8+ T cells and virus specific Granzyme B (GrB) and IFNgamma expressing CD8+ T cells were measured in BAL and lung parenchyma of wild type and A20myel-KO mice. A clear increase in CD8+ T cells could be detected at day 7 and 10 post infection, but no differences were observed between A20myel-KO and wild type mice (figure S2A and figure S2C). Also, the number of GrB and IFNgamma CD8+ T cells as well as IFNgamma expression levels in the lungs were not altered by the absence of A20 in myeloid cells (figure S2A-C).
Protection against IAV infection is also provided by the humoral immune response. To test whether loss of A20 in myeloid cells affects B cell mediated immunity, we determined hemagglutinin (HA) antibody titers in the serum of A20myel-KO and wild type littermates. However, no differences could be detected between wild type and A20myel-KO animals (figure S2D), indicating that humoral immunity is not affected by A20 expression in myeloid cells. Together, these data suggest that mechanisms other than adaptive immunity, such as an increased innate immune response, characterized by an increased influx of neutrophils and increased numbers of alveolar macrophages, contribute to the better viral clearance in A20myel-KO mice.
It is generally believed that IAV-induced mortality is due to an excessive proinflammatory response in the lung. We therefore analyzed whether the increased proinflammatory cytokine production and infiltration of proinflammatory cells in A20myel-KO mice affects mortality induced by intranasal infection with a lethal dose of IAV X-47. Surprisingly, almost all A20myel-KO mice survived (10/11), while all control mice succumbed (0/11) within 16 days after infection (figure 4A). A20myel-KO mice still showed significant weight loss and lung damage (as reflected by increased total protein concentration in the BAL; data not shown) during the course of infection but were able to recover, in contrast to wild type mice that succumbed (figure 4B). Similar to our observations with sublethal IAV infection, pulmonary KC and MIP-2 production was stronger in A20myel-KO animals compared to wild type mice following lethal IAV infection (figure 4C), which correlates with the increased numbers of neutrophils in the lungs of these mice (figure 4C). Also levels of the proinflammatory cytokines IL-6, TNF and IL-1beta, which are often associated with immunopathogenesis in humans [64], were increased in the lungs of A20myel-KO mice compared to control animals (figure 4C and figure S3A). Again, MCP-1 production was not increased and even lower in A20myel-KO mice (figure 4C), and also monocyte recruitment was not different between both groups of mice. We could also not detect any differences in viral clearance or antiviral adaptive immunity at 6 h post infection (figure S3B-F). Collectively these data indicate that A20 deficiency in myeloid cells is associated with an increased innate immune response and protection against a lethal IAV infection.","[{'offsets': [[1542, 1544]], 'text': ['KC'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1549, 1554]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1578, 1582]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1832, 1837]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1909, 1911]], 'text': ['KC'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1940, 1944]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1970, 1975]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[2020, 2025]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[2186, 2188]], 'text': ['KC'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[2193, 2198]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[2272, 2277]], 'text': ['F4/80'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[2681, 2686]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2780, 2785]], 'text': ['F4/80'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[3176, 3186]], 'text': ['Granzyme B'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[3188, 3191]], 'text': ['GrB'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[3508, 3511]], 'text': ['GrB'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[5201, 5203]], 'text': ['KC'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[5208, 5213]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[5475, 5479]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[5481, 5484]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[5489, 5497]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[5676, 5681]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T28'}]",[],[],[],[],[]
206,PMC-3320587-24-Caption-Figure_2,"MTb induces NFAT5 gene expression and knockdown of NFAT5 impairs HIV-1 replication during MTb co-infection.
(A) MTb but not HIV-1 increases NFAT5 mRNA synthesis in human macrophages. MDM were isolated from PBMC obtained from four normal donors. The cells were incubated for 24 or 48 hours with heat-inactivated or live R5-tropic HIV-1 subtype B, C, or E isolates, live MTb strain CDC1551 (1:1 MDM:bacilli), or left untreated. Quantitative real-time PCR analysis of NFAT5 mRNA expression levels revealed that the low, constitutively present level of NFAT5 mRNA expressed in untreated cells was not affected by exposure to live or inactivated HIV-1, but was significantly increased at both 24 (*, p<0.05) and 48 (**, p<0.01) hours following infection with MTb. (B) NFAT5-specific siRNA effectively suppresses NFAT5 expression in MDM in both the absence and presence of MTb co-infection. MDM (1x106 cells/well in a 6-well plate) from four normal donors were transfected with siRNA specific for NFAT5 or, as a control, GFP, and were then infected with MTb (1:1 MDM:bacilli) or left uninfected. In the cells transfected with control siRNA, MTb infection significantly increased NFAT5 expression in comparison to uninfected cells (open bars). When MDM were transfected with NFAT5-specific siRNA, both constitutively expressed (p = 0.048) and MTb-induced (p = 0.021) NFAT5 mRNA were significantly suppressed (grey bars). (C) HIV-1 subtype B replication is significantly suppressed in the presence of MTb co-infection when NFAT5 expression is abrogated in human MDM. MDM from four normal donors were transfected with NFAT5-specific and control siRNAs as described in 2B. Cells were then infected with HIV-1Lai/Bal-env followed by co-infection with MTb CDC1551. Virus replication was measured at days 6, 9, and 12 post-infection. At day 12, virus replication was significantly reduced in cells transfected with NFAT5-specific siRNA in comparison to cells transfected with control siRNA (*, p<0.05). We monitored the morphology of cells within the infected cultures and did not observe noticeable macrophage necrosis even at the final timepoint of viral harvest.","[{'offsets': [[12, 17]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[51, 56]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[140, 145]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[465, 470]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[549, 554]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[763, 768]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[807, 812]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[991, 996]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1015, 1018]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1173, 1178]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1268, 1273]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1360, 1365]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1515, 1520]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1609, 1614]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1706, 1709]], 'text': ['env'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1902, 1907]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T16'}]",[],[],[],[],[]
207,PMC-1359074-01-Introduction,"Sry type HMG box (Sox6) is a member of the Sox transcription factor family characterized by the conserved high mobility group (HMG) domain, consisting of 79 amino acids involved in DNA recognition and binding [1]. Sox transcription factors bind to the minor groove of DNA and cause a 70degrees-85degrees bend of the DNA that leads to local conformational changes [2,3], while most other transcription factors target the major groove of DNA [4]. Therefore, Sox proteins may perform part of their function as architectural proteins by organizing local chromatin structure and assembling other DNA-bound transcription factors into biologically active, sterically defined multiprotein complexes. Sox6 has been reported to be able to act as either an activator or a repressor, depending on its interactors and its target promoter context [5,6]. Intriguingly, Sox6 has also been shown to act as a general splicing factor that participates in pre-mRNA splicing [7]. Depletion of Sox6 in HeLa cell extracts blocked splicing of multiple substrates, and expression of the HMG domain of either Sox6, Sox9, or Sry in the extracts restored splicing, indicating functional overlap of these proteins [7]. Regardless of how Sox6 functions in regulating gene expression, previous studies have demonstrated that Sox6 is an important regulatory molecule that plays a role in the development of the central nervous system [8-11], cartilage [6,12,13], and muscle [14,15]. A Sox6-null mutant mouse (p100H) has previously been identified in our laboratory [14]. Mice homozygous for p100H show delayed growth, develop myopathy and arterioventricular heart block, and die within 2 wk after birth [14]. The p100H mutant allele is associated with a Chromosome 7 inversion that disrupts both the p gene and the Sox6 gene (and no other gene within 50,000 nucleotides of the chromosomal breakpoints) [14]. Because the p gene functions solely in pigmentation [16], the Sox6 transcription factor is implicated in all other phenotypes.
Among the HMG box proteins distantly related to Sry (the first member identified of the Sox transcription factor family) that similarly bind to the minor groove and bend DNA, but without sequence specificity, are the ubiquitously expressed HMG1 and HMG2 proteins [17]. Modulation of DNA structure by these and other HMG proteins can mediate long-range enhancer function on both DNA and chromatin-assembled genes by bringing together distant regions of DNA and associated factors. Specifically, HMG proteins have been shown to modulate beta-globin genes [18-21].
The mouse beta-globin genes {epsilony, betah1, beta-major, and beta-minor} are clustered on Chromosome 7 and they are highly homologous to their human counterparts in organizational structure and function [22]. High-level expression of these genes requires a regulatory element, the locus control region that is characterized by a set of nuclease hypersensitive sites spread over 25 kb located 5' of the epsilony gene [23]. The beta-globin genes are expressed in a tissue- and development-specific fashion. In mice, erythropoiesis originates in the embryonic yolk sac where primitive erythroid cells express epsilony and betah-1 globins [22]. At 11.5 d post coitus (dpc), erythropoiesis shifts to the fetal liver where definitive erythroid cells express adult beta globins (beta major and minor) [22]. The epsilony gene is silenced in definitive erythroid cells. The mechanism of silencing of its human counterpart, epsilon globin, has been studied extensively. In definitive erythropoiesis, epsilon is activated and silenced autonomously [24,25], although in primitive erythropoiesis epsilon also appears to be regulated competitively [26]. The gamma-globin to adult beta-globin switch is controlled by promoter competition for the LCR [24,25].
All the elements responsible for silencing the epsilon globin gene are within the epsilon gene or in adjacent sequences [27], suggesting that silencing is primarily gene autonomous. Using promoter deletion analyses in transgenic mouse models and cell transfection assays, multiple DNA elements important to the silencing process have been previously identified in both the proximal and the distal epsilon gene promoter [27]. Their corresponding transcription factors, such as GATA-1, YY-1, COUP-TF, and DRED have been identified and shown to directly bind to these DNA elements (as part of protein complexes) to regulate epsilon silencing [27]. Thus, it appears that the silencing of the epsilon gene involves a complicated network of multiple cis elements and transacting proteins.
In addition to playing an important role in the development of the central nervous system [8-11], cartilage [6,12,13], and muscle [14,15], it was shown that Sox6 is upregulated in long-term hematopoiesis stem cells (LT-HSC) compared with multipotent progenitors of adult mouse bone marrow lineage [28]. In this study, we describe that Sox6 also exerts pleiotropic effects on erythropoiesis. These effects include delayed maturation of erythrocytes (that normally enucleate prior to entering the bloodstream [27]) and higher expression of embryonic globin genes. The most extreme effect is the persistence of high expression of the embryonic epsilony globin gene. Here we describe and characterize the effects of Sox6 on the epsilony globin gene. We show that Sox6 binds to the proximal promoter of epsilony globin and represses its transcription. In wild-type (WT) mice, Sox6 is not expressed in yolk sac blood islands, but is expressed in fetal liver, the opposite expression pattern of epsilony globin. In the absence of Sox6, epsilony globin is ectopically expressed in the fetal liver, demonstrating that Sox6 functions in definitive erythropoiesis.","[{'offsets': [[0, 3]], 'text': ['Sry'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[18, 22]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[692, 696]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[854, 858]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[972, 976]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1083, 1087]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1089, 1093]], 'text': ['Sox9'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1098, 1101]], 'text': ['Sry'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1208, 1212]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1294, 1298]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1453, 1457]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1768, 1769]], 'text': ['p'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1783, 1787]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1888, 1889]], 'text': ['p'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1938, 1942]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2051, 2054]], 'text': ['Sry'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2243, 2247]], 'text': ['HMG1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2252, 2256]], 'text': ['HMG2'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2594, 2602]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2604, 2610]], 'text': ['betah1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2612, 2622]], 'text': ['beta-major'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2628, 2638]], 'text': ['beta-minor'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2969, 2977]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3173, 3181]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3186, 3201]], 'text': ['betah-1 globins'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3339, 3349]], 'text': ['beta major'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3354, 3359]], 'text': ['minor'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3371, 3379]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3481, 3495]], 'text': ['epsilon globin'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3557, 3564]], 'text': ['epsilon'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3650, 3657]], 'text': ['epsilon'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3711, 3723]], 'text': ['gamma-globin'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3733, 3744]], 'text': ['beta-globin'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[3858, 3872]], 'text': ['epsilon globin'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3893, 3900]], 'text': ['epsilon'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[4208, 4215]], 'text': ['epsilon'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[4287, 4293]], 'text': ['GATA-1'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[4295, 4299]], 'text': ['YY-1'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[4301, 4308]], 'text': ['COUP-TF'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[4314, 4318]], 'text': ['DRED'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[4432, 4439]], 'text': ['epsilon'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[4499, 4506]], 'text': ['epsilon'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[4751, 4755]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[4929, 4933]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[5235, 5250]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[5306, 5310]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[5318, 5333]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[5353, 5357]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[5392, 5407]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[5465, 5469]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[5582, 5597]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[5617, 5621]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[5623, 5638]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[5703, 5707]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T54'}]",[],[],[],[],[]
208,PMC-3586680-07-Authors_Contribution,"Ming-Fu Chiang and Chun-I Sze wrote the sections dealing with TMZ; Pei-Yi Chou wrote the review sections for p53 and WWOX and designed graphs; Wan-Jen Wang managed citations; Nan-Shan Chang conceived ideas, wrote and thoroughly revised the manuscript, and discussed with coauthors.","[{'offsets': [[109, 112]], 'text': ['p53'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[117, 121]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
209,PMC-3312845-13-Results,"Effect of sTNFp55R infusion on SE-induced serum-protein extravasation and neuronal damage
In our previous [5,7,8,20] and preliminary data, vasogenic edema and neuronal damage were noticeable at 1 day and 3 days after SE, respectively. Therefore, we determined that 3 days after SE was the best time point to evaluate the effect of sTNFp55R infusion on both vasogenic edema and neuronal damages induced by SE. In saline-treated animals, the PC was stained diffusely with anti-rat IgG (Figure 2A). The volume of vasogenic edema was 17.1 +/- 1.5 mm3 (Figure 2E). The number of FJB-positive neurons in the PC was 236,145 +/- 49,469 (Figure 2B). In sTNFp55R-treated animals, SE-induced vasogenic edema was attenuated to 9.8 +/- 0.7 mm3 (Figures 2C and 2E). In addition, the number of FJB-positive neurons in the PC was 89,138 +/- 5,698 (Figures 2D-E). Thus, sTNFp55R infusion attenuated SE-induced vasogenic edema and neuronal damage compared to saline-infused animals (p < 0.05).","[{'offsets': [[11, 18]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[332, 339]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[645, 652]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[854, 861]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
210,PMC-3317373-07-2._Methods_and_Materials,"2.6. Western Blot
To obtain total protein lysates, cells were homogenized in RIPA buffer (1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM EGTA, 1 mM Na3VO4, 20 mM NaF, 0.5 mM DTT, 1 mM PMSF, and protease inhibitor cocktail in PBS pH 7.4) and centrifuged at 12,000 g for 15 min at 4degreesC. Protein concentrations were estimated by Coomassie Plus Protein Assay Reagent (Pierce, IL, USA). Fifty micrograms of the resulting cytosolic protein extracts were heat-denatured in Laemmli sample loading buffer, separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis, and electroblotted onto a nitrocellulose membrane. For immunoblotting, membranes were blocked with 5% nonfat dry milk in saline buffer overnight at 4degreesC, and the following antibodies were used: anti-beta-actin (sc-130657, Santa Cruz Biotechnology, CA, USA, 43 kDa) and anti-matrix metallopeptidase 9 (MMP9) (sc-6841, Santa Cruz Biotechnology, CA, USA, 92 kDa). Each primary antibody was diluted appropriately in blocking buffer and then added to the blots for 1 h at room temperature. The blots were washed three times in the washing buffer and covered with the horseradish peroxidase-linked secondary antibody at a 1 : 2000 dilution for 1 h. Blots were incubated with enhanced chemiluminescence (ECL) detection system (Amersham Biosciences, Bucks, UK) and exposed to radiographic film (Fuji Hyperfilm, Tokyo, Japan). ImageJ was used to analyze the intensity of the blots. The level of beta-actin was used as internal standard.","[{'offsets': [[898, 902]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
211,PMC-2817507-07-2._Methods,"2.6. Electrophoretic Mobility Shift Assay (EMSA)
Nuclear proteins were isolated from brain tissue. Briefly, after removal of supernatant (cytoplasmic extract), the pellets were resuspended in nuclear extraction reagent. The tubes containing pellets were put on vortex for 15 seconds every 10 minutes, for a total of 40 minutes. The tubes were centrifuged at maximum speed (~16,000 x g) in a micro centrifuge for 10 minutes. The supernatants (nuclear extract) were transferred to a clean prechilled tube and stored at -80degreesC until use. EMSA was performed as described previously [8]. NFkappaB binding activity was examined in a 15 muL binding reaction mixture containing 15 mug of nuclear proteins and 35 fmol [gamma-32P] labeled double-stranded NFkappaB consensus oligonucleotide. A super shift assay using antibodies to P65 and P50 was performed to confirm NFkappaB binding specificity as previously described.","[{'offsets': [[826, 829]], 'text': ['P65'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[834, 837]], 'text': ['P50'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
212,PMC-1064895-14-Results,"Regulation of IL-17 production in RA PBMC by inflammatory cytokines and chemokines
Because RA PBMC include several cell types in addition to T cells, some inflammatory cytokines released from macrophages and other lymphocytes might have affected the production of IL-17 from T cells. To evaluate the effects of inflammatory cytokines released by activated PBMC, we tested the effects of several cytokines and chemokines on IL-17 production. We detected an increase in IL-17 level after stimulation with IL-15 (10 ng/ml), whereas with IL-1beta (10 ng/ml), TNF-alpha (10 ng/ml), IL-18 (10 ng/ml) or TGF-beta (10 ng/ml) the levels in IL-17 were unchanged (Fig. 2a). When treated with MCP-1 (10 ng/ml) or IL-6 (10 ng/ml), significant upregulations of IL-17 proteins were observed (62 +/- 42 and 50 +/- 10 versus 31 +/- 11 pg/ml, respectively; P < 0.05), whereas none was observed with IL-8 (10 ng/ml), MIP-1alpha (10 ng/ml) or MIP-1beta (10 ng/ml) (Fig. 2b).","[{'offsets': [[14, 19]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[264, 269]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[423, 428]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[468, 473]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[503, 508]], 'text': ['IL-15'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[534, 542]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[555, 564]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[577, 582]], 'text': ['IL-18'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[597, 605]], 'text': ['TGF-beta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[631, 636]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[681, 686]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[701, 705]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[747, 752]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[881, 885]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[898, 908]], 'text': ['MIP-1alpha'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[923, 932]], 'text': ['MIP-1beta'], 'type': 'Protein', 'id': 'T16'}]",[],[],[],[],[]
213,PMC-3585731-06-Results,"The Akt Signaling Pathway Contributes to the Regulation of Necroptosis
We next determined whether the necroptosis-associated increase in Thr308 phosphorylation results in an increase in Akt kinase activity. Under necroptotic conditions, we observed an increase in the phosphorylation of multiple known Akt substrates (Forkhead box class O (FoxO) proteins, GSK-3 kinases and mouse double minute 2 (MDM2)) as well as downstream molecules (p70 ribosomal protein S6 Kinase (p70S6K), S6) (Fig. 5A). In some cases (FoxO1, FoxO4, MDM2), a robust increase was observed. In other cases (FoxO3a, GSK-3alpha/beta, p70S6K and its substrate S6), the changes were less pronounced (Fig. 5A). The timing of the phosphorylation changes paralleled the increase in Akt phosphorylation (Fig. 5B, S5A, B). In the case of pFoxO1 we occasionally observed a shift in migration rather than an increase in band intensity (e.g. comparing Fig. 5A and B), suggesting that phosphorylation events in addition to Thr24 take place during necroptosis. Notably, in all cases the necroptosis-associated increases in Akt substrates were abrogated by Nec-1 (Fig. 5A, Fig. S5A, B). Overall, these data suggested that a significant part of the ""canonical"" Akt signaling network is activated at the onset of necroptotic cell death in a RIP1 dependent fashion.
Akt kinase is considered to be a pro-survival protein that inhibits apoptosis through the control of multiple effectors including mTORC1, GSK-3 and others [28]. An important question is whether these same molecules reverse their pro-survival roles during necroptosis. We found that inhibition of mTORC1 by rapamycin, an inhibitor of the mTOR co-factor Raptor [29], protected cells from necroptosis (Fig. 5C). Similarly, the direct mTOR kinase inhibitor Torin1 [30] and the dual PI3K/mTOR inhibitor PI-103 [31] also efficiently inhibited necroptosis (Fig. 5C). Knockdown of mTOR using siRNA further validated the small-molecule inhibitor data indicating a role for mTOR in necroptosis by protecting cells from both zVAD.fmk and TNFalpha induced death (Fig. 5D).
mTORC1 regulates translation through activation of p70S6 kinase and, subsequently, ribosomal protein S6 [32]. Notably, a genome-wide siRNA screen [10] suggested an important role for protein translation in necroptosis. Consistently, we found that the small molecule inhibitor of p70S6K PF-4708671 [33] attenuated necroptosis at the concentrations required to block S6 phosphorylation (Fig. S5C, D). Partial siRNA knockdown of S6 protein attenuated necroptosis as well (Fig. S5E), suggesting that translational control by p70S6K/S6 may play a role in necroptosis. Overall, while the full repertoire of Akt targets during necroptosis remains to be fully explored, our data provide evidence that the activity of an anti-apoptotic branch of Akt signaling can promote necroptosis.
RIP1 kinase, Akt, mTORC1 and JNK control the upregulation of TNFalpha accompanying necroptosis. Hitomi et al. [10] have recently reported that the induction of necroptosis by zVAD.fmk in L929 cells is associated with increased synthesis of TNFalpha, which potentiates cell death. Therefore, we examined whether Akt and its effectors contribute to TNFalpha synthesis. Consistent with a RIP1-dependent increase in TNFalpha protein (Fig. S6A, B), we found that TNFalpha mRNA levels increased during necroptosis in L929 cells in a RIP1 (Fig. S6C. Under serum free conditions, bFGF alone triggered some induction of TNFalpha mRNA, while its combination with zVAD.fmk (but not zVAD.fmk alone) caused a pronounced further increase (Fig. 6A). Conversely, PDGF caused a modest upregulation of TNFalpha mRNA, which was not further increased in the presence of zVAD.fmk (Fig. 6A), demonstrating that activation of necroptosis is specifically accompanied by a marked increase in autocrine TNFalpha synthesis.
Further analysis suggested that both Akt and mTORC1 contribute to the upregulation of TNFalpha mRNA during necroptosis as both small-molecule inhibition and siRNA knockdown of Akt and mTOR reduced TNFalpha mRNA levels in necroptotic cells (Fig. 6B,C,D). Notably, RIP1 and Akt inhibitors had no effect on the levels of TNFalpha mRNA in control cells or in the cells stimulated with bFGF alone (Fig. 6A,B, Fig. S6C), suggesting that these kinases specifically mediate necroptosis-dependent increase in TNFalpha synthesis.","[{'offsets': [[380, 395]], 'text': ['double minute 2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[397, 401]], 'text': ['MDM2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[437, 468]], 'text': ['p70 ribosomal protein S6 Kinase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[470, 476]], 'text': ['p70S6K'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[479, 481]], 'text': ['S6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[509, 514]], 'text': ['FoxO1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[516, 521]], 'text': ['FoxO4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[523, 527]], 'text': ['MDM2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[578, 584]], 'text': ['FoxO3a'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[586, 596]], 'text': ['GSK-3alpha'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[597, 601]], 'text': ['beta'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[603, 609]], 'text': ['p70S6K'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[628, 630]], 'text': ['S6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[800, 806]], 'text': ['pFoxO1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1295, 1299]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1671, 1677]], 'text': ['Raptor'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2046, 2054]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2131, 2143]], 'text': ['p70S6 kinase'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2181, 2183]], 'text': ['S6'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2359, 2365]], 'text': ['p70S6K'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2445, 2447]], 'text': ['S6'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2506, 2508]], 'text': ['S6'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2601, 2607]], 'text': ['p70S6K'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2608, 2610]], 'text': ['S6'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2856, 2860]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2917, 2925]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3096, 3104]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3203, 3211]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3241, 3245]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3268, 3276]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3314, 3322]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3383, 3387]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[3428, 3432]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[3467, 3475]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[3640, 3648]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3833, 3841]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3939, 3947]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[4050, 4058]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[4116, 4120]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[4171, 4179]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[4234, 4238]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[4353, 4361]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T42'}]",[],[],[],[],[]
214,PMC-3342329-16-Materials_and_Methods,"Protein Immuno-arrays
The tumor and spleen tissues were excised and homogenized in PBS with protease inhibitor cocktail (Sigma-Aldrich, USA) and Triton X-100 (final concentration 1%). The samples were frozen at -70degreesC, thawed, and centrifuged at 10,000xg for 5 min to remove cellular debris. The tissue lysates were performed protein assay in the same way as for western blotting. 4.5 mg of proteins, collected from three samples per group, were used for Mouse cytokine array as the protocol provided by supplier (Proteome Profiler(TM), #ARY006, R&D Systems, USA).",[],[],[],[],[],[]
215,PMC-3291650-07-Materials_and_Methods,"Mice
A20fl/fl mice were generated as previously described [56]. A20fl/fl mice were crossed with LysM-Cre mice [84] (provided by I. Forster, Institute of Genetics, University of Cologne, Germany) to generate A20fl/fl LysMCre transgenes and are described in detail elsewhere [48]. Mice were housed in individually ventilated cages at the VIB Department of Molecular Biomedical Research in specific pathogen-free animal facilities. Influenza infections were performed on age- (between 7 and 9 weeks old) and sex-matched littermates. A20fl/fl LysM-Cre animals were backcrossed three times to the C57Bl/6 background. A20fl/fl mice expressing or lacking the LysM-Cre transgene were termed A20myel-KO and wild type (A20myel-WT) respectively.",[],[],[],[],[],[]
216,PMC-1064873-04-Materials_and_methods,"Culture of CD4+ T cells
PB CD4+ T-cell populations were resuspended at a density of 1 x 106 cells/ml in culture medium with 10% FCS, and 0.5 ml cell suspensions were dispensed into the wells of 24-well microtiter plates (Coster) coated with 1 mug/ml anti-CD3 mAb (Immunotech, Marseille, France). The cells were incubated with 1 mug/ml anti-CD28 mAb (Immunotech) in the presence or absence of the indicated concentrations of IL-10 (Becton Dickinson, San Jose, CA, USA) at 37degreesC in a humidified atmosphere containing 5% CO2 [28]. Culture supernatants were collected 36 hours later and cell-free samples were stored at -30degreesC until cytokine assay.
To examine the effect of IL-6 on T-cell responsiveness to IL-10, CD4+ T cells from healthy controls were incubated in culture medium with 10% FCS in the presence or absence of 10 ng/ml IL-6 (Becton Dickinson) for 36 hours. Cells were then stimulated for 36 hours with anti-CD3 mAb and anti-CD28 mAb in the presence or absence of 1 ng/ml IL-10. Culture supernatants were measured for IFN-gamma concentrations.","[{'offsets': [[11, 14]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[27, 30]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[340, 344]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[424, 429]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[680, 684]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[713, 718]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[720, 723]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[840, 844]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[945, 949]], 'text': ['CD28'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[992, 997]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1038, 1047]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T11'}]",[],[],[],[],[]
217,PMC-3320587-19-Results,"NF-kappaB and NFAT5 binding play independent activating roles in MTb-mediated induction of HIV-1 replication
We next examined the functional impact of specifically disrupting NF-kappaB or NFAT5 binding on regulation of HIV-1 replication by infecting bulk PBMC from four normal donors with the wild-type or mutant HIV-1Lai/Bal-env molecular clones. After overnight infection, cells were co-infected with MTb (CDC1551) or mock-infected and free virus levels were detected by measuring p24 levels in culture supernatants at days 4, 7, and 12 post-HIV-1 infection.
Replication of each mutant virus was reduced in comparison to wild-type virus in mock- and MTb-co-infected cells at all timepoints examined (Figures 4A-4B). As depicted in the histograms displayed in Figure 4C, at day 12 post-HIV-1 infection in MTb-co-infected cells there was a significant reduction in levels of HIV-1Lai/Bal-env-kappaB I-Mut, HIV-1Lai/Bal-env-kappaB II-Mut, HIV-1Lai/Bal-env-kappaB I+II-Mut, and HIV-1Lai/Bal-env -N5-Mut in comparison to wild-type virus (Figure 4C). In the absence of MTb co-infection, p24 levels were also significantly lower in the PBMC cultures infected with HIV-1Lai/Bal-env-kappaB II-Mut, HIV-1Lai/Bal-env-kappaB I+II-Mut and HIV-1Lai/Bal-env-N5-Mut, but not HIV-1Lai/Bal-env-kappaB I-Mut, in comparison to wild-type virus (Figure 4C). None of the mutations completely abolished viral induction by MTb co-infection. However, the replication of each mutant virus was impaired to a more significant extent in the context of MTb co-infection, consistent with important roles for both NF-kappaB and NFAT5 in MTb-induced HIV-1 replication.
To specifically examine the functional impact of NF-kappaB and NFAT5 binding site usage in MDM, which are efficiently infected by both pathogens, we next isolated MDM from four normal donors and infected these cells with 1000 TCID50 of wild-type HIV-1Lai/Bal-env or with the mutant viral clones HIV-1Lai/Bal-env-kappaB I-Mut, HIV-1Lai/Bal-env-kappaB II-Mut, HIV-1Lai/Bal-env-kappaB I+II-Mut, or HIV-1Lai/Bal-env-N5-Mut. After overnight incubation, cell cultures were co-infected with MTb (CDC1551) or left infected with virus alone. Supernatants were collected at days 4, 7, and 12 post-HIV-1 infection and virus replication was measured. As shown in Figures 5A and 5C, in the absence of MTb co-infection, replication of mutant viral molecular clones (HIV-1Lai/Bal-env-kappaB I-Mut (p<0.05), HIV-1Lai/Bal-env-kappaB II-Mut (p<0.01), and HIV-1Lai/Bal-env-kappaB I+II-Mut (p<0.01) as well as HIV-1Lai/Bal-env-N5-Mut (p<0.01) were significantly reduced in comparison to the wild-type virus (Figures 5A-5C).
When the cultures were co-infected with MTb, p24 levels increased when the cells were infected with either the wild-type or, to lower levels, with the kappaB-I mutant virus (Figure 5B). However, p24 levels were significantly inhibited in cells infected with HIV-1Lai/Bal-env -N5-Mut (p<0.01) (Figure 5D). Moreover, p24 levels were significantly lower at day 12 in cultures infected with HIV-1Lai/Bal-env-kappaB II-Mut and HIV-1Lai/Bal-env-kappaB I+II-Mut as compared to infection of cells with wild-type virus (Figure 5D). Notably, although replication of the mutant virus with the single, proximal NF-kappaB binding site mutation in the shared NFAT5/NF-kappaB element (HIV-1Lai/Bal-env-kappaB I-Mut) was diminished, this was not significant at day 12 (Figures 5B-5D).
We note that overall p24 levels were noticeably lower in the cultures co-infected with MTb compared with those infected with HIV-1 alone. This is consistent with previous observations showing that MTb infection of human primary macrophage cultures ex vivo suppresses HIV-1 infection due to chemokine synthesis and the enhanced expression of cellular inhibitory factors [48]-[50]. Given that NF-kappaB is efficiently activated in primary MDM in response to TLR agonists [51] and as we have shown in Figure 2, NFAT5 gene expression is also induced by TLR agonists, MDM are a suitable experimental system to analyze the effect of NF-kappaB versus NFAT5 binding site mutations on virus replication in isolated MDM in the absence or presence of MTb co-infection. Taken together, the results from PBMC and MDM co-infection experiments demonstrate that the conserved NFAT5 binding site plays as important a transcriptional role in LTR regulation by MTb as do the NF-kappaB sites.","[{'offsets': [[14, 19]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[188, 193]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[326, 329]], 'text': ['env'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[483, 486]], 'text': ['p24'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[888, 891]], 'text': ['env'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[919, 922]], 'text': ['env'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[951, 954]], 'text': ['env'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[989, 992]], 'text': ['env'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1083, 1086]], 'text': ['p24'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1172, 1175]], 'text': ['env'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1204, 1207]], 'text': ['env'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1241, 1244]], 'text': ['env'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1274, 1277]], 'text': ['env'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1597, 1602]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1896, 1899]], 'text': ['env'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1945, 1948]], 'text': ['env'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1976, 1979]], 'text': ['env'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2008, 2011]], 'text': ['env'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2045, 2048]], 'text': ['env'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2402, 2405]], 'text': ['env'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2442, 2445]], 'text': ['env'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2487, 2490]], 'text': ['env'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2540, 2543]], 'text': ['env'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2686, 2689]], 'text': ['p24'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[2836, 2839]], 'text': ['p24'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2912, 2915]], 'text': ['env'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2956, 2959]], 'text': ['p24'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3041, 3044]], 'text': ['env'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3076, 3079]], 'text': ['env'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3324, 3327]], 'text': ['env'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3431, 3434]], 'text': ['p24'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3918, 3923]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T32'}]",[],[],[],[],[]
218,PMC-3586680-02-WW_Domain-Containing_Oxidoreductase_WWOX,"Recently, tumor suppressors p53 and WWOX were shown to regulate the apoptosis of glioblastoma cells (Chiang et al., 2012). WW domain-containing oxidoreductase, known as WWOX, FOR, or WOX1, is encoded by human or mouse WWOX/Wwox gene. This gene is located in chromosome 16q23.3-24.1, an area known as the common fragile site FRA16D. The full-length WWOX protein is composed of two N-terminal WW domains, a C-terminal short-chain alcohol dehydrogenase/reductase (SDR) domain, and a proapoptotic C-terminal tail D3 (Chang et al., 2001, 2007, 2010; Aqeilan et al., 2004, 2007; Hong et al., 2007; Salah et al., 2012) (Figure 1). WWOX may act as an alternative receptor for sex steroid hormones, since its SDR domain possesses an NSYK motif capable of interacting with androgen and estrogen (Chang et al., 2005a; Su et al., 2012).
Expression of WWOX is either altered or lost from epigenetic modification in multiple malignant cancers, such as non-small cell lung carcinoma (Donati et al., 2007), hematopoietic malignancies (Ishii and Furukawa, 2004), gastric carcinoma (Aqeilan et al., 2004), pancreatic carcinoma (Kuroki et al., 2004), breast carcinoma (Guler et al., 2004; Aqeilan et al., 2007), and glioblastoma multiforme (Kosla et al., 2011). Restoration of WWOX gene prevents the growth of lung cancer (Fabbri et al., 2005), pancreatic cancer (Nakayama et al., 2008), and prostate cancer (Hong et al., 2009).
The first WW domain of WWOX may interact with proteins possessing a PPxY motif(s) such as AP-2gamma, p73, ErbB4, Ezrin, SIMPLE, c-Jun, RUNX4, and many others (Chang et al., 2007; Salah et al., 2012; Su et al., 2012; Figure 1). Transiently overexpressed WWOX binds transcription factors AP-2, p73, and c-Jun and block their nuclear relocation in vitro, which suppresses cancer cell survival (Salah et al., 2012). In stark contrast, Wwox co-migrates with proapoptotic and pro-survival transcription factors to the nuclei of neurons upon sciatic nerve axotomy in rats (Li et al., 2009). No blocking of translocation of transcription factors to the nuclei by Wwox was observed.
Under stress conditions, WWOX is activated via phosphorylation at Tyr33, and binds proteins independently of the PPxY motif (Chang et al., 2001, 2003, 2005a,b, 2007, 2010). Activated WWOX physically interacts with serine 46-phosphorylated p53 (Figure 1), which stabilizes p53 and its apoptotic function (Chang et al., 2005b). Also, WWOX binds Disheveled proteins (Dvl), which are key components in Wnt/beta-catenin signaling pathway (Figure 1). No PPxY motif is in Dvl. Transiently overexpressed WWOX sequesters Dvl-2 in the cytoplasm and thereby blocks Dvl-2-mediated TCF transcriptional activity (Bouteille et al., 2009).
Overexpressed WWOX induces apoptosis and inhibits proliferation of human hepatic carcinoma cells (Hu et al., 2012) and many cancer cell types (Chang et al., 2007, 2010; Salah et al., 2012; Su et al., 2012). WWOX enhances the cytotoxic function of tumor necrosis factor by down-regulating apoptosis inhibitor Bcl-2 and Bcl-xL and up-regulating apoptotic p53 (Chang et al., 2001). Also, WWOX mediates cell death synergistically with p53. Upon exposure to chemicals or environmental stress, such as UV irradiation and chemotherapeutic drugs, WWOX undergoes phosphorylation in Tyr33 and probably others sites, followed by relocating to mitochondria or nuclei for inducing apoptosis (Chang et al., 2007, 2010).
WWOX binds MEK in Jurkat T cells (Lin et al., 2011). Phorbol myristate acetate (PMA) dissociates the MEK/WWOX complex and induces WWOX to translocate to the mitochondria to induce apoptosis, whereas MEK relocates to the lipid raft. Inhibition of MEK activity increases TMZ-induced suppression of cancer cell growth (Holt et al., 2012). Ectopic expression of WWOX in A549 cells induces procaspase-3 and procaspase-9 activation and induces cytochrome C releasing from the mitochondria (Zhang et al., 2012a). Complement C1q induces ectopic WWOX phosphorylation in Try33 and leads to cell apoptosis independently of the classical complement activation pathway (Hong et al., 2009). A portion of WWOX is anchored in the membrane/cytoskeleton area via binding with hyaluronidase Hyal-2 (Hsu et al., 2009) and Phospho-Ezrin (Jin et al., 2006). Transforming growth factor beta1 binds Hyal-2 as a cognate receptor to signal the formation of the WWOX/Hyal-2/Smad4 complex to relocate to the nucleus for enhancing the SMAD-driven promoter activity (Hsu et al., 2009).","[{'offsets': [[28, 31]], 'text': ['p53'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[36, 40]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[123, 158]], 'text': ['WW domain-containing oxidoreductase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[169, 173]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[175, 178]], 'text': ['FOR'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[183, 187]], 'text': ['WOX1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[218, 222]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[223, 227]], 'text': ['Wwox'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[348, 352]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[624, 628]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[839, 843]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1258, 1262]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1433, 1437]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1500, 1509]], 'text': ['AP-2gamma'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1511, 1514]], 'text': ['p73'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1516, 1521]], 'text': ['ErbB4'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1523, 1528]], 'text': ['Ezrin'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1530, 1536]], 'text': ['SIMPLE'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1538, 1543]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1545, 1550]], 'text': ['RUNX4'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1663, 1667]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1696, 1700]], 'text': ['AP-2'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1702, 1705]], 'text': ['p73'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1711, 1716]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1841, 1845]], 'text': ['Wwox'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[2065, 2069]], 'text': ['Wwox'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2109, 2113]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2267, 2271]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2323, 2326]], 'text': ['p53'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2356, 2359]], 'text': ['p53'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2416, 2420]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2486, 2498]], 'text': ['beta-catenin'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2580, 2584]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2596, 2601]], 'text': ['Dvl-2'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2638, 2643]], 'text': ['Dvl-2'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2722, 2726]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2915, 2919]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2955, 2976]], 'text': ['tumor necrosis factor'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3016, 3021]], 'text': ['Bcl-2'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3026, 3032]], 'text': ['Bcl-xL'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3061, 3064]], 'text': ['p53'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3093, 3097]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3139, 3142]], 'text': ['p53'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3247, 3251]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3414, 3418]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3544, 3548]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3772, 3776]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3799, 3811]], 'text': ['procaspase-3'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3816, 3828]], 'text': ['procaspase-9'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3951, 3955]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4104, 4108]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4186, 4192]], 'text': ['Hyal-2'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4224, 4229]], 'text': ['Ezrin'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4250, 4282]], 'text': ['Transforming growth factor beta1'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4289, 4295]], 'text': ['Hyal-2'], 'type': 'Protein', 'id': 'T55'}]",[],[],[],[],[]
219,PMC-1472690-16-Methods,"Inhibition of transcription factors
To inhibit translocation and binding of transcription factors to the IL-1RA promoter, PBMC were incubated for 1 h with each of the following substances (concentrations were based upon 50% inhibition): 50 mug/ml of CAPE (caffeic-3,4-dihydroxycinnamic-acid-phenyl-ester), (Biomol, Hamburg, Germany); 400 ng/ml cyclosporin A (Calbiochem-Merck Biosciences, Bad Soden, Germany); 10 mug/ml cycloheximide (Santa Cruz Biotechnology) prior to incubation with GP. Band shifts were determined after 1 h incubation with GP as described before, including mutated oligos for NFIL-6 (TTA CAA CAG TGG ATT GCG ACA CTT AGT GGG) and NFATP2/3 (GGC GCA GAA AAG GTA AAA TAT TTA CTA TCT) binding sites within the IL-1RA promoter. PBMC RNA was isolated with an RNeasy kit (Qiagen, Germany) and messenger RNA was transcribed into cDNA with Reactin Ready First Strand kit (Biomol) and analysed for IL-1RA and GAPDH transcripts by PCR with a HotStart ""sweet"" PCR mastermix (Biomol) (95degreesC, 30 sec, 55degreesC, 30 sec, 72degreesC, 30 sec, 25 cycles for IL-1RA and 94degreesC for 30 sec, 50degreesC for 30 sec and 72degreesC for 45 sec, 25 cycles for GAPDH) following 18 h incubation with GP. IL-1RA protein was measured in the supernatant by ELISA after 24 h incubation with GP.","[{'offsets': [[105, 111]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[597, 603]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[650, 656]], 'text': ['NFATP2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[657, 658]], 'text': ['3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[726, 732]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[908, 914]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[919, 924]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1205, 1211]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
220,PMC-3320587-05-Materials_and_Methods,"LTR plasmid construction and reporter assay
LTR reporter plasmids were constructed by inserting nucleotides -208 to +64 relative to the transcriptional initiation site of HIV-1Lai, HIV-1Bal (B subtype), HIV-198IN17, HIV-198IN22, HIV-198CH01, HIV-1CM9 (C subtype), HIV-193TH64, HIV-192TH53, HIV-192TH51, and HIV-1KR25 (E subtype) into the reporter vector pGL3 (Promega BioSciences, www.promega.com) using Xho I and Hind III restriction enzyme sites. Sequences were aligned and analyzed with CLUSTAL W (www.ebi.ac.uk/clustalw/). The HIV-1Lai NFAT5 binding site-mutant (N5-Mut) reporter plasmid was created by standard PCR-based mutagenesis methods [34]. THP-1 cells (0.8x106/ml) were transfected with 0.3 microg/ml LTR wild-type (WT) or mutated reporter plasmids in combination with 0.03 microg/ml Renilla luciferase (pRL-TK) control vector using Effectene transfection reagent (Qiagen; www.qiagen.com). Cells were incubated at 37degreesC for 16 hours after which they were stimulated with 10 microg/ml MTb CDC1551 lysate or left unstimulated for 8 hours. Reporter gene expression was quantitated by dual-luciferase reporter assay according to the manufacturer's protocol (Promega; www.promega.com).","[{'offsets': [[804, 814]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1054, 1067]], 'text': ['Reporter gene'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1103, 1113]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
221,PMC-1472690-07-Discussion,"Animal models of sepsis and myocardial injury suggest that a beta-1 to 3-D-glucan like GP mediates its protective mechanisms, in part, via a rapid shift from NFkappaB- to PI3K-signaling [22,37]. Our study provides novel evidence that downstream of recognition and signaling pro-inflammatory transcription factor binding and cytokine expression of human leukocytes is switched to an anti-inflammatory phenotype by GP.
We confirmed and extended previous results [13-16] indicating that, in the absence of other stimuli, beta-1 to 3-D-glucans induced binding of NFkappaB-, NFIL-6- and NFAT-mers to cytokine promoters. Because of the multiple band shifts observed for NFAT binding (Fig. 1A), one could speculate that there is activation of several different NFAT isoforms, probably derived from alternative splicing [38]. Interestingly, the GP-induced transcription factor binding transformed only into a very limited cytokine response, namely IL-8 and IL-1RA (Fig. 3B). Hence, our data are in aggreement with the few reports describing a beta-1 to 3-D-glucan-mediated IL-8 [6,16,19] and IL-1RA production [17]. In addition, our EMSA/supershift and immunoblotting results demonstrated a GP-mediated predominant binding of NFkappaB p65 and to a lesser extent of p50 to a kappaB consensus site of the IL-8 promoter (Figs. 1A, 2). Results by Schulte and colleagues [28] pointed to an induction of IL-8 transcription depending on activation via an NFkappaB p65/65 homodimer, rather than via p65/50 heterodimers, which might be the case for the GP-mediated IL-8 transcription. A GP-mediated IL-8 transcription based upon a cooperation between transactivated NFkappaB p65 and NFIL-6 [13,39] or NFATc2 dimer binding to the IL-8kappaB site [38] seems also possible. The IL-8kappaB consensus site exhibits a preferentially p65 binding half site and thus differs from the kappaB half site described for TNFalpha and IL-1beta [27,40], supporting the idea of regulating NFkappaB binding through combinatorial associations of the subunits and the specific sequence of the decameric kappaB motif [41,42]. Unlike LPS or TSST-1, we found that GP did not induce IL-1beta, but it strongly induced IL-1RA, suggesting an immediate anti-inflammatory potential of GP. Analysing the IL-1RA promoter [34], we discovered four new binding sites (Fig. 8): an NFkappaB3 site (between -100 and -130), an NFkappaB consensus site (-266 and -280), another NFkappaB2/3 site (-288 and -302) and a more distal NFATP2/3 site (-471 and -490). Our data indicated that GP leads to production of IL-1RA primarily via induction of NFATP2/3 and NFIL-6 DNA binding, which might be due to differences in the binding motif or the composition of the activated transcription factors (NFAT) between the IFNgamma, IL-6 and IL-1RA promoter. The differential decrease of NFkappaB, NFAT and NFIL-6 binding to sites in the IL-1RA promoter as well as of IL-1RA mRNA and protein induced by selective inhibitors prior to GP treatment might suggest that these steps are linked to each other and necessary for induction of IL-1RA (Fig. 7). Regarding cellular sources, both, monocytes as well as neutrophils have been reported to produce IL-1RA [32]. Flow cytometric experiments seemed to confirm that monocytes and neutrophils were able to produce IL-8 just as IL-1RA in response to GP (data not shown). This GP-induced cytokine profile was substantially more restricted than that of LPS or TSST-1, which is likely due to differences in recognition and signaling between LPS, TSST-1 and GP. Recognition of LPS is mainly mediated through Toll-like receptor 4 and subsequent signaling via the NFkappaB pathway, leading to expression of pro-inflammatory mediators like TNFalpha [43]. A bacterial superantigen like TSST-1 acts through binding to MHC-II molecules and subsequently the T cell receptor, leading to release of mainly IFNgamma and TNFalpha, the latter via both, PI3K and p38 mitogen-activated kinase signaling [44,45]. Altogether, the induction of the neutrophil-attracting IL-8 and the anti-inflammatory IL-1RA by fungal carbohydrates (GP) may well fit to a benign PAMP response, mounting defensive mechanisms against a possible microbial attack.
Potentially even more relevant than the specific cytokine panel induced by GP, we found that, in the presence of other stimuli (LPS or TSST-1), GP ameliorated their pro-inflammatory immune reactions, similar to the effects in murine models of sepsis and inflammation [21-24]. Mainly, GP altered the TSST-1-induced IL-1beta/IL-1RA ratio from a pro- to an anti-inflammatory profile via down-regulation of IL-1beta and IL-6, at the same time there was a synergistic up-regulation of IL-1RA. In part, this change may be caused by GP-mediated modulations of the TSST-1 induced binding of NFkappaB, NFIL-6 and NFAT to known and up to now unknown sites within the IL-8 and IL-1RA promoter instead of the TNFalpha, IL-1beta, IL-6 or IFNgamma promoter. Accordingly, we found that the TSST-1-induced binding of NFkappaB to sites from the TNFalpha promoter negatively correlated with the GP-mediated enhancement of the TSST-1-induced IL-1RA production (r = -0.88; p < 0.01; data not shown in detail). Of the four examined NFkappaB sites from the IL-1RA promoter, mostly the TSST-1- and LPS-induced binding to the NFkappaB3 and the TSST-1-induced binding to the new NFkappaB consensus site seemed to be increased by GP. So, while we observed a GP-mediated down-regulation of the LPS- and the TSST-1-induced NFkappaB binding to sites of the TNFalpha promoter, there was an up-regulation to NFkappaB3 and NFkappaB consensus sites of the IL-1RA promoter. These seemingly contradictory data could be explained by differences in either NFkappaB subunits or conserved nucleotides (#1, 2, 3, 10) within the decameric NFkappaB binding motif between the TNFalpha and the IL-1RA promoter (for NFkappaB3 the IL-1RA motif contains a T on position 10 instead of the conserved C in the TNFalpha motif, see Table 1), probably leading to differences in binding [41,42]. Despite the location of the new NFkappaB consensus site (-266 and -280) in the inhibitory element (-250 and -294) of the IL-1RA promoter [30], we observed no inhibition. On the other side, we found an inhibitory NFkappaB2/3 site (-288 and -302) towards the end of the inhibitory element, demonstrating down-regulations of the LPS- and TSST-1-induced binding, which could not be altered by GP. In our opinion, this site may therefore represent at least a part of the previoulsy described inhibitory element [30]. The GP-modulated increase in TSST-1-induced binding to the new NFkappaB3 and NFkappaB consensus site, the NFIL-6 site [32] as well as to the novel NFATP2/3 site may explain the synergistic up-regulation of the TSST-1-induced IL-1RA production. We think that this GP-modulated activation of transcription was reflected by the decrease of the IL-1beta/IL-1RA ratio following GP + TSST-1 (Fig. 6). In this context, it has been postulated that in vitro a 100fold excess of IL-1RA over IL-1beta might control the biological effects of IL-1 [46,47]. Since, in fact, the IL-1beta/IL-1RA ratio following GP + TSST-1 is partially less than 0.01, it is not unreasonable to assume that IL-1beta bioactivity is inactivated in our system. Indeed, GP reduced the TSST-1-induced, IL-1-dependent IL-2 production of murine EL-4 cells (data not shown in detail).
The weaker modulating effects of GP on the LPS-induced immune response observed in this study, may be attributed to delicately balanced differences in signaling pathways between LPS and TSST-1 [43-45]. TSST-1 has been shown to use the PI3K pathway for signaling [44] and this effect may be sustained by GP treatment [22,37]. It has been demonstrated that in septic/LPS-adapted leukocytes the PI3K pathway selectively controls sIL-1RA but not IL-1beta production [48]. Signaling via PI3K has been reported to be involved in the activation of NFAT in T cells [49]. Activation of NFkappaB can also take place via PI3K [50], which may offer an explanation for a difference in signaling between GP (PI3K) and LPS (mitogen-activated kinase signaling). This idea may be supported by another study showing that despite the use of similar PRR, LPS and peptidoglycan activated the IL-1RA gene through different mechanisms/DNA-binding proteins and acted synergistically in combination, suggestive of signals which are not equivalent in all parts [51].","[{'offsets': [[570, 576]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[582, 586]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[664, 668]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[754, 758]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[940, 944]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[949, 955]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1065, 1069]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1084, 1090]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1227, 1230]], 'text': ['p65'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1257, 1260]], 'text': ['p50'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1295, 1299]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1390, 1394]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1449, 1452]], 'text': ['p65'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1453, 1455]], 'text': ['65'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1483, 1486]], 'text': ['p65'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1487, 1489]], 'text': ['50'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1548, 1552]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1582, 1586]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1658, 1661]], 'text': ['p65'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1666, 1672]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1684, 1690]], 'text': ['NFATc2'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1712, 1716]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1758, 1762]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1810, 1813]], 'text': ['p65'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1889, 1897]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1902, 1910]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[2101, 2107]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[2141, 2149]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[2175, 2181]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[2256, 2262]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2586, 2592]], 'text': ['NFATP2'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2593, 2594]], 'text': ['3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2599, 2605]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2733, 2737]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2751, 2759]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2761, 2765]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2770, 2776]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2826, 2830]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2835, 2841]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2866, 2872]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2896, 2902]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3061, 3067]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3175, 3181]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3286, 3290]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[3299, 3305]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[3429, 3435]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[3514, 3520]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[3575, 3595]], 'text': ['Toll-like receptor 4'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3704, 3712]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3749, 3755]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[3864, 3872]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[3877, 3885]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[3917, 3945]], 'text': ['p38 mitogen-activated kinase'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[4020, 4024]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[4051, 4057]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[4329, 4335]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[4493, 4499]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[4508, 4516]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[4517, 4523]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[4597, 4605]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[4610, 4614]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[4674, 4680]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[4751, 4757]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[4787, 4793]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[4798, 4802]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[4851, 4855]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[4860, 4866]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[4891, 4899]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[4901, 4909]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[4911, 4915]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[4919, 4927]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[4969, 4975]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[5022, 5030]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[5102, 5108]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[5117, 5123]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T75'}, {'offsets': [[5229, 5235]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T76'}, {'offsets': [[5257, 5263]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T77'}, {'offsets': [[5314, 5320]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T78'}, {'offsets': [[5474, 5480]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T79'}, {'offsets': [[5522, 5530]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T80'}, {'offsets': [[5617, 5623]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T81'}, {'offsets': [[5827, 5835]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T82'}, {'offsets': [[5844, 5850]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T83'}, {'offsets': [[6157, 6163]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T84'}, {'offsets': [[6371, 6377]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T85'}, {'offsets': [[6577, 6583]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T86'}, {'offsets': [[6758, 6764]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T87'}, {'offsets': [[6773, 6779]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T88'}, {'offsets': [[6889, 6897]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T89'}, {'offsets': [[6898, 6904]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T90'}, {'offsets': [[6926, 6932]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T91'}, {'offsets': [[7017, 7023]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T92'}, {'offsets': [[7029, 7037]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T93'}, {'offsets': [[7078, 7082]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T94'}, {'offsets': [[7112, 7120]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T95'}, {'offsets': [[7121, 7127]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T96'}, {'offsets': [[7149, 7155]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T97'}, {'offsets': [[7223, 7231]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T98'}, {'offsets': [[7297, 7303]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T99'}, {'offsets': [[7313, 7317]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T100'}, {'offsets': [[7328, 7332]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T101'}, {'offsets': [[7579, 7585]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T102'}, {'offsets': [[7595, 7601]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T103'}, {'offsets': [[7820, 7826]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T104'}, {'offsets': [[7835, 7843]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T105'}, {'offsets': [[7934, 7938]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T106'}, {'offsets': [[8264, 8270]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T107'}]",[],[],[],[],[]
222,PMC-3320587-28-Caption-Figure_6,"Disruption of the NFAT5 site in HIV-1 subtype C significantly impairs MTb-induced viral replication.
(A) Mutation of the NFAT5 binding site in an HIV-1 subtype C infectious molecular clone. NFAT5 binding site mutations were introduced into the LTR of subtype C HIV-198IN22-WT. The NFAT5 binding site mutant (HIV-198IN22 N5-Mut) LTR sequence is shown alongside that of HIV-198IN22-WT. The HIV-198IN22 isolate analyzed here contains three NF-kappaB and two NFAT5 binding sites. The unique 3' terminal adenine, which is important for NFAT5 binding to its site, is shown in blocks. Mutations were introduced into the 3' LTR of the HIV-198IN22-WT proviral sequence. PBMC from four normal donors were infected with 1000 TCID50 of HIV-198IN22-WT or HIV-198IN22-N5-Mut. Cells were then (B) left infected with virus alone or (C) co-infected with MTb strain CDC1551 (10:1 cells:bacilli). Culture supernatants were collected at days 3, 7 and 11 post-infection and viral p24 levels were measured. Replication of HIV-198IN22-N5-Mut was significantly reduced at day 11 post-infection in comparison to HIV-198IN22-WT (*, p<0.05) in the presence of MTb co-infection.","[{'offsets': [[531, 536]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[959, 962]], 'text': ['p24'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
223,PMC-3291650-16-Materials_and_Methods,"Statistics
Results are expressed as the mean +/- SEM. Statistical significance between groups was assessed using two-way ANOVA. The differences for in vivo experiments (at least 5 mice per group) were calculated using the Mann-Whitney U-test for unpaired data. Statistical significance of differences between survival rates was analyzed by comparing Kaplan-Meier curves using the log-rank test (GraphPad Prism version 5, GraphPad, San Diego, CA).",[],[],[],[],[],[]
224,PMC-3589482-08-Experimental_Procedures,"Lentiviral shRNAs, Packaging and Transduction
pLKO.1-puro lentiviral vectors carrying short hairpin RNAs (shRNA) specific for human and mouse cebpb were used in these studies. Because the human and mouse cebpb 3' untranslated regions are not identical, these species-specific shRNAs cannot knockdown expression of endogenous C/EBP-beta when used on cells of the other species; therefore we used the human CEBPB shRNA as a control in these experiments as in [38]. To produce lentiviral particles, HEK-293T cells were transfected with a mixture of plasmids: each shRNA expression plasmid (1 microg), pCMV-deltaR8.2dvpr packaging plasmid (0.75 microg), and pCMV-VSV-G envelope plasmid (0.25 microg) using Lipofectamine 2000 reagent (Invitrogen). The lentiviral supernatant was collected 48 hrs after transfection, cleared by centrifugation at 2,000 g for 10 mins and passed through a 0.45 microm filter. The target cells were treated with the lentiviral supernatant and 8 microg/ml Polybrene (American Bioanalytical) for 24 hrs. The lentiviral supernatant was replaced with fresh growth media and incubated further for 72 hrs to allow for effective gene knockdown. C/EBP-beta knockdown was confirmed by western blot analysis.","[{'offsets': [[142, 147]], 'text': ['cebpb'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[204, 209]], 'text': ['cebpb'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[325, 335]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1162, 1172]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
225,PMC-1359074-13-Materials_and_Methods,"Northern blot.
A mouse embryonic tissue Northern blot filter (Seegene, Rockville, Maryland, United States) was hybridized with a Sox6 probe generated by RT-PCR (nucleotides 1353-1927) and labeled with [alpha-32P]dCTP, by random primer labeling (RediprimeII; Amersham Biosciences, Buckinghamshire, England, United Kingdom). The hybridization was performed in phosphate buffered 7% SDS hybridization solution. Blots were washed with 0.2x SSC, 1% SDS at 60 degreesC prior to exposure to X-ray film (Kodak, Rochester, New York, United States) at -80 degreesC for 6 d.","[{'offsets': [[129, 133]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
226,PMC-3585731-32-Caption-Figure_7,"Over expression of constitutively active Akt restores necroptosis under serum free conditions.
(A,B) L929 cells were stably infected with empty MSCV retrovirus or viruses encoding Myr-Akt or the catalytically inactive Myr-Akt K179M. Necroptosis was induced by the addition of zVAD.fmk under serum free conditions (A) or serum or serum free conditions with Nec-1 (B). Viability assays were performed after 24 hr. (C) Myr-Akt and Myr-Akt K179M cells were treated with zVAD.fmk and/or Nec-1 under serum free conditions for 9 hr, followed by western blot using the indicated antibodies. Endogenous Akt (~) and Myr-Akt (*) bands are indicated. (D) L929 cells, stably infected with Myr-Akt and Myr-Akt K179KM, were stimulated with zVAD.fmk for 9 hr under serum free conditions. TNFalpha mRNA levels were determined by qRT-PCR and normalized using mouse 18S RNA. (E-G) L929 cells expressing Myr-Akt and Ala and Asp mutants of Thr308 and Ser473 were treated with zVAD.fmk under serum free conditions, followed by viability assay at 24 hr (E), western blot at 9 hr (F), or evaluation of TNFalpha mRNA levels by qRT-PCR at 9 hrs (G). In all graphs, average+/-SD was plotted.","[{'offsets': [[772, 780]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[847, 850]], 'text': ['18S'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1078, 1086]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
227,PMC-3218875-04-Negative_regulation_of_NF-+%A6B_signalling_in_RA,"Since NF-kappaB activation is so crucial to many cellular processes, a tight regulation of the NF-kappaB signalling pathway and the genes it induces is an absolute requirement to fine-tune the inflammatory response. Moreover, terminating an NF-kappaB response is essential to prevent persistent NF-kappaB activation that may lead to chronic inflammation and/or tumorigenesis. To achieve this, cells employ different mechanisms, including the expression of inhibitory proteins that downregulate NF-kappaB signalling [32]. Below we give an overview of a number of proteins that are involved in the dampening or termination of the NF-kappaB response, some of them under the control of NF-kappaB itself and thus acting in a negative feedback loop. In addition, we discuss the potential role of these NF-kappaB inhibitory factors in the immunopathology of RA. Several other proteins involved in the negative regulation of NF-kappaB-dependent inflammatory responses, such as MyD88s, IRAK-M, and TOLLIP, have been described (reviewed in [33]). These proteins are not discussed here, since a link with RA pathology has not yet been reported.Although IKK1 is a critical component of the non-canonical NF-kappaB pathway, it should be mentioned that this kinase also plays a prominent role in the negative regulation of both canonical and noncanonical NF-kappaB pathways. Macrophages from IKK1-deficient mice or knockin mice expressing inactive IKK1 show increased production of proinflammatory cytokines as a result of enhanced IKK2 activation and IkappaBalpha degradation [34]. IKK1 has also been shown to inhibit nuclear NF-kappaB and to downregulate proinflammatory signalling by phosphorylating STAT1 [35]. Interestingly, a recent study has demonstrated that IKK1 phosphorylates NIK in negative feedback regulation of the noncanonical NF-kappaB pathway [36], supporting the idea that IKK1 plays important roles in terminating both canonical and noncanonical NF-kappaB pathways with possible implications for chronic inflammatory diseases like RA.","[{'offsets': [[969, 975]], 'text': ['MyD88s'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[977, 983]], 'text': ['IRAK-M'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[989, 995]], 'text': ['TOLLIP'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1142, 1146]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1378, 1382]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1434, 1438]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1518, 1522]], 'text': ['IKK2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1538, 1550]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1569, 1573]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1689, 1694]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1753, 1757]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1773, 1776]], 'text': ['NIK'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1878, 1882]], 'text': ['IKK1'], 'type': 'Protein', 'id': 'T13'}]",[],[],[],[],[]
228,PMC-1472690-01-Background,"beta-1 to 3-D-glucans occur as a principal component of microbial cell walls or can be secreted from both, non-pathogenic and pathogenic fungi such as S. cerevisae and C. albicans [1]. These beta-1 to 3-D-linked glucose polymers are characterized as a fungal pathogen-associated molecular pattern (PAMP) [2]. The primary cellular recognition of beta-1 to 3-D-glucans is mediated by several beta-1 to 3-D-glucan receptors on phagocytes [3,4] and other cells [5,6]. Human as well as murine Dectin-1 has been demonstrated to be the major pattern recognition receptor (PRR) for intact yeast and beta-1 to 3-D-glucan-containing particles (i.e. zymosan) on monocytes/macrophages as well as neutrophils and on primary cells [7-11]. In the murine system, binding of zymosan to Dectin-1 resulted in production of TNFalpha through Toll-like receptor 2 and the adaptor protein MyD88 [12]. Another water-soluble beta-1 to 3-D-glucan (PGG-glucan) has been described to activate NFkappaB and NFIL-6 in murine cell lines [13,14]. Similarly, it has been shown that beta-1 to 3-D-glucans activate NFkappaB in a human monocyte-like cell line [15] and in human polymorphonuclear neutrophils (PMN), in the latter case without secretion of pro-inflammatory cytokines (IL-1, IL-6, TNFalpha) [16]. One study proposed that the production of the anti-inflammatory IL-1RA, but not IL-1 by human monocytes may be a potentially protective mechanism induced by beta-1 to 3-D-glucan [17]. Three other investigations have reported that human leukocytes and human vascular endothelial cells produce IL-8 in response to zymosan [18] or a water-soluble beta-1 to 3-D-glucan [6,19].
In addition, beta-1 to 3-D-glucans seem to be able to modify the response to pro-inflammatory stimuli or even sepsis. In a murine polymicrobial sepsis model, beta-1 to 3-D-glucan [20] treatment resulted in decreased septic morbidity and mortality mediated via inhibition of NFkappaB and stimulation of the phosphoinositide-3-kinase (PI3K) pathway [21,22]. These and other animal studies [23,24] as well as a clinical trial [25] support a protective role of beta-1 to 3-D-glucan in certain pro-inflammatory conditions. The mechanisms underlying these beneficial effects of beta-1 to 3-D-glucan are only partially resolved, especially in humans. Thus, the aim of this study was to elucidate molecular and cellular mechanisms of beta-1 to 3-D-glucans on human leukocytes in pro-inflammatory conditions with special emphasis on the cytokine profile and its transcriptional regulation. For this purpose, peripheral blood mononuclear cells (PBMC) were exposed to a well-defined beta-1 to 3-D-glucan, i.e. glucan phosphate (GP) [20,26], alone or simultaneously with LPS from gram-negative bacteria or the superantigen TSST-1 from gram-positive bacteria over 48 h. Because of the potential effect of beta-1 to 3-D-glucan on cytokine production [12,16-19], TNFalpha, IL-1beta, IL-6, IL-8 and IL-1RA were measured as well as IFNgamma, IL-2, IL-4, IL-10, IL-12 and TGFbeta1. Correspondingly, four NFkappaB sites from the TNFalpha promoter (kappa consensus, kappa1, kappa2, kappa3) [27], a kappa consensus site from the IL-8 promoter [28], an NFAT site from the IFNgamma promoter (ATP2) [29] and a consensus NFIL-6 site from the IL-6 promoter [13] were examined. Because of the anti-inflammatory role of IL-1RA, we focused on binding of transcription factors to the IL-1RA promoter. An inhibitory element and three positive-acting LPS-response elements (LRE-1, LRE-2 and LRE-3) in the IL-1RA promoter, including NFkappaB, PU.1 and NFIL-6 sites, have been characterized previously [30-33]. Using computational analysis for homology search [34], we looked for new binding motifs in the IL-1RA promoter.","[{'offsets': [[488, 496]], 'text': ['Dectin-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[769, 777]], 'text': ['Dectin-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[804, 812]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[821, 841]], 'text': ['Toll-like receptor 2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[866, 871]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[978, 984]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1247, 1251]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1253, 1257]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1259, 1267]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1339, 1345]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1355, 1359]], 'text': ['IL-1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1567, 1571]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2759, 2765]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2896, 2904]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2906, 2914]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2916, 2920]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2922, 2926]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2931, 2937]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2963, 2971]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2973, 2977]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2979, 2983]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2985, 2990]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2992, 2997]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3002, 3010]], 'text': ['TGFbeta1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3058, 3066]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3156, 3160]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[3198, 3206]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[3265, 3269]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[3340, 3346]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[3402, 3408]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3521, 3527]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[3720, 3726]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T32'}]",[],[],[],[],[]
229,PMC-3342329-02-Results,"Inhibition of Tumor Development in CCR5-/- Mice
The effect of CCR5 in tumor development was investigated using CCR5+/+ and CCR5-/- mice. B16-F0 melanoma cells were inoculated subcutaneously into CCR5+/+ and CCR5-/- mice (n = 20). Tumor growth was monitored for 31 days. Tumor growth in the CCR5-/- mice was significantly lower than that in the CCR5+/+ mice. The tumor growth in the CCR5-/- mice was reduced to 19.1%, whereas the tumor growth in the CCR5+/+ mice was only reduced to 24.3%, in both tumor weight (Figure 1A and 1B) and tumor volume, respectively (Figure 1A and 1C). These results correlated with mice survival rates. There was a significant difference in survival rates between CCR5-/- mice (75% of starting time) and CCR5+/+ mice (15%) at the end of the experiment (Figure 1D). There was a significant difference in survival rates between CCR5-/- mice and CCR5+/+ mice. At the end of the experiment, 75% of the CCR5-/- mice survived while only 15% of the CCR5+/+ mice survived. Subcutaneous tumors were harvested from the sacrificed mice 31 days after inoculation. The immunohistochemical analysis of tumor sections, stained with H&E and for proliferation antigen PCNA, revealed greater inhibition of tumor cell growth in CCR5-/- mice. The histologic findings after H&E staining indicated that the tumor tissues of the CCR5-/- mice, but not those of the CCR5+/+ mice, contained large areas of necrosis. PCNA reactive cells were significantly reduced in the CCR5-/- mice (Figure 1E).","[{'offsets': [[35, 39]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[62, 66]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[111, 115]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[123, 127]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[195, 199]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[207, 211]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[290, 294]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[344, 348]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[382, 386]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[449, 453]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[692, 696]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[732, 736]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[854, 858]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[871, 875]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[926, 930]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[970, 974]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1237, 1241]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1334, 1338]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1369, 1373]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1472, 1476]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T20'}]",[],[],[],[],[]
230,PMC-3589482-14-Results,"The SerpinB2 Proximal Promoter Confers LPS Responsiveness
To investigate cis-acting regulatory elements responsive to LPS in the 5' flanking region of the murine SerpinB2 gene, nucleotides -4480 to +92 and a series of generated deletion mutants of the 5' flanking region were cloned upstream of a promoter-less firefly luciferase reporter gene (pGL3 Basic) (Fig. 2A). The reporter constructs were then transiently transfected into sub-confluent RAW264.7 macrophages and assayed for luciferase activity in the presence and absence of LPS or PMA, for comparison. PMA-induced SerpinB2 gene regulation has been extensively studied in human macrophage cell lines [45]-[47], and has been shown to occur through several proximal and distal AP-1 responsive elements [30]; [37]; [47]-[51]. As shown in Fig. 2B, the SerpinB2 5' flanking region from -4480 to +92 directs both PMA- and LPS-inducible transcription, approximately 2-fold and 7-fold, respectively. Deletion of the murine SerpinB2 promoter from -1686 to -1341 increased LPS-inducibility to approximately 16-fold, indicating the presence of a silencer element in this region. Further deletion beyond -539 abolished the LPS-response of the promoter, indicating the presence of an essential LPS response element in the region between -539 and -189; however, the response of the murine SerpinB2 promoter to PMA is less affected by this deletion. While deletion of the SerpinB2 promoter from -189 to -87 eliminated the LPS response and marginally reduced the PMA response, the -87 murine SerpinB2 promoter construct was still partially responsive to PMA, indicating that cis-acting elements mediating the response of the murine SerpinB2 promoter to PMA also lie downstream of nucleotide -87.","[{'offsets': [[4, 12]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[162, 170]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[319, 329]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[482, 492]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[573, 581]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[806, 814]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[973, 981]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1333, 1341]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1415, 1423]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1534, 1542]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1674, 1682]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T11'}]",[],[],[],[],[]
231,PMC-3585731-25-Materials_and_Methods,"In vitro Akt Kinase Assay
Akt kinase activity was measured using the Akt kinase assay kit (nonradioactive) from Cell Signaling Technology. In brief, Myr-Akt was immunoprecipitated from L929 cells using anti-FLAG M2 magnetic beads (Sigma). The in vitro assay was performed in the presence of a GSK fusion protein substrate. Phosphorylation of the GSK fusion protein was visualized by western blot.","[{'offsets': [[149, 156]], 'text': ['Myr-Akt'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
232,PMC-3320587-23-Caption-Figure_1,"NFAT5 interaction with the LTR is important for MTb-induced HIV-1 transcription.
(A) MTb stimulation increases activity of LTRs derived from HIV-1 subtypes B, C, and E. HIV-1 LTRs (-208 to +64 nt relative to the transcription start site) from representative subtype B, C, and E viral isolates were cloned into plasmid pGL3. THP-1 cells (0.8x106/ml) were transfected with each reporter plasmid (0.3 microg/ml) plus the Renilla luciferase control plasmid pRL-TK (0.03 microg/ml) and incubated at 37degreesC for 16 hours. Cells were then either left untreated or treated with 10 microg/ml MTb lysate for 8 hours before termination of the cultures. In the histogram, open bars represent individual LTR activities in untreated cells. Light grey bars represent mean values of LTR activities from each subtype in untreated cells. Black bars represent individual LTR activities in MTb lysate-treated cells, and dark grey bars represent mean values of LTR activities from each subtype in cells treated with MTb lysate. LTR transcriptional activity for all of the representative LTRs tested was significantly increased in cultures treated with MTb lysate in comparison to untreated cultures. Results are from three independent experiments performed in duplicate (*, p<0.05; **, p<0.01 as compared to unstimulated cultures). (B) Specific disruption of the NFAT5 binding site significantly reduces LTR-reporter gene activity in monocytic cells in response to MTb lysate treatment. THP-1 cells were transfected with luciferase expression vectors encoding nucleotides 208 to +64 of the wild-type HIV-1Lai LTR and an HIV-1Lai LTR containing the NFAT5 binding site mutations (N5-Mut). After 16 hours, the cells were left untreated or exposed to 10 microg/ml MTb lysate for 8 hours at 37degreesC. Disruption of NFAT5 binding to the enhancer region significantly suppressed LTR-driven reporter gene expression in comparison to the wild-type LTR when cells were treated with MTb lysate (p<0.01). LTR activity was also suppressed in the untreated cells but to a lesser extent (p<0.05). Results are from three independent experiments performed in duplicate and adjusted to Renilla luciferase control expression (*, p<0.05; **, p<0.01). Nucleotide sequences representing the wild-type and NFAT5 binding site-mutated HIV-1Lai LTRs are shown at the bottom of the figure. (C) MTb lysate increases NFAT5 protein levels in monocytic cells. THP-1 cells were left untreated (control) or exposed to 10 microg/ml MTb lysate for 8 or 24 hours at 37degreesC. Whole cell extracts were collected and analyzed by western blot with anti-NFAT5 antibody. An antibody directed against Lamin-B1 was used as a loading control. The histogram shows densitometric analysis of the NFAT5 bands from the western blot autoradiograph displayed and values represent mean band intensities at 0, 8, and 24 hours post-stimulation with MTb lysate.","[{'offsets': [[0, 5]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[426, 436]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1503, 1513]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1794, 1799]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[2160, 2170]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[2372, 2377]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[2645, 2653]], 'text': ['Lamin-B1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[2735, 2740]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
233,PMC-2817507-00-TIAB,"Activation of TLR4-Mediated NFkappaB Signaling in Hemorrhagic Brain in Rats
Inflammation and immunity play a crucial role in the pathogenesis of Intracerebral hemorrhage (ICH). Toll-like receptor 4- (TLR4-) mediated nuclear factor kappa-B (NFkappaB) signaling plays critical roles in the activation and regulation of inflammatory responses in injured brain. However, the involvement of TLR4-mediated NFkappaB signaling in the pathogenesis of ICH remains unknown. The present study was to evaluate the temporal profile of the expression of TLR4 and the activation of TLR4-mediated NFkappaB signaling in brain tissues of Wistar rats after ICH. TLR4 mRNA and protein, the phosphorylation of inhibitors of kappa B (p-IkappaBalpha), and the activity of NFkappaB were examined in hemorrhagic cerebral tissue by Rt-PCR, Western blots, immunohistochemistry staining, and EMSA. Compared with saline control, the TLR4 mRNA and protein significantly increased starting at 6 hours after ICH, peaked on the 3rd day after ICH, and then decreased but still maintained at a higher level on the 7th day after ICH (P < .05). The level of p-IkappaBalpha and the activity of NFkappaB also increased in the brain after ICH compared with saline control. The present study firstly suggests that TLR4-mediated NFkappaB signaling participates in the pathogenesis of ICH, which may become a therapeutic target for ICH-induced brain damage.","[{'offsets': [[14, 18]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[177, 197]], 'text': ['Toll-like receptor 4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[200, 204]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[386, 390]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[539, 543]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[566, 570]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[642, 646]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[688, 709]], 'text': ['inhibitors of kappa B'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[713, 725]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[903, 907]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1122, 1134]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1272, 1276]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
234,PMC-3312845-22-Caption-Figure_4,"Quantitative analyses of the effect of sTNFp55R infusion on NF-kappaB phosphorylation and SMI-71 expression. (A) Quantitative analysis of NF-kappaB phosphorylation 12 hr after SE (mean +/- S.E.M). Significant differences from saline-infused animals, *p < 0.05. (B) Quantitative analysis of SMI-71 expression 1 day after SE (mean +/- S.E.M). Significant differences from saline-infused animals, *p < 0.05. (C) Linear regression analysis between p65-Thr435 phosphorylation and SMI-71 in the PC following SE.","[{'offsets': [[40, 47]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[444, 447]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
235,PMC-1064895-06-Materials_and_methods,"Enzyme-linked immunosorbent assay of IL-17
IL-17 in culture supernatants was measured by sandwich enzyme-linked immunosorbent assay as described previously [20]. In brief, a 96-well plate (Nunc) was coated with 4 mug/ml monoclonal antibodies against IL-17 (R & D Systems) at 4degreesC overnight. After blocking with phosphate-buffered saline/1% bovine serum albumin (BSA)/0.05% Tween 20 for 2 hours at room temperature (22-25degreesC), test samples and the standard recombinant IL-17 (R & D Systems) were added to the 96-well plate and incubated at room temperature for 2 hours. Plates were washed four times with phosphate-buffered saline/Tween 20, and then incubated with 500 ng/ml biotinylated mouse monoclonal antibodies against IL-17 (R & D Systems) for 2 hours at room temperature. After washing, streptavidin-alkaline phosphate-horseradish peroxidase conjugate (Sigma) was incubated for 2 hours, then washed again and incubated with 1 mg/ml p-nitrophenyl phosphate (Sigma) dissolved in diethanolamine (Sigma) to develop the color reaction. The reaction was stopped by the addition of 1 M NaOH and the optical density of each well was read at 405 nm. The lower limit of IL-17 detection was 10 pg/ml. Recombinant human IL-17 diluted in culture medium was used as a calibration standard, ranging from 10 to 2000 pg/ml. A standard curve was drawn by plotting optical density against the log of the concentration of recombinant cytokines, and used for determination of IL-17 in test samples.","[{'offsets': [[37, 42]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[43, 48]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[250, 255]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[478, 483]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[733, 738]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1176, 1181]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1224, 1229]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1471, 1476]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
236,PMC-3589482-26-Caption-Figure_3,"Potential cis-acting regulatory elements in the LPS responsive region of the murine SerpinB2 promoter
-563/-1. Mouse and human nucleotide sequences were aligned using Clustal W software. Cis-acting elements conserved between the human and murine SerpinB2 promoters are boxed and labeled. AP-1 =  activator protein 1; C/EBP =  CCAAT enhancer binding protein; CRE = cAMP response element; Oct1 =  octamer transcription factor 1/POU2F1; PU.1 =  purine box binding protein 1. The putative transcription initiation site (tis) is indicated and exon 1 is presented in uppercase. The location of the 5' ends of the -539, -189 and -87 reporter constructs are also shown.","[{'offsets': [[84, 92]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[246, 254]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[387, 391]], 'text': ['Oct1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[395, 425]], 'text': ['octamer transcription factor 1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[426, 432]], 'text': ['POU2F1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[434, 438]], 'text': ['PU.1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[442, 470]], 'text': ['purine box binding protein 1'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
237,PMC-1472690-20-Caption-Figure_3,"A, IL-1beta was down-regulated (12 h - 24 h) following GP + TSST-1 when compared to TSST-1. Time course (48 h) of IL-1beta production (pg/ml) by human PBMC incubated with medium control, 100 mug GP, 250 ng TSST-1, GP + TSST-1, 250 ng LPS and GP + LPS. At 18 h and 24 h there was a marked reduction in IL-1beta production following GP + TSST-1 when compared to TSST-1 (* = p < 0.05). Graphs depicting the theoretical values for GP/LPS calc. and GP/TSST-1 calc. are also shown. IL-1beta levels in the supernatnant were obtained by Elisa and are shown as mean +/- SEM (n = 3). B, IL-1RA was exaggerated following GP + TSST-1 (12 h - 48 h) when compared to TSST-1. Time course (48 h) of IL-1RA production (pg/ml) by human PBMC incubated with medium control, 100 mug GP, 250 ng TSST-1, GP + TSST-1, 250 ng LPS and GP + LPS. Between 18 h and 48 h a simultaneous treatment of PBMC with GP + TSST-1 led to a synergistic effect, i.e. a higher IL-1RA production when compared to an addition of the single values for TSST-1 and GP (* = p < 0.05). Graphs depicting the theoretical values for GP/LPS calc. and GP/TSST-1 calc. are included. IL-1RA levels in the supernatnant were obtained by Elisa and are shown as mean +/- SEM (n = 3).","[{'offsets': [[3, 11]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[60, 66]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[84, 90]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[114, 122]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[206, 212]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[219, 225]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[301, 309]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[336, 342]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[360, 366]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[447, 453]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[476, 484]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[577, 583]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[615, 621]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[653, 659]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[683, 689]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[773, 779]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[786, 792]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[884, 890]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[934, 940]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1006, 1012]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1100, 1106]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1127, 1133]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T22'}]",[],[],[],[],[]
238,PMC-3585731-16-Materials_and_Methods,"QPCR Primers
Mouse TNFalpha: forward 5'-CCCTCACACTCAGATCATCTTCT-3', reverse 5'-GCTACGACGTGGGCTACAG-3';mouse 18S: forward 5-' ATAACAGGTCTGTGATGCCCTTAG-3, reverse 5'-CTAAACCATCCAATCGGTAGTAGC-3';human TNFalpha: forward 5'- ATGAGCACTGAAAGCATGATCC-3', human TNFalpha: reverse 5'-GAGGGCTGATTAGAGAGAGGTC-3'; human 18S: forward 5'- CAGCCACCCGAGATTGAGCA -3, human 18S: reverse 5'-TAGTAGCGACGGGCGGTGTG-3'.","[{'offsets': [[19, 27]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[108, 111]], 'text': ['18S'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[198, 206]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[253, 261]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[307, 310]], 'text': ['18S'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[355, 358]], 'text': ['18S'], 'type': 'Protein', 'id': 'T6'}]",[],[],[],[],[]
239,PMC-3291650-02-Results,"A20 inhibits RIG-I-induced NF-kappaB and IRF3 activation
RIG-I signaling induces the activation of NF-kappaB, IRF3 and IRF7 transcription factors, which promote the expression of proinflammatory cytokines and type I IFNs that restrict further viral propagation. Previous studies have shown that ectopically expressed A20 negatively regulates NF-kappaB and IRF3 activation upon RIG-I stimulation [50]-[52]. Similarly, we show that A20 overexpression in HEK293T cells prevents NF-kappaB- and IRF3-dependent luciferase reporter gene activation induced by transfection of a truncated constitutive active form of RIG-I [53], corresponding to only the two N-terminal CARD domains of RIG-I [RIG-I (2CARD)] (figure 1A, left and middle graph). We next investigated whether A20 also inhibits IRF7 activation. Unlike IRF3, IRF7 is not or weakly expressed under naive conditions and IRF7 protein levels are rapidly upregulated upon virus-induced IRF3 activation [54], [55]. To determine the effect of A20 on IRF7 activation, we therefore transfected minor amounts of an IRF7 expression plasmid together with plasmids encoding RIG-I (2CARD), A20 and an IRF7-specific IFNalpha4 luciferase reporter construct. RIG-I (2CARD) expression in the absence of IRF7 co-expression showed negligible IFNalpha4 promoter activation (grey bar, figure 1A, right graph), whereas significant reporter gene expression was observed in the presence of IRF7. Similar to its inhibitory effect on NF-kappaB and IRF3 activation, A20 also prevented RIG-I-induced IRF7 activation (figure 1A, right graph). These results demonstrate the potential of A20 to inhibit RIG-I-induced NF-kappaB and IRF3/7 activation.
To study the effect of endogenously expressed A20 on RIG-I-induced signaling in a more immunological relevant context, we performed further experiments in A20 deficient primary macrophages. Since A20 full knockout mice die prematurely as a result of severe multi-organ inflammation [37], we generated mice carrying a conditional A20 allele in which exon IV and exon V were flanked by two loxP sites [56]. Crossing these mice with transgenic mice expressing Cre recombinase under control of the lysozyme M promoter leads to specific deletion in myeloid cells and allowed us to generate myeloid cell specific A20 knockout mice [48]. To stimulate the RIG-I receptor, we transfected A20myel-KO BMDM and wild type control cells with minimal amounts of low molecular weight (LMW) poly(I:C), which is known to preferentially bind and activate RIG-I rather than MDA5 [57]. Of note, this concentration of poly(I:C) was unable to induce significant TLR3 dependent NF-kappaB and IRF3 activation or cytokine production (data not shown). As expected, poly(I:C) transfection induced the rapid expression of A20 in wild type, but not in A20myel-KO BMDM (figure 1B, upper panel). At early time points, slightly slower migrating forms of A20 were observed, indicating that A20 undergoes a yet unknown modification upon poly(I:C) transfection. Compared to wild type BMBM, A20 deficient cells showed enhanced NF-kappaB activation as indicated by increased phosphorylation and sustained degradation of IkappaBalpha (figure 1B). Furthermore, nuclear translocation of the p65 NF-kappaB subunit was enhanced in poly(I:C) transfected A20myel-KO BMDM, reaching a maximum at earlier time points compared to wild type cells (figure 1C). IRF3 is known to be activated upon phosphorylation of a series of carboxyl terminal serine residues by the IKK-like kinases TBK1 and IKKepsilon [58], leading to its dimerization and subsequent translocation to the nucleus [59]. Using immunoblotting with an antibody directed against phosphorylated Ser396, maximum IRF3 phosphorylation was detected at earlier time points in A20myel-KO BMDM compared to wild type BMDM (figure 1B). Similar to p65, IRF3 nuclear translocation reached its maximum at an earlier time point in A20 deficient BMDM compared to wild type cells (figure 1C). NF-kappaB controls the expression of IL-6 and TNF, and NF-kappaB and IRF3 control the expression of IFNbeta. In line with the enhanced activation of NF-kappaB and IRF3 as described above, A20myel-KO BMDM secreted increased amounts of IL-6, TNF and IFNbeta (figure 1D). Similar results were obtained using peritoneal macrophages (data not shown). Together, these results demonstrate that A20 plays an important role in the negative regulation of RIG-I-induced NF-kappaB and IRF3 activation in primary macrophages.","[{'offsets': [[13, 18]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[41, 45]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[57, 62]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[110, 114]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[119, 123]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[356, 360]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[377, 382]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[490, 494]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[505, 515]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[570, 604]], 'text': ['truncated constitutive active form'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[608, 613]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[677, 682]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[782, 786]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[806, 810]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[812, 816]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[871, 875]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[934, 938]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[996, 1000]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1058, 1062]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1140, 1144]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1164, 1174]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1238, 1242]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1418, 1422]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1474, 1478]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1510, 1515]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1524, 1528]], 'text': ['IRF7'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1624, 1629]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1652, 1656]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1657, 1658]], 'text': ['7'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1724, 1729]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2319, 2324]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2507, 2512]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2525, 2529]], 'text': ['MDA5'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2610, 2614]], 'text': ['TLR3'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2639, 2643]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[3153, 3165]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[3221, 3224]], 'text': ['p65'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[3381, 3385]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[3505, 3509]], 'text': ['TBK1'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[3514, 3524]], 'text': ['IKKepsilon'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[3695, 3699]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[3822, 3825]], 'text': ['p65'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[3827, 3831]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[3999, 4003]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[4008, 4011]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[4031, 4035]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[4062, 4069]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[4125, 4129]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[4196, 4200]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[4202, 4205]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[4210, 4217]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[4407, 4412]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[4435, 4439]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T53'}]",[],[],[],[],[]
240,PMC-1064895-12-Results,"IL-17 production in PBMC from patients with RA, patients with OA and normal individuals
PBMC were separated and cultured with PHA (5 mug/ml) from patients with RA, patients with OA, and age-matched normal controls; IL-17 levels were then determined in the culture supernatants (Fig. 1). Although the amounts of basal IL-17 secretion were not different between RA, OA and normal controls (62 +/- 31, 43 +/- 19 and 43 +/- 10 pg/ml, respectively), the IL-17 production stimulated by PHA was significantly higher in RA PBMC than in those from OA and controls (768 +/- 295 versus 463 +/- 211 pg/ml [P < 0.05] and 241 +/- 29 pg/ml [P < 0.001]).","[{'offsets': [[0, 5]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[126, 129]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[215, 220]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[317, 322]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[449, 454]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[480, 483]], 'text': ['PHA'], 'type': 'Protein', 'id': 'T6'}]",[],[],[],[],[]
241,PMC-3320587-12-Materials_and_Methods,"Quantitative PCR
The mRNA expression levels were determined by SYBR Green-based real-time PCR (Applied Biosystems, www.appliedbiosystems.com). The reaction conditions were 95degreesC for 10 min followed by 40 cycles of 95degreesC for 15 sec and 60degreesC for 1 min. The results were normalized using beta-actin mRNA as an internal control and expressed as relative values.","[{'offsets': [[301, 311]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T1'}]",[],[],[],[],[]
242,PMC-3585731-04-Results,"TNFalpha Induces Delayed Akt Thr308 Phosphorylation and Necroptosis Independent of Growth Factor Stimulation
Consistent with TNFalpha inducing necroptosis independently of growth factors (Fig. 1A), FGFR inhibitors did not attenuate TNFalpha-induced changes in Akt or JNK phosphorylation, while efficiently preventing these changes in response to zVAD.fmk (Fig. S4A). Furthermore, addition of TNFalpha led to comparable late activation of Akt p308 signal under both normal and serum free conditions (Fig. S4B, C), indicating that TNFalpha signaling to Akt Thr308 is growth factor-independent. In contrast, activation of JNK by TNFalpha followed different kinetics from zVAD.fmk-induced changes. TNFalpha treatment caused an early and robust increase in the phosphorylation of JNK and c-Jun. Nec-1 did not affect this early increase, however, it reduced levels of pJNK/Jun at the late, 9 hr time point (Fig. S4B, C). This again separated early RIP1-independent changes, which likely reflect the ability of additional upstream kinases, such as Ask1 to activate JNK [27], from the late RIP1 kinase-dependent necroptotic signaling.","[{'offsets': [[0, 8]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[125, 133]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[232, 240]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[392, 400]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[529, 537]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[626, 634]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[694, 702]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[783, 788]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[942, 946]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1041, 1045]], 'text': ['Ask1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1082, 1086]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T11'}]",[],[],[],[],[]
243,PMC-3320587-27-Caption-Figure_5,"Disruption of NF-kappaB or NFAT5 sites in the LTR inhibits MTb-induced HIV-1 replication in MDM.
MDM from four normal donors were infected with 1000 TCID50 of HIV-1Lai/Bal-env-WT or the mutants HIV-1Lai/Bal-env-kappaB I-Mut, HIV-1Lai/Bal-env-kappaB II-Mut, HIV-1Lai/Bal-env-kappaB I+II-Mut, or HIV-1Lai/Bal-env-N5-Mut, and were either (A) left infected with virus alone or (B) co-infected with MTb CDC1551 (1:1 MDM:bacilli). Viral p24 levels in the culture supernatants were measured at days 4, 7 and 12 post-infection. Presentation of viral p24 levels at day 12 in cultures infected with (C) HIV-1 alone or (D) co-infected with MTb are shown as histograms. (*, p<0.05; **, p<0.01, as compared to HIV-1Lai/Bal-env-WT).","[{'offsets': [[172, 175]], 'text': ['env'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[207, 210]], 'text': ['env'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[238, 241]], 'text': ['env'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[270, 273]], 'text': ['env'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[307, 310]], 'text': ['env'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[431, 434]], 'text': ['p24'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[542, 545]], 'text': ['p24'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[710, 713]], 'text': ['env'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
244,PMC-2817507-05-2._Methods,"2.4. Immunohistochemistry (IHC)
The IHC staining for TLR4 was performed as described previously [8]. The primary antibody employed was rabbit anti-TLR4 (WuHan, BA1717). The biotinylated secondary antibody and antibody-biotin-avidin-peroxidase complexes (ABC reagent, SC-2018) were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Slides processed without primary antibodies served as negative controls.","[{'offsets': [[53, 57]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[225, 231]], 'text': ['avidin'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
245,PMC-1064873-02-Materials_and_methods,"Patients and samples
The total patient population consisted of 32 patients with RA (25 women and seven men; mean +/- standard deviation age, 52.8 +/- 12.4 years) diagnosed according to the revised 1987 criteria of the American College of Rheumatology (formally, the American Rheumatism Association) [25]. All patients were receiving prednisolone (<= 7.5 mg/day) and disease-modifying antirheumatic drugs. Clinical parameters in the study patients were as follows (mean +/- standard deviation): erythrocyte sedimentation rate, 55.9 +/- 35.4 mm/hour; serum C-reactive protein (CRP) level, 32.0 +/- 32.0 mg/l; and IgM class rheumatoid factor titer, 142 +/- 158 U/ml. Patients were divided into two groups: 24 patients with active disease, who had multiple tender and/or swollen joints and elevated serum CRP level (>= 10 mg/l); and eight patients with inactive disease, who satisfied the American College of Rheumatology preliminary criteria for clinical remission [26]. Sixteen healthy volunteers (11 women and five men; age, 45.8 +/- 11.2 years) served as controls. ST samples were obtained from three RA patients undergoing total knee replacement. All patients gave informed consent.",[],[],[],[],[],[]
246,PMC-3317373-05-2._Methods_and_Materials,"2.4. Electrophoretic Mobility Shift Assay (EMSA)
Monolayers of astrocytes were washed with PBS and harvested by scraping into cold PBS. The cell pellet obtained by centrifugation was resuspended in buffer containing 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1.0 mM DTT, and 0.5 mM phenylmethylsulfonyl fluoride. Then 10% Nonidet P-40 was added and vortexed briefly, and the nuclei were pelleted by centrifugation. The nuclear proteins were extracted with buffer containing 20 mM HEPES (pH 7.9), 0.4 mM NaCl, 1.0 mM EDTA, 1.0 mM EGTA, 1.0 mM DTT, and 1.0 mM phenylmethylsulfonyl fluoride. Insoluble material was removed by centrifugation at 14000 rpm, and the supernatant containing the nuclear proteins was stored at -80degreesC until use. Protein concentration was determined using a bicinchoninic acid assay kit with bovine serum albumin as the standard (Pierce Biochemicals, Rockford, IL, USA). EMSA was performed using gel shift assay system (Promega, Madison, WI, USA). Consensus oligonucleotide probe (5'-AGTTGAGGGGACTTTCCCAGGG-3') was end-labeled by T4-polynucleotide kinase using [gamma-32P]-ATP (Free Biotech., Beijing, China). Nuclear protein (20 mug) was preincubated in 20 muL binding buffer containing 10 mM Tris-HCl (PH 7.5), 1 mM MgCl2, 0.5 mM NaCl, 4% glycerol, 0.5 mM EDTA, 0.5 mM DTT, and 2 mug poly dI-dC for 20 minutes on ice. After addition of the 1 muL 32P-labled oligonucleotide probe, the incubation was continued for 20 minutes on ice. The DNA-protein complexes were separated by electrophoresis on 4% nondenaturing polyacrylamide gel in 0.5 x TBE buffer (tris-borate-EDTA) at 390 V for 1 hour at 4degreesC. After electrophoresis, the gel was dried and exposed to X-ray film (Fuji Hyperfilm, Tokyo, Japan). Levels of NF-kappaB DNA binding activity were quantified by software ImageJ.",[],[],[],[],[],[]
247,PMC-3342329-14-Materials_and_Methods,"Gel Electromobility Shift Assay
A gel electromobility shift assay (EMSA) was performed according to the manufacturer's recommendations (Promega, Madison, WI). The tumor tissues were briefly homogenized in 200 microl of solution A (10 mM HEPES [pH 7.9], 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, 0.2 mM phenylmethylsulfonylfluoride), vortexed vigorously, incubated on ice for 10 min, and then centrifuged at 15000 rpm for 15 min. The pelleted nuclei were resuspended in solution C (solution A supplemented with 420 mM NaCl and 20% glycerol), and incubated on ice for 20 min. The resuspended pellet was centrifuged at 15000 rpm for 15 min, and the resulting nuclear extracts supernatant were collected in a chilled Eppendorf tube. Consensus oligonucleotides were end-labeled using T4 polynucleotide kinase and [P32]-ATP for 10 min at 37degreesC. The gel shift reactions were assembled and incubated at room temperature. Subsequently, 1 ml of gel loading buffer was added to each reaction and loaded onto a 6% non-denaturating gel. The gel was subjected to electrophoresis until the dye was four-fifths of the way down the gel. The gel was dried for 1 h at 80degreesC and exposed to film overnight at -70degreesC.",[],[],[],[],[],[]
248,PMC-3585731-31-Caption-Figure_6,"Akt and mTORC1 control autocrine TNFalpha synthesis and JNK activation during necroptosis.
(A) Cells were treated under serum free conditions with bFGF or PDGF with or without zVAD.fmk for 9 hr, followed by qRT-PCR analysis of mTNFalpha. Data was normalized to mouse 18S RNA. (B) Necroptosis was induced by zVAD.fmk or TNFalpha in cells treated with Nec-1, rapamycin (rapa), or Akt inh. VIII inh. followed by qRT-PCR analysis of TNFalpha mRNA levels. (C-F) L929 cells with siRNA knockdown of Akt isoforms (C,E) or mTOR (D,F) were stimulated with zVAD.fmk or TNFalpha for 9 hr, followed by qRT-PCR analysis of mTNFalpha (C,D) or western blot (E,F). In all graphs, average+/-SD was plotted.","[{'offsets': [[33, 41]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[147, 151]], 'text': ['bFGF'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[227, 236]], 'text': ['mTNFalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[267, 270]], 'text': ['18S'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[319, 327]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[429, 437]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[558, 566]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[609, 618]], 'text': ['mTNFalpha'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
249,PMC-3312845-08-Methods,"Fluoro-Jade B staining
Fluoro-Jade B (FJB) staining was used to identify degenerating neurons in tissues obtained from non-SE and 3 days post-SE animals in every group. In our previous [18,25] and preliminary data, neuronal damage was first detectable at 3 days after SE. Therefore, we determined 3 days after SE as the best time point to look FJB. Briefly, sections were rinsed in distilled water, and mounted onto gelatin-coated slides and then dried on a slide warmer. The slides were immersed in 100% ethanol for 3 min, followed by 70% ethanol for 2 min and distilled water for 2 min. The slides were then transferred to 0.06% potassium permanganate for 15 min and gently agitated. After rinsing in distilled water for 2 min, the slides were incubated for 30 min in 0.001% FJB (Histo-Chem Inc., Jefferson, AR), freshly prepared by adding 20 ml of a 0.01% stock FJB solution to 180 ml of 0.1% acetic acid, with gentle shaking in the dark. After rinsing for 1 min in each of three changes of distilled water, the slides were dried, dehydrated in xylene and coverslipped with DPX (Sigma-Aldrich Co., St. Louis, MO). For stereological study, every sixth section in the series throughout the entire PC was used (see below).",[],[],[],[],[],[]
250,PMC-3320587-17-Results,"RNAi directed against NFAT5 inhibits replication of subtype B HIV-1
To extend the results we obtained in the reporter assays to a physiological TB/HIV co-infection model, we next tested the effect of siRNA-mediated ablation of NFAT5 mRNA levels in MDM co-infected with a subtype B HIV-1Lai infectious molecular clone and a clinical isolate of MTb. To perform this experiment, we first constructed an HIV-1Lai clone bearing the CCR5-tropic envelope region of HIV-1Bal (HIV-1Lai/Bal-env) so that it would efficiently infect primary MDM. We used this approach to ensure that our analysis of the roles of NF-kappaB and NFAT5 in MTb-induced HIV-1 replication could be interpreted in the proper context of previous research findings that examined LTR regulation in the context of full-length viral replication [41]-[46]. The HIV-1Lai/Bal-Env infectious clone is isogenic for the entire sequence of the parental HIV-1Lai infectious clone except for the substitution of the HIV-1Bal envelope co-receptor binding region in place of the HIV-1Lai envelope co-receptor binding region. We note that we confirmed that HIV-1Lai/Bal-Env grew in PBMC at a similar rate to wild-type HIV-1Bal, indicating proper co-receptor engagement and internalization of this infectious clone (data not shown).
Next, we knocked down NFAT5 mRNA levels in MDM using an siRNA that suppresses both NFAT5 mRNA and NFAT5 protein levels [31]. As shown in Figure 2, transfection of the siRNA specific for NFAT5 reduces NFAT5 mRNA levels in both MTb-uninfected (p = 0.048) and MTb-infected (p = 0.021) MDM as compared to transfection of control GFP siRNA into MTb-uninfected or -infected MDM (Figure 2B). We note that although siRNA normally is effective for 48-72 hours in cell lines that divide rapidly, in human MDM, which are non-dividing cells, siRNA to host factors remains detectable and functional up to at least 15 days post-transfection [47].
MDM in which NFAT5 expression had been inhibited with NFAT5 siRNA or that were transfected with control GFP siRNA were then infected with 1000 TCID50 of HIV-1Lai/Bal-env. After overnight virus infection, the cells were then co-infected with the MTb clinical strain CDC1551. Free virus levels were then measured in culture supernatants from MDM transfected with NFAT5-specific siRNA or GFP control siRNA at days 6, 9 and 12 post-HIV-1 infection to measure the impact of NFAT5 inhibition on MTb-induced HIV replication.
As shown in Figure 2C, HIV-1 replication was suppressed at days 6 and 9 post-infection in the NFAT5 siRNA-treated cells as compared to cells treated with control siRNA, and it was significantly inhibited by day 12 post-infection (p<0.05) (Figure 2C). Thus, knock down of NFAT5 expression significantly impairs HIV-1 subtype B replication in MDM co-infected with MTb.","[{'offsets': [[22, 27]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[227, 232]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[427, 431]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[481, 484]], 'text': ['env'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[615, 620]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[832, 835]], 'text': ['Env'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[975, 983]], 'text': ['envelope'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1036, 1044]], 'text': ['envelope'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1117, 1120]], 'text': ['Env'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1301, 1306]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1362, 1367]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1377, 1382]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1465, 1470]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1479, 1484]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1604, 1607]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1925, 1930]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1966, 1971]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2016, 2019]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2078, 2081]], 'text': ['env'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2273, 2278]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2297, 2300]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[2381, 2386]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[2524, 2529]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[2701, 2706]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T24'}]",[],[],[],[],[]
251,PMC-1472690-24-Caption-Figure_7,"Inhibition of GP-induced NFkappaB, NFAT and NFIL-6 DNA binding to the IL-1RA promoter. A, A representative autoradiogram (lane 1: control, lane 2: GP, lane 3: GP + unlabeled mutated NFATP2/3 oligo, lane 4: GP + CAPE, lane 5: GP + CyA, lane 6: GP + CHX, lane 7: GP + unlabeled NFATP2/3 oligo, lane 8: water) as well as a graphical summary for the NFATP2/3 site, depicting a decrease in binding following inhibition when compared to GP is displayed (* = p < 0.05). Data are shown as mean +/- SEM (n = 4). B, Inhibition of NFkappaB, NFAT and NFIL-6 resulted in decreased IL-1RA mRNA following CHX, CAPE or CyA compared to GP. GAPDH is used as housekeeping control (representative gel, n = 4). C, Inhibition of NFkappaB, NFAT and NFIL-6 significantly reduced the production of IL-1RA by human PBMC following treatment with CHX, CAPE or CyA when compared to GP (* = p < 0.05; ** = p < 0.01). Data are shown as mean +/- SEM (n = 3).","[{'offsets': [[35, 39]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[44, 50]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[70, 76]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[530, 534]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[539, 545]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[568, 574]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[623, 628]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[717, 721]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[726, 732]], 'text': ['NFIL-6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[773, 779]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T10'}]",[],[],[],[],[]
252,PMC-1472690-14-Methods,"Immuno (Dot) blot
To determine whether the DNA binding proteins were related to NFkappaB and NFAT, dot blots using a SRC96D SNS minifold I dot blotter (Schleicher & Schull, Dassel, Germany) were performed with the following positive controls and antibodies (all from Santa Cruz Biotechnology, Heidelberg, Germany): positive controls (10 ng/dot): NFkappaB p52 (80 kD) sc-4095WB, c-Rel (61 kD) sc-4030WB; Jurkat nuclear extract, PMA-stimulated; primary antibodies (1 mug/dot): anti-NFkappaB p50 (NLS) sc-114, anti-NFkappaB p65 (A) sc-109, anti-NFkappaB p52 (447) sc-848, a rabbit polyclonal IgG1 antiserum, anti-c-rel (N466) sc-272, anti-NFATc2 (M-20) sc-1151, anti-NFATc1 (K-18) sc-1149, two goat polyclonal IgG1 antisera; secondary antibodies (0.8 mug/dot): goat anti-rabbit IgG AP-conjugate sc-2007, and donkey anti-goat IgG AP-conjugate sc-2022. The nuclear proteins were blotted onto a nitrocellulose membrane (Bio-Rad). After blocking with PBS/3% BSA (Fluka, Deisenhofen, Germany), the blot was incubated overnight with the primary antibodies diluted 1:2000 in PBS/1% BSA, washed again and incubated with the alkaline phosphatase-conjugated secondary antibody (1:500 in PBS/1% BSA). The blot was developed using the Vectastain(R) staining kit (Vector Laboratories Inc. Burlingame, CA, USA).","[{'offsets': [[93, 97]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[355, 358]], 'text': ['p52'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[378, 383]], 'text': ['c-Rel'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[489, 492]], 'text': ['p50'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[521, 524]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[551, 554]], 'text': ['p52'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[610, 615]], 'text': ['c-rel'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[636, 642]], 'text': ['NFATc2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[664, 670]], 'text': ['NFATc1'], 'type': 'Protein', 'id': 'T9'}]",[],[],[],[],[]
253,PMC-1359074-11-Materials_and_Methods,"In situ hybridization.
Antisense probes were designed to murine epsilony globin nucleotides 509-584; betamaj globin nucleotides 458-549; and mouse Sox6 nucleotides 1353-1927. Embryos were fixed overnight by immersion in 4% paraformaldehyde, embedded in paraffin, sectioned at 5 mum, and adhered to charge modified slides (VWR, West Chester, Pennsylvania, United States). Slides were processed for in situ hybridization as described [52] using in vitro transcribed RNA probes labeled with 33P. Darkfield and brightfield images were obtained with a Nikon Optiphot microscope (Nikon, Melville, New York, United States) and SPOT RT-Slider digital camera (Diagnostic Instruments, Sterling Heights, Michigan, United States). Objectives used were 1x (NA = 0.04) and 10x (NA = 0.5). Images were processed, pseudocolored, and combined using Photoshop (Adobe, San Jose, California, United States) software with Fovea Pro (Reindeer Graphics, Asheville, North Carolina, United States) plugins. Original images are available.","[{'offsets': [[64, 79]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[101, 115]], 'text': ['betamaj globin'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[147, 151]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
254,PMC-3291650-14-Materials_and_Methods,"Cytokine quantification
For TNF ELISA, 96-well plates were coated with TNF coating (TN3-19, eBioscience) and detection (R4-6A2, eBioscience) antibodies. IFNalpha and IFNbeta protein levels were determined with an ELISA kit (PBL Biomedical Laboratories). For IFNgamma ELISA, 96-well plates were coated with IFNgamma coating (XMG1.2) and detection (R4-6A2) antibodies (eBiosciences). Detection of MCP-1, KC, TNF, IL-1beta and IL-6 in BAL fluid was performed using Bioplex (BioRad) technology according to the manufacturer's instructions. Milliplex technology (Millipore) was used for the detection of MIP-2 in BAL fluid.","[{'offsets': [[28, 31]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[71, 74]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[166, 173]], 'text': ['IFNbeta'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[395, 400]], 'text': ['MCP-1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[402, 404]], 'text': ['KC'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[406, 409]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[411, 419]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[424, 428]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
255,PMC-1359074-07-Results,"Mutant p100H Mice Have Higher Numbers of Nucleated Red Cells
Among the other Sox6 effects in erythropoiesis, we have noticed that there are more nucleated red blood cells circulating in p100H mutant mice than in WT mice at 14.5 dpc and 18.5 dpc (Figure 7A). However, at postnatal day 10.5, we do not see circulating nucleated red cells in either WT or mutant mice, suggesting that this may be a transient effect. In addition, the mutant liver shows a significant increase in hematopoietic precursor cells including nucleated erythrocytes at 18.5 dpc (Figure 7B). This alteration is noted as early as 14.5 dpc. These observations suggest that besides silencing the epsilony globin gene, Sox6 may affect red cell maturation.","[{'offsets': [[77, 81]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[664, 679]], 'text': ['epsilony globin'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[686, 690]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
256,PMC-3320587-03-Materials_and_Methods,"Cell culture
PBMC from normal unidentified donors were isolated by Ficoll-Hypaque (Pharmacia Corporation, Peapack, NJ) density gradient centrifugation and were cultured in RPMI 1640 medium with 2 mM L-glutamine (BioWhittaker, Inc., Walkersville, MD) supplemented with 10% heat-inactivated fetal calf serum (FCS) (Gemini Bio-Products, www.gembio.com). Human monocytes were isolated from PBMC preparations by positive selection with CD14 microbeads from Miltenyi Biotec (www.miltenyibiotec.com) as described by the manufacturer, and were cultured at 1x106 cells per well in 6-well plates in Macrophage-SFM medium (Gibco, www.invitrogen.com) supplemented with 15 ng/ml recombinant human MCSF (R&D, www.rndsystems.com) and 5% heat-inactivated human AB serum (Nabi, Boca Raton, FL). The cell cultures were incubated at 37degreesC and 5% CO2 for 5 days, after which supernatant was replaced with fresh medium lacking MCSF before manipulation. More than 95% of the adherent cells obtained with this technique were CD14+ macrophages as verified by flow cytometry. THP-1 cells were obtained from ATCC (www.atcc.org) and cultured in RPMI 1640 medium supplemented with 10% FCS (BioWhittaker, www.lonzabio.com). 293T cells were obtained from ATCC (www.atcc.org) and were maintained in Dulbecco's Modified Eagle's medium (DMEM) (Gibco, www.invitrogen.com) supplemented with 10% FCS.","[{'offsets': [[431, 435]], 'text': ['CD14'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[684, 688]], 'text': ['MCSF'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[911, 915]], 'text': ['MCSF'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[1007, 1011]], 'text': ['CD14'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
257,PMC-3589482-06-Experimental_Procedures,"Construction of SerpinB2 Reporter Gene Plasmids
The PCR primers DW5'LUC, containing a Kpn I restriction site, and DW3'LUC, containing an Xho I restriction site, were used to PCR amplify and clone the SerpinB2 promoter (-3261 to +92) from pDB9406 into the Kpn I/Xho I polylinker restriction sites of pGL3 Basic (Promega) to produce pGLmP-3261. The EcoR I insert of pDB9402-42 was sub-cloned immediately upstream of the SerpinB2 promoter EcoR I site (-3261) of pGLmP-3261 to produce pGLmP-4480. Additional murine SerpinB2 luciferase reporter constructs (pGLmP-2751, pGLmP-2614, pGLmP-1686, pGLmP-1341, pGLmP-694, pGLmP-539 and pGLmP-189) were generated by digesting pGLmP-3261 with EcoR I and a second restriction enzyme (Sfi I, Apa I, BstX I, Bsu36 I, Pac I, Hae III and Apo I respectively), blunt ending the resultant 5' or 3' overhangs with T4 DNA polymerase (NEB) and re-ligating the vector ends with T4 DNA ligase. The PCR primers BSPCR2 and DW3'LUC were used to subclone the murine SerpinB2 promoter regions -87 to +92 into the Kpn I/Xho I polylinker restriction sites of pGL3 Basic to produce pGLmP-87. The control empty vector was pGL3 Basic (Promega).
Luciferase reporter constructs containing mutations in the SerpinB2 promoter LPS-responsive regions E box, PU.1, Oct-1 and C/EBP (pGLmP-539mEbox, pGLmP-539mPU.1, pGLmP-539mOct and pGLmP-539mC/EBP respectively) were generated as described [36]. The mutant oligonucleotide PCR primer sequences are provided in Fig. S1, and were used as follows: pGLmP-539mEbox: mPAI2mEboxa and mPAI2mEboxb; pGLmP-539mPU.1: mPAI2mPU.1a and mPAI2mPU.1b; pGLmP-539mOct: mPAI2mOct-2a and mPAI2mOct-2b; pGLmP-539mC/EBP: mPAI2mCEBPa and mPAI2mCEBPb. The oligonucleotide PCR primers used to generate mutants, pGLmP-539mCRE, pGLmP-539mAP-1a, and pGLmP-539mAP-1b were reported previously [37]. The flanking oligonucleotide PCR primers were RVprimer3 (Promega) and GLprimer2 (Promega). pGLmP-539 was used as the template in each case. Recombinant PCR products were digested with EcoR I and Xho I and cloned between the EcoR I and Xho I restriction sites of pGLmP-539 in place of the -539/+92 region of the wild-type murine SerpinB2 promoter. Sequence verified constructs were used in the experiments.","[{'offsets': [[16, 38]], 'text': ['SerpinB2 Reporter Gene'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[200, 208]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[418, 426]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[511, 539]], 'text': ['SerpinB2 luciferase reporter'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[680, 686]], 'text': ['EcoR I'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[720, 725]], 'text': ['Sfi I'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[727, 732]], 'text': ['Apa I'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[734, 740]], 'text': ['BstX I'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[742, 749]], 'text': ['Bsu36 I'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[751, 756]], 'text': ['Pac I'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[758, 765]], 'text': ['Hae III'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[770, 775]], 'text': ['Apo I'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[842, 859]], 'text': ['T4 DNA polymerase'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[903, 916]], 'text': ['T4 DNA ligase'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[986, 994]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1159, 1178]], 'text': ['Luciferase reporter'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1218, 1226]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2009, 2015]], 'text': ['EcoR I'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2020, 2025]], 'text': ['Xho I'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[2153, 2161]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T20'}]",[],[],[],[],[]
258,PMC-3317373-15-4._Discussion,"The present study demonstrated that scratch injury induced the upregulation of NF-kappaB DNA binding activity and overexpression of TNF-alpha, IL-1beta, IL-6, and MMP9 in cultured astrocytes. Also we revealed that scratch injury induced higher activity of NF-kappaB and enhanced expression of proinflammatory cytokines in Nrf2 knockout cultured astrocytes than those in wildtype astrocytes for the first time.
It has been demonstrated that NF-kappaB is activated in brain and spinal cord after traumatic injury [2, 9]. As a transcript factor, NF-kappaB binds with DNA once it was activated and induces transcription of MMP9 and a battery of proinflammatory cytokines, including TNF-alpha, IL-1beta, and IL-6, in brain tissues after TBI [3, 10, 11]. Our results also revealed that scratch injury induced elevation of NF-kappaB DNA binding activity, overexpression of MMP9, and proinflammatory mediators mentioned above in cultured astrocytes. It has been demonstrated that there is an autoregulatory loop among these proinflammatory mediators. For example, TNF-alpha and IL-1beta are potent stimulators for MMP9 in astrocytes [12, 13], and IL-6 induces overexpression of MMP9 in human colon carcinoma cells [14], and TNF-alpha and IL-1beta also can induce activation of NF-kappaB [15, 16]. This autoregulatory loop extremely aggravates the damaging effect of inflammation and induces secondary injury to brain. It is a good choice for targeting on an upstream factor to prevent such autoregulatory loop after TBI.
Nrf2-ARE pathway has been proved to be the key regulator in reducing oxidative stress, inflammatory damage, and accumulation of toxic metabolites, which are all involved in TBI. Our previous study has proved the augmentation of Nrf2 in brain tissue after TBI [17]. Enhanced level of Nrf2 activates transcription of a group of antioxidant genes, such as heme oxygenase-1 (HO-1) and NAD (P)H: quinone oxidoreductase-1 (NQO1), which would subsequently reduce the damage in brain [18]. Postinjury administration of SFN, an inducer of Nrf2, significantly improves spatial memory of rat and decreases the immunoreactivity for 4-Hydroxynonenal (4-HNE), a marker of lipid peroxidation, in the cortex and the CA3 subfield of hippocampus after TBI [19]. On the other hand, Nrf2-deficient mice appear more susceptible to TBI. Depletion of Nrf2 induces higher expression of proinflammatory mediators in brain after TBI [20]. Here, our results revealed that overexpression of TNF-alpha, IL-1beta, IL-6, and MMP9 after scratch injury was more aggravated in cultured Nrf2 knockout astrocytes than in wildtype astrocyetes for the first time, and overexpression of these proinflammatory mediators led to more astrocytes deaths.
Data obtained from animal studies suggest the possibility that antioxidant effect of Nrf2 may be achieved by suppression of proinflammatory pathways which are mediated by NF-kappaB signaling. Administration of SFN is found to be able to inhibit IKK/IkappaB phosphorylation and p65 NF-kappaB subunit nuclear translocation, consequently alleviating NF-kappaB signaling [21]. And NF-kappaB activation induced by lipopolysaccharide (LPS) could be attenuated by diverse Nrf2 activators, such as SFN and curcumin (CUR) [22]. Furthermore, our previous studies indicate that depletion of Nrf2 induces augmentation of NF-kappaB activity and inflammatory response in lung, brain, and intestine after TBI [4, 5, 23]. Results from this study further confirmed such relationship existed in cultured astrocytes after scratch injury. Enhanced activation of NF-kappaB is also discovered in lung, macrophages, and mouse embryonic fibroblasts of Nrf2-deficient mice after experimental sepsis [24]. Interestingly, it is reported that NF-kappaB can inhibit Nrf2 at transcriptional level. NF-kappaB p65 subunit repressed the Nrf2-ARE pathway at transcriptional level by competitive interaction with the CH1-KIX domain of CBP or local histone hypoacetylation [25]. All these findings indicate the potential complicate crosstalk between NF-kappaB and Nrf2, which may be regulated by the upstream mitogen-activated protein kinase (MAPKs) pathway [26].
It has been confirmed that Nrf2 is mainly detected in nucleus of astrocytes after TBI [18]. In view of the fact that Nrf2 is a transcription factor which should take function mainly in nucleus, it can be reasoned that astrocytes may be one kind of respondent cells in activation of Nrf2-ARE pathway after TBI. Previous study identified the expression of TNF-alpha, IL-1beta, and IL-6 in cultured astrocytes after treatment with LPS or oxyhemoglobin [27, 28]. Another study revealed that after middle cerebral artery occlusion, MMP9-positive astrocytes were observed in brain tissues by immunohistochemistry [29]. Those results indicate the role of astrocytes in inflammatory process after brain injury. But till now, there is no study focused on the relationship among astrocytes, Nrf2, and proinflammatory mediators after TBI. Our results demonstrated the upregulated expression of TNF-alpha, IL-1beta, IL-6, and MMP9 in Nrf2 knockout astrocytes after scratch injury for the first time.
In conclusion, depletion of Nrf2 induced the activation of NF-kappaB and the expression of TNF-alpha, IL-1beta, IL-6, and MMP9 resulting in more cell deaths in astrocytes after scratch injury. These results suggest that Nrf2 may be an important target for anti-inflammatory therapy after TBI.","[{'offsets': [[143, 151]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[153, 157]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[163, 167]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[619, 623]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[689, 697]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[703, 707]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[866, 870]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1070, 1078]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1106, 1110]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1139, 1143]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1170, 1174]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1230, 1238]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1866, 1882]], 'text': ['heme oxygenase-1'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1884, 1888]], 'text': ['HO-1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2487, 2495]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2497, 2501]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2507, 2511]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[3001, 3004]], 'text': ['p65'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[3802, 3805]], 'text': ['p65'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[4517, 4525]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[4531, 4535]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[4679, 4683]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[5046, 5054]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[5056, 5060]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[5066, 5070]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[5242, 5250]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[5252, 5256]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[5262, 5266]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T40'}]",[],[],[],[],[]
259,PMC-2817507-11-3._Results,"3.3. Distribution of TLR4 in Brain Subjected to ICH
To explore the distribution of TLR4 protein, the TLR4 was detected by immunohistochemistry (IHC). Results showed that TLR4 immunoreactivity was not detectable in brain tissue from normal and sham control. However, immunoreactivity for TLR4 was consistently demonstrated in peri-hemorrhage areas, the hippocampus, cortex, thalamic nuclei, and some white matter tracts (Figure 3).","[{'offsets': [[21, 25]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[83, 87]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[101, 105]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[170, 174]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[287, 291]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
260,PMC-3589482-11-Experimental_Procedures,"Chromatin Immunoprecipitation (ChIP) Assay
ChIP assays were performed using a commercially available Magna-ChIP(TM) kit (Millipore), as recommended by the manufacturer, with minor modifications. Briefly, after crosslinking the chromatin with 1% formaldehyde at room temperature for 10 min and neutralizing with glycine for 5 min at room temperature, cells were washed with cold PBS, scraped and collected on ice. Cells extracts were prepared using a commercially available kit (Millipore). Nuclear lysates were sonicated 5 times for 15 sec with 1 min intervals on ice using a Sonic Dismembrator (Fisher). An equal amount of chromatin was immunoprecipitated at 4degreesC overnight with at least 1 microg of the following antibodies: C/EBP-beta (sc-150X), p-C/EBP-beta (T217) (sc-16993X), normal rabbit IgG (sc-2027)(Santa Cruz Biotechnologies) and RNA polymerase II (Clone CTD4H8)(Millipore). Immunoprecipitated products were collected after incubation with Protein G coated magnetic beads (Millipore). The beads were washed, the bound chromatin was eluted in ChIP Elution Buffer (Millipore) and the proteins were digested with Proteinase K for 2 hrs at 62degreesC. The DNA was then purified using the QIAquick PCR Purification Kit (Qiagen). DNA was amplified by semi-quantitative PCR or by qPCR using the SYBR green method and primers specific for the SerpinB2 proximal promoter: forward (-338/-315) 5'AAGACTCCCACAGATGGTGGCTGT3'; reverse (-5/+19) 5'TTCTTGGAAAGCTGGCACTGTGTG3'.","[{'offsets': [[957, 966]], 'text': ['Protein G'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[1127, 1139]], 'text': ['Proteinase K'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[1352, 1360]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
261,PMC-3320587-25-Caption-Figure_3,"Specific disruption of NFAT5 or NF-kappaB binding sites in the LTR of HIV-1 subtype B.
(A) Mutations introduced into a HIV-1Lai/Bal-env infectious molecular clone. NF-kappaB and NFAT5 binding site mutations were introduced into the LTR of the HIV-1Lai/Bal-env-wild type (WT) infectious molecular clone. The NF-kappaB binding site mutants (HIV-1Lai/Bal-env-kappaB I-Mut, HIV-1Lai/Bal-env-kappaB II-Mut, HIV-1Lai/Bal-env-kappaB I+II-Mut), and NFAT5 binding site mutant (HIV-1Lai/Bal-env-N5-Mut) are shown along with the HIV-1Lai/Bal-env-WT sequence. Mutations were introduced into the 3' LTR of the HIV-1Lai/Bal-env-WT proviral sequence. (B) Specific mutation of the NFAT5 binding site abolishes NFAT5 binding to the viral LTR but does not affect NF-kappaB p50/p65 binding to the overlapping NF-kappaB binding site. Quantitative DNaseI footprinting analysis is shown using HIV-1 LTR fragments (-262 to +4 nt relative to the transcription start site) from HIV-1Lai/Bal-env-WT and HIV-1Lai/Bal-env-N5-Mut and increasing concentrations of recombinant NF-kappaB (p50/p65) (25 ng, 100 ng, and 500 ng), or NFAT5 (10 ng, 50 ng, and 250 ng). The regions that are protected from DNase I cleavage by the binding of NF-kappaB and NFAT5 are indicated with a bars. (C) Specific disruption of the HIV-1 subtype B NF-kappaB binding sites effectively abrogates recombinant p50/p65 binding. Quantitative DNaseI footprinting analysis is shown of nucleotides -262 to +4 from HIV-1Lai/Bal-env-WT, HIV-1Lai/Bal-env-kappaB I-Mut, HIV-1Lai/Bal-env-kappaB II-Mut, and HIV-1Lai/Bal-env-kappaB I+II-Mut and increasing concentrations of recombinant NF-kappaB (p50/p65) (25 ng, 100 ng, and 500 ng). The regions that are protected from DNase I cleavage by the binding of recombinant NF-kappaB are indicated with a bars. (D) Specific disruption of the HIV-1 subtype B NF-kappaB binding site does not inhibit but enhances NFAT5 binding to this region. Quantitative DNaseI footprinting analysis is shown of nucleotides -262 to +4 from HIV-1Lai/Bal-env-WT, HIV-1Lai/Bal-env-kappaB I-Mut, HIV-1Lai/Bal-env-kappaB II-Mut, and HIV-1Lai/Bal-env-kappaB I+II-Mut and increasing concentrations of recombinant NFAT5 (10 ng, 50 ng, and 250 ng). The regions that are protected from DNase I cleavage by the binding of recombinant NFAT5 are indicated with a bars.","[{'offsets': [[132, 135]], 'text': ['env'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[256, 259]], 'text': ['env'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[352, 355]], 'text': ['env'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[383, 386]], 'text': ['env'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[415, 418]], 'text': ['env'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[481, 484]], 'text': ['env'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[531, 534]], 'text': ['env'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[610, 613]], 'text': ['env'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[694, 699]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[755, 758]], 'text': ['p50'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[759, 762]], 'text': ['p65'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[827, 833]], 'text': ['DNaseI'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[966, 969]], 'text': ['env'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[990, 993]], 'text': ['env'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1057, 1060]], 'text': ['p50'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1061, 1064]], 'text': ['p65'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1098, 1103]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1168, 1175]], 'text': ['DNase I'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1217, 1222]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1355, 1358]], 'text': ['p50'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1359, 1362]], 'text': ['p65'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1385, 1391]], 'text': ['DNaseI'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1467, 1470]], 'text': ['env'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1488, 1491]], 'text': ['env'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1519, 1522]], 'text': ['env'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1555, 1558]], 'text': ['env'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1631, 1634]], 'text': ['p50'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1635, 1638]], 'text': ['p65'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1705, 1712]], 'text': ['DNase I'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1889, 1894]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1932, 1938]], 'text': ['DNaseI'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2014, 2017]], 'text': ['env'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2035, 2038]], 'text': ['env'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2066, 2069]], 'text': ['env'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2102, 2105]], 'text': ['env'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2167, 2172]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2237, 2244]], 'text': ['DNase I'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2284, 2289]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T38'}]",[],[],[],[],[]
262,PMC-3218875-08-Negative_regulation_of_NF-+%A6B_signalling_in_RA,"Single-immunoglobulin IL-1 receptor-related protein
Single-immunoglobulin IL-1 receptor-related (SIGIRR) protein, also known as TIR-8, is a member of the TLR/IL-1R family that has been extensively characterised as an inhibitor of IL-1R and TLR signalling, probably through direct interaction with these receptors, MyD88, IRAK1 or TRAF6 [67] (Figure 1). Given the important role of IL-1R and TLR signalling in the chronic inflammation observed in RA [68], a regulatory role for SIGIRR in RA is not unlikely. SIGIRR has a very restricted expression pattern, being expressed in epithelial cells, monocytes and immature dendritic cells, but not in mature macro-phages [69,70]. Recently, SIGIRR overexpression was shown to inhibit the spontaneous release of inflammatory cytokines by human RA synovial cells. This inhibitory function of SIGIRR was further confirmed in vivo, since SIGIRR-deficient mice developed a more severe disease in zymosan-induced arthritis, as well as collagen-induced arthritis mouse models [70]. It will be interesting to compare the expression of SIGIRR in RA patients with its expression in control patients, or to investigate whether the function of SIGIRR is compromised in RA patients. Because of its restricted expression pattern, SIGIRR may also be an interesting therapeutic target in RA.","[{'offsets': [[0, 43]], 'text': ['Single-immunoglobulin IL-1 receptor-related'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[52, 95]], 'text': ['Single-immunoglobulin IL-1 receptor-related'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[97, 103]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[128, 133]], 'text': ['TIR-8'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[230, 235]], 'text': ['IL-1R'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[314, 319]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[321, 326]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[330, 335]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[381, 386]], 'text': ['IL-1R'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[477, 483]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[507, 513]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[683, 689]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[832, 838]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[876, 882]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1069, 1075]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1174, 1180]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1258, 1264]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T17'}]",[],[],[],[],[]
263,PMC-1064873-12-Results,"Defective IL-10-mediated STAT3 phosphorylation in RA CD4+ T cells
The interaction of IL-10R with IL-10 induces tyrosine phosphorylation and activation of the latent transcription factors STAT1 and STAT3 [3]. Macrophage-specific STAT3-deficient mice demonstrated that STAT3 plays a dominant role in IL-10-mediated anti-inflammatory responses [5], which has recently been confirmed in human macrophages by studies of dominant-negative STAT3 overexpression [30]. The induction of STAT1 and STAT3 phosphorylation by IL-10 in PB CD4+ T cells from active RA patients and from healthy controls was examined using western blotting. STAT3 phosphorylation was dose-dependently induced after IL-10 activation for 20 min in normal CD4+ T cells (Fig. 4a,4b). In contrast, STAT3 was phosphorylated in freshly isolated PB CD4+ cells from RA patients and this STAT3 phosphorylation was detectable for up to 6 hours. STAT3 phosphorylation was augmented only when activated by as much as 10 ng/ml IL-10. Both sustained STAT3 phosphorylation and defective IL-10-induced STAT3 phosphorylation were found in RA ST CD4+ T cells (Fig. 4c). On the other hand, IL-10-induced STAT1 phosphorylation was not detected in either RA CD4+ T cells or normal CD4+ T cells (Fig. 4a). These results indicate that STAT3 is the major IL-10-activated STAT in CD4+ T cells, and IL-10-induced STAT3 activation may be diminished in active RA, in association with sustained STAT3 phosphorylation.","[{'offsets': [[10, 15]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[25, 30]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[53, 56]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[85, 91]], 'text': ['IL-10R'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[97, 102]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[187, 192]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[197, 202]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[228, 233]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[267, 272]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[298, 303]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[433, 438]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[477, 482]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[487, 492]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[512, 517]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[524, 527]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[624, 629]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[681, 686]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[719, 722]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[759, 764]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[807, 810]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[844, 849]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[900, 905]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[979, 984]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1001, 1006]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1037, 1042]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1051, 1056]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1093, 1096]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1136, 1141]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1150, 1155]], 'text': ['STAT1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1202, 1205]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1225, 1228]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1277, 1282]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1296, 1301]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1320, 1323]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1338, 1343]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1352, 1357]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1431, 1436]], 'text': ['STAT3'], 'type': 'Protein', 'id': 'T37'}]",[],[],[],[],[]
264,PMC-3342329-10-Materials_and_Methods,"Tumor Inoculation and Tumor Monitoring
B16 melanoma cells were injected subcutaneously [5x105 tumor cells in 0.1 ml Phosphate buffered saline(PBS)/animal] using a 27 G needle into the right-lower flanks of the carrier mice as previously described [54]. The body weights and tumor volumes of the animals were monitored twice weekly. The tumor volumes were measured with Vernier calipers and calculated using the following formula: (AxB2)/2, where A is the larger and B is the smaller of the two dimensions. At the end of the experiment, the animals were sacrificed. The tumors were separated from the surrounding muscles and dermis.",[],[],[],[],[],[]
265,PMC-3589482-18-Results,"C/EBP-beta is a LPS-induced Nuclear Factor that Binds to the C/EBP Element of the SerpinB2 Proximal Promoter
The C/EBP family of basic leucine zipper transcription factors are known for their roles in cellular differentiation and inflammation [59]. Consisting of six members, the C/EBP transcription factors can homo-/heterodimerize and display similar DNA binding specificities [60]. Four family members, C/EBP-alpha, C/EBP-beta, C/EBP-delta and C/EBP-epsilon, are present in myeloid cells and play different roles in differentiating myeloid cells depending on the extracellular environment [61]. To determine which C/EBP proteins were involved in the formation of the different nucleo-protein complexes, and particularly of the LPS-inducible complex, EMSA was performed after incubating the nucleo-protein complexes with antibodies specific for C/EBP-alpha, C/EBP-beta, C/EBP-delta and C/EBP-epsilon. Each antibody detects the carboxy-terminal DNA-binding region of the respective protein, so that pre-incubation of antibody with nuclear extract is expected to abolish DNA binding by EMSA [62]. Only antibodies against C/EBP-beta abolished the formation of the LPS-inducible complex (Fig. 5C). Taken together these data show that the LPS-induced complex with the C/EBP element (-203/-192) contains C/EBP-beta.","[{'offsets': [[0, 10]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[82, 90]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[406, 417]], 'text': ['C/EBP-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[419, 429]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[431, 442]], 'text': ['C/EBP-delta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[447, 460]], 'text': ['C/EBP-epsilon'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[847, 858]], 'text': ['C/EBP-alpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[860, 870]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[872, 883]], 'text': ['C/EBP-delta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[888, 901]], 'text': ['C/EBP-epsilon'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1121, 1131]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1300, 1310]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
266,PMC-3342329-06-Results,"Induction of CD8 T cells and NK Cell Infiltration into Tumor and Spleen of CCR5-/- Mice
To investigate whether the inhibition of tumor growth in CCR5-/- mice is related to tumor-specific immune responses, we analyzed the distribution patterns of CD8+ cytotoxic T cell and CD57+ Natural Killer cells in tumor and spleen tissues. By staining the tumor sections from CCR5-/- mice, we found that there was a significant influx of CD8+ cells into the tumor, as well as an increase in the number of infiltrating NK cells (Figure 5A). CD8+ T cells and CD57+ NK cells were spread diffusely throughout the entire sections. To further investigate the differences in the numbers of CD8+ T cells and CD57+ NK cells between CCR5+/+ mice and CCR5-/- mice in immunity-related organ, we also analyzed the CD8 and CD57 reactive cell number in spleen tissues. The number of CD8+ T cells and CD57+ NK cells were higher in the spleen of the CCR5-/- mice than in the spleen of the CCR5+/+ mice (Figure 5B). These data suggest that by promoting the infiltration of CD8 T cells and NK cells, which are potent cytotoxic effectors for tumors, could play a role in an anti-tumor effect in CCR5-/- mice.
To analyze the cell phenotype change in CCR5-/- mice and CCR5+/+ mice by inoculation of the melanoma cell, lymphocytes were isolated from the tumor and spleen tissues. The B, CD3 T, CD4 T, CD 8 T and NK cell portion of CCR5-/- mice tumor tissue were 7.2%, 48.2%, 16.9%, 32.1% and 7.8%, respectively, compared to 2.9%, 11.1%, 2.3%, 0.6% and 3.1% of CCR5+/+ mice (Figure 5C). The lymphocytes that infiltrated the tumor tissue of the CCR5-/- mice also had higher levels of CD19, CD3, CD4, CD8 and CD57 when compared to the CCR5+/+ mice. The B, CD3 T, CD4 T, CD 8 T and NK cell portion of the CCR5-/- mice spleen were 61.3%, 33.4%, 17.6%, 9.2% and 0.6%, respectively compared to 38.3%, 5.9%, 4.0%, 1.0% and 3.9% of the CCR5+/+ mice (Figure 5D). These data suggest that by promoting the infiltration of CD8 T cells and NK cells, which are potent cytotoxic effectors for tumors, could play a role in the inhibition of tumor growth in CCR5-/- mice.","[{'offsets': [[75, 79]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[145, 149]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[364, 368]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[711, 715]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[728, 732]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[921, 925]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[960, 964]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1163, 1167]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1217, 1221]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1234, 1238]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1359, 1362]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1396, 1400]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1525, 1529]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1608, 1612]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1647, 1651]], 'text': ['CD19'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1658, 1661]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1697, 1701]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1725, 1728]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1766, 1770]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1892, 1896]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[2105, 2109]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T21'}]",[],[],[],[],[]
267,PMC-3342329-19-Caption-Figure_2,"Decrease of NF-kappaB activity in tumor tissue of CCR5-/- mice.
A, The DNA binding activity of NF-kappaB was determined in the nuclear extracts of the CCR5-/- mice and CCR5+/+ mice tumor tissues by EMSA described in material and methods. B, Expression of p50 and p65 phosphorylation in nuclear extracts (NE), and IkappaB and IkappaB phosphorylation in the cytosol (CE) determined by Western blotting. C, Immunolfluorescence analysis of p50 confirmed that the intensities of nuclear staining for p50 were decreased in the tumor tissues of CCR5-/- mice. Data are means +/- S.D. of four experimental animals. * indicates significant difference from CCR5+/+ mice (p<0.05). Scale bar indicates 50 microm.","[{'offsets': [[50, 54]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[151, 155]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[168, 172]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[255, 258]], 'text': ['p50'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[263, 266]], 'text': ['p65'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[436, 439]], 'text': ['p50'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[495, 498]], 'text': ['p50'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[538, 542]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[646, 650]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T9'}]",[],[],[],[],[]
268,PMC-1472690-03-Results,"Cytokine profile of human PBMC following a 48 h in vitro stimulation with LPS, TSST-1, GP, GP + LPS and GP + TSST-1
Because of the GP-induced band shifts to seven sites from the TNFalpha, IL-8, IL-6 and IFNgamma promoters, it could be assumed that GP treatment of human PBMC would lead to production of TNFalpha, IL-8, IL-6, IFNgamma and other pro-inflammatory mediators. Previous studies reported that beta-1 to 3-D-glucans induced only a limited cytokine secretion of human blood cells [15-18]. Corroborating and extending these singular findings in terms of examining pro- (eight) as well as anti- (three) inflammatory cytokines over time (48 h) and six additional transcription factor binding sites, our comprehensive analysis revealed the following cytokine profile of human leukocytes in response to a highly purified water soluble beta-1 to 3-D-glucan and in comparison to two pro-inflammatory mediators (LPS, TSST-1):
(i) IL-1beta
There was no IL-1beta production detectable following PBMC treatment with 1 nor 100 mug GP. An insignificant up-regulation of IL-1beta production for GP + LPS was observed in comparison with LPS. For GP + TSST-1 we found a significant reduction in IL-1beta from 18 h - 24 h, for the latter by about 40% when compared to TSST-1 or the theoretical value of GP/TSST-1 calc. (n = 6; both p = 0.01). On the whole, GP mediated a reduction of the TSST-1-induced amount of IL-1beta by about 50% (Fig. 3A).
(ii) IL-6
GP induced only a small amount of IL-6 and there was no significant alteration of the LPS-induced IL-6 production by GP. On the contrary, we observed a decreased IL-6 production for GP + TSST-1 when compared to TSST-1 or GP/TSST-1 calc., especially at 24 h by about 40% (n = 5; both p = 0.02), (data not shown in detail).
(iii) IL-8
We found that GP induced a substantial IL-8 production, in comparison with medium control, especially at 24 h (n = 13; p < 0.01). A combination of GP and LPS resulted in a non-significant increase of IL-8 production when compared to LPS or GP/LPS calc. There was no significant alteration in IL-8 production following GP + TSST-1 when compared to TSST-1 or GP/TSST-1 calc. (data not shown in detail).
(iv) IL-1RA
Besides IL-8, IL-1RA was the only mediator which was produced in significant quantities following GP treatment, especially at 24 h (n = 14, p < 0.01). When compared to LPS stimulation or GP/LPS calc., GP + LPS did not alter the kinetic course of the IL-1RA production. However, following GP + TSST-1 we found a synergistic increase in IL-1RA production from 18 h to 48 h, when compared to TSST-1 (for instance at 24 h: n = 6; p = 0.01) or to the theoretical value of GP/TSST-1 calc. (from 18 h to 36 h). Over the time course of 48 h, GP elevated the TSST-1-induced amount of IL-1RA by approximately 200% (Fig. 3B).
Positive correlation between GP-induced IL-8 and IL-1RA productions. Following stimulation with GP (24 h), we observed a positive correlation between IL-8 and IL-1RA. Moreover, we found this correlation to be dose-dependent, since 100 mug of GP induced larger amounts of IL-8 and IL-1RA than 1 mug GP (n = 5, p <= 0.002, r = 0.9 and 0.98, respectively).
(v) TNFalpha
With respect to TNFalpha production, 100 mug of GP yielded minor, statistically not distinguishable amounts, when compared to medium control. GP + LPS did not change the TNFalpha production when compared to LPS supplementation or GP/LPS calc. When combined with TSST-1 or GP/TSST-1 calc., GP seemed to exert a synergistic effect on TNFalpha secretion after 36 h (n = 3; p < 0.05), but overall an enhancement of only 10% was observed (p > 0.05; data not shown in detail).
(vi) IFNgamma
No IFNgamma production was detectable following treatment of PBMC with 100 mug GP. There was a minor increase in IFNgamma production following GP + LPS at 36 h, when compared to LPS or GP/LPS calc., and a slight down-regulation following GP + TSST-1 at 24 h and 36 h, when compared to TSST-1 or GP/TSST-1 calc. (data not shown).
(vii) IL-2, IL-12, IL-4, IL-10, TGFbeta1
The production of IL-2, IL-12, IL-4, IL-10 and TGFbeta 1 was not induced by GP. There were also no significant differences between medium control, LPS, TSST-1, GP, GP + LPS, GP/LPS calc. and GP + TSST-1 or GP/TSST-1 calc. over 48 h (data not shown).","[{'offsets': [[79, 85]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[109, 115]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[178, 186]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[188, 192]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[194, 198]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[203, 211]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[303, 311]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[313, 317]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[319, 323]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[325, 333]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[917, 923]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[930, 938]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[952, 960]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1065, 1073]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1144, 1150]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1187, 1195]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1259, 1265]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1297, 1303]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1379, 1385]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1404, 1412]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1442, 1446]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1481, 1485]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1545, 1549]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1609, 1613]], 'text': ['IL-6'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1634, 1640]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1658, 1664]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1671, 1677]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1775, 1779]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1819, 1823]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1980, 1984]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[2072, 2076]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2103, 2109]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2127, 2133]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[2140, 2146]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[2186, 2192]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[2201, 2205]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[2207, 2213]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[2443, 2449]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[2486, 2492]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[2528, 2534]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[2582, 2588]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[2663, 2669]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[2743, 2749]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[2768, 2774]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[2848, 2852]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[2857, 2863]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[2958, 2962]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[2967, 2973]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[3079, 3083]], 'text': ['IL-8'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[3088, 3094]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[3166, 3174]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[3191, 3199]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[3345, 3353]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[3437, 3443]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[3450, 3456]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[3507, 3515]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T56'}, {'offsets': [[3651, 3659]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T57'}, {'offsets': [[3663, 3671]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T58'}, {'offsets': [[3773, 3781]], 'text': ['IFNgamma'], 'type': 'Protein', 'id': 'T59'}, {'offsets': [[3903, 3909]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T60'}, {'offsets': [[3945, 3951]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T61'}, {'offsets': [[3958, 3964]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T62'}, {'offsets': [[3995, 3999]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T63'}, {'offsets': [[4001, 4006]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T64'}, {'offsets': [[4008, 4012]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T65'}, {'offsets': [[4014, 4019]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T66'}, {'offsets': [[4021, 4029]], 'text': ['TGFbeta1'], 'type': 'Protein', 'id': 'T67'}, {'offsets': [[4048, 4052]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T68'}, {'offsets': [[4054, 4059]], 'text': ['IL-12'], 'type': 'Protein', 'id': 'T69'}, {'offsets': [[4061, 4065]], 'text': ['IL-4'], 'type': 'Protein', 'id': 'T70'}, {'offsets': [[4067, 4072]], 'text': ['IL-10'], 'type': 'Protein', 'id': 'T71'}, {'offsets': [[4077, 4086]], 'text': ['TGFbeta 1'], 'type': 'Protein', 'id': 'T72'}, {'offsets': [[4182, 4188]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T73'}, {'offsets': [[4226, 4232]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T74'}, {'offsets': [[4239, 4245]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T75'}]",[],[],[],[],[]
269,PMC-3218875-00-TIAB,"Negative regulation of NF-kappaB and its involvement in rheumatoid arthritis
The transcription factor NF-kappaB plays crucial roles in the regulation of inflammation and mmune responses, and inappropriate NF-kappaB activity has been linked with many autoimmune and inflammatory diseases, including rheumatoid arthritis. Cells employ a multilayered control system to keep NF-kappaB signalling in check, including a repertoire of negative feedback regulators ensuring termination of NF-kappaB responses. Here we will review various negative regulatory mechanisms that have evolved to control NF-kappaB signalling and which have been implicated in the pathogenesis of rheumatoid arthritis.",[],[],[],[],[],[]
270,PMC-3312845-04-Methods,"Seizure induction
Three days after surgery, rats were treated with pilocarpine (380 mg/kg, i.p.; Sigma-Aldrich Co., St. Louis, MO) at 20 min after methylscopolamine (5 mg/kg, i.p.; Sigma-Aldrich Co., St. Louis, MO). Using this treatment paradigm, behavioral seizures typically began within 20-40 min. Approximately 80% of pilocarpine treated rats showed acute behavioral features of SE (including akinesia, facial automatisms, limbic seizures consisting of forelimb clonus with rearing, salivation, masticatory jaw movements, and falling). We applied the 2 hr-SE rat model, because > 90% of the rats that we monitored in our previous studies [25] displayed spontaneous, recurrent seizures within 1-3 months after pilocarpine-induced status epilepticus. Diazepam (10 mg/kg, i.p.; Hoffman Ia Roche, Neuilly sur-Seine) was administered 2 hours after onset of SE and repeated, as needed. The rats were then observed 3 - 4 hours a day in the vivarium for general behavior and occurrence of spontaneous seizures. Non-experienced SE (non-SE) rats (showing only acute seizure behaviors during 10 - 30 min, n = 8) and age-matched normal rats were used as controls (n = 7).",[],[],[],[],[],[]
271,PMC-1472690-10-Methods,"Isolation of human PBMC
Buffy coats were obtained from healthy blood donors in compliance with the Helsinki declaration and with the approval of the ethics committee of the University of Luebeck. The buffy coats were separated over a Ficoll-Hypaque (Biochrom, Berlin, Germany) gradient [54,55]. Following isolation, PBMC were cultured at a final concentration of 3 x 106 cells/ml (for ELISA measurements) or 5 x 106/ml (for gel shifts) or 1 x 106 cells/ml (for flow cytometry) in RPMI 1640 medium (BioWhittaker, Heidelberg, Germany, LPS-free), containing 10% heat-inactivated fetal calf serum (FCS, low-LPS, Invitrogen, Karlsruhe, Germany), 1% penicillin (10000 U/ml), 1% streptomycin (10000 mug/ml), and 1% 200 mM L-glutamine (BioWhittaker).",[],[],[],[],[],[]
272,PMC-1472690-08-Conclusion,"In summary, our data demonstrated that in vitro glucan phosphate induced a transcription factor binding and a subsequent cytokine profile different from LPS and also from TSST-1 and, moreover, switched a pro-inflammatory TSST-1-induced response to an IL-1RA-mediated anti-inflammatory reaction. Our results also generated new insights into a very complex interplay of transcription factor binding to various known and newly identified sites in the IL-1RA promoter (Fig. 8), which can be regulated differentially by a fungal carbohydrate. Together with the in vivo studies [22,37], our findings might support the concept of protective effects mediated by glucan phosphate in pro-inflammatory conditions, especially with a dysregulated IL-1beta/IL-1RA ratio [52,53].","[{'offsets': [[171, 177]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[221, 227]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[251, 257]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[448, 454]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[734, 742]], 'text': ['IL-1beta'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[743, 749]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T6'}]",[],[],[],[],[]
273,PMC-3291650-10-Materials_and_Methods,"In vivo intracellular GrB and IFNgamma staining of activated CD8+ T cells
Granzyme B (GrB) and IFNgamma expressing CD8+ T cells were determined by treating the mice intranasally with 50 microg Brefeldin A (Sigma) as previously described [86]. 6 h later, BAL and lungs were isolated and single cell suspensions were prepared from the lung in the presence of 3 microg/ml Brefeldin A. Cells were stained, fixed and permeabilized (Cytofix/Cytoperm, BD Biosciences) according to the manufacturer's instructions. Activated CD8+ T cells were analyzed by flow cytometry based on CD62lo CD3+ and CD8+ expression. Live/Dead fixable aqua dead cell stain kit (Molecular Probes) was used to discriminate live from dead cells.","[{'offsets': [[22, 25]], 'text': ['GrB'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[61, 64]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[74, 84]], 'text': ['Granzyme B'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[86, 89]], 'text': ['GrB'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[115, 118]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[517, 520]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[578, 581]], 'text': ['CD3'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[587, 590]], 'text': ['CD8'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
274,PMC-3317373-10-2._Methods_and_Materials,"2.9. Statistical Analysis
Data were expressed as mean +/- SD and evaluated by ANOVA and LSD multiple comparison test. P values <0.05 were considered to be significant. All analyses were performed by using SPSS 18.0 software.",[],[],[],[],[],[]
275,PMC-3589482-28-Caption-Figure_5,"The LPS-inducible nuclear factor binding the murine SerpinB2 proximal promoter C/EBP site contains C/EBP-beta.
(A) EMSA with nuclear extracts from untreated (UN) and 10 hr LPS treated (LPS) RAW 264.7 cells incubated with either the murine SerpinB2 promoter -212/-185 probe containing an intact (SerpinB2 C/EBP) or mutated (mutant C/EBP) C/EBP site or with the rat albumin promoter DEI region C/EBP (rat albumin C/EBP) probe. (B) Cold competition EMSAs performed with the radiolabelled murine SerpinB2 promoter -212/-185 probe and a 100-fold molar excess of each of the double stranded oligonucleotides described in (A) demonstrate the specificity of the DNA-protein complexes. (C) Supershift assays were performed with the -212/-185 probe by after preincubation with the indicated specific C/EBP antibody. The LPS-inducible complex is indicated with an arrowhead.","[{'offsets': [[52, 60]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[99, 109]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[239, 247]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[295, 303]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[364, 371]], 'text': ['albumin'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[403, 410]], 'text': ['albumin'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[492, 500]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
276,PMC-1359074-03-Results,"Transfection Studies Using GM979 Cells Indicate That Sox6 Directly Represses the epsilony Gene Promoter at the Transcriptional Level
Real-time PCR assays (Figure 1) measure steady-state levels of epsilony mRNA, not transcriptional activity of the epsilony promoter. To investigate whether Sox6 directly acts on the epsilony gene promoter at the transcriptional level, we used an in vitro transient transfection assay and GM979 cells, a murine erythroleukemic cell line that expresses both epsilony and adult beta globins [30]. We generated an epsilony promoter reporter construct (E-Luc) by fusing a micro-LCR (muLCR) element (2.5 kb) [31] to the epsilony proximal promoter (2.2 kb), followed by the luciferase reporter gene, as shown in Figure 2A (detailed in Materials and Methods). Overexpression of Sox6 in GM979 cells by transient transfection leads to a dosage-dependent repression of E-Luc reporter activity (Figure 2B). In contrast, overexpression of a truncated Sox6 protein that lacks its HMG domain [32] (similar to the p100H mouse allele) fails to repress E-Luc activity (Figure 2B). These data indicate that Sox6 acts to repress the epsilony promoter at the transcriptional level.
Sox6 has been shown to act as a repressor and to interact with a widely expressed co-repressor, CtBP2, on the fgf-3 promoter [5]. CtBP2 is expressed in GM979 cells (unpublished data). To investigate whether the interaction with CtBP2 is required for Sox6 repression of the epsilony promoter, we introduced a point mutation (L386H) in the Sox6 protein that has been previously reported to be sufficient to abolish Sox6-CtBP2 interaction [5]. This amino acid change is not in the HMG DNA binding domain. However, this mutant version of Sox6 retains the ability to repress the epsilony promoter in the transfection assay (Figure 2B), indicating that Sox6 represses the epsilony promoter in a CtBP2-independent manner. Deletion analysis of the epsilony promoter, as shown in Figure 2C, defined a region (-63 to -37) within the epsilony proximal promoter that is critical for Sox6 repression. Analysis of this short region reveals two Sox/Sox6 consensus binding sites [5] (Figure 3A).","[{'offsets': [[53, 57]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[81, 89]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[196, 204]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[247, 255]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[289, 293]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[315, 323]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[489, 497]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[508, 520]], 'text': ['beta globins'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[543, 551]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[647, 655]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[700, 710]], 'text': ['luciferase'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[803, 807]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[971, 975]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1121, 1125]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1146, 1154]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1194, 1198]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1290, 1295]], 'text': ['CtBP2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1304, 1309]], 'text': ['fgf-3'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1324, 1329]], 'text': ['CtBP2'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1422, 1427]], 'text': ['CtBP2'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1444, 1448]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1467, 1475]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1532, 1536]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1607, 1611]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1612, 1617]], 'text': ['CtBP2'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1728, 1732]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1768, 1776]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1841, 1845]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1860, 1868]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1883, 1888]], 'text': ['CtBP2'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1934, 1942]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[2017, 2025]], 'text': ['epsilony'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[2065, 2069]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T33'}]",[],[],[],[],[]
277,PMC-3312845-24-Caption-Figure_6,"Effect of sTNFp55R infusion on neutrophil infiltration and MIP-2 expression following SE. (A) Neutrophil infiltration in vasogenic edema lesion 1 day after SE. (B) MIP-2 expression in the PC 1 day after SE. (C) Astroglial expression of MIP-2 (arrows). Bars = 12.5 (A and C) and 150 (B) mum. (D) Quantitative analysis of neutrophil infiltration 1 day after SE (mean +/- S.E.M). Significant differences from saline-infused animals, *p < 0.05. (E) Linear regression analysis between the number of infiltrated neutrophils/area in the vasogenic edema region and the area of vasogenic edema in the PC. (F) Quantitative analysis of the number of MIP-2 positive cells per the unit area of vasogenic edema 1 day after SE (mean +/- S.E.M). There is no difference in the number of MIP-2-positive cells per unit area of vasogenic edema between sTNFp55R-infused animals and saline-infused animals. (G) Linear regression analysis between the number of MIP-2 positive cells per unit area in vasogenic edema region and the area of vasogenic edema in the PC.","[{'offsets': [[11, 18]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[59, 64]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[164, 169]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[236, 241]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[639, 644]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[770, 775]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[833, 840]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[938, 943]], 'text': ['MIP-2'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
278,PMC-1472690-22-Caption-Figure_5,"GP modulated TSST-1-induced DNA binding to a new NFATP2/3 site in the IL-1RA promoter. Binding was up-regulated for GP + LPS and GP + TSST-1, when compared to GP and, in the latter case, to both GP and TSST-1 (* = p < 0.05). Human PBMC were incubated with medium control, LPS, TSST-1, GP, GP + TSST-1 and GP + LPS for 1 h at 37degreesC. Schematic representation of the elevated NFAT-DNA binding activity to the site in the IL-1RA promoter. Bars depicting the theoretical values for GP/LPS calc. and GP/TSST-1 calc. are added. Medium control levels were set equal to 1 +/- SEM (n = 6). An autoradiogram of a representative experiment is shown in the lower panel (lane 1: water; lane 2: medium control; lane 3: GP; lane 4: LPS; lane 5: TSST-1, lane 6: GP + LPS; lane 7: GP + TSST-1).","[{'offsets': [[13, 19]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[70, 76]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[134, 140]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[202, 208]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[277, 283]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[294, 300]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[378, 382]], 'text': ['NFAT'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[423, 429]], 'text': ['IL-1RA'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[502, 508]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[734, 740]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[773, 779]], 'text': ['TSST-1'], 'type': 'Protein', 'id': 'T11'}]",[],[],[],[],[]
279,PMC-3312845-15-Results,"SMI-71 expression
Previously, we reported that SMI-71 (an endothelial barrier antigen) immunoreactivity decreased in the PC 1 day after SE [5]. Similarly, in 1 day-post SE animals of the saline-infused group, loss of SMI-71 immunoreactivity was detected in layer III/IV of the PC as compared to non-SE animals (Figures 4B and 5C-E, p < 0.05). Thus, loss of SMI-71 immunoreactivity correlated with volume of vasogenic edema following SE. This reduction in SMI-71 was accompanied by increased p65-Thr435 phosphorylation (Figures 5C-D). Therefore, the degree of SMI-71 immunoreactivity was inversely correlated to p65-Thr435 phosphorylation with a linear coefficient of correlation of -0.6324 (p < 0.05; Figure 4C). In addition, sTNFp55R infusion effectively alleviated p65-Thr435 phosphorylation and preserved SMI-71 immunoreactivity in endothelial cells following SE, as compared to saline infusion (p < 0.05; Figures 4A-B, 5D and 5F).","[{'offsets': [[491, 494]], 'text': ['p65'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[611, 614]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[727, 734]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[767, 770]], 'text': ['p65'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
280,PMC-3218875-12-Caption-Figure_1,"Canonical NF-kappaB signalling and negative regulators. Ligand engagement of specific membrane receptors such as TNFR1, CD40, RANK, and TLR4 trigger the recruitment of specific adaptor proteins (TNF receptor 1-associated death domain protein (TRADD), MyD88, MAL, TIR domain-containing adaptor-inducing IFNbeta (TRIF)), kinases (RIP1, IRAK1, IRAK4), and ubiquitin ligases (TRAF2, TRAF6, cIAP1, cIAP2) to the receptor. K63-linked polyubiquitination of TRAFs, RIP1 and IRAK1, is recognised by NEMO and TAB proteins, resulting in the recruitment and activation of respectively IKK2 and TAK1. TAK1 then phosphorylates and activates IKK2, which in turn phosphorylates IkappaBalpha, triggering its K48-linked ubiquitination and proteasomal degradation. This allows NF-kappaB (here shown as a heterodimer of p65 and p50) to translocate to the nucleus and promote target gene expression. TRAF1, which has no ubiquitin ligase activity, can negatively regulate NF-kappaB activation, most probably by competing with other TRAFs. A20 and CYLD are deubiquitinating enzymes that control NF-kappaB activation by targeting specific signalling proteins including RIP1 and TRAF6, to which they are recruited using specific ubiquitin-binding adaptor proteins such as ABIN-1 and p62. miR-146 is thought to negatively regulate TLR signalling by inhibiting expression of IRAK1 and TRAF6. Finally, TLR signalling can also be inhibited by the transmembrane protein SIGIRR, which has been proposed to compete with TLR4 for binding to IRAK1 and TRAF6. The expression of many of these negative regulatory molecules is NF-kappaB dependent, implicating them in the negative feedback regulation of NF-kappaB activation. ABIN, A20-binding inhibitor of NF-kappaB; cIAP, cellular inhibitor of apoptosis; CYLD, cylindromatosis; IKK, IkappaB kinase; IkappaB, inhibitor of NF-kappaB; IRAK, IL-1R-associated kinase; MyD88, myeloid differentiation primary response gene 88; NEMO, NF-kappaB essential modulator; NF, nuclear factor; RANK, receptor activator of NF-kappaB; RIP1, receptor interacting protein 1; SIGIRR, single-immunoglobulinIL-1 receptor-related; TIR, Toll-like receptor/IL-1R; TRAF, TNF receptor-associated factor; TLR, Toll-like receptor; TNF, tumour necrosis factor.","[{'offsets': [[113, 118]], 'text': ['TNFR1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[120, 124]], 'text': ['CD40'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[126, 130]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[136, 140]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[195, 241]], 'text': ['TNF receptor 1-associated death domain protein'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[243, 248]], 'text': ['TRADD'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[251, 256]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[258, 261]], 'text': ['MAL'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[263, 309]], 'text': ['TIR domain-containing adaptor-inducing IFNbeta'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[311, 315]], 'text': ['TRIF'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[328, 332]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[334, 339]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[341, 346]], 'text': ['IRAK4'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[372, 377]], 'text': ['TRAF2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[379, 384]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[386, 391]], 'text': ['cIAP1'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[393, 398]], 'text': ['cIAP2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[457, 461]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[466, 471]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[490, 494]], 'text': ['NEMO'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[573, 577]], 'text': ['IKK2'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[582, 586]], 'text': ['TAK1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[588, 592]], 'text': ['TAK1'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[627, 631]], 'text': ['IKK2'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[662, 674]], 'text': ['IkappaBalpha'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[800, 803]], 'text': ['p65'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[808, 811]], 'text': ['p50'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[879, 884]], 'text': ['TRAF1'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1017, 1020]], 'text': ['A20'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1025, 1029]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T30'}, {'offsets': [[1145, 1149]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T31'}, {'offsets': [[1154, 1159]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T32'}, {'offsets': [[1247, 1253]], 'text': ['ABIN-1'], 'type': 'Protein', 'id': 'T33'}, {'offsets': [[1258, 1261]], 'text': ['p62'], 'type': 'Protein', 'id': 'T34'}, {'offsets': [[1348, 1353]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T35'}, {'offsets': [[1358, 1363]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T36'}, {'offsets': [[1440, 1446]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T37'}, {'offsets': [[1488, 1492]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T38'}, {'offsets': [[1508, 1513]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T39'}, {'offsets': [[1518, 1523]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T40'}, {'offsets': [[1689, 1693]], 'text': ['ABIN'], 'type': 'Protein', 'id': 'T41'}, {'offsets': [[1695, 1729]], 'text': ['A20-binding inhibitor of NF-kappaB'], 'type': 'Protein', 'id': 'T42'}, {'offsets': [[1770, 1774]], 'text': ['CYLD'], 'type': 'Protein', 'id': 'T43'}, {'offsets': [[1776, 1791]], 'text': ['cylindromatosis'], 'type': 'Protein', 'id': 'T44'}, {'offsets': [[1878, 1883]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T45'}, {'offsets': [[1885, 1933]], 'text': ['myeloid differentiation primary response gene 88'], 'type': 'Protein', 'id': 'T46'}, {'offsets': [[1935, 1939]], 'text': ['NEMO'], 'type': 'Protein', 'id': 'T47'}, {'offsets': [[1941, 1970]], 'text': ['NF-kappaB essential modulator'], 'type': 'Protein', 'id': 'T48'}, {'offsets': [[1992, 1996]], 'text': ['RANK'], 'type': 'Protein', 'id': 'T49'}, {'offsets': [[1998, 2029]], 'text': ['receptor activator of NF-kappaB'], 'type': 'Protein', 'id': 'T50'}, {'offsets': [[2031, 2035]], 'text': ['RIP1'], 'type': 'Protein', 'id': 'T51'}, {'offsets': [[2037, 2067]], 'text': ['receptor interacting protein 1'], 'type': 'Protein', 'id': 'T52'}, {'offsets': [[2069, 2075]], 'text': ['SIGIRR'], 'type': 'Protein', 'id': 'T53'}, {'offsets': [[2077, 2119]], 'text': ['single-immunoglobulinIL-1 receptor-related'], 'type': 'Protein', 'id': 'T54'}, {'offsets': [[2215, 2218]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T55'}, {'offsets': [[2220, 2242]], 'text': ['tumour necrosis factor'], 'type': 'Protein', 'id': 'T56'}]",[],[],[],[],[]
281,PMC-3317373-14-3._Results,"3.4. Expression and Activity of MMP9 Were Greatly Enhanced in Nrf2 Knockout Astrocytes after Scratch Injury
MMP9 is an important gelatinase to induce or aggravate the inflammation process. In the present study, we elevated the mRNA, protein levels, and activity of MMP9 in astrocytes at 24 h after scratch injury by RT-PCR, western blot, and gelatine zymography. Expression of MMP9 was elevated after scratch injury in WT and KO astrocytes as compared with their sham counterparts. The mRNA level of MMP9 was higher in group KO TBI than in group WT TBI (1.36 +/- 0.090 versus 1.01 +/- 0.068, P < 0.01) (Figures 3(a) and 3(e)). Significant difference was also discovered in MMP9 protein level by western blot, as 1.44 +/- 0.076 for group KO TBI and 1.13 +/- 0.048 for group WT TBI (P < 0.01) (Figure 5). Gelatine zymography revealed higher MMP9 activity in group KO TBI than that in group WT TBI too (101.76 +/- 6.343 versus 76.32 +/- 3.388, P < 0.01) (Figure 6).","[{'offsets': [[32, 36]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[108, 112]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[265, 269]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[377, 381]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[500, 504]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[673, 677]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[839, 843]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
282,PMC-3589482-02-Experimental_Procedures,"Cell Culture
Murine macrophage RAW 264.7 cells (ATCC TIB-71) were maintained in RPMI 1640 media (Gibco BRL), supplemented with 2 mM L-glutamine (Gibco BRL), 10% serum supreme (BioWhittaker), 200 microg/ml penicillin, 100 microg/ml streptomycin, 25 mM N-2-hydroxyethylpiperazine-N-2-ethane sulphonic acid (HEPES) and 25 mM sodium bicarbonate, in 5% CO2 and 95% humidified air atmosphere at 37degreesC. Wild-type (Cebpb+/+) and knockout (Cebpb-/-) mouse embryonic fibroblasts (MEFs) [34] were grown in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin/glutamate solution (Cellgro). Primary peritoneal macrophages were obtained by injecting C57BL/6 mice with 3% thioglycollate broth followed by peritoneal lavage 3-5 days later, and maintained in 50% DMEM/F12 media (Gibco BRL). Precautions were taken to exclude bacterial lipopolysaccharide contamination from all cell cultures through the use of certified LPS-free serum. Cell viability was determined using the trypan blue (Sigma) dye exclusion method. All cultures were routinely checked to exclude Mycoplasma infection by nuclear staining using Hoechst stain 33258 (Sigma) and the MycoAlert Detection Kit (Lonza). Bacterial lipopolysaccharide (LPS) (Salmonella minnesota Strain Re595) was obtained from Sigma.","[{'offsets': [[412, 417]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[436, 441]], 'text': ['Cebpb'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
283,PMC-3585731-33-Caption-Figure_8,"Akt signaling contributes to autocrine TNFalpha production in multiple cell types.
FADD deficient Jurkat cells were treated with TNFalpha followed by measurement of (A) human TNFalpha mRNA levels by qRT-PCR and normalized using human 18S RNA or (B) western blot at 9 hr. RAW 264.7 or J774A.1 cells were treated with zVAD.fmk (100 uM or 50 uM respectively) followed by (C,E) measurement of TNFalpha mRNA levels by qRT-PCR or (D,F) western blot at 9 hr. (G) Akt null mouse lung fibroblasts expressing Myr-Akt or K179M were treated with zVAD.fmk and TNFalpha followed by measurement of TNFalpha mRNA levels by qRT-PCR at 9 hr. (H) Mouse lung fibroblasts expressing only endogenous Akt1 or Akt2 were treated with zVAD.fmk and TNFalpha followed by measurement of TNFalpha mRNA levels by qRT-PCR at 9 hr.","[{'offsets': [[39, 47]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[83, 87]], 'text': ['FADD'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[129, 137]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[175, 183]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[234, 237]], 'text': ['18S'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[389, 397]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[547, 555]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[583, 591]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[678, 682]], 'text': ['Akt1'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[686, 690]], 'text': ['Akt2'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[722, 730]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[758, 766]], 'text': ['TNFalpha'], 'type': 'Protein', 'id': 'T12'}]",[],[],[],[],[]
284,PMC-1064895-16-Results,"IL-17 mRNA expression in RA PBMC
To see whether enhanced IL-17 production could be regulated at a transcriptional level, semi-quantatitive reverse transcription-polymerase chain reaction was performed. We observed a dose-dependent increase in IL-17 mRNA transcripts after stimulation with anti-CD3; this was inhibited by the PI3K inhibitor LY294002 and by the NF-kappaB inhibitor PDTC (Fig. 5).","[{'offsets': [[0, 5]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[57, 62]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[243, 248]], 'text': ['IL-17'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
285,PMC-1064895-02-Materials_and_methods,"Patients
Informed consent was obtained from 24 patients (5 men and 19 women) with RA who fulfilled the 1987 revised criteria of the American College of Rheumatology (formerly the American Rheumatism Association) [17]. The age of the patients with RA was 50 +/- 8 (mean +/- SEM) years (range 23-71 years). All medications were stopped 48 hours before entry to the study. Comparisons were made with 14 patients with OA (3 men and 11 women) and with 14 healthy controls (3 men and 11 women) who had no rheumatic diseases. The mean ages of the patients with OA and the healthy controls were 50 +/- 8 years (range 34-68 years) and 30 +/- 6 years (range 24-57 years). Informed consent was obtained, and the protocol was approved by the Catholic University of Korea Human Research Ethics Committee.",[],[],[],[],[],[]
286,PMC-3586680-05-p53_and_WWOX_Alterations_in_GBMs,"p53 mutants are considered as unfavorable factors for the effectiveness in radiotherapy and TMZ treatment in glioma cells (Gjerset et al., 1995; Hirose et al., 2001; Squatrito et al., 2010; Blough et al., 2011). Loss of functional p53 confers sensitivity to TMZ in glioma cells, whereas wild type p53 increases the TMZ resistance (Blough et al., 2011). p53 mutants reduce TMZ sensitivity in gliomas (Blough et al., 2011).
Altered WWOX expression is shown in GBMs, in which downregulation of WWOX is associated with loss of heterozygosity and promoter methylation (Kosla et al., 2011). Recently, we demonstrated that overexpressed WWOX induces apoptosis of glioblastoma U373-MG cells harboring mutant p53 by causing hypoploidy and DNA fragmentation (Chiang et al., 2012). However, ectopic WWOX has no effect with U87-MG expressing wild type p53. Unlike TMZ, WWOX induces apoptosis of U373-MG cells via a mitochondria-independent and caspase-3-independent pathway (Chiang et al., 2012). While the underlying mechanisms are unknown, it is reasonable to assume that the survival of human glioblastoma cells depends upon interactions between the gain-of-function of p53 mutants and WWOX. Activated WWOX binds wild type p53 with Ser46 phosphorylation (Chang et al., 2005b). UV irradiation enhances the binding interactions. Despite the presence of Ser46 in delta40p53, binding of this protein with WWOX remains to be determined. We postulate that in GBM cells, both wild type p53 and ectopic WWOX proteins appear to have a functional antagonism, thereby nullifying each other's function in inducing apoptosis (Figure 2). Mutant p53 proteins cannot bind ectopic WWOX in GBM cells, and WWOX is able to induce apoptosis. Whether WWOX causes apoptosis in GBM expressing p53 isoforms is unknown and remains to be established.","[{'offsets': [[0, 3]], 'text': ['p53'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[231, 234]], 'text': ['p53'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[297, 300]], 'text': ['p53'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[353, 356]], 'text': ['p53'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[430, 434]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[491, 495]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[630, 634]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[700, 703]], 'text': ['p53'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[788, 792]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[840, 843]], 'text': ['p53'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[857, 861]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[932, 941]], 'text': ['caspase-3'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1161, 1164]], 'text': ['p53'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1177, 1181]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1193, 1197]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1214, 1217]], 'text': ['p53'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1351, 1361]], 'text': ['delta40p53'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1392, 1396]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1470, 1473]], 'text': ['p53'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1486, 1490]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1622, 1625]], 'text': ['p53'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1655, 1659]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1678, 1682]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1720, 1724]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1760, 1763]], 'text': ['p53'], 'type': 'Protein', 'id': 'T25'}]",[],[],[],[],[]
287,PMC-3312845-00-TIAB,"Tumor necrosis factor-alpha-mediated threonine 435 phosphorylation of p65 nuclear factor-kappaB subunit in endothelial cells induces vasogenic edema and neutrophil infiltration in the rat piriform cortex following status epilepticus
Background
Status epilepticus (SE) induces severe vasogenic edema in the piriform cortex (PC) accompanied by neuronal and astroglial damages. To elucidate the mechanism of SE-induced vasogenic edema, we investigated the roles of tumor necrosis factor (TNF)-alpha in blood-brain barrier (BBB) disruption during vasogenic edema and its related events in rat epilepsy models provoked by pilocarpine-induced SE.
Methods
SE was induced by pilocarpine in rats that were intracerebroventricularly infused with saline-, and soluble TNF p55 receptor (sTNFp55R) prior to SE induction. Thereafter, we performed Fluoro-Jade B staining and immunohistochemical studies for TNF-alpha and NF-kappaB subunits.
Results
Following SE, most activated microglia showed strong TNF-alpha immunoreactivity. In addition, TNF p75 receptor expression was detected in endothelial cells as well as astrocytes. In addition, only p65-Thr435 phosphorylation was increased in endothelial cells accompanied by SMI-71 expression (an endothelial barrier antigen). Neutralization of TNF-alpha by soluble TNF p55 receptor (sTNFp55R) infusion attenuated SE-induced vasogenic edema and neuronal damages via inhibition of p65-Thr435 phosphorylation in endothelial cells. Furthermore, sTNFp55R infusion reduced SE-induced neutrophil infiltration in the PC.
Conclusion
These findings suggest that impairments of endothelial cell functions via TNF-alpha-mediated p65-Thr 485 NF-kappaB phosphorylation may be involved in SE-induced vasogenic edema. Subsequently, vasogenic edema results in extensive neutrophil infiltration and neuronal-astroglial loss.","[{'offsets': [[0, 27]], 'text': ['Tumor necrosis factor-alpha'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[70, 73]], 'text': ['p65'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[462, 495]], 'text': ['tumor necrosis factor (TNF)-alpha'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[757, 773]], 'text': ['TNF p55 receptor'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[776, 783]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[892, 901]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[987, 996]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1028, 1044]], 'text': ['TNF p75 receptor'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1131, 1134]], 'text': ['p65'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1278, 1287]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1299, 1315]], 'text': ['TNF p55 receptor'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1318, 1325]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1413, 1416]], 'text': ['p65'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1476, 1483]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1632, 1641]], 'text': ['TNF-alpha'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1651, 1654]], 'text': ['p65'], 'type': 'Protein', 'id': 'T16'}]",[],[],[],[],[]
288,PMC-3342329-00-TIAB,"Deficiency of C-C Chemokine Receptor 5 Suppresses Tumor DevelopmentviaInactivation of NF-?B and Upregulation of IL-1Ra in Melanoma Model
To evaluate the relevance of C-C chemokine receptor type 5 (CCR5) expression and tumor development, we compared melanoma growth in CCR5 knockout (CCR5-/-) mice and wild type (CCR5+/+) mice. CCR5-/- mice showed reduced tumor volume, tumor weight, and increased survival rate when compared to CCR5+/+ mice. We investigated the activation of NF-kappaB since it is an implicated transcription factor in the regulation of genes involving cell growth, apoptosis, and tumor growth. Significant inhibition of DNA binding activity of NF-kappaB, and translocation of p50 and p65 into the nucleus through the inhibition of phosphorylation of IkappaB was found in the melanoma tissues of CCR5-/- mice compared to melanoma tissues of CCR5+/+ mice. NF-kappaB target apoptotic protein expression, such as cleaved caspase-3, cleaved PARP, and Bax, was elevated, whereas the survival protein expression levels, such as Bcl-2, C-IAP1, was decreased in the melanoma tissues of CCR5-/- mice. Interestingly, we found that the level of IL-1Ra, a tumor growth suppressive cytokine, was significantly elevated in tumor tissue and spleen of CCR5-/- mice compared to the level in CCR5+/+ mice. Moreover, infiltration of CD8+ cytotoxic T cell and CD57+ natural killer cells was significantly increased in melanoma tumor and spleen tissue of CCR5-/- mice compared to that of CCR5+/+ mice. Therefore, these results showed that CCR5 deficiency caused apoptotic cell death of melanoma through inhibition of NF-kappaB and upregulation of IL-1Ra.","[{'offsets': [[14, 38]], 'text': ['C-C Chemokine Receptor 5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[112, 118]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[166, 195]], 'text': ['C-C chemokine receptor type 5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[197, 201]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[268, 272]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[283, 287]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[312, 316]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[327, 331]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[428, 432]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[694, 697]], 'text': ['p50'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[702, 705]], 'text': ['p65'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[813, 817]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[858, 862]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1046, 1052]], 'text': ['C-IAP1'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1095, 1099]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1151, 1157]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1253, 1257]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1291, 1295]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1451, 1455]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1484, 1488]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1535, 1539]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1643, 1649]], 'text': ['IL-1Ra'], 'type': 'Protein', 'id': 'T22'}]",[],[],[],[],[]
289,PMC-3320587-29-Caption-Figure_7,"The MyD88-mediated signaling cascade is important for MTb induction of NFAT5 expression in human monocytes.
(A) Engagement of TLR2 significantly enhances NFAT5 mRNA synthesis in monocytes. THP-1 cells were incubated with the TLR2-specific ligand Pam3Cys (5 microg/ml), infected with MTb strain CDC1551 (1:1 cells:bacilli), or left untreated. After 16 hours, NFAT5 mRNA levels were measured. NFAT5 mRNA expression was significantly increased when the cells were incubated with Pam3Cys (*, p<0.05) or infected with MTb (**, p<0.01). (B) MyD88 is important for MTb induction of NFAT5 gene expression in human monocytes. THP-1 cells that constitutively express lentivirally-delivered shRNA targeting MyD88 or control shRNA targeting GFP were constructed as described in Materials and Methods. Cells were infected with MTb strain CDC1551 (1:1 cells:bacilli) or left uninfected for 16 hours at 37degreesC, and RNA was analyzed. NFAT5 mRNA levels were significantly inhibited in the cells transduced with MyD88-specific shRNA (black bars) compared with the cells transduced with control shRNA (open bars) in both, the absence or presence of MTb infection. TNF and CD86 mRNAs, the expression of which are MyD88-dependent and -independent, respectively, during MTb infection, were measured as controls. (C, D) IRAK1 and TRAF6 are required for MTb induction of NFAT5 gene expression in human monocytes. THP-1 cells that constitutively express lentivirally-delivered IRAK1- or TRAF6-specific shRNA were constructed as described in Materials and Methods. THP-1 cells expressing control shRNA were used as described in 7B. Cells were infected with MTb strain CDC1551 or left uninfected for 16 hours at 37degreesC, and RNA was analyzed. NFAT5 expression was significantly inhibited in the MTb-infected cells expressing either IRAK1 (C) or TRAF6 (D) shRNA (black bars) compared to cells expressing control shRNA (open bars). TNF and CD86 mRNAs, both of which require IRAK1 and TRAF6 to be induced by PRR activation, were measured as controls. (*, p<0.05; **, p<0.01).","[{'offsets': [[4, 9]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[71, 76]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[126, 130]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[154, 159]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[225, 229]], 'text': ['TLR2'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[358, 363]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[391, 396]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[535, 540]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[575, 580]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[696, 701]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[729, 732]], 'text': ['GFP'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[922, 927]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[998, 1003]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1149, 1152]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1157, 1161]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1197, 1202]], 'text': ['MyD88'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1301, 1306]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1311, 1316]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1351, 1356]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1456, 1461]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1466, 1471]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1574, 1579]], 'text': ['shRNA'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1723, 1728]], 'text': ['NFAT5'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1812, 1817]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[1825, 1830]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[1891, 1896]], 'text': ['shRNA'], 'type': 'Protein', 'id': 'T26'}, {'offsets': [[1910, 1913]], 'text': ['TNF'], 'type': 'Protein', 'id': 'T27'}, {'offsets': [[1918, 1922]], 'text': ['CD86'], 'type': 'Protein', 'id': 'T28'}, {'offsets': [[1952, 1957]], 'text': ['IRAK1'], 'type': 'Protein', 'id': 'T29'}, {'offsets': [[1962, 1967]], 'text': ['TRAF6'], 'type': 'Protein', 'id': 'T30'}]",[],[],[],[],[]
290,PMC-3585731-08-Results,"PI3-kinase and PDK1 Mediate the Increase in Akt Thr308 Phosphorylation Under Necroptotic Conditions
Typical regulation of Akt by growth factors involves its recruitment to the plasma membrane, which is mediated by the binding of the pleckstrin homology (PH) domain of Akt to the product of PI3K, phosphatidylinositol-3,4,5-triphosphate (PIP3). In the membrane, Akt is phosphorylated on Thr308 and Ser473 by 3-phosphoinositide dependent protein kinase-1 (PDK1) and mTORC2 (or DNA-PK), respectively [35]. Since our results showed that only Thr308 Akt phosphorylation is increased during necroptosis, we next examined whether it is still dependent on PI3K and PDK1. Inhibition of PI3K and PDK1 using the specific inhibitors LY249002 and BX912 [36] resulted in the efficient inhibition of cell death and Akt Thr308 phosphorylation (Fig. S7A-D). Likewise, siRNA knockdown of PDK1 protected cells from death and inhibited Akt Thr308 phosphorylation (Fig. S7E,F) Therefore, PI3K and PDK1 activity is still required for non-canonical Akt activation during necroptosis.","[{'offsets': [[15, 19]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[407, 452]], 'text': ['3-phosphoinositide dependent protein kinase-1'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[454, 458]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[657, 661]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[686, 690]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[870, 874]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[976, 980]], 'text': ['PDK1'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
291,PMC-1472690-09-Methods,"Materials
Water soluble phosphorylated beta-1 to 3-D-glucan (GP) was prepared as done before [20]. The physicochemical characteristics of GP were determined as reported previously [20,26]. GP was dissolved in aqueous media, filter-sterilized (0.2 mum) and screened for endotoxin contamination with the Endospecy assay (Seigakaku, Tokyo, Japan), which is specific for endotoxin but does not respond to beta-1 to 3-D-glucans.",[],[],[],[],[],[]
292,PMC-3317373-09-2._Methods_and_Materials,"2.8. Gelatine Zymography
Cells of four groups were homogenized in lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM CaCl2, 0.2 mM NaN3, and 0.01% Triton. Soluble extracts were separated by centrifugation and stored at -20degreesC. Gelatin zymography was performed according to the manufacturer's instructions (Genmed Scientifics Inc, MA, USA). Briefly, 40 mug cytosolic protein extracts were separated by electrophoresis. Then the proteins were renatured by incubation in 2.5% Triton X-100 and then incubated in substrate buffer for 40 h at 37degreesC to enable the MMP9 to cleave the gelatin. After rinsing in water, each gel was stained with Coomassie blue for 1 h and destained in 50% methanol. Proteolytic activities were showed by clear bands in blue gel which indicates the lysis of the substrate. Quantification of MMP9 band density was performed with image analysis program ImageJ.","[{'offsets': [[583, 587]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[839, 843]], 'text': ['MMP9'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
293,PMC-1064873-06-Materials_and_methods,"Immunoassay for IFN-gamma and IL-2
Concentrations of IFN-gamma and IL-2 in culture supernatants of CD4+ T cells were measured in duplicate by the quantitative sandwich ELISA using cytokine-specific capture with biotinylated detection mAb and recombinant cytokine proteins (all from Becton Dickinson), according to the manufacturer's protocol. The detection limits for IFN-gamma and IL-2 were 15 pg/ml.","[{'offsets': [[16, 25]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[30, 34]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[53, 62]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[67, 71]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[99, 102]], 'text': ['CD4'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[368, 377]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[382, 386]], 'text': ['IL-2'], 'type': 'Protein', 'id': 'T7'}]",[],[],[],[],[]
294,PMC-3589482-01-Introduction,"The inflammatory response is a double-edged sword. Properly orchestrated, it results in the clearing of foreign molecules and invading pathogens from the body. Uncontrolled, it may lead to organ damage, sepsis, and even cancer [1]-[3]. Many of the pathological manifestations of the inflammatory response are mediated by cytokines and other inducible gene products expressed by macrophages upon exposure to the gram-negative bacterial cell wall component LPS. As macrophages are key effectors of pathogen-induced innate immune responses, their survival is critical for initial pathogen neutralization and subsequent development of adaptive immune responses. One of the most LPS-inducible macrophage gene products known is the ovalbumin-like serine protease inhibitor (ov-serpin) SerpinB2, a widely recognized macrophage survival factor [4]; [5]. SerpinB2 was first identified as an inhibitor of urokinase-type plasminogen activator (uPA)[6]-[8], a serine protease involved in the degradation and turnover of the extracellular matrix through the activation of plasminogen [7]; [9]. Such function requires SerpinB2 to be secreted from the cell yet SerpinB2 exists primarily as a nonglycosylated intracellular protein [10]. Over the past decade, intracellular roles for SerpinB2 in cell survival [11]-[17], proliferation and differentiation [18]-[21], signal transduction [15]; [22]; [23] and innate immunity [24]-[28], have been described.
The SerpinB2 gene is highly regulated in a cell type specific manner analogous to that of cytokines and oncogenes [29]; [30]. It is one of the most responsive genes known [31], and can be induced over 1000-fold by LPS [31]-[32], and is up-regulated by a range of inflammatory mediators [9]. LPS activates immune responses through multiple signalling pathways. The toll-like receptor 4 (TLR4) is responsible for the recognition of LPS and other microbial products and plays a central role in the initiation of innate immune responses, including cytokine release. The binding of LPS to TLR4 on the surface of macrophages leads to the recruitment of adaptor molecules and the activation of protein kinases, generating signals to the nuclear factor-kappaB (NF-kappaB), mitogen-activated protein kinase (MAPK) and/or phosphoinositide 3(PI3)-kinase pathways [33].
In studies aimed at identifying LPS-inducible pro-survival factors downstream of p38 MAPK, SerpinB2 was identified as a factor whose expression was upregulated by cooperation of the IKKbeta/NF-kappaB and p38 MAPK/CREB pathways [16]. Our previously published data indicated that SerpinB2 is distinctly regulated from other LPS-inducible genes in terms of kinetics, LPS dose response and sensitivity to IFN-gamma co-stimulation [4]; however, the cis-acting elements in the SerpinB2 promoter responsible for LPS-dependent transcription in macrophages and the specific LPS-responsive transcription factors that bind the SerpinB2 promoter were not defined. Here we show that LPS induction of SerpinB2 is dependent upon cis-acting regulatory sequences in the region between nucleotides -189 and -539 of the murine SerpinB2 promoter, and is critically dependent upon a C/EBP binding site at -203/-195. C/EBP-beta directly bound to this site in vivo and its deficiency abrogated constitutive SerpinB2 expression and SerpinB2 induction by LPS. Importantly, a C/EBP-beta phospho-acceptor site was found to negatively regulate LPS-induced SerpinB2 promoter activity. Together, these findings provide new insight into the transcriptional regulation of the SerpinB2 gene.","[{'offsets': [[779, 787]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[846, 854]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[895, 931]], 'text': ['urokinase-type plasminogen activator'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[933, 936]], 'text': ['uPA'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[1059, 1070]], 'text': ['plasminogen'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[1104, 1112]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[1146, 1154]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[1267, 1275]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[1442, 1450]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[1802, 1822]], 'text': ['toll-like receptor 4'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1824, 1828]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[2022, 2026]], 'text': ['TLR4'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[2387, 2395]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[2478, 2485]], 'text': ['IKKbeta'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[2574, 2582]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[2697, 2706]], 'text': ['IFN-gamma'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[2767, 2775]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[2912, 2920]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[2983, 2991]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[3104, 3112]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[3191, 3201]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[3280, 3288]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[3304, 3312]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[3346, 3356]], 'text': ['C/EBP-beta'], 'type': 'Protein', 'id': 'T24'}, {'offsets': [[3424, 3432]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T25'}, {'offsets': [[3540, 3548]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T26'}]",[],[],[],[],[]
295,PMC-3291650-09-Materials_and_Methods,"Determination of HAI (hemagglutination inhibition) titers
To determine the HAI titers in infected mice, sera of these were treated with receptor-destroying enzyme (RDE/Cholera filtrate; Sigma) to remove sialic acids from serum proteins capable of aspecific inhibition of agglutination. After incubation overnight at 37degreesC, the RDE was inactivated by addition of 0.75% sodium citrate in PBS and heating to 56degreesC for 30 min. To remove sialic acid binding proteins, sera were cleared with 1/10 volume 50% chicken RBC. Titration was done by incubating a two-fold dilution series of sera with 4 HA units of X-47 virus for 1 hour at room temperature in 96-well U-bottom plates. Finally, an equal volume of 0.5% chicken RBC was added and titers were read 30 min later. Negative controls included PBS instead of immune serum (agglutination control) or PR8 instead of X-47 virus (control for agglutination effect of sera); as positive control, serum from a mouse infected twice with a sublethal dose of X-47 was used.",[],[],[],[],[],[]
296,PMC-3589482-24-Caption-Figure_1,"LPS induction of SerpinB2 mRNA and protein expression in murine macrophage cells.
RAW264.7 macrophages were treated for the indicated times with 100 ng/ml LPS. (A) qPCR analysis of murine SerpinB2 mRNA levels, relative to beta-actin. The plot is representative of at least two independent experiments performed in triplicate. (B) Immunoblot analysis of SerpinB2 protein expression in whole cell lysates. Blot was reprobed for GAPDH as a loading control.","[{'offsets': [[17, 25]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[188, 196]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[222, 232]], 'text': ['beta-actin'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[353, 361]], 'text': ['SerpinB2'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[426, 431]], 'text': ['GAPDH'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
297,PMC-3586680-09-Caption-Figure_1,"Schematic diagrams of WWOX structure and its role in signaling. WWOX contains two N-terminal WW domains, a C-terminal short-chain alcohol dehydrogenase/reductase (SDR) domain, and a D3 region. A nuclear localization signal (NLS) is in between the WW domains (Chang et al., 2003, 2007; Del Mare et al., 2011; Salah et al., 2012; Su et al., 2012; reviews). The SDR domain possesses a mitochondria-binding region. There are two conserved tyrosine phosphorylation sites, Tyr33 and Tyr287. Other phosphorylation sites predicted by NetPhos 2.0 Server are Tyr6, Thr12, Ser14, Tyr61, Tyr293, and Thr3B3, respectively. Upon stress stimulation, WWOX is phosphorylated in Tyr33 and binds p53. The WWOX/p53 complex then translocates to mitochondria or nucleus to induce apoptosis. WWOX also binds PPxY motif-containing transcription factors, such as RUNX2, c-Jun, and ERBB4, via its first WW domain, and the binding blocks the activity of these proteins by retaining them in the cytoplasm. WWOX binds Tau via its SDR domain. WWOX participates in the Wnt/beta-catenin signal pathway by binding Dvl and inhibiting its nuclear import. Phorbol ester stimulates the dissociation of MEK/WWOX complex in Jurkat T cell, and the released WWOX translocates to the mitochondria for causing cell death. WWOX is recruited to the membrane area by association with Hyal-2 and phospho-Ezrin. Hyal-2 is an alternative receptor for TGF-beta1. In response to TGF-beta1, WWOX binds Hyal-2 and forms a complex, followed by relocating to the nucleus and enhancing the SMAD-driven promoter activity. Ack1, activated Cdc42-associated kinase 1; Hyal-2, hyaluronoglucosaminidase 2; CKI, casein kinase; GSK, glycogen synthase kinase; PKA, protein kinase A.","[{'offsets': [[22, 26]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[64, 68]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[635, 639]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[677, 680]], 'text': ['p53'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[769, 773]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[838, 843]], 'text': ['RUNX2'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[845, 850]], 'text': ['c-Jun'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[856, 861]], 'text': ['ERBB4'], 'type': 'Protein', 'id': 'T8'}, {'offsets': [[978, 982]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T9'}, {'offsets': [[989, 992]], 'text': ['Tau'], 'type': 'Protein', 'id': 'T10'}, {'offsets': [[1013, 1017]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T11'}, {'offsets': [[1217, 1221]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T12'}, {'offsets': [[1279, 1283]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T13'}, {'offsets': [[1338, 1344]], 'text': ['Hyal-2'], 'type': 'Protein', 'id': 'T14'}, {'offsets': [[1357, 1362]], 'text': ['Ezrin'], 'type': 'Protein', 'id': 'T15'}, {'offsets': [[1364, 1370]], 'text': ['Hyal-2'], 'type': 'Protein', 'id': 'T16'}, {'offsets': [[1402, 1411]], 'text': ['TGF-beta1'], 'type': 'Protein', 'id': 'T17'}, {'offsets': [[1428, 1437]], 'text': ['TGF-beta1'], 'type': 'Protein', 'id': 'T18'}, {'offsets': [[1439, 1443]], 'text': ['WWOX'], 'type': 'Protein', 'id': 'T19'}, {'offsets': [[1450, 1456]], 'text': ['Hyal-2'], 'type': 'Protein', 'id': 'T20'}, {'offsets': [[1565, 1569]], 'text': ['Ack1'], 'type': 'Protein', 'id': 'T21'}, {'offsets': [[1571, 1606]], 'text': ['activated Cdc42-associated kinase 1'], 'type': 'Protein', 'id': 'T22'}, {'offsets': [[1608, 1614]], 'text': ['Hyal-2'], 'type': 'Protein', 'id': 'T23'}, {'offsets': [[1616, 1642]], 'text': ['hyaluronoglucosaminidase 2'], 'type': 'Protein', 'id': 'T24'}]",[],[],[],[],[]
298,PMC-3312845-20-Caption-Figure_2,"Effect of sTNFp55R infusion on SE-induced serum-protein extravasation and neuronal damage. (A-D) Serum-protein extravasation and FJB-positive neuronal damages in the PC 3 days after SE. Compared to saline-infused animals, serum-protein extravasation and FJB-positive neuronal damage is markedly ameliorated in sTNFp55R-infused animals. Bars = 400 (A and C) and 50 (B and D) mum. (E) Quantitative analyses of serum-protein extravasation and FJB-positive neuronal damage in the PC 3 days after SE (mean +/- S.E.M). Significant differences from saline-treated animals, *p < 0.05.","[{'offsets': [[11, 18]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[311, 318]], 'text': ['TNFp55R'], 'type': 'Protein', 'id': 'T2'}]",[],[],[],[],[]
299,PMC-1064895-11-Materials_and_methods,"Statistical analysis
Data are expressed as means +/- SEM. Statistical analysis was performed with Student's t-test for matched pairs. P values less than 0.05 were considered significant.",[],[],[],[],[],[]
300,PMC-3585731-21-Materials_and_Methods,"qRT-PCR
Cells were treated as described for Western blots. Total RNA was isolated using ZR Miniprep kit (Zymo Research). 1 microg of RNA was converted to cDNA using random primers (M-MuLV cDNA kit, New England Biolabs). 1 microL of cDNA was used with 500 pM primers in qPCR reactions. Reactions were performs using SYBRGreen 2xMaster mix (SABiosciences) in a LightCycler480 (Roche).",[],[],[],[],[],[]
301,PMC-3342329-09-Materials_and_Methods,"Animals
The CCR5 wild type (CCR5+/+) and CCR5 knockout (CCR5-/-) mice were purchased from The Jackson Laboratory (Bar Harbor, Maine 04609 USA). The mice were housed and bred under specific pathogen free conditions at the Laboratory Animal Research Center of Chungbuk National University, Korea. The mice (n = 4/cage) were maintained in a room with a constant temperature of 22+/-1degreesC, relative humidity of 55+/-10%, and 12-h light/dark cycle, and fed standard rodent chow (Samyang, Korea) and purified tap water ad libitum. The CCR5+/+ mice (n = 20) and CCR5-/- mice (n = 20), that were used, had matched ages (10-11 weeks old) and weights (16-19 g). Control mice (B6129PF2/J) were F2 hybrid mice from the C57BL/6J-AW-J and 129P3/J parental strains. CCR5 mice (B6, 129P2-Ccr5tm1Kuz/J) have the entire coding region of the CCR5 gene deleted from the parental strains, B6;129P2-Ccr5tm1kuz and B6;129P2-Cmkbr5tm1Kuz.","[{'offsets': [[12, 16]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[28, 32]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[41, 45]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[56, 60]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[533, 537]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T5'}, {'offsets': [[559, 563]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T6'}, {'offsets': [[755, 759]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T7'}, {'offsets': [[827, 831]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T8'}]",[],[],[],[],[]
302,PMC-3291650-00-TIAB,"A20 (Tnfaip3) Deficiency in Myeloid Cells Protects against Influenza A Virus Infection
The innate immune response provides the first line of defense against viruses and other pathogens by responding to specific microbial molecules. Influenza A virus (IAV) produces double-stranded RNA as an intermediate during the replication life cycle, which activates the intracellular pathogen recognition receptor RIG-I and induces the production of proinflammatory cytokines and antiviral interferon. Understanding the mechanisms that regulate innate immune responses to IAV and other viruses is of key importance to develop novel therapeutic strategies. Here we used myeloid cell specific A20 knockout mice to examine the role of the ubiquitin-editing protein A20 in the response of myeloid cells to IAV infection. A20 deficient macrophages were hyperresponsive to double stranded RNA and IAV infection, as illustrated by enhanced NF-kappaB and IRF3 activation, concomitant with increased production of proinflammatory cytokines, chemokines and type I interferon. In vivo this was associated with an increased number of alveolar macrophages and neutrophils in the lungs of IAV infected mice. Surprisingly, myeloid cell specific A20 knockout mice are protected against lethal IAV infection. These results challenge the general belief that an excessive host proinflammatory response is associated with IAV-induced lethality, and suggest that under certain conditions inhibition of A20 might be of interest in the management of IAV infections.","[{'offsets': [[5, 12]], 'text': ['Tnfaip3'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[373, 402]], 'text': ['pathogen recognition receptor'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[403, 408]], 'text': ['RIG-I'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[936, 940]], 'text': ['IRF3'], 'type': 'Protein', 'id': 'T4'}]",[],[],[],[],[]
303,PMC-1359074-15-Materials_and_Methods,"Nuclear protein extract and in vitro translation of Sox6.
Nuclear extracts were prepared from MEL cells (2 x 107) using a kit (Active Motif, Carlsbad, California, United States). The Sox6 in vitro translation expression vector, tagged with c-Myc and HA, was described before [15]. The translation was performed in a reticulocyte lysate based in vitro translational system (TNT(R) Quick Coupled Transcription/Translation Systems, Promega). A vector without the Sox6 coding sequence was also translated as a negative control.","[{'offsets': [[52, 56]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[183, 187]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[240, 245]], 'text': ['c-Myc'], 'type': 'Protein', 'id': 'T3'}, {'offsets': [[250, 252]], 'text': ['HA'], 'type': 'Protein', 'id': 'T4'}, {'offsets': [[460, 464]], 'text': ['Sox6'], 'type': 'Protein', 'id': 'T5'}]",[],[],[],[],[]
304,PMC-3320587-07-Materials_and_Methods,"HIV-1 infectious molecular clones
The plasmid encoding the full-length infectious molecular clone of HIV-1Lai was obtained from the NIH AIDS Reagent and Reference Program. The HIV-1Lai/Bal-Env infectious molecular clone was constructed by replacing the envelope (env) gp160 amino acids 103-717 of the HIV-1Lai (B subtype that utilizes CXCR4) molecular clone with the corresponding region of HIV-1Bal (B subtype that utilizes CCR5). The HIV-1Lai/Bal-Env chimeric virus uses CCR5 as a secondary receptor. The infectious molecular clone of HIV-198IN22 was constructed using DNA extracted from PBMC that were infected with a primary isolate of HIV-198IN22. HIV-1Lai/Bal-Env and HIV-198IN22 mutant viruses were constructed by introducing point mutations using standard PCR-based mutagenesis methods.","[{'offsets': [[268, 273]], 'text': ['gp160'], 'type': 'Protein', 'id': 'T1'}, {'offsets': [[335, 340]], 'text': ['CXCR4'], 'type': 'Protein', 'id': 'T2'}, {'offsets': [[425, 429]], 'text': ['CCR5'], 'type': 'Protein', 'id': 'T3'}]",[],[],[],[],[]
